<SEC-DOCUMENT>0001178913-23-001080.txt : 20230321
<SEC-HEADER>0001178913-23-001080.hdr.sgml : 20230321
<ACCEPTANCE-DATETIME>20230321161058
ACCESSION NUMBER:		0001178913-23-001080
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20230321
DATE AS OF CHANGE:		20230321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269218
		FILM NUMBER:		23749826

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>zk2329412.htm
<DESCRIPTION>S-1/A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">As filed with the Securities and Exchange Commission on March 21, 2023</div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;">Registration No. 333-269218</div>
      <div style="line-height: 1.25;">&#160;
        <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Amendment No. 3<br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">to</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM S-1&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REGISTRATION STATEMENT</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">UNDER</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">CHEMOMAB THERAPEUTICS LTD.&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;(Exact name of registrant as specified in its charter)</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z6954c2f7e6d34cbf960b389b761a6070" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Israel</div>
            </td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2834</div>
            </td>
            <td style="width: 33.34%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">81-3676773</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(State or other jurisdiction of</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">incorporation or organization)</div>
            </td>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Primary Standard Industrial</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Classification Code Number)</div>
            </td>
            <td style="width: 33.34%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(I.R.S. Employer</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Identification No.)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Tel Aviv, 6158002,&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Israel&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;+972-77-331-0156&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">
        <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Chemomab Therapeutics, Inc.<br>
        One Kendall Square<br>
        Building 1400E<br>
        Suite 14-105<br>
        Cambridge, MA 02139<br>
        (857) 259-4622</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25;">
        <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">Copies to:</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z983371d34c4140f58572349fe942da60" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 33.53%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 33.53%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 32.88%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.53%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Brent D. Fassett</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Jesse F. Schumaker</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Wilson Sonsini Goodrich &amp; Rosati, P.C.</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">1881 9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Street, Suite 110</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Boulder, CO 80023</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(303) 256-5900</div>
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 33.53%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">David S. Glatt</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ronen Bezalel<br>
                Jonathan M. Nathan</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Matthew Rudolph<br>
                Meitar | Law Offices<br>
                16 Abba Hillel Rd.<br>
                Ramat Gan 5250608, Israel<br>
                +972 (3) 610-3100</div>
            </td>
            <td style="width: 32.88%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Anthony W. Basch</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">J. Britton Williston</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kaufman &amp; Canoles, P.C.<br>
                Two James Center, 14th Floor</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">1021 E. Cary St.</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Richmond, VA 23219</div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">+1.804.771.5700</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Approximate date of commencement of proposed sale to the public:</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">As soon as practicable after the effective date of this Registration Statement.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement
        number of the earlier effective registration statement for the same offering. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
        effective registration statement for the same offering. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
        effective registration statement for the same offering. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
        definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
      <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zb2c7b96d1cb043428ec1729e120a6a35" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 15%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Large accelerated filer</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 15%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Accelerated filer</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 15%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Non-accelerated filer</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
            </td>
            <td style="width: 15%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Smaller reporting company</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 15%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 15%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Emerging growth company</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 7(a)(2)(B) of the Securities Act. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> <br>
        </font></div>
      <div style="line-height: 1.25;">
        <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically
        states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to
        said Section 8(a), may determine.</div>
    </div>
    <div> <br>
    </div>
    <div> <font style="font-family: 'Times New Roman',Times,serif;"> </font>
      <div><br>
        <div> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div>
        <div><br>
        </div>
        <div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The
            information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not
            an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25">Subject to Completion, dated March 21, 2023 <br>
              </div>
            </div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">PRELIMINARY PROSPECTUS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <img src="image00003.jpg"></div>
          <div style="line-height: 1.25;"> <br>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Up t<font style="font-weight: bold;">o </font>6,578,947&#160;Units Each Consisting of One American Depositary Share and One Warrant to Purchase One </font></div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">American Depositary Share</font></div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Or up to<font style="font-weight: bold;"> </font>6,578,947 Pre-Funded Units Each Consisting of One Pre-Funded Warrant to Purchase One American </font></div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Depositary Share and One Warrant to Purchase One American Depositary Share</font></div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; <br>
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">We are offering up to 6,578,947 units (&#8220;Units&#8221;) (not inclusive of the Pre-Funded Units, as defined below), each consisting of one American Depositary Share (&#8220;ADS&#8221;), each ADS representing twenty
            (20) of our ordinary shares, no par value per share (&#8220;Ordinary Shares&#8221;), and one warrant (a &#8220;Warrant&#8221;) to purchase one ADS (a &#8220;Warrant ADS&#8221;), in a firm commitment underwritten offering. The assumed public offering price for each Unit is $1.52,
            which is the last reported sale price of the ADSs on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) on March 16, 2023. &#160;The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The ADSs and underlying
            Warrants are immediately separable and will be issued separately in this offering. The Warrants offered hereby will be immediately exercisable on the date of issuance and will expire five years from the date of issuance. Each Warrant has an
            assumed exercise price of $1.52 per ADS, which is the last reported sale price of the ADSs on Nasdaq on March 16, 2023.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are also offering to those purchasers, if any, whose purchase of Units in this offering would otherwise result in the purchaser, together with its affiliates and certain
            related parties, beneficially owning more than 4.99% of our outstanding Ordinary Shares immediately following the consummation of this offering, the opportunity to purchase, if they so choose, up to 6,578,947 pre-funded units (each, a
            &#8220;Pre-Funded Unit&#8221;), in lieu of the Units that would otherwise result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Ordinary Shares, with each Pre-Funded Unit consisting of a pre-funded warrant
            to purchase one ADS (a &#8220;Pre-Funded Warrant ADS&#8221;) and one Warrant. The purchase price of each Pre-Funded Unit will equal the price per Unit, minus $0.001, and the exercise price of each Pre-Funded Warrant included in the Pre-Funded Unit will be
            $0.001 per ADS. The Pre-Funded Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The Pre-Funded Warrants and Warrants are immediately separable and will be issued separately in this offering. The
            Pre-Funded Warrants offered hereby will be immediately exercisable subject to the beneficial ownership limitations and may be exercised on the date of issuance at any time until exercised in full. A purchaser may, at their option, purchase both
            Units and Pre-Funded Units and is not required to purchase any Pre-Funded Units if purchasing Units would cause the purchaser to exceed the disclosed beneficial ownership amounts. A purchaser exceeding the disclosed beneficial ownership amounts
            would trigger a requirement of the purchaser to make securities filings under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), disclosing such fact.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For each Pre-Funded Unit we sell, the number of Units we are offering will be decreased on a one-for-one basis. Because we will issue a Warrant as part of each Unit or Pre-Funded
            Unit, the number of Warrants sold in this offering will not change as a result of a change in the mix of the Units and Pre-Funded Units sold.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; We refer to the ADSs, the Warrants, the Pre-Funded Warrants, the Warrants ADSs, the Pre-Funded Warrants ADSs, and the Ordinary Shares
            underlying the ADSs, the Warrants ADSs, and the Pre-Funded Warrants ADSs, collectively, as the &#8220;Securities&#8221;. We are registering all Securities.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The ADSs are listed on Nasdaq under the symbol &#8220;CMMB.&#8221;&#160; On March 16, 2023, the last reported sale price of the ADSs on Nasdaq was $1.52 per
            ADS. There is no established public trading market for the Warrants or Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Warrants or Pre-Funded Warrants on any securities exchange or
            other nationally recognized trading system. Without an active trading market, the liquidity of the Warrants and Pre-Funded Warrants will be extremely limited.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under U.S. federal securities laws and, as such, we have
            elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Investing in the Securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 8 of this prospectus to
            read about factors you should consider before buying the Securities.</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" id="z073e2a7b87194b65aad48f98a592a09e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 71.46%; vertical-align: bottom;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Per Unit</div>
                </td>
                <td style="width: 0.48%; vertical-align: bottom;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Per Pre-Funded Unit</div>
                </td>
                <td style="width: 0.06%; vertical-align: top;">&#160;</td>
                <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total</div>
                </td>
              </tr>
              <tr>
                <td style="width: 71.46%; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="text-align: justify; line-height: 1.25;">Public offering price</div>
                </td>
                <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">$</div>
                </td>
                <td style="width: 0.48%; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">$</div>
                </td>
                <td style="width: 0.06%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
                <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">$</div>
                </td>
              </tr>
              <tr>
                <td style="width: 71.46%; vertical-align: bottom;">
                  <div style="text-align: justify; line-height: 1.25;">Underwriting discounts <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
                </td>
                <td style="width: 9%; vertical-align: bottom;">
                  <div style="text-align: justify; line-height: 1.25;">$</div>
                </td>
                <td style="width: 0.48%; vertical-align: bottom;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 9%; vertical-align: bottom;">
                  <div style="text-align: justify; line-height: 1.25;">$</div>
                </td>
                <td style="width: 0.06%; vertical-align: top;">&#160;</td>
                <td style="width: 9%; vertical-align: bottom;">
                  <div style="text-align: justify; line-height: 1.25;">$</div>
                </td>
              </tr>
              <tr>
                <td style="width: 71.46%; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="text-align: justify; line-height: 1.25;">Proceeds, before expenses, to us<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
                </td>
                <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">$</div>
                </td>
                <td style="width: 0.48%; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">$</div>
                </td>
                <td style="width: 0.06%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
                <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">$</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z515cea1dd55a48708ec23fb92be0991d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 3.44%; vertical-align: top;">
                  <div style="line-height: 1.25;">(1)</div>
                </td>
                <td style="width: 96.56%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">See &#8220;Underwriting&#8221; beginning on page 50 of this prospectus for a description of the compensation payable to the underwriter.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 3.44%; vertical-align: top;">
                  <div style="line-height: 1.25;">(2)</div>
                </td>
                <td style="width: 96.56%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The amount of proceeds, before expenses, to us does not give effect to the exercise of the Warrants.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
              <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We have granted the underwriter an option to purchase from us, at the public offering price, less the underwriting discounts, up to
                986,842 additional ADSs and/or Pre-Funded Warrants, and/or up to 986,842&#160; over-allotment Warrants, within 30 days after the closing of this offering to cover over-allotments, if any. The underwriter may exercise the over-allotment option
                with respect to ADSs only, Pre-Funded Warrants only, Warrants only, or any combination thereof. The purchase price to be paid per additional Ordinary Share or Pre-Funded Warrant will be equal to the public offering price of one Unit or
                Pre-Funded Unit (less $0.01 allocated to each Warrant), as applicable, less the underwriting discounts, and the purchase price to be paid per over-allotment Warrant will be $0.01. No underwriting discounts will be paid on any Warrants
                purchased pursuant to the underwriter&#8217;s over-allotment option.</div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
            prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The underwriter expects to deliver the Securities on or about&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2023.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">Sole Book-Running Manager</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z09b6ef786b71455985353923d056baea">

              <tr>
                <td style="width: 100%; vertical-align: top; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: center; line-height: 1.25;">Aegis Capital Corp.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25;">The date of this prospectus is&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2023.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="2" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z5bc1b1c3240c4b9c85337bc4a8dde051">

              <tr>
                <td style="width: 95.44%; vertical-align: bottom;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Page</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#PROSPECTUSSUMMARY">PROSPECTUS SUMMARY</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">1</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#THEOFFERING">THE OFFERING</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom; text-align: center;">7</td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#RISKFACTORS">RISK FACTORS</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">8</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#FORWARD-LOOKINGSTATEMENTS">FORWARD-LOOKING STATEMENTS</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">12</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;" rowspan="1">
                  <div style="line-height: 1.25;"><a href="#DATA"><u>MARKET, INDUSTRY AND OTHER DATA</u></a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom; text-align: center;" rowspan="1">13<br>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#USEOFPROCEEDS">USE OF PROCEEDS</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">14</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#CAPITALIZATION">CAPITALIZATION</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">15</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#DILUTION">DILUTION</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">16</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#DIVIDENDPOLICY">DIVIDEND POLICY</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">17</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#Management">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">18</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#EXECUTIVECOMPENSATION">EXECUTIVE COMPENSATION</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">24</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#SECURITY">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">31<br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#SHARECAPITAL">DESCRIPTION OF SHARE CAPITAL</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">33</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#DESCRIPTIONOFSECURITIES">DESCRIPTION OF SECURITIES WE ARE OFFERING</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">38</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#MATERIALTAXCONSIDERATIONS">MATERIAL TAX CONSIDERATIONS</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">46</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#UNDERWRITINGN">UNDERWRITING</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom; text-align: center;">53</td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#LEGALMATTERS">LEGAL MATTERS</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">57</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#EXPERTS">EXPERTS</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom; text-align: center;">57</td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#ENFORCEMENTOFCIVILLIABILI">ENFORCEMENT OF CIVIL LIABILITIES</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">58</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#WHERE">WHERE YOU CAN FIND MORE INFORMATION</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom;">
                  <div style="text-align: center; line-height: 1.25;">59</div>
                </td>
              </tr>
              <tr>
                <td style="width: 95.44%; vertical-align: top;">
                  <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;"><a href="#INCORPORATIONBYREFERENCE">INCORPORATION BY REFERENCE</a></div>
                </td>
                <td nowrap="nowrap" style="width: 4.56%; vertical-align: bottom; text-align: center;">59</td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You should rely only on the information contained in this prospectus. Neither we nor the underwriters have authorized anyone to provide any information or to make any
            representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance
            as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the Securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information
            contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of Securities. Our business, financial condition, results of operations and prospects may
            have changed since that date.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this
            prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions
            relating to, the offering of the Securities and the distribution of this prospectus outside the United States.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We use our trademarks and our logo in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of other organizations.
            Solely for convenience, trademarks and tradenames referred to in this prospectus appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
            law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.</div>
          <div style="text-align: center; line-height: 1.25;"> <br>
          </div>
          <div style="text-align: center; line-height: 1.25;">ii</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%1%%%-->
          <div style="line-height: 1.25;">
            <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
              <div>
                <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
                </div>
                <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="PROSPECTUSSUMMARY"><!--Anchor--></a>PROSPECTUS SUMMARY</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; line-height: 1.25; font-style: italic;">This summary highlights, and is qualified in its entirety by, the more detailed information contained in other parts of this prospectus, including any applicable free
                  writing prospectus and the documents incorporated by reference herein. This summary does not contain all of the information that may be important to you in making your investment decision. You should read this entire prospectus carefully,
                  especially the &#8220;Risk Factors&#8221; section beginning on page 8 and our financial statements and the related notes incorporated by reference herein, before deciding to invest in our Securities. As used in this prospectus, unless the context
                  otherwise requires, references to &#8220;Chemomab Therapeutics Ltd.&#8221;, &#8220;Chemomab,&#8221; the &#8220;Company,&#8221; &#8220;us,&#8221; &#8220;we&#8221; and &#8220;our&#8221; refer to Chemomab Therapeutics Ltd., an Israeli company and its consolidated subsidiaries; however, with respect to the
                  presentation of financial results for historical periods that preceded the Merger (as defined below), these terms refer to the financial results of the Company&#8217;s wholly owned subsidiary, Chemomab Ltd. (the &#8220;Subsidiary&#8221;), which was the
                  accounting acquirer in the Merger. References to the &#8220;Merger&#8221; refer to the merger involving Anchiano Therapeutics Ltd., or Anchiano, and the Subsidiary, whereby a wholly owned subsidiary of Anchiano merged with and into the Subsidiary,
                  with the Subsidiary surviving as a wholly owned subsidiary of Anchiano. Upon consummation of the Merger on March 16, 2021, Anchiano changed its name to &#8220;Chemomab Therapeutics Ltd.&#8221; and the business conducted by the Subsidiary became
                  primarily the business conducted by the Company.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Company Overview</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Chemomab is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high
                  unmet needs. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the
                  potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.</div>
                <div style="line-height: 1.25;">&#160;
                  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Chemomab has pioneered the therapeutic targeting of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and fibrotic
                    activities through the CCR3 receptor. The chemokine is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual
                    anti-fibrotic and anti-inflammatory activity that modulates the complex interplay of both of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and clinical fibrotic diseases. This innovative approach is
                    being developed for difficult to treat rare diseases, also known as orphan indications or diseases, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), and systemic sclerosis (&#8220;SSc&#8221;), for which patients have no established disease modifying
                    or standard of care treatment options. We estimate that there are approximately 77 thousand patients suffering from PSC in the U.S., EU and Japan, representing over a $1 billion market opportunity, and approximately 170 thousand
                    patients suffering from SSc in those same markets, representing over a $1.5 billion market opportunity.</div>
                  <div style="line-height: 1.25">&#160;</div>
                  <div style="line-height: 1.25">
                    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">CM-101, our lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of the soluble chemokine CCL24,
                      also known as eotaxin-2, as a regulator of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of
                      action. Based on these findings, we are actively advancing CM-101 in Phase 2 clinical studies directed toward two distinct clinical indications that include patients with liver or skin, and/or lung fibrosis. We are currently
                      conducting a Phase 2 clinical study in PSC, a rare obstructive and cholestatic liver disease. The study is actively recruiting patients in the U.S., Europe and Israel and is being expanded by adding clinical sites, an additional high
                      dose arm (20mg/kg) as well as an open label extension. We had earlier proposed to add both low and high dose arms to the study but the recent encouraging results reported from our Phase 2 liver fibrosis trial in NASH patients, dosed
                      at 5mg/kg, along the positive Phase 1b data we previously reported in non-alcoholic fibrotic liver disease (&#8220;NAFLD&#8221;) patients dosed at 5mg/kg and 2,5mg/kg, are seen as providing us sufficient data on the performance of the lower dose
                      to drop it from the current trial, which is focusing on the 10mg/kg and 20g/kg doses. We believe this change will facilitate timely conduct and completion of the trial. If regulators in the future do not agree that the existing low
                      dose data are sufficient, we always have the option to add a lower dose group as part of the Phase 3 clinical program.</div>
                    <div style="line-height: 1.25">&#160;
                      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are also planning to open a Phase 2 clinical trial in SSc<font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;"> around midyear </font>of 2023. The trial in SSc, a rare autoimmune rheumatic disease characterized by fibrosis in the
                        skin and lung and other organs, will focus on establishing biological and clinical proof of concept in this patient population. Although our primary focus is on these two rare indications, as we noted, an additional Phase 2 clinical
                        study in patients with liver fibrosis due to non-alcoholic steatohepatitis, or NASH has recently been completed.&#160; This trial provided safety and pharmacokinetic (&#8220;PK&#8221;) data and is informative in determining whether the company
                        advances the development of its current subcutaneous formulation of CM-101. Additionally, the trial measured a number of biomarkers that may be relevant to the potential activity of CM-101 in other fibro-inflammatory conditions. We
                        recently reported results from this trial, which showed that the trial met its primary endpoint of safety and tolerability, and that CM-101 demonstrated encouraging activity in secondary endpoints that include a range of liver
                        fibrosis biomarkers and physiologic assessments.</div>
                    </div>
                    <div style="line-height: 1.25">&#160;</div>
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">1</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="line-height: 1.25;">
            <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
              <div>&#160;
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Fibrosis is the abnormal and excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, which provides
                  structural and biochemical support to surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and thickening of connective tissues, affecting tissue properties and potentially leading to
                  organ dysfunction and failure. Fibrosis can occur in many different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive fibrotic conditions. Fibrosis and
                  inflammation are intrinsically linked. While a healthy inflammatory response is necessary for efficient tissue repair; after disease or injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis that in turn can
                  further stimulate inflammatory processes in a fibro-inflammatory vicious cycle.&#160;</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Associated with Our Business</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company. These risks are described more fully in the
                  section titled &#8220;Risk Factors&#8221; in this prospectus as well as in our Annual Report on Form 10-K for the year ended December 31, 2022 and our subsequent Quarterly Reports on Form 10-Q. These risks include, but are not limited to, the
                  following:</div>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="zc09bc9f49bdb4f7cb95265686c040482" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>We have incurred significant losses since inception and anticipate that we will continue to incur increasing levels of operating losses over the next several&#160;years and for the foreseeable future. We are unable to predict the
                          extent of any future losses or when we will become profitable, if at all.&#160;Even if we become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z21bc9b3177154357827f3f9ba0c7f510" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>We have a limited operating history and funding, which may make it difficult to evaluate our prospects and likelihood of success.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="zf9487b6b6ce84f20b169169b6b2a1a14" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>Our business is highly dependent on the success of our lead product candidate, CM-101, and any other product candidates that we advance into clinical studies. All of our programs will require significant additional clinical
                          development.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z90ad86facdf64e5493c8707b83eda7bc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>Our&#160;central objective is to design and develop targeted treatments for inflammation and fibrosis with an initial focus on the antagonism of CCL24 signaling, which is known to regulate fibrotic and inflammatory processes. While
                          several studies are currently underway, our approach in the area of fibrotic diseases is novel and unproven and may not result in marketable products.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="zed05a7201baf4188b2c3db4121824553" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>The successful completion of clinical studies is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable foreign regulatory authorities, for each product candidate and,
                          consequently, the ultimate approval and commercial marketing of any product candidates. We may experience negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional
                          clinical studies or trials or abandon some or all of its product development programs, which could have a material adverse effect on our business.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="za9f6f9838a084c68a583b09c26961050" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>We may encounter difficulties enrolling patients in our clinical studies, including due to the continuing effects of the COVID-19 pandemic, or other public health emergencies and related clinical development activities could be
                          delayed or otherwise adversely affected.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z011727e2a58e4760bbb82ba68eb0859b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>Our ongoing and future clinical studies may reveal significant adverse events or immunogenicity-related responses and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of our
                          product candidate.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z726f8f8c84fc46daa243026cd6ba7c1b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for CM-101 or any other
                          product candidates, our business will be substantially harmed.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z58243e261cb440078bcb7ee0ce0d7e51" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business will be harmed.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="zfa15ec98e19b40669c8ffa0b13d9443c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="zdf243186dcc54efd82835166985a09a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>We have been granted Orphan Drug Designation for CM-101 in connection with three indications and may seek Orphan Drug Designation for other indications or product candidates, and we may be unable to maintain the benefits
                          associated with Orphan Drug Designation, including the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for its other product candidates.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z7b75e72713f04b2c82e809e36aef83f8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>We expect to experience significant growth in the number of our employees over time and the scope of our operations, particularly in the areas of product candidate development, regulatory affairs and sales and marketing. We
                          will therefore need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
              </div>
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="line-height: 1.25;">
            <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
              <div>
                <div> <br>
                </div>
                <table cellspacing="0" cellpadding="0" id="z794996de1b3d49058c4e1c91245dc771" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>If we are unable to protect our patents or other proprietary rights, or if we infringe the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged. In addition,
                          changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z95a777df955e4042a488452d2ac66b41" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>Risks related to our operations in Israel could materially adversely impact our business, financial condition and results of operations.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">
                  <table cellspacing="0" cellpadding="0" id="z635ceddfb5cb4e0280b2104f93923ce6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 20.25pt;"><br>
                        </td>
                        <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                        <td style="width: auto; vertical-align: top; text-align: justify;">
                          <div>Our principal executive offices are located in Israel and certain of our product candidates may be manufactured at third-party facilities located in Europe. In addition, our business strategy includes potentially expanding
                            internationally if any of its product candidates receives regulatory approval. A variety of risks associated with operating internationally could materially adversely affect our business.</div>
                        </td>
                      </tr>

                  </table>
                  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                  </div>
                </div>
                <table cellspacing="0" cellpadding="0" id="z66859546921b451e9cbe9bd6bebe19ed" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>Holders of ADSs are not treated as holders of our ordinary shares.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z7e161d33b2934acbb4cad5a2dab1ade7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>Holders of ADSs may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise their right to vote.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="ze0db5a06ab0f4d0eab7df73e1b216efd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>
                          <div style="text-align: left; line-height: 1.25;">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</div>
                        </div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z7c125818c0664f1997ad5ec670f7b707" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>We are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" id="z6b4ee396a67c4df69e17830cf3e98086" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="zcce5f51e7fcf48b492c730ca0bd1ac87" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>We presently anticipate that we will be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences to U.S. Holders of our ordinary shares.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="z0d87c5a3fa7042d0b0f2b32198c377d2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>The Warrants are speculative in nature.</div>
                      </td>
                    </tr>

                </table>
                <div style="text-align: justify; text-indent: -27pt; margin-left: 47.25pt; line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="z6f58b153539d44868d51caeeda0dc0ff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>There is no established market for the Warrants being offered in this offering.</div>
                      </td>
                    </tr>

                </table>
                <div style="text-align: justify; text-indent: -27pt; margin-left: 47.25pt; line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="zce21247703a747ebacde8a1df95e0d1e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>Holders of the Warrants will have no rights as a shareholder until they acquire our ordinary shares.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="zf2f7827d93a14769ac2d8e5d67499a85" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>The Warrants offered by this prospectus may not have any value.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="z931d7630bd4e4999931d4b0002536bcf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>As our Warrant holders exercise their Warrants into Warrant ADSs and underlying ordinary shares, our shareholders&#8217; ownership will be diluted.</div>
                      </td>
                    </tr>

                </table>
                <br>
                <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Recent Developments</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="line-height: 1.25; font-style: italic; font-weight: bold;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-style: italic; font-weight: bold;">FDA Clearance of our IND Application for CM-101 in Phase 2 Trial in SSc Patients</div>
                  <div style="line-height: 1.25">&#160;
                    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: normal; font-weight: normal;">On February 21, 2023, we reported U.S. Food and Drug Administration (&#8220;FDA&#8221;)
                      clearance of our Investigational New Drug (&#8220;IND&#8221;) Application to evaluate CM-101 in a Phase 2 trial in adults with systemic sclerosis (&#8220;SSc&#8221;). The Phase 2 ABATE trial is a multicenter, randomized, double-blind, proof-of-biology study
                      to evaluate the SAfety, ToleraBility, and Activity of CM-101 in Patients with SysTEmic Sclerosis. It will enroll 45 patients with clinically active dermatologic, vascular or pulmonary SSc. The study population is expected to be
                      roughly split between patients with diffuse SSc and patients with limited SSc. The primary outcome measure is safety. Secondary endpoints include multiple serum-based biological markers and a variety of exploratory biological and
                      clinical outcomes, including the American College of Rheumatology Composite Response Index in Systemic Sclerosis (&#8220;ACR-CRISS&#8221;) score and its revisions (&#8220;rCRISS&#8221;). The trial includes a 24-week double blind period during which active
                      treatment patients will receive 10 mg/kg of CM-101 by intravenous infusion every three weeks, followed by a 24-week open label extension, where all patients will receive a 10 mg/kg dose. The trial includes multiple clinical
                      assessments of the skin, vasculature and pulmonary function. It is expected to generate additional information about disease mechanisms, provide data relevant to future patient stratification strategies and inform the selection of
                      appropriate endpoints for future studies. The trial is expected&#160; to begin enrolling patients <font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">around midyear o</font>f 2023.A top-line data read-out is planned for the second half of 2024.</div>
                  </div>
                  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',serif; font-weight: normal; font-style: normal;">
                    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
                    </div>
                  </div>
                </div>
                <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Report Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On January 3, 2023, we reported positive top-line results from our Phase 2a liver fibrosis biomarker trial of CM-101 in NASH patients. This trial was primarily designed
                  to assess a subcutaneous formulation of CM-101 and to evaluate the drug&#8217;s impact on liver fibrosis biomarkers relevant to both NASH and the fibro-inflammatory conditions that represent the focus for the company, such as PSC and SSc. The
                  trial met its primary endpoint of safety and tolerability, and CM-101 demonstrated encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments measured at baseline and at week
                  20.</div>
                &#160;</div>
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
              <div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
                  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                  </div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The randomized, placebo-controlled trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo. Patients received a dose
                    of&#160;5-mg/kg of study drug administered by subcutaneous (&#8220;SC&#8221;) injection once every two weeks, for a treatment period of 16 weeks. Key findings of the CM-101 Phase 2a trial included the following.</div>
                </div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="z9629fdc76af046f8b365e8c46edad191" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>CM-101 appeared to be safe and well tolerated when administered subcutaneously. Most reported adverse events observed were mild, with one unrelated serious adverse event reported. No significant injection site reactions were
                          reported and no anti-drug antibodies were detected.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="z4f9e007a78834bbfbc3117ea6abf29ef" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>CM-101 administered subcutaneously demonstrated favorable pharmacokinetics and target engagement profiles as expected, and were similar to what the company has previously reported.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="zf0dfec8033754cccab565c49ee976267" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>CM-101-treated patients showed greater improvements than the placebo group in a number of liver fibrosis-related biomarkers, including ProC-3, ProC-4, ProC-18, TIMP-1 and ELF.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="za89527436a04468a88173d2d47f28a14" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>A majority of CM-101-treated patients showed improvements in multiple liver fibrosis-related biomarkers&#8212;almost 60% of CM-101 patients were &#8220;multiple responders&#8221;, responding in at least three biomarkers at week 20, compared to
                          no patients in the placebo group.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="z4665f886b7454268afafb431b69085e2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>CM-101-treated patients with higher CCL24 levels at baseline showed greater reductions in fibrosis-related biomarkers than patients with lower levels of CCL24 at baseline. More CM-101-treated patients with higher CCL24 levels
                          also were &#8220;multiple responders&#8221;, responding in three or more of the fibrosis-related biomarkers, compared to patients with lower CCL24 levels at baseline.&#160; These findings further add to the growing body of evidence validating the
                          role of CCL24 in the pathophysiology of fibrotic liver disease.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="zc18b9effac8948afaa0fbe66d9d318fb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>A higher proportion of patients in the CM-101-treated group showed improvement in a physiologic measure of liver stiffness as compared to placebo (reduction of at least one grade of fibrosis score as assessed by the
                          non-invasive elastography method known as FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>).</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" id="zfe8d159f10de4736aeff45c63fd39fa1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 20.25pt;"><br>
                      </td>
                      <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>After completion of the study, the unblinded data showed that patients in the CM-101-treated group had higher baseline levels of fibrosis compared to placebo patients. The impact of this difference on the results, if any, is
                          unknown.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;We believe that the data from this trial provide important insights in support of the CM-101 development program, including the favorable safety and tolerability of
                  CM-101 in patients with serious liver disease, confirmation of early signs of biomarker activity that are relevant for a number of fibro-inflammatory disorders, and support for the tolerability and pharmacokinetic data needed to assess
                  next steps in the development of our SC formulation<font style="font-style: italic;">.</font></div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Results Reported for Clinical Study of CM-101 in Patients with COVID-19-Derived Lung Damage</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On November 9, 2022, positive clinical data from an investigator-initiated clinical study assessing CM-101 activity and safety in hospitalized patients with severe lung
                  injury derived from COVID-19 was presented at the 2022 Union Conference, an international conference on lung health. Some of the mechanisms underlying lung inflammation resulting from COVID-19 infection are similar to those seen in system
                  sclerosis and other chronic diseases involving lung inflammation and fibrosis. The objective of the study was to evaluate the drug&#8217;s safety and activity in hospitalized COVID-19 patients with severe pneumonia, including its impact on
                  biomarkers related to lung inflammation that are also relevant in SSc.<font style="font-weight: bold;">&#160;</font>The open label, single arm trial enrolled 16 hospitalized adult COVID-19 patients with severe respiratory involvement. All
                  patients were receiving standard of care therapy. All were treated with a single 10mg/kg intravenous dose of CM-101 on the first day of the study and followed for 30 days.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Administration of CM-101 to this acutely ill patient population appeared safe and was well tolerated. CM-101 exposures and target engagement profiles were similar to
                  what our researchers have seen in previous clinical studies of CM-101. Importantly, rapid reductions in serum biomarkers of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment with CM-101.<font style="font-weight: bold;">&#160;</font>Overall, this study confirmed and extended the safety and tolerability profile of CM-101 and demonstrated clinically relevant changes in biomarkers associated with lung inflammation and fibrogenesis,
                  further supporting CM-101&#8217;s anti-inflammatory and anti-fibrotic effects.<font style="font-weight: bold;">&#160;</font>Moreover, we believe that these results add to the data suggesting that CM-101 has the potential to attenuate lung
                  inflammation and fibrosis, further strengthening the rationale for treating SSc patients with this drug. These new clinical data also contribute to a growing body of evidence demonstrating CM-101&#8217;s anti-fibrotic and anti-inflammatory
                  effects in varied organs including the lung, liver and skin.</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">New Executive Appointments</div>
                <div style="text-align: justify; line-height: 1.25;">&#160;
                  <div style="text-indent: 36pt; line-height: 1.25;">On August 29, 2022, Christina Crater, MD, joined us as our Vice President of Clinical Development. Dr. Crater has an extensive background in medical affairs and clinical trial design and
                    execution across a broad range of therapeutic indications, Dr. Crater has served as a medical monitor, safety physician, therapeutic expert and study director in all phases of clinical development. Her career spans working in-house at
                    pharmaceutical and biotechnology firms, and at major clinical research organizations (&#8220;CROs&#8221;). Previously Dr. Crater was a Senior Clinical Trial Physician at Bristol-Myers Squibb, and she served in senior clinical development roles with
                    PRA Health Sciences and PAREXEL International. Earlier in her career, Dr. Crater worked as an internal medicine physician. She received an MD degree from the University of Tennessee and holds a BS degree from Rhodes College.</div>
                </div>
                &#160; <br>
              </div>
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
              <div>&#160;
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On November 14, 2022, Matthew Frankel, MD, MBA joined us as our Chief Medical Officer and Vice President of Drug Development. Dr. Frankel brings a wealth of experience
                  across all aspects of clinical development and medical affairs, along with a strong track record in helping to bring biologic and small molecule drugs to market for both rare and chronic diseases. Before joining us. Dr. Frankel served as
                  Vice President, Clinical Development and Medical Affairs, Specialty Pharma at Boehringer Ingelheim, where he developed new drugs for oncology, immunology, pulmonary, and central nervous system diseases. Previously Dr. Frankel was Vice
                  President &amp; Head, Immunology and Dermatology Medical Unit at Novartis, where he oversaw medical affairs and late phase clinical development for Cosentyx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,
                  Ilaris<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, and Zortress<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>.&#160; At the Sandoz unit of Novartis, Dr. Frankel led the
                  medical affairs organization supporting the biopharmaceutical, biosimilar and generics businesses for launches including Kerydin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, Glatopa<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and Zarxio<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. Earlier in his career, Dr. Frankel held clinical development
                  leadership roles across geographies and therapeutic diseases at Reata, Fibrogen, Abbott Labs, and Schering Plough. Dr. Frankel received a BA degree from Vassar College, an MD degree from the University of California School of Medicine,
                  Los Angeles and an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University.&#160; He is board certified in internal medicine. Dr. Frankel replaced interim Chief Medical Officer David Weiner, MD, who has continued in
                  the role of Strategic Advisor to Chemomab.</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On November 21, 2022, Mitchell L. Jones, MD, PhD, joined us as our Vice President of Corporate Development &amp; Strategy. Dr. Jones brings more than 15 years of
                  leadership experience in biopharmaceutical research, clinical development, corporate strategy and entrepreneurship, organizational development and team-building, technology transfer and licensing and acquisitions.&#160;Dr. Jones formerly was
                  Vice President Clinical Discovery and Development at Finch Therapeutics, where he contributed to a successful IPO and helped oversee the clinical development of novel therapeutics for inflammatory bowel disease and cancer. Previously Dr.
                  Jones was Vice President of Translational and Clinical Development at Biora Therapeutics, formerly Progenity, developing clinical program strategy and overseeing development of its novel drug delivery technologies. Earlier, Dr. Jones
                  managed the successful trade sale of the technology platform and assets of Interface Biosciences. Dr. Jones also founded Micropharma, where he served as Head of R&amp;D, concluded major licensing agreements and managed the company&#8217;s half
                  billion-dollar acquisition. Dr. Jones is the author or co-author of numerous scientific abstracts, proceedings and publications and an inventor on almost 200 filed or granted patents. He received his MD, PhD, master&#8217;s in biomedical
                  engineering and BS degrees from McGill University in Canada.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The Repurchase Arrangement</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">
                  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As previously reported in&#160; our Registration Statement on Form S-4 (File No. 333-252070), filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on January
                    13, 2021 and declared effective by the SEC on February 10, 2021, the Subsidiary filed an application with the Israel Tax Authority for a tax ruling (the &#8220;Tax Ruling&#8221;) in connection with the Merger, pursuant to which certain of the
                    Subsidiary&#8217;s shareholders were entitled to defer an immediate Israeli tax liability resulting from the exchange of shares that otherwise would have been deemed a sale. The deferral of the aforementioned tax liability is set to lapse on
                    March 16, 2023, which is the two-year anniversary of the closing date of the Merger. Dr. Adi Mor, co-founder of the Subsidiary and both our Chief Scientific Officer and a Class III director, and Professor Kobi George, co-founder of the
                    Subsidiary (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), will be required to pay a substantial tax liability to the Israeli Tax Authority upon the expiration date of the deferral period. In order to pay this tax liability, the
                    Co-Founders had to sell part of their holdings in the Company. In light of the foregoing, Chemomab elected to enter into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with the Co-Founders whereby we agreed, subject to the
                    requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which we received on November 14, 2022, to repurchase up to 582,023 of&#160; ADSs owned by the Co-Founders, for
                    consideration not to exceed an aggregate amount of $2,500,000, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, we repurchased the entire amount of 582,023 ADSs from the
                    Co-Founders at a weighted average price of $2.0848 and for total consideration of approximately $1.2 million.&#160;</div>
                  <div style="line-height: 1.25">&#160;</div>
                </div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We do not expect any change in our cash runway as a result of the Repurchase Arrangement. Our current cash, cash equivalents and short-term bank deposits are expected
                  to last through at least March 31, 2024.&#160;Based on our planned use of the net proceeds from this offering and our existing cash, cash equivalents and short-term bank deposits, this financing will enable us to advance our clinical
                  development programs for PSC and SSc. We are likely to need to secure additional financing to complete those programs which are projected to have topline readouts in the second half of 2024. We continue to manage our cash runway and
                  believe additional capital will be available when required.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Corporate Information</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We were incorporated on September 22, 2011, under the laws of the State of Israel. In March 2021, in connection with the Merger, we changed our name from Anchiano
                  Therapeutics Ltd. to Chemomab Therapeutics Ltd. Our principal executive offices are located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002, and our phone number is +972-77-331-0156. Our website is: <font style="font-style: italic;">www.chemomab.com.</font> The information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus and should not be considered to be part of this prospectus. We have
                  included our website address as an inactive textual reference only.</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
                </div>
              </div>
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          &#160;
          <div style="line-height: 1.25;">
            <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
              <div>&#160;
                <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Implications of Being an Emerging Growth Company and a Smaller Reporting Company</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. We will remain an emerging growth
                  company until the earliest to occur of: the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held
                  by non-affiliates; the issuance, in any three-year period, by us of more than $1.0 billion in non-convertible debt securities; and the last day of the fiscal year ending after the fifth anniversary of our initial public offering. As a
                  result of this status, we have taken advantage of reduced reporting requirements in this prospectus and may elect to take advantage of other reduced reporting requirements in our future filings with the SEC. In particular, in this
                  prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. In addition, the
                  JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to
                  private companies. We have elected to use this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date
                  we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply
                  with the new or revised accounting standards as of public company effective dates.</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">To the extent that we continue to qualify as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, after we
                  cease to qualify as an emerging growth company, we will continue to be permitted to make certain reduced disclosures in our periodic reports and other documents that we file with the SEC. Specifically, as a smaller reporting company we
                  may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K&#160;and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations
                  regarding executive compensation. We will continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by&#160;non-affiliates&#160;is less than $250&#160;million or (ii)&#160;our annual revenue is less than $100&#160;million during
                  the most recently completed fiscal year and the market value of our stock held by&#160;non-affiliates&#160;is less than $700&#160;million.</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
                </div>
              </div>
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">
            <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
              <div>&#160;
                <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="THEOFFERING"><!--Anchor--></a>THE OFFERING</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="line-height: 1.25;">
                  <table cellspacing="0" cellpadding="0" id="z5fb5ee60f4e24d8da3a2bb7e9daa3744" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 38%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">Units</div>
                        </td>
                        <td style="width: 62%; vertical-align: top;">
                          <div style="line-height: 1.25;">Up to 6,578,947 Units, each consisting of one ADS and one Warrant to purchase one ADS. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The ADSs
                            and Warrants are immediately separable and will be issued separately in this offering.</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 38%; vertical-align: top;">&#160;</td>
                        <td style="width: 62%; vertical-align: top;">&#160;</td>
                      </tr>
                      <tr>
                        <td style="width: 38%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">Pre-Funded Units</div>
                        </td>
                        <td style="width: 62%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">We are also potentially offering up to 6,578,947 Pre-Funded Units, each consisting of a Pre-Funded Warrant to purchase one ADS and one Warrant. The Pre-Funded Units have no
                            stand-alone rights and will not be certificated or issued as stand-alone securities. The Pre-Funded Warrants and Warrants are immediately separable and will be issued separately in this offering.</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 38%; vertical-align: top;">&#160;</td>
                        <td style="width: 62%; vertical-align: top;">&#160;</td>
                      </tr>
                      <tr>
                        <td style="width: 38%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">The American Depositary Shares</div>
                        </td>
                        <td style="width: 62%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">The underwriters will deliver American Depositary Shares (&#8220;ADSs&#8221;) representing our ordinary shares. Each ADS represents twenty of our ordinary shares, no par value per share.</div>
                          <div style="line-height: 1.25;">&#160;</div>
                          <div style="text-align: justify; line-height: 1.25;">As an ADS holder, you will not be treated as one of our shareholders and you will not have shareholder rights. The depositary, The Bank of New York Mellon, will be the holder of
                            the ordinary shares underlying the ADSs. You will have the rights of an ADS holder or beneficial owner (as applicable) as provided in the deposit agreement among us, the depositary and holders and beneficial owners of ADSs from
                            time to time. To better understand the terms of the ADSs, see &#8220;Description of Securities We Are Offering.&#8221; We also encourage you to read the deposit agreement, the form of which is filed as an exhibit to the registration
                            statement of which this prospectus forms a part.</div>
                          <div style="line-height: 1.25;">&#160;</div>
                          <div style="line-height: 1.25;">You may turn in the ADSs to the depositary to cancel the ADSs and withdraw the ordinary shares. The depositary will charge you fees for any cancellation and withdrawal.</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 38%; vertical-align: top;">&#160;</td>
                        <td style="width: 62%; vertical-align: top;">&#160;</td>
                      </tr>
                      <tr>
                        <td style="width: 38%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">Pre-Funded Warrants</div>
                        </td>
                        <td style="width: 62%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">The purchase price of each Pre-Funded Unit will equal the price per Unit, minus $0.001, and the exercise price of each Pre-Funded Warrant included in the Pre-Funded Unit will be
                            $0.001 per ADS. The Pre-Funded Warrants offered hereby will be immediately exercisable and may be exercised on the date of issuance at any time until exercised in full. To better understand the terms of the Pre-Funded Warrants,
                            you should carefully read the &#8220;Description of the Offered Securities&#8221; section of this prospectus. You should also read the form of the Pre-Funded Warrant, which is filed as an exhibit to the registration statement that includes
                            this prospectus.</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 38%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 62%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 38%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">Warrants</div>
                        </td>
                        <td style="width: 62%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">The Warrants offered hereby will be immediately exercisable on the date of issuance and will expire five years from the date of issuance. Each Warrant has an assumed exercise
                            price of $1.52 per ADS, which is the last reported sale price of the ADSs on Nasdaq on March 16, 2023. To better understand the terms of the warrants, you should carefully read the &#8220;Description of the Offered Securities&#8221; section
                            of this prospectus. You should also read the form of warrant, which is filed as an exhibit to the registration statement that includes this prospectus.</div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div style="line-height: 1.25;">
                  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                  </div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 38%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">
                            <div style="text-align: left; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Over-allotment Option</div>
                          </div>
                        </td>
                        <td style="width: 62%; vertical-align: top;">
                          <div style="text-align: justify; line-height: 1.25;">
                            <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">We have granted the underwriter an option to purchase from us, at the public offering price, less the underwriting discounts, up to
                              986,842&#160; additional ADSs and/or Pre-Funded Warrants, and/or up to 986,842&#160; over-allotment Warrants, within 30 days after the closing of this offering to cover over-allotments, if any. The underwriter may exercise the
                              over-allotment option with respect to ADSs only, Pre-Funded Warrants only, Warrants only, or any combination thereof.</div>
                          </div>
                        </td>
                      </tr>

                  </table>
                  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                  </div>
                </div>
                <table cellspacing="0" cellpadding="0" id="zc2e7737986da4da884870f58708af5c2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                    <tr>
                      <td style="width: 38%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">ADSs outstanding prior to this offering</div>
                      </td>
                      <td style="width: 62%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">11,049,812 ADSs.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd467b9d2338a49a69202b2deaa3020da">

                    <tr>
                      <td style="width: 38%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">ADSs outstanding after this offering</div>
                      </td>
                      <td style="width: 62%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">
                          <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
                            <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">17,628,759 ADSs (assuming full exercise of the Pre-Funded Warrants).</div>
                          </div>
                        </div>
                      </td>
                    </tr>

                </table>
                <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za10f5ddb51554a64bec69fdbda283d34">

                    <tr>
                      <td style="width: 38%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">Use of proceeds</div>
                      </td>
                      <td style="width: 62%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">
                          <div style="text-align: left; line-height: 1.25;">We estimate the net proceeds from this offering will be approximately $8.8 million, after deducting estimated underwriting discounts and commissions and estimated offering expenses
                            payable by us. We intend to use the net proceeds from this offering for continued clinical development of our product candidates, research activities, and for other general corporate purposes. See &#8220;Use of Proceeds&#8221; on page 12 of
                            this prospectus.</div>
                        </div>
                      </td>
                    </tr>

                </table>
                <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zecd85386713f432fab645a7223506cb2">

                    <tr>
                      <td style="width: 38%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">Risk factors</div>
                      </td>
                      <td style="width: 62%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">See &#8220;Risk Factors&#8221; beginning on page 8 for a discussion of factors you should carefully consider before deciding to invest in our securities.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd110e51816f648e4998b2fd27c39e631">

                    <tr>
                      <td style="width: 38%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">ADS depositary</div>
                      </td>
                      <td style="width: 62%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">The Bank of New York Mellon.</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd445aeb7b7584ab3b60a06e7dc2ec3d3">

                    <tr>
                      <td style="width: 38%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">Nasdaq Capital Market symbol</div>
                      </td>
                      <td style="width: 62%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">
                          <div style="text-align: left; line-height: 1.25;">The ADSs are listed on Nasdaq under the symbol &#8220;CMMB.&#8221; We do not intend to list the Warrants on any securities exchange or nationally recognized trading system.</div>
                        </div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
                    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">The number of ADSs to be outstanding after this offering is based on 11,049,812 ADSs outstanding as of December 31, 2022, and does not account
                      for:</div>
                    <div style="line-height: 1.25">&#160;</div>
                  </div>
                </div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z955be787e80a42df89bb85d44c06285e">

                    <tr>
                      <td style="width: 0.57%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                      <td style="width: 3.02%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
                      </td>
                      <td style="width: 96.4%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">
                          <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
                            <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">1,747,077 ADSs issuable upon the exercise of outstanding options to purchase ADSs, at a weighted average exercise price of $6.60 per ADS;</div>
                          </div>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 0.57%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                      <td style="width: 3.02%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                      <td style="width: 96.4%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 0.57%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                      <td style="width: 3.02%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
                      </td>
                      <td style="width: 96.4%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">
                          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
                            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">
                              <div style="line-height: 1.25;">
                                <div style="line-height: 1.25;">an aggregate of 655,869 ADSs reserved for future issuance under the Chemomab Ltd. 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;), which was assumed by the Company upon effectiveness of the
                                  Merger, and the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221; and together with the 2015 Plan, the &#8220;Share Incentive Plans&#8221;), as of December 31, 2022, as well as any automatic increases in the number of ADSs reserved
                                  for future issuance under the 2017 Plan;</div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 0.57%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                      <td style="width: 3.02%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                      <td style="width: 96.4%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 0.57%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                      <td style="width: 3.02%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
                      </td>
                      <td style="width: 96.4%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">261,929 ADSs issuable upon the exercise of outstanding warrants to purchase ADSs at a weighted average exercise price of $17.35088 per ADS, which warrants are expected to remain
                          outstanding at the consummation of this offering; and</div>
                      </td>
                    </tr>

                </table>
                <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb99bb1b69efa4a07a7929e936288c590">

                    <tr>
                      <td style="width: 0.57%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                      </td>
                      <td style="width: 3.02%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
                      </td>
                      <td style="width: 96.4%; vertical-align: top;">
                        <div style="text-align: justify; line-height: 1.25;">
                          <div style="text-align: left; line-height: 1.25;">6,578,947 ADSs issuable upon exercise of the Warrants issued in this offering.</div>
                        </div>
                      </td>
                    </tr>

                </table>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;
                  <div style="text-indent: 36pt; line-height: 1.25;">Except as otherwise indicated, all information in this prospectus assumes no exercise of the underwriter&#8217;s option to purchase additional ADSs or Warrants to cover over-allotments and no
                    exercise of outstanding options and warrants described above and no exercise of the Warrants issued in this offering.</div>
                </div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
                </div>
              </div>
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="RISKFACTORS"><!--Anchor--></a>RISK FACTORS</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br>
            </div>
            <div style="line-height: 1.25">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Investing in our Securities involve a high degree of risk. You should carefully consider the following risk factors, in addition to the
                  risk factors included in our Annual Report on Form 10-K for the year ended December 31, 20<font style="font-style: italic;">22 </font>filed on March 20, 2023<font style="font-style: italic;"> an</font>d in subsequent Quarterly Reports on
                  Form 10-Q, as well as all of the other information contained in this prospectus</font>&#160;<font style="font-style: italic;">and the information incorporated by reference in this prospectus, before deciding to invest in our Securities. Our
                  business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of the ADSs could decline and you could lose all or part of your
                  investment. Our actual results could differ materially and adversely from those anticipated in any forward-looking statements in this prospectus as a result of certain factors, including those set forth below. See &#8220;Forward-Looking
                  Statements.&#8221;</font></div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Related to This Offering</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">You may experience future dilution as a result of future equity offerings.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In order to raise additional capital, we expect to offer in the future additional ADSs or other securities convertible into or exchangeable for the ADSs. We cannot assure
              you that we will be able to sell ADSs or other securities in any other offering at a price per share that is equal to or greater than the price per ADS paid by investors in this offering, and investors purchasing shares or other securities in
              the future could have rights superior to existing shareholders. The price per ADS at which we sell additional ADSs or other securities convertible into or exchangeable for the ADSs in future transactions may be higher or lower than the price
              per ADS in this offering.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25">
              <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The exercise of our pre-funded warrants or common warrants could cause our stock price to fall.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Sales of a substantial number of shares of our common stock in the public market, the perception that these sales might occur or the exercise of pre-funded warrants or
                common warrants could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing
                market price of our common stock. In addition, the sale of substantial amounts of our common stock could adversely impact its trading price.&#160;</div>
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25">&#160;</div>
                <div style="line-height: 1.25; font-style: italic; font-weight: bold;">There is no public market for the pre-funded warrants or common warrants being offered in this offering.</div>
              </div>
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-indent: 36pt; line-height: 1.25;">There is no established public trading market for the pre-funded warrants or common warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not
                  intend to apply to list the pre-funded warrants or common warrants on any national securities exchange or other nationally recognized trading system, including Nasdaq. Without an active market, the liquidity of the pre-funded warrants or
                  common warrants will be limited.</div>
              </div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
            <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We have broad discretion to determine how to use the funds raised in this offering, and may use them in ways that may not enhance our operating results
              or the price of the ADSs.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our management will have broad discretion over the use of proceeds from this offering, and we could spend the proceeds from this offering in ways the ADS holders may not
              agree with or that do not yield a favorable return, if at all. We intend to use the net proceeds from this offering for continued clinical development of our product candidates,&#160;research activities, and for other general corporate purposes.
              However, our use of these proceeds may differ substantially from our current plans. If we do not invest or apply the proceeds of this offering in ways that improve our operating results, we may fail to achieve expected financial results,
              which could cause the ADS price to decline.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The trading price of the ADSs has been highly volatile, and purchasers of the ADSs could incur substantial losses.</div>
            <div style="line-height: 1.25">&#160;
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The trading price of the ADSs has been highly volatile, particularly over the last year. For example, on January 11, 2022, the closing price of the ADSs was $6.98 per ADS
                and on March 13, 2023, it was $1.44 per ADS. This volatility may affect the price at which you are able to sell ADSs, and the sale of the ADSs in this offering could adversely affect the price of the ADSs. Our ADS price is likely to
                continue to be volatile and subject to significant price and volume fluctuations in response to market and economic factors that are beyond our control. As a result, you may not be able to sell the ADSs at or above the price at which you
                purchase them. In addition, while the stock market in general has experienced high volatility, biotechnology companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
                to operating performance. Broad market and industry factors may negatively affect the market price of the ADSs, regardless of our actual operating performance.</div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We have not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the
            value of the ADSs.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have never paid dividends and do not anticipate paying dividends in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements,
            financial condition, prospects and other factors our board of directors may deem relevant. If we do not pay dividends, the ADSs may be less valuable because a return on your investment will only occur if our ADS price appreciates and you sell
            your ADS thereafter. In addition, the Companies Law imposes restrictions on our ability to declare and pay dividends. See &#8220;Description of Share Capital &#8212; Dividend and Liquidation Rights&#8221; for additional information. The payment of dividends may
            be subject to Israeli withholding taxes. See &#8220;Material Tax Considerations &#8212;Israeli Taxation&#8221; for additional information.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If we fail to continue to meet all applicable Nasdaq requirements, Nasdaq may delist the ADSs, which could have an adverse impact on the liquidity and
              market price of the ADSs.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The ADSs are currently listed on Nasdaq, which has qualitative and quantitative listing criteria. If we are unable to meet any of the Nasdaq listing requirements in the
              future, including, for example, if the closing bid price for the ADSs falls below $1.00 per share for 30 consecutive trading days, Nasdaq could determine to delist the ADSs, which could adversely affect the market liquidity of the ADSs and
              the market price of the ADSs could decrease. Such delisting could also adversely affect our ability to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, customers and employees.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Holders of ADSs are not treated as holders of our ordinary shares.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Holders of ADSs are not treated as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement
              and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to
              the deposit agreement.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">You may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise your
            right to vote.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Except as described in the deposit agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by the ADSs. If we
            request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the
            matters to be voted on and explain how ADS holders may instruct the depositary how to vote. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary
            shares underlying their ADSs. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Israel and the provisions of our articles of
            association or similar documents, to vote or to have its agents vote the ordinary shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send
            voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Otherwise, ADS holders will not be able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, ADS holders may not
            know about the meeting far enough in advance to withdraw those ordinary shares. In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed. In addition,
            the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote and there may be nothing
            you can do if your ordinary shares are not voted as you requested.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">ADSs are transferable on the books of the depositary. However, the depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the
              depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so. These limitations on transfer may have a material adverse effect on the value of the ADSs.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit
            agreement, without the prior consent of the ADS holders.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are entitled to amend the deposit agreement and to change the rights of the ADS holders under the terms of such agreement without the prior consent of the ADS holders.
              We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us or to the depositary. Amendments may reflect, among other things, operational changes in the ADS program, legal
              developments affecting ADSs or changes in the terms of our business relationship with the depositary. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for
              registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the
              amendment. At the time an amendment becomes effective, you are considered, by continuing to hold the ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended. If we make an amendment to the deposit
              agreement that is disadvantageous to ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their ADSs and become direct holders of the underlying ordinary shares, but they will have no
              right to any compensation whatsoever.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes
            to the plaintiff(s) in any such action.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs
            irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to the ADSs or the deposit agreement.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the
            depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. We believe that
            a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which governs the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial
            waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If any holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including
            claims under federal securities laws, such holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is
            brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes
            than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of
            the hearing.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance
            with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We presently anticipate that we will be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax
            consequences to U.S. Holders of our ordinary shares.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We would be classified as a passive foreign investment company, or PFIC, for any taxable year if, after the application of certain look-through rules, either: (i) 75% or more
            of our gross income for such year is &#8220;passive income&#8221; (as defined in the relevant provisions of the Internal Revenue Code of 1986, as amended, or the Code), or (ii) 50% or more of the value of our assets (generally determined on the basis of a
            quarterly average) during such year is attributable to assets that produce or are held for the production of passive income. Passive income generally includes, among other things, rents, dividends, interest, royalties, gains from the
            disposition of passive assets, and gains from commodities and securities transactions. For purposes of this test, we will be treated as owning a proportionate share of the assets and earning a proportionate share of the income of any other
            corporation of which we own, directly or indirectly, at least 25% (by value) of the stock. Based on the nature, composition and value of our income, operations and assets currently and in the future, we presently anticipate that we will be a
            PFIC for United States federal income tax purposes for the current taxable year and in the foreseeable future. See &#8220;<font style="font-style: italic;">Certain Material U.S. Federal Income Tax Consequences &#8212; Passive Foreign Investment Company
              Consequences</font>.&#8221;</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25; font-style: italic; font-weight: bold;">The Warrants are speculative in nature.</div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25">&#160;
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Except as otherwise set forth therein, the Warrants offered in this offering do not confer any rights of ADS ownership on their holders, such as voting rights, but
                  rather merely represent the right to acquire ADSs at a fixed price. Specifically with respect to the Warrants, commencing on the date of issuance, holders of the Warrants may exercise their right to acquire ADSs and pay an assumed
                  exercise price of $1.52 per ADS, which is the assumed offering price of the ADSs in this offering, prior to five years from the date of issuance, after which date any unexercised Warrants will expire and have no further value. There can
                  be no assurance that the market price of the ADSs will continue to equal or exceed the exercise price of the Warrants offered by this prospectus. In the event that our ADS price does not exceed the exercise price of such Warrants during
                  the period when such Warrants are exercisable, the Warrants may not have any value.</div>
                <div style="line-height: 1.25">&#160;</div>
              </div>
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25; font-style: italic; font-weight: bold;">There is no established market for the Warrants being offered in this offering.</div>
            <div style="line-height: 1.25;">&#160;</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There is no established trading market for the Warrants offered in this offering. We do not intend to apply for listing of the Warrants on any securities exchange or other
              nationally recognized trading system. Without an active market, the liquidity of the Warrants will be limited.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">10</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <!--PROfilePageNumberReset%Num%11%%%-->
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Holders of the Warrants will have no rights as a shareholder until they acquire our ordinary shares.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-indent: 36pt; line-height: 1.25;">Until you acquire the ordinary shares underlying the Warrant ADSs, you will have no rights with respect to the ordinary shares underlying the Warrant ADSs underlying the Warrants. Upon exercise
              of your Warrants and subsequent delivery of the ordinary shares by the Company&#8217;s depositary, you will be entitled to exercise the rights of an ordinary shareholder only as to matters for which the record date occurs after the exercise date.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25; font-style: italic; font-weight: bold;">The Warrants offered by this prospectus may not have any value.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <div style="text-indent: 36pt; line-height: 1.25;">The Warrants offered by this prospectus will be exercisable for five years from the date of issuance. There can be no assurance that the market price of the ADSs will ever exceed the exercise
                price of the Warrants. In the event that our ADS price does not exceed the exercise price of the Warrants during the term of the Warrants, the Warrants may not have any value.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="line-height: 1.25; font-style: italic; font-weight: bold;">As our Warrant holders exercise their Warrants into Warrant ADSs and underlying ordinary shares, our shareholders&#8217; ownership will be diluted.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">The exercise of some or all of our Warrants will result in the issuance of ADSs and ordinary shares that dilute the ownership interests of existing shareholders. Any sales of ADSs or ordinary
                shares underlying the Warrants could adversely affect prevailing market prices of the ADSs and ordinary shares.</div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">11</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%12%%%-->
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="FORWARD-LOOKINGSTATEMENTS"><!--Anchor--></a>FORWARD-LOOKING STATEMENTS</div>
          <div style="text-align: center; line-height: 1.25;">&#160;<font style="font-weight: bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</font></div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus and the information incorporated by reference in this prospectus contain forward-looking statements within the meaning of Section 27A of the Securities Act,
            and Section 21E of the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) that involve substantial risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only
            be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in
            the forward-looking statements. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in
            this prospectus.&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All statements other than present and historical facts and conditions contained in this prospectus, and the information incorporated by reference in this prospectus,
            including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue&#8221; &#8220;could,&#8221;
            &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;ongoing,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and &#8220;would,&#8221; or the negative of these and similar expressions identify forward-looking statements.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We cannot assure you that the forward-looking statements in this prospectus and the information incorporated by reference in this prospectus will prove to be accurate.
            Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or
            warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future
            events or otherwise, except as required by law.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You should read this prospectus and the information incorporated by reference in this prospectus completely and with the understanding that our actual future results may be
            materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus and the information incorporated by reference in this prospectus may contain market data and industry forecasts that were obtained from industry publications.
            These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information included in this prospectus and
            the information incorporated by reference in this prospectus is generally reliable, we have not independently verified any third-party information and cannot guarantee its accuracy and completeness.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">12</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">MARKET, INDUSTRY AND OTHER <a name="DATA"><!--Anchor--></a>DATA</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus contains estimates, projections and other information concerning our industry and our business. We obtained the industry, market and similar data set forth
              in this prospectus from our internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties. We do not expressly refer to the sources from which this information is
              derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances
              that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been
              verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates. The sources listed below are not a part of this prospectus and are not incorporated by reference in this prospectus.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 14.4pt; line-height: 1.25;">The sources and citations of industry, market and other data, as well as published studies, contained in this prospectus are listed below:</div>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zfaea339cbc204c4fb9ae070f8a5ae11e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">1.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Ablin, J. N., M. Entin-Meer, V. Aloush, S. Oren, O. Elkayam, J. George, and I. Barshack. 2010. 'Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritis', Clin Exp Immunol, 161: 276-83.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zd52b216972fc4f8a81e360dd6c2beaba" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">2.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Bhattacharyya, S., J. Wei, and J. Varga. 2011. 'Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities', Nat Rev Rheumatol, 8: 42-54.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z9eac5fefd1b042a7b1aee0b10a15a26e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">3.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Bocchino, V., G. Bertorelli, C. P. Bertrand, P. D. Ponath, W. Newman, C. Franco, A. Marruchella, S. Merlini, M. Del Donno, X. Zhuo, and D. Olivieri. 2002. 'Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis',
                      Allergy, 57: 17-22.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z27f1ffeca4f24486a5946e65389f82f9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">4.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Henderson, N. C., F. Rieder, and T. A. Wynn. 2020. 'Fibrosis: from mechanisms to medicines', Nature, 587: 555-66.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z5e29d05e3c9e435f982e348baa6027b7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">5.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Jimenez, S. A., E. Hitraya, and J. Varga. 1996. 'Pathogenesis of scleroderma. Collagen', Rheum Dis Clin North Am, 22: 647-74.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z16b41944ab684f0f984b5f9437079ed0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">6.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Jose, P. J., D. A. Griffiths-Johnson, P. D. Collins, D. T. Walsh, R. Moqbel, N. F. Totty, O. Truong, J. J. Hsuan, and T. J. Williams. 1994. 'Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of
                      allergic airways inflammation', J Exp Med, 179: 881-7.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zd42361138aab4364839e0e33e96e5e0c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">7.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Karlsen, T. H., T. Folseraas, D. Thorburn, and M. Vesterhus. 2017. 'Primary sclerosing cholangitis - a comprehensive review', J Hepatol, 67: 1298-323.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zf423b5b1ba7949ebafd7c400e305de12" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">8.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Kitaura, M., T. Nakajima, T. Imai, S. Harada, C. Combadiere, H. L. Tiffany, P. M. Murphy, and O. Yoshie. 1996. 'Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil
                      eotaxin receptor, CC chemokine receptor 3', J Biol Chem, 271: 7725-30.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zf23c9baf67a54eb0b282c1655c8f0197" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">9.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Kohan, M., I. Puxeddu, R. Reich, F. Levi-Schaffer, and N. Berkman. 2010. 'Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblasts', Ann Allergy Asthma Immunol, 104: 66-72.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z44ea1ebb788941d29d6a2933a9fd3361" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">10.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Mor, A. , Afek, A. , Entin-Meer, M. , Keren, G. and George, J. 2013. 'Anti eotaxin-2 antibodies attenuate the initiation and progression of experimental atherosclerosis.', World Journal of Cardiovascular Diseases, 3: 339-46.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zf486c48d6a714864a487cbcbe6d2a018" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">11.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Mor, A., M. Segal Salto, A. Katav, N. Barashi, V. Edelshtein, M. Manetti, Y. Levi, J. George, and M. Matucci-Cerinic. 2019. 'Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis', Ann
                      Rheum Dis, 78: 1260-68.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z350f85a25331486eac937f45ed9243e5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">12.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Ponath, P. D., S. Qin, D. J. Ringler, I. Clark-Lewis, J. Wang, N. Kassam, H. Smith, X. Shi, J. A. Gonzalo, W. Newman, J. C. Gutierrez-Ramos, and C. R. Mackay. 1996. 'Cloning of the human eosinophil chemoattractant, eotaxin.
                      Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils', J Clin Invest, 97: 604-12.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zb3cdef72d15c4814b549ddacfbe37a0f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">13.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Segal-Salto, M., N. Barashi, A. Katav, V. Edelshtein, A. Aharon, S. Hashmueli, J. George, Y. Maor, M. Pinzani, D. Haberman, A. Hall, S. Friedman, and A. Mor. 2020. 'A blocking monoclonal antibody to CCL24 alleviates liver fibrosis
                      and inflammation in experimental models of liver damage', JHEP Rep, 2: 100064.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zc4ffeb70fe344dbdb835e0b3978f01ee" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">14.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Wynn, T. A. 2008. 'Cellular and molecular mechanisms of fibrosis', J Pathol, 214: 199-210.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">13</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="USEOFPROCEEDS"><!--Anchor--></a>USE OF PROCEEDS</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; We estimate that the net proceeds from this offering will be approximately $8.8 million, assuming a public offering price of $1.52 per ADS and accompanying Warrant, which was the last reported sale
              price per share of the ADSs on Nasdaq on March 16, 2023, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We currently expect to use the net proceeds from this offering for continued clinical development of our product candidates,&#160;research activities, and for other general
            corporate purposes. We have not determined the amount of net proceeds to be used specifically for the foregoing purposes. This expected use of the net proceeds from this offering represents our intentions based upon our current plans and
            business conditions. Amounts and timing of our actual expenditures will depend upon a number of factors, including our sales, marketing and commercialization efforts, regulatory approval and demand for our product candidates, operating costs,
            among other factors. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our
            decisions on how to use the proceeds.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pending use of the net proceeds, we intend to invest any proceeds in a variety of capital preservation instruments, including short-term deposits and interest-bearing
            instruments.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Based on our planned use of the net proceeds from this offering and our existing cash, cash equivalents and short-term bank deposits, we estimate that this financing will
            enable us to advance our clinical development programs for PSC and SSc. We are likely to need to secure additional financing to complete those programs which are projected to have topline readouts in the second half of 2024. We continue to
            manage our cash runway and believe additional capital will be available when required. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.
            In any event, we will require additional funding to complete the clinical development of, and commercialize, our future therapeutic candidates. We may satisfy our future cash needs through the sale of equity securities, debt financings, working
            capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">14</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="CAPITALIZATION"><!--Anchor--></a>CAPITALIZATION</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth our cash, cash equivalents and short-term bank deposits, and our capitalization as of December 31, 2022:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z36623668ffbb45f58556c1cd72a016ed">

              <tr>
                <td style="width: 2.01%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 1%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 1%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 96%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">on an actual basis; and</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1a9c91deebe64741b4a0cabdac73a0a5">

              <tr>
                <td style="width: 2.01%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 1%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 1%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 96%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">
                    <div style="text-align: left; line-height: 1.25;">on an as adjusted basis to give effect to the sale of 6,578,947 ADSs in this offering, at an assumed public offering price of $1.52 per ADS and accompanying Warrant, and after deducting
                      the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The pro forma as-adjusted information below is illustrative only and our capitalization following the completion of this offering is subject to various adjustments. See
            &#8220;Underwriting&#8221; below in this prospectus. You should read this table together with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this prospectus for the fiscal year ended December
            31, 2022, and our financial statements and the related notes incorporated by reference into this prospectus.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zbb6bb37bc27042a1ab1bbac3a7cf5649" class="cfttable">

                <tr>
                  <td valign="bottom" style="vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">As of December 31 , 2022</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">(in thousands)(unaudited)</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Actual</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">As Adjusted</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="6">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 4px;">
                    <div style="line-height: 1.25;">Cash and cash equivalents and short-term bank deposits</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1" class="cftcurrcell">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">39,970</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">48,743</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%;">
                    <div style="line-height: 1.25;">Shareholders&#8217; equity</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25;">Ordinary Shares, no par value - Authorized: 650,000,000 ordinary shares as of December 31, 2022</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">&#8212;</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%;">
                    <div style="line-height: 1.25;">Issued and outstanding: 232,636,700 ordinary shares issued and outstanding actual;&#160; 373,280,480 ordinary shares issued and outstanding as adjusted</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25;">Additional paid-in capital</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">101,260</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">110,033</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%;">
                    <div style="line-height: 1.25;">Treasury stock at cost</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">(1,218</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">(1,218</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">Accumulated deficit</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">(63,819</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">(63,819</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">Total shareholders&#8217; equity</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">36,223</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">44,996</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25;"><font style="font-weight: bold;">Total liabilities and shareholders&#8217; equity</font>&#160;</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">43,063</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">51,836</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"> <br>
          </div>
          <div style="line-height: 1.25;"> </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The information above is based on 11,049,812 ADSs outstanding as of December 31, 2022, and does not account for the following:</div>
          </div>
          <div style="text-align: justify; line-height: 1.25;"><br>
            <table cellspacing="0" cellpadding="0" id="zfce4d53ab1a44780977186f15819daaf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#9679;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">1,747,077 ADSs issuable upon the exercise of outstanding options to purchase ADSs, at a weighted average exercise price of $6.60 per ADS;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#9679;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="line-height: 1.25;">an aggregate of 655,869 ADSs reserved for future issuance under our Share Incentive Plans, as of December 31,2022, as well as any automatic increases in the number of ADSs reserved for future issuance
                      under the 2017 Plan;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#9679;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">261,929 ADSs issuable upon the exercise of outstanding warrants to purchase ADSs at a weighted average exercise price of $17.35088 per ADS, which warrants are expected to remain
                      outstanding at the consummation of this offering; and</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#9679;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">6,578,947 ADSs issuable upon exercise of the Warrants issued in this offering.</div>
                  </td>
                </tr>

            </table>
            &#160;</div>
          <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">Except as otherwise indicated, all information in this prospectus assumes no exercise of the underwriter&#8217;s option to purchase
            additional ADSs or Warrants to cover over-allotments and no exercise of the outstanding options and warrants described above and no exercise of the Warrants issued in this offering.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">15</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DILUTION"><!--Anchor--></a>DILUTION</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">If you invest in our Securities in this offering, your ownership interest may be diluted to the extent of the difference between the public offering price per ADS and accompanying Warrant and
              the as adjusted net tangible book value per ADS after this offering. Net tangible book value per ADS is calculated by subtracting our total liabilities from our total tangible assets, which is total assets, and dividing this amount by the
              number of ADSs outstanding. Our net tangible book value as of December 31, 2022 was approximately $36.2 million, or $3.28 per ADS.</div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">After giving effect to the sale of 6,578,947 ADSs and accompanying Warrants in this offering at an assumed public offering price of $1.52 per ADS and accompanying Warrant, and after deducting
              commissions and other estimated offering expenses payable by us, our as adjusted net tangible book value as of December 31, 2022 would have been approximately $46.4 million, or $2.49 per ADS. This amount represents an immediate dilution in
              the net tangible book value of $0.61 per ADS to our existing shareholders and an immediate increase in net tangible book value of $0.97 per ADS to new investors purchasing ADSs in this offering. The following table illustrates this per ADS
              dilution:</div>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z76359bc2c66b4e86b071dcad405651f6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 75.99%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">Assumed offering price per ADS and accompanying Warrant</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 10%; vertical-align: bottom; background-color: #CCEEFF;" colspan="2">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: right; line-height: 1.25;">1.52</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 75.99%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">Net tangible book value per ADS as of December 31, 2022</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom;">
                    <div style="text-align: right; line-height: 1.25;">3.28</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom;">
                    <div style="text-align: right; line-height: 1.25;">&#160;</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 75.99%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">Net dilution&#160; in net tangible book value per ADS attributable to existing shareholders</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: right; line-height: 1.25;">(0.73</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: right; line-height: 1.25;">&#160;</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 75.99%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">As adjusted net tangible book value per ADS after this offering</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom;">
                    <div style="text-align: right; line-height: 1.25;">&#160;</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom;">
                    <div style="text-align: right; line-height: 1.25;">2.55</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 75.99%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">Net increase in net tangible book value per ADS to new investors in this offering</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: right; line-height: 1.25;">&#160;</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: right; line-height: 1.25;">1.03</div>
                  </td>
                  <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">The table above assumes for illustrative purposes that an aggregate of&#160;6,578,947 ADSs are sold at a price of $1.52 per ADS and accompanying Warrant and for aggregate gross proceeds of
              approximately $10.0 million.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: left; text-indent: 36pt; line-height: 1.25;">The information above is based on 11,049,812 ADSs outstanding as of&#160;December 31, 2022, and does not account for the following:</div>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z2e880b1236894c7b85a9efc28582e41c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#9679;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">1,747,077 ADSs issuable upon the exercise of outstanding options to purchase ADSs, at a weighted average exercise price of $6.60 per ADS;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#9679;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="line-height: 1.25;">an aggregate of 655,869 ADSs reserved for future issuance under our Share Incentive Plans, as of &#160;December 31,2022, as well as any automatic increases in the number of ADSs reserved for future issuance
                      under the 2017 Plan;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#9679;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">261,929 ADSs issuable upon the exercise of outstanding warrants to purchase ADSs at a weighted average exercise price of $17.35088 per ADS, which warrants are expected to remain
                      outstanding at the consummation of this offering; and</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 0.56%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 3.02%; vertical-align: top;">
                    <div style="text-align: center; line-height: 1.25;">&#9679;</div>
                  </td>
                  <td style="width: 96.42%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">6,578,947 ADSs issuable upon exercise of the Warrants issued in this offering.</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="text-align: justify; line-height: 1.25;"> <br>
          </div>
          <div style="text-align: justify; line-height: 1.25;"> </div>
          <div style="line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">To the extent that additional ADSs are issued pursuant to the foregoing, investors purchasing&#160; ADSs in this offering will experience further dilution. In addition, we may offer other securities
              in other offerings due to market conditions or strategic considerations. To the extent we issue such securities, you may experience further dilution.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">16</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DIVIDENDPOLICY"><!--Anchor--></a>DIVIDEND POLICY</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have never declared nor paid any cash dividends on the ADSs or our ordinary shares. We currently intend to retain any future earnings and do not expect to pay any
              dividends in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our Board of Directors, subject to applicable laws, and will depend on a number of factors, including our financial
              condition, results of operations, capital requirements, contractual restrictions, general business conditions, and other factors that our Board of Directors may deem relevant. In addition, the Companies Law imposes restrictions on our ability
              to declare and pay dividends. See &#8220;Description of Share Capital &#8212; Dividend and Liquidation Rights&#8221; for additional information. The payment of dividends may be subject to Israeli withholding taxes. See &#8220;Material Tax Considerations &#8212;Israeli
              Taxation&#8221; for additional information.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">17</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="Management"><!--Anchor--></a>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-style: italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial
              statements. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and
              uncertainties. You should read &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; and Item 1A &#8220;Risk Factors&#8221; of our Annual Report on Form&#160;10-K filed on March 20, 2023 for a discussion of important factors that could cause actual
              results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Overview</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25;">We are a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet
              needs. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, we developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. We believe CM-101 has demonstrated the
              potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; line-height: 1.25;">
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 35.25pt; line-height: 1.25;">We have pioneered the therapeutic targeting of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and fibrotic activities through the CCR3
                receptor. The chemokine is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory
                activity that modulates the complex interplay of both of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and clinical fibrotic diseases. This innovative approach is being developed for difficult to treat
                rare diseases, also known as orphan indications or diseases, such as primary sclerosing cholangitis (&#8220;PSC&#8221;) and systemic sclerosis (&#8220;SSc&#8221;) for which patients have no established disease-modifying treatment options. We estimate that there
                are approximately 77 thousand patients suffering from PSC in the U.S., EU and Japan, representing over a $1 billion market opportunity, and approximately 170 thousand patients suffering from SSc in those same markets, representing over a
                $1.5 billion market opportunity.</div>
              <div style="text-indent: 35.25pt; line-height: 1.25;"> <br>
              </div>
              <div style="text-indent: 35.25pt; line-height: 1.25;">
                <div style="text-indent: 35.25pt; line-height: 1.25;">CM-101, our lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of the soluble chemokine CCL24, also known as eotaxin-2,
                  as a regulator of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of action. Based on these
                  findings, we are actively advancing CM-101 in Phase 2 clinical studies directed toward two distinct clinical indications that include patients with liver or skin, and/or lung fibrosis. We are currently conducting a Phase 2 clinical study
                  in PSC, a rare obstructive and cholestatic liver disease. The study is actively recruiting patients in the U.S., Europe and Israel and is being expanded by adding clinical sites, an additional high dose arm (20mg/kg) as well as an open
                  label extension. We had earlier proposed to add both low and high dose arms to the study but the recent encouraging results reported from our Phase 2 liver fibrosis trial in NASH patients, dosed at 5mg/kg, along with the positive Phase 1b
                  data we previously reported in non-alcoholic fibrotic liver disease (&#8220;NAFLD&#8221;) patients dosed at 5mg/kg and 2.5mg/kg, are seen as providing us sufficient data on the performance of the lower dose to drop it from the current trial, which is
                  focusing on the 10mg/kg and 20g/kg doses. We believe this change will facilitate timely conduct and completion of the trial. If regulators in the future do not agree that the existing low dose data is sufficient, we always have the option
                  to add a lower dose group as part of the Phase 3 clinical program.</div>
                <div style="line-height: 1.25">&#160;</div>
                <div style="line-height: 1.25">
                  <div style="text-indent: 35.25pt; line-height: 1.25;">We are also planning to open a Phase 2 clinical trial in SSc<font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;"> around midyear o</font>f 2023. The trial in SSc, a rare autoimmune rheumatic disease characterized by fibrosis in the skin and lung and other
                    organs, will focus on establishing biological and clinical proof of concept in this patient population. Although our primary focus is on these two rare indications, as we noted, an additional Phase 2 clinical study in patients with
                    liver fibrosis due to non-alcoholic steatohepatitis (&#8220;NASH&#8221;) has recently been completed.&#160; This trial provided safety and pharmacokinetic (&#8220;PK&#8221;) data and was informative in determining whether we will advance the development of our
                    current subcutaneous formulation of CM-101. Additionally, the trial measured a number of biomarkers that may be relevant to the potential activity of CM-101 in other fibro-inflammatory conditions. We recently reported results from this
                    trial, which showed that the trial met its primary endpoint of safety and tolerability, and that CM-101 demonstrated encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic
                    assessments.</div>
                  &#160;</div>
              </div>
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Components of Operating Results</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Revenues</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales in the near future. If development efforts for our
            product candidates are successful and result in our receipt of necessary regulatory approvals, or if our development efforts otherwise lead to any commercialized products or additional license agreements with third parties, then we may generate
            revenue in the future from product sales.</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">18</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Research and Development Expenses, net</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. These expenses include:</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zd7cb0eb4f1c241deb3a1665632479538" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>expenses incurred under agreements with clinical research organizations and contract manufacturing organizations, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other
                    scientific development services;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z6c5d5ce660684c35977dccb022799182" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z98e5fbb77236415a9ef481af367fc9d8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>employee-related expenses, including salaries, related benefits, travel and share-based compensation expenses for employees engaged in research and development functions, as well as external costs, such as fees paid to outside
                    consultants engaged in such activities;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z3b1327732f784322a8c6424daade21f0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>license maintenance fees and milestone fees incurred in connection with various license agreements;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z91c598977c2e4d17bb2610957694c6f5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>costs related to compliance with regulatory requirements; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z54d35686cc4449afaf8d0c2915d86458" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>depreciation and other expenses.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these resources are deployed across
            multiple programs and, as such, the related costs are not separately classified. We use internal resources primarily to oversee our research, as well as for managing our preclinical development, process development, manufacturing and clinical
            development activities. Our employees work across multiple programs; therefore, we do not track the related expenses by program.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Research and development activities are fundamental to our business. Product candidates in later stages of clinical development generally have higher development costs than
            those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next
            several years as we continue to advance the development of our product candidates. We also expect to incur additional expenses related to milestone and royalty payments payable to third parties with whom we have entered into license agreements.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">General and Administrative Expenses</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">General and administrative expenses consist primarily of salaries and related benefits, share-based compensation expenses for personnel in executive and administrative
            functions, insurance and professional fees for legal, consulting, accounting and audit services.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">We anticipate that our general and administrative expenses will increase in the future due to increased headcount and professional fees to support our continued research
            activities and development of our product candidates. We also anticipate that we will continue to incur accounting, audit, legal, regulatory, compliance, director and officer insurance costs, as well as investor and public relations expenses
            associated with being a public company. Additionally, once we believe that regulatory approval of a product candidate appears likely, we will begin to incur a material increase in payroll and related expenses as a result of preparation for
            commercial operations, particularly in respect of sales and marketing.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Financing Expenses, Net</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Financing expenses, net consist primarily of income or expenses related to revaluation of foreign currencies and interest income on our bank deposits.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Results of Operations</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">The following table summarizes our results of operations for the years ended December 31, 2022 and 2021:</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zd92efa2b64dc4dc9b4b3d7b225aac638" class="cfttable">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Year ended December 31,</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> 2022</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2021</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">Operating Expenses:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="6">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">(in thousands</font>)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-align: justify; text-indent: -8.65pt; margin-left: 17.3pt; line-height: 1.25;">Research and development&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">16,977</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">6,334</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; text-indent: -8.65pt; margin-left: 17.3pt; line-height: 1.25;">General and administrative&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">11,556</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">6,033</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-align: justify; text-indent: -8.65pt; margin-left: 25.9pt; line-height: 1.25;">Total operating expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">28,533</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">12,367</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-align: justify; line-height: 1.25;">Financing (income) expense, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(353</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">111</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Loss before taxes</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">28,180</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">12,478</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-align: justify; line-height: 1.25;">Taxes on income (benefit)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(534</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-align: justify; line-height: 1.25;">Net loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">27,646</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">12,478</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Our results of operations have varied in the past and can be expected to vary in the future due to numerous factors. We believe that period-to-period comparisons of our
            operating results are not necessarily meaningful and should not be relied upon as indications of future performance.</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">19</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <br>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Year ended December&#160;31, 2022 Compared to the Year Ended December&#160;31, 2021</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Research and development expenses</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Research and development expenses increased by approximately $10.7 million, or 168%, to approximately $17.0 million for the year ended December&#160;31, 2022 compared to
            approximately $6.3 million for the year ended December&#160;31, 2021. The increase resulted primarily from an increase in headcount and payments to consultants and subcontractors for clinical and pre-clinical activities.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">General and administrative expenses</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">General and administrative expenses increased by approximately $5.6 million, or 92%, to approximately $11.6 million for the year ended December&#160;31, 2022 compared to
            approximately $6.0 million for the year ended December&#160;31, 2021. This increase was primarily due to increase in headcount and professional fees and insurance expense and share-based compensation.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-style: italic;">Financing (income) expense, net</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Financing expenses, net, increased by approximately $464 thousand, or 418%, to net income of $353 thousand for the year ended December&#160;31, 2022 compared to a net loss of $111
            thousand for the year ended December&#160;31, 2021. Financing expense, net for the year ended December&#160;31, 2022 was primarily related to foreign currency exchange rate differences, offset by interest income on deposits. Financing income, net for
            2021 was primarily related to interest income on deposits, offset by foreign currency exchange rate differences.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-style: italic;">Taxes on Income</div>
          <div style="line-height: 1.25">
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Taxes on income, net, for the year ended December 31, 2022 were $534 thousand. The tax benefit is related&#160;to a tax return of Chemomab Therapeutics Inc., a wholly owned
              subsidiary of the Company, derived by carryback of net operating losses. Chemomab Therapeutics Inc. received $351 thousand in December 2022 on account of previous years and expects to receive the remainder $183 thousand in 2023.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Cash Flows</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">The following table summarizes our cash flows for the years ended December 31, 2022 and 2021:</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z9b42424c2abb4c4cab356a55f0d53768" class="cfttable">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Year ended<br>
                    December 31,</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Increase/(decrease)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> 2022</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2021</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="2">$ <br>
                </td>
                <td valign="bottom" nowrap="nowrap" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2" class="cftcurrcell" rowspan="1">
                  <div>
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">%</div>
                    </div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                  <div style="text-align: center; line-height: 1.25; font-style: italic;">(in thousands)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right;" colspan="1" class="cftnumcell">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">Net cash used in operating activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(20,370</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(12,374</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(7,996</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">65</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">%</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div style="text-align: justify; line-height: 1.25;">Net cash provided by (used in) investing activities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">19,533</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(45,186</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">64,719</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(143</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)%</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">Net cash provided by (used in) financing activities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(808</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">61,074</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(61,882</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25;">(101</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25;">)%</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Net increase (decrease) in cash, cash equivalents and restricted cash</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25; font-weight: bold;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25; font-weight: bold;">(1,645</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25; font-weight: bold;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25; font-weight: bold;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25; font-weight: bold;">3,514</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
                  <div style="line-height: 1.25; font-weight: bold;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25; font-weight: bold;">(5,159</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25; font-weight: bold;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                  <div style="line-height: 1.25; font-weight: bold;">(147</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
                  <div style="line-height: 1.25; font-weight: bold;">)%</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Operating activities</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Net cash used in operating activities for the year ended December 31, 2022 was approximately $20.4 million and included net loss of $27.6 million, partially offset by net
            cash used by changes in operating assets and liabilities of approximately $4.0 million and non-cash charges of $3.3 million, which mainly included share-based compensation expenses.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25;">Net cash used in operating activities for the years ended December 31, 2021 was approximately $12.4 million and included net loss of $12.5 million, partially offset by net cash provided by
              changes in operating assets and liabilities of $1.9 million and non-cash charges of $2.0 million, which mainly included share-based compensation expenses.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">20</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Investing activities</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Net cash provided by investing activities for the year ended December 31, 2022 was approximately $19.5 million, which was primarily related to investment in short-term
            deposits offset by purchasing of fixed assets.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25;">Net cash used in investing activities for the year ended December 31, 2021 was $45.2 million, which was primarily related to purchase of fixed assets and investment in bank deposits.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Financing activities</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25;">Net cash used in financing activities for the year ended December 31, 2022 was approximately $0.8 million, consisting of $0.3 million of proceeds from the sale of ADSs, $0.1 million of proceeds
              from the exercise of stock options offset by the repurchase of shares in the amount of $1.2 million.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25;">Net cash provided by financing activities for the year ended December 31, 2021 was $61.1 million, consisting of $58.7 million of proceeds from the sale of ADSs, primarily from the Private
              Placement (as defined and described below) and issuances under the Sales Agreement with Cantor, and $2.4 million of cash acquired in the Merger.</div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Funding Requirements</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">We expect our expenses to increase substantially as we advance the clinical trials of our product candidate. In addition, we expect to continue to incur additional costs
            associated with operating as a public company.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">We believe that our existing cash, cash equivalents and bank deposits will enable us to fund our operating expenses and capital expenditure requirements at least through
            March 31, 2024. We have based these estimates on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. If we receive regulatory approval for any of our product candidates, we expect to incur
            significant commercialization expenses related to product manufacturing, sales, marketing and distribution.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25;">Until such time, if ever, that we generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through the sales of our securities and through other outside
              funding sources. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital
              expenditures or declaring dividends. If we raise additional funds through government and other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, then we may
              have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or
              debt financings when needed, then we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise
              prefer to develop and market.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Liquidity and Capital Resources</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25">
            <div style="line-height: 1.25">
              <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">In connection with the Merger, on March 15, 2021, we entered into Securities Purchase Agreements with certain investors, pursuant to which we agreed to sell approximately
                $45.5 million of the ADSs in a private placement transaction (the &#8220;Private Placement&#8221;). The Private Placement closed on March 22, 2021, at which time we sold 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an
                exercise price of $17.35 per ADS. The warrants expire five years from the date of issuance, and, if exercised in full, will provide proceeds of approximately $4.5 million.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">On April 30, 2021, we entered into the Sales Agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;). Pursuant to the Sales Agreement, we may offer and sell, from time to
                time,&#160; ADSs having an aggregate offering price of up to $75 million through Cantor (the &#8220;ATM Facility&#8221;). Sales of&#160; ADSs, if any, under the Sales Agreement will be issued and sold pursuant to our Registration Statement on Form S-3 which was
                declared effective on May 17, 2021 and will be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act.&#160; Pursuant to the Sales Agreement, Cantor has agreed to act as sales
                agent on a best efforts basis and use commercially reasonable efforts to sell on our behalf all of the ADSs we requested to be sold in accordance with the Sales Agreement, consistent with Cantor&#8217;s normal trading and sales practices, on
                mutually agreed terms.</div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">On April 25, 2022, we filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000 of ADSs in connection with the reactivation of the ATM
              Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities we are able to offer and sell under such registration statement during any twelve month period to one-third
              of our unaffiliated public float.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">During the year ended December 31, 2022, we sold 130,505 ADSs at an average price of USD 2.11 per ADS, through the ATM facility, resulting in gross proceeds of $275,000.</div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25; font-family: 'Times New Roman', serif;">As shown in the accompanying consolidated financial statements, we have incurred losses and cash flow deficits from operations since inception, resulting
              in an accumulated deficit at December&#160;31, 2022 of approximately $64 million. We have financed operations to date primarily through public and private placements of equity securities. We anticipate that we will continue to incur net losses for
              the foreseeable future. We believe that our existing cash, cash equivalents and bank deposits will be sufficient to fund our projected cash needs only through March 31, 2024.&#160;To meet future capital needs we would need to raise additional
              capital through equity or debt financing or other strategic transactions.&#160;However, any such financing may not be available to us on favorable terms or at all.&#160;Our failure to obtain sufficient funds on commercially acceptable terms when needed
              would have a material adverse effect on our business, results of operations and financial condition.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">21</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Current Outlook</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">We estimate that our current cash resources will allow us to execute our business plans at least through March 31, 2024.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Developing drugs, conducting preclinical and clinical trials, obtaining commercial manufacturing capabilities and commercializing products is expensive, and we will need to
            raise substantial additional funds to achieve our strategic objectives. We will require significant additional financing in the future to fund our operations, including if and when we progress into clinical trials of our product candidates,
            obtain regulatory approval for one or more of our product candidates, obtain commercial manufacturing capabilities and commercialize one or more of our product candidates. Our future capital requirements will depend on many factors, including,
            but not limited to:</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25">
            <table cellspacing="0" cellpadding="0" id="z0bae70403080436ba24afc84225fce69" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the progress and costs of our preclinical and clinical trials and other research and development activities;</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="z8f97cb36f15847dd8e3b1c505b8276e7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the scope, prioritization and number of our preclinical and clinical trials and other research and development programs;</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="z76ad62a0a15d4fa9b2a21d207e75e630" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the amount of revenues and contributions we receive under future licensing, collaboration, development and commercialization arrangements with respect to our product candidates;</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="zf08b6049885945b0bbeb18d920a683a3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the costs of development and expansion of our operational infrastructure;</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="zd6e3ea1bee694d638a85ca0ab7a957b8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the costs and timing of obtaining regulatory approval for one or more of our product candidates</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="z790eff89d54c4a628438a13ceeb70bad" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>our ability, or that of our collaborators, to achieve development milestones, marketing approval and other events or developments under potential future licensing agreements;</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="z59a3f1753f6946fcb778d2ad9192c32d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="z1515eaadbf0e467fbb894e129af9309a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the costs and timing of securing manufacturing arrangements for clinical or commercial production;</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="ze144d1ff3b5d4dd1904d2632c8b95c61" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves;</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="za6cf3cc19a5c4a93961ce7a85d788d32" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or technology;</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="z4e09c8a7456a47d98210761c544a4c31" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>the magnitude of our general and administrative expenses; and</div>
                  </td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" id="ze0479fcf21aa406697dd49c3b9b895ee" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.5pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>any additional costs that we may incur under future in- and out-licensing arrangements relating to one or more of our product candidates.</div>
                  </td>
                </tr>

            </table>
          </div>
          <br>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25;">Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through capital raising or by out-licensing and/or co-developing applications of one or more of
              our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development
              plans for, or commercialization efforts with respect to, one or more of our product candidates and make the necessary change to our operations to reduce the level of our expenditures in line with available resources.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">We are a development-stage company and it is not possible for us to predict with any degree of accuracy the outcome of our research and development efforts. As such, it is
            not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would
            cause financial information to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are described in this item.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Critical Accounting Estimates</div>
          <div style="line-height: 1.25">&#160;
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Our financial statements are prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). The preparation of our financial statements
              and related disclosures in accordance with GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our
              financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the
              carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or
              conditions.</div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">22</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements, we believe that the following accounting estimates
            are those that include a higher degree of judgment or complexity and are reasonably likely to have a material impact on our financial condition or results of operations and are therefore considered critical accounting estimates.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Share-Based Compensation</div>
          <div style="line-height: 1.25">&#160;
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">We apply Accounting Standard Codification (&#8220;ASC&#8221;) 718-10, &#8220;Share-Based Payment,&#8221; which requires the measurement and recognition of compensation expenses for all share-based
              payment awards made to employees and directors, including employee options under our option plans based on estimated fair values.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">ASC 718-10 requires that we estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The fair value of the award is
            recognized as an expense over the requisite service periods in our statements of comprehensive loss. We recognize share-based award forfeitures as they occur, rather than estimate by applying a forfeiture rate.</div>
          <div style="line-height: 1.25">&#160;
            <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">In June 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07, &#8220;Compensation-Stock Compensation (Topic 718):
              Improvements to Nonemployee Share-Based Payment Accounting&#8221;, which simplifies the accounting for nonemployee share-based payment transactions by aligning the measurement and classification guidance, with certain exceptions, to that for
              share-based payment awards to employees. The amendments expand the scope of the accounting standard for share-based payment awards to include share-based payment awards granted to non-employees in exchange for goods or services used or
              consumed in an entity&#8217;s own operations and supersedes the guidance related to equity-based payments to non-employees. We adopted these amendments on January 1, 2019.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">We recognize compensation expenses for the fair value of non-employee awards over the requisite service period of each award.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25;">
              <div style="text-indent: 18pt; line-height: 1.25;">We estimate the fair value of options granted as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most
                significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). We determine the fair value per share of the underlying stock by taking into
                consideration our most recent sales of stock, as well as additional factors that we deem relevant. Our board determined the fair value of ordinary shares based on valuations performed using the Option Pricing Method subject to relevant
                facts and circumstances. We have historically been a private company and lack company-specific historical and implied volatility information of our stock. Expected volatility is estimated based on volatility of similar companies in the
                biotechnology sector. Historically, we have&#160;not paid dividends and have no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected
                option term is calculated for options granted to employees and directors using the &#8220;simplified&#8221; method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value
                of the options granted and our results of operations.</div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Quantitative and Qualitative Disclosures about Market Risks</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Foreign Currency Exchange Risk</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25;">Our functional currency is the U.S. Dollar. We are exposed to foreign exchange rate risk. We are located in Israel, where part of our general and administrative expenses costs is incurred in
              New Israeli Shekels. During each of the years ended December 31, 2022 and 2021, we recognized foreign currency transaction loss of $609 thousand and $176 thousand, respectively. These foreign currency transaction gains and losses were
              recorded in financial expenses. We believe that a 10% change in the exchange rate between the U.S. Dollar and New Israeli Shekel would not have a material impact on our financial position or results of operations.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">
            <div style="text-indent: 18pt; line-height: 1.25;">As we continue to grow our business, our results of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could adversely impact our
              results of operations. To date, we have not entered into any foreign currency hedging contracts to mitigate our exposure to foreign currency exchange risk.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">23</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXECUTIVECOMPENSATION"><!--Anchor--></a>EXECUTIVE COMPENSATION</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Summary Compensation Table</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">The table and summary below outline the compensation granted to individuals who served in the role of chief executive officer during the previous fiscal year and our three most highly
              compensated executive officers with respect to the year ended December 31, 2022. For purposes of the table and the summary below, &#8220;compensation&#8221; includes base salary, bonuses, equity-based compensation, retirement or termination payments,
              benefits and perquisites such as car, phone and social benefits and any undertaking to provide such compensation.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <table cellspacing="0" cellpadding="0" class="cfttable" id="zfda7b0c3d2934420b68cd782a35e5077" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 30%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="line-height: 1.25;">Name and Principal Position</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25;">Year</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25;">Salary (1) ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25;">Bonus (2) ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25;">Option<br>
                    Awards (3) ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25;">All Other</div>
                  <div style="text-align: center; line-height: 1.25;">Compensation (4) ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25;">Total ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 30%;">
                  <div style="line-height: 1.25;">Dale Pfost</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 9%;">
                  <div style="text-align: center; line-height: 1.25;">2021</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">182,557</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">300,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">22,868</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">505,425</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 30%;">
                  <div style="line-height: 1.25;"><font style="font-style: italic;">Chief Executive Officer and Chairman</font> (5)</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; width: 9%;">
                  <div style="text-align: center; line-height: 1.25;">2022</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">600,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">300,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">1,500,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">75,160</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">2,475,160</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 9%;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 30%;">
                  <div style="line-height: 1.25;">Adi Mor</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; width: 9%;">
                  <div style="text-align: center; line-height: 1.25;">2021</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">248,547</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">167,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">8,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">64,453</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">488,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%;">
                  <div style="line-height: 1.25;"><font style="font-style: italic;">Chief Scientific Officer, Director and Previous Chief Executive Officer </font>(6)</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
                <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%; text-align: center;">
                  <div style="line-height: 1.25;">2022</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">298,470</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">120,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">16,926</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">435,396</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 30%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; width: 9%;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%;">
                  <div style="line-height: 1.25;">Donald Marvin</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 9%;">
                  <div style="text-align: center; line-height: 1.25;">2021</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">88,276</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">102,390</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">11,590</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">202,256</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 30%;">
                  <div style="line-height: 1.25;"><font style="font-style: italic;">Chief Financial Officer, Executive Vice President and Chief Operating Officer</font> (7)</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; width: 9%;">
                  <div style="text-align: center; line-height: 1.25;">2022</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">460,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">207,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">660,252</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">60,397</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">1,387,649</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 9%;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 30%;">
                  <div style="line-height: 1.25;">Sigal Fattal</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; width: 9%;">
                  <div style="text-align: center; line-height: 1.25;">2021</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">127,050</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">122,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">616,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">8,952</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">874,002</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 30%;">
                  <div style="line-height: 1.25;"><font style="font-style: italic;">Previous Interim Chief Financial Officer</font> (8)</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 9%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(1) Salary includes gross base salary.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">(2) Bonuses disclosed under row &#8220;2021&#8221; relate to bonuses accrued in 2021 and paid in 2021 and 2022. Bonuses disclosed under &#8220;2022&#8221; represent target bonuses for 2022 (the information&#160;is not
            final and based on certain estimates due to the fact that the Company has not yet determined actual bonuses for 2022).</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">(3) Represents the equity-based compensation expenses recorded in our consolidated financial statements for the years ended December 31, 2021 and 2022, based on the options&#8217; fair value on the grant date,
              calculated in accordance with applicable accounting guidance for equity-based compensation. For a discussion of the assumptions used in reaching this valuation, see Note 8C to our consolidated financial statements filed with our Annual Report
              on Form 10-K for the year ended December 31, 2022 incorporated by reference in this prospectus.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">(4) Represents payments by us of social benefits on behalf of the officer. Such benefits may include, to the extent applicable, payments, contributions and/or allocations for risk insurance
            (e.g., life, or work disability insurance), payments for social security, vacation, medical insurance and benefits, and other benefits and perquisites consistent with our policies.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(5) Dr. Dale Pfost&#8217;s terms of compensation were approved by the Company&#8217;s shareholders on October 25, 2021, which includes an annual base salary of $600,000. Dr. Pfost&#8217;s compensation data set
            forth in the above table is pro-rated to reflect time served as the Company&#8217;s chief executive officer in 2021.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(6) In addition to her current positions of Chief Scientific Officer and a member of our Board, Dr. Adi Mor previously served as our Chief Executive Officer, and resigned from such role
            concurrent with the commencement of Dr. Dale Pfost&#8217;s service as our Chief Executive Officer on October 25, 2021.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(7) Mr. Donald Marvin&#8217;s employment with the Company commenced on November 4, 2021, which include an annual base salary of $460,000. The compensation data set forth in the above table is
            pro-rated to reflect time served as the Company&#8217;s Chief Financial Officer, Executive Vice President and Chief Operating Officer in 2021.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(8)&#160; Ms. Sigal Fattal previously served as our interim Chief Financial Officer, and resigned from such role concurrent with the commencement of Mr. Marvin&#8217;s service as our Chief Financial
            Officer on November 8, 2021.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">24</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Outstanding Equity Awards at Fiscal Year-End</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">The table below outlines the options to purchase ADSs held by our named executive officers outstanding as of December 31, 2022.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" border="0" class="cfttable" id="ze22ff4c43c954e9991db22f922713830" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="12" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Option awards</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="line-height: 1.25; font-weight: bold;">Name</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of securities<br>
                    underlying<br>
                    unexercised options<br>
                    (#) exercisable</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of<br>
                    securities<br>
                    underlying<br>
                    unexercised options<br>
                    (#)<br>
                    unexercsiable</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Option<br>
                    exercise<br>
                    price ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Option expiration<br>
                    date</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Dale Pfost,&#160;<font style="font-style: italic;">Chief Executive Officer and Chairman of the Board</font></div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">133,977</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">325,376</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup>&#160;</div>
                  </div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">10.05</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">October 25, 2031</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Adi Mor,&#160;<font style="font-style: italic;">Chief Scientific Officer, Director and Previous Chief Executive Officer</font></div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">131,698</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">1.49</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">March 15, 2028</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Donald Marvin,&#160;<font style="font-style: italic;">Chief Financial Officer, Executive Vice President and Chief Operating Officer</font>&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">53,320</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">143,555</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup>&#160;</div>
                  </div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">9.77</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">November 8, 2031</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(1) The options granted to Dr. Pfost vest and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on October 25, 2022, the first anniversary of the
            grant date, and the remainder in equal amounts over the ensuing 36 monthly periods, subject to Dr. Pfost&#8217;s continued service.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">(2) The options granted to Mr. Marvin vest and become exercisable over a period of four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022, the first anniversary of
            the grant date, and the remainder in equal amounts over the ensuing 36 monthly periods, subject to Mr. Marvin&#8217;s continued service.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Employment Agreements</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-style: italic;">Employment Agreement with Dr. Dale Pfost, our Chief Executive Officer</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On September 1,&#160;2021, the Company&#8217;s board of directors approved the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company, and on October 25, 2021, the
              shareholders of the Company approved the terms of employment of Dr. Pfost, pursuant to an Executive Employment Agreement entered into between Dr. Pfost and Chemomab Therapeutics Inc., the Company&#8217;s wholly owned subsidiary. In accordance with
              terms of Dr. Pfost&#8217;s employment agreement, Dr. Pfost receives: (i) an annual base salary of $600,000 (the &#8220;Base Salary&#8221;); (ii) an initial target annual cash incentive bonus of 50% of the Base Salary and an additional potential bonus of 10% of
              the Base Salary based on Dr. Pfost&#8217;s achievement of certain predetermined goals, which shall be determined at the discretion of the Company&#8217;s board of directors; (iii) options to purchase&#160;459,353 ADSs of the Company (the&#160; &#8220;Options&#8221;),
              constituting 3.5% of the outstanding and issued ADSs of the Company (on a fully diluted basis) which will vest over a period of four (4) years with one quarter (1/4) of the Options vesting on the first anniversary of the grant date and the
              remainder in equal amounts over the ensuing 36 monthly periods, unless such options have been cancelled in accordance with the terms and conditions of the 2015 Plan (as defined below); (iv) a one-time signing bonus in an amount of $80,000;
              (v) a one-time bonus in an amount of $80,000 upon the establishment of a new office in the United State and Dr. Pfost&#8217;s domiciling in the location of the new office, which will be payable within 15 days of such domiciling; (vi) 25 days of
              paid time off (&#8220;PTO&#8221;) per year, capped at 50 days of accrued PTO; and (vii) certain severance benefits payable in the event that the Company terminates Dr. Pfost&#8217;s employment without Cause (as defined in the employment agreement), provided
              that the total amount of the cash portion of severance benefits will not exceed two hundred percent (200%) of Dr. Pfost&#8217;s annual base salary at the rate in effect on the date of termination.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Additionally, in the event of termination of Dr. Pfost&#8217;s employment without Cause (as defined therein) as the result of a merger or sale of all or substantially all of the
            Company&#8217;s capital stock or assets, (i.e. a change in control of the Company), vesting of all unvested Options will accelerate and all unvested Options will immediately vest and become exercisable. Furthermore, in the event of termination of Dr.
            Pfost&#8217;s employment without Cause, other than as a result of a merger or sale of all or substantially all of the Company&#8217;s capital stock or assets (i.e. a change in control of the Company) or if Dr. Pfost terminates his employment for Good
            Reason (as defined in the employment agreement): (a) any time-based Options then outstanding and due to vest on the twelve (12) month anniversary of Dr. Pfost&#8217;s employment commencement date will accelerate and become exercisable if Dr. Pfost
            has been employed by the Company at such time for six (6) months or more but less than twelve (12) months; and (b) all time-based Options then outstanding will accelerate and become exercisable if Dr. Pfost has been employed by the Company at
            such time for twelve (12) months or longer.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The foregoing description of Dr. Pfost&#8217;s employment agreement is qualified in its entirety by reference to the full text of the employment agreement, a copy of which is filed
            as Exhibit 10.9 hereto.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">25</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><font style="font-style: italic;">Employment Agreement with Dr. Adi Mor, our Chief Scientific Officer (and former Chief Executive Officer</font>)</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Dr. Adi Mor provides services to the Company pursuant to the terms of a consulting agreement among Dr. Mor, an Israeli company co-owned by Dr. Mor, and the Subsidiary, dated
            April 18, 2022 (the &#8220;Consulting Agreement&#8221;).&#160; Pursuant to the terms of the Consulting Agreement, Dr. Mor is entitled to a gross monthly payment, an annual performance bonus, subject to her meeting certain performance milestones, as to be
            determined by our board of directors on an annual basis, and certain other benefits.&#160; Dr. Mor&#8217;s current monthly payment and annual performance bonus target were set and approved by the Company&#8217;s shareholders as described below.&#160; In addition,
            Dr. Mor is entitled to other benefits that are provided for by Israeli law or that are customary for senior executives in Israel, including reimbursement for reasonable expenses incurred in connection with her services and payment for variable
            and fixed costs of a car. The Consulting Agreement is terminable by either party upon 60 days prior written notice, and contains customary provisions regarding noncompetition, confidentiality of information, and assignment of inventions.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As required under Israeli law, the terms of Dr. Mor&#8217;s Consulting Agreement with the Subsidiary were approved by the board of directors and presented to the shareholders for
            approval.&#160; At the annual meeting of our shareholders that took place on June 7, 2022, our shareholders approved for following terms of employment for Dr. Mor: (a) an increase to her base gross monthly salary from 67,500 NIS (approximately
            $21,090) (plus social benefits) to 74,250 NIS (approximately $23,200), (plus social benefits) which represents an increase of 6,750 NIS (approximately $2,110), effective as of March 7, 2022; (b) an increase in her 2021 gross annual bonus from
            $100,000 to $110,250, an increase of approximately 10%; and (c) an increase in her annual gross target bonus opportunity from $100,000 to 45% of Dr. Mor&#8217;s annual gross payment, effective as of January 1, 2022.&#160; In lieu of the monthly salary
            payment of 74,250 NIS (plus social benefits), as approved by the shareholders, Dr. Mor receives the equivalent amount in the form of a monthly payment equal to 98,730 NIS under the Consulting Agreement.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The foregoing description of the Consulting Agreement is qualified in its entirety by reference to the full text of the consulting agreement, a copy of which is filed as
            Exhibit 10.11 hereto.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic;">Employment Agreement with Mr. Donald Marvin, our Chief Financial Officer, Executive Vice President and Chief Operating Officer</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On November 8, 2021, Chemomab Therapeutics Inc. entered into an Executive Employment Agreement with Mr. Donald Marvin. In accordance with his employment agreement, Mr.
              Marvin receives an annual base salary of $460,000, and is a part of the Company&#8217;s bonus program with a yearly bonus potential of 45% of his base annual base salary, which bonus will be based on the achievement of mutually agreeable objectives
              to be determined by Mr. Marvin and the Chief Executive Officer of the Company. Additionally, in accordance with his employment agreement, Mr. Marvin received (i) 1.5% of the outstanding equity of the Company, which exercise price is based on
              the average of the ADS market value over the 30 calendar days preceding November 8, 2021, and vesting over four years, (ii) an additional 0.5% of the outstanding equity of the Company for the achievement of strategic goals as agreed upon with
              the Compensation Committee and approved by the Board of Directors, (iii) a $25,000 signing bonus, and (iv) a 12-month initial severance package, which will increase by one month every two years that Mr. Marvin is employed by the Company,
              provided however that such amount does not exceed 18 months.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Additionally, in the event of termination of Mr. Marvin&#8217;s employment without Cause as the result of a merger or sale of all or substantially all of the Company&#8217;s capital
            stock or assets, (i.e. a change in control of the Company), vesting of all unvested Options will accelerate and all unvested Options will immediately vest and become exercisable. Furthermore, in the event of termination of Mr. Marvin&#8217;s
            employment without Cause, other than as a result of a merger or sale of all or substantially all of the Company&#8217;s capital stock or assets (i.e. a change in control of the Company) or if Mr. Marvin terminates his employment for Good Reason (as
            defined in the employment agreement): (a) any time-based Options then outstanding and due to vest on the twelve (12) month anniversary of Mr. Marvin&#8217;s employment commencement date will accelerate and become exercisable if Mr. Marvin has been
            employed by the Company at such time for six (6) months or more but less than twelve (12) months; and (b) all time-based Options due to vest on or before December 31 of the year in which termination occurs then outstanding will accelerate and
            become exercisable if Mr. Marvin has been employed by the Company at such time for twelve (12) months or longer.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The foregoing description of Mr. Marvin&#8217;s employment agreement is qualified in its entirety by reference to the full text of the employment agreement, a copy of which is
            filed as Exhibit 10.10 hereto.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">26</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Director Compensation Table</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">The table below outlines compensation earned by our non-executive directors for the fiscal year ended December 31, 2022, including fees earned in cash
            and options awarded for services provided as a director:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" class="cfttable" id="z09e12782d0a945048115124afde5eb5b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="line-height: 1.25; font-weight: bold;">Name</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fees earned or paid<br>
                    in cash ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Option<br>
                    awards ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 64%;">
                  <div style="line-height: 1.25;">Nissim Darvish</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">47,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">76,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
                  <div style="line-height: 1.25;">(1)</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">123,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 64%;">
                  <div style="line-height: 1.25;">Jill Quigley</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">23,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">15,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
                  <div style="line-height: 1.25;">(2)</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">38,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 64%;">
                  <div style="line-height: 1.25;">Alan Moses</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">43,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">76,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
                  <div style="line-height: 1.25;">(3)</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">119,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 64%;">
                  <div style="line-height: 1.25;">Claude Nicaise</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">47,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">76,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
                  <div style="line-height: 1.25;">(4)</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">123,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 64%;">
                  <div style="line-height: 1.25;">Neil Cohen</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">47,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">76,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
                  <div style="line-height: 1.25;">(5)</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">123,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(1) (i) 11,884 of the options granted to Dr. Darvish vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, and (ii) 6,820 options vest
            and become exercisable on March 16, 2023, subject to Dr. Darvish&#8217;s continued service. Additional 10,123 options have fully vested.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(2) The options granted to Ms. Quigley vest and become exercisable&#160;in equal monthly installments over a 36 month period commencing on June 16, 2022, subject to Ms. Quigley&#8217;s continued service.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(3)&#160; (i) 11,884 of the options granted to Dr. Moses vest and become in equal monthly installments over a 36 month period commencing on March 16, 2021, and (ii) 6,820 of the options granted to
            Dr. Moses vest and become exercisable on March 16, 2023, subject to Dr. Moses&#8217; continued service.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(4) (i) 11,884 of the options granted to Dr. Nicaise vest and become in equal monthly installments over a 36 month period commencing on March 16, 2021, and (ii) 6,820 of the options granted to
            Dr. Nicaise vest and become exercisable on March 16, 2023, subject to Dr. Nicaise's continued service.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">(5) (i) 11,884 of the options granted to Mr. Cohen vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, (ii) 6,820 options vest and
            become exercisable on March 16, 2023, and (iii) 688 options vest and become exercisable over a period of three (3) years with one quarter (1/4) of the options vesting on July 16, 2021, the first anniversary of the grant date, and the remainder
            in equal amounts over the ensuing 24 monthly periods commencing on October 16, 2021, subject to Mr. Cohen&#8217;s continued service.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Director Compensation</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">We have adopted a Compensation Policy regarding the terms of office and employment of its &#8220;office holders&#8221; (as defined in the Israeli Companies Law,
            5759-1999), including cash compensation, equity-based awards, releases from liability, indemnification and insurance, severance and other benefits. Chemomab compensates its directors and senior management team in accordance with the
            recommendation of its compensation committee and, generally, subject to the approval of our Board and shareholders. That compensation will generally need to be consistent with the terms of our Compensation Policy, which will require periodic
            approval, in accordance with the requirements of the Companies Law.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25;">In addition to the Compensation Policy, on March 15, 2021, our shareholders approved certain actual compensation terms applicable to our current and
            future directors (the &#8220;Director Compensation Package&#8221;), pursuant to which (and among other terms) (i) our non-employee directors are entitled to receive an annual option grant of up to 0.05% of the Company&#8217;s share capital on a fully diluted
            basis, (ii) the chairman of our Board is entitled to receive an annual option grant of up to 0.2% of the Company&#8217;s share capital on a fully diluted basis and (iii) our non-employee directors are entitled to receive an annual cash fee of
            $35,000. The Director Compensation Policy implements terms for actual equity compensation that will be granted to directors on a regular basis and determines the annual cash fee that may be paid to non-employee directors. In accordance with the
            Companies Law, equity grants to our directors that are within the limitations of the Director Compensation Package require the approval of our compensation committee and Board, but not our shareholders, while any contemplated compensation made
            in excess of the Director Compensation Package will require the approval of our shareholders. Furthermore, any such compensation, including the annual cash fee payable to our non-employee directors, must be limited to the framework of the
            Director Compensation Package.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">27</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Outstanding Equity Awards at Fiscal Year End</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The table below outlines options to purchase ADSs held by our non-employee directors outstanding as of December 31, 2022.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" border="0" class="cfttable" id="zfebb1e8cdf164dd8a9f721583dd454d3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="12" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Option awards</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="line-height: 1.25; font-weight: bold;">Name</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of ADSs<br>
                    underlying<br>
                    unexercised options<br>
                    (#) exercisable</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of<br>
                    ADSs<br>
                    underlying<br>
                    unexercised options<br>
                    (#)<br>
                    unexercsiable</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Option<br>
                    exercise<br>
                    price ($)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Option expiration<br>
                    date</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Nissim Darvish</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">10,123</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">0.80</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">October 27, 2026</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 52%;">
                  <div style="line-height: 1.25;">Nissim Darvish</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">6,932</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">4,952</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">27.26</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">April 19, 2031</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Nissim Darvish</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">6,820</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">3.53</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">March 7, 2032</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Alan Moses</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">6,932</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">4,952</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">27.26</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">April 19, 2031</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div style="line-height: 1.25;">Alan Moses</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">6,820</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">3.53</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">March 7, 2032</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div style="line-height: 1.25;">Claude Nicaise</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">6,932</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">4,952</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">27.26</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">April 19, 2031</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Claude Nicaise</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">6,820</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">3.53</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">March 7, 2032</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Neil Cohen</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">515</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">173</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">13.20</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">July 16, 2030</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div style="line-height: 1.25;">Neil Cohen</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">6,932</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">4,952</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">27.26</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">April 19, 2031</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Neil Cohen</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">6,820</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">3.53</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">March 7, 2032</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 12%;">
                  <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
                  <div style="line-height: 1.25;">Jill Quigley</div>
                </td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">2,273</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">11,367</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">3.25</div>
                </td>
                <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 12%;">
                  <div style="text-align: center; line-height: 1.25;">June 16, 2032</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Equity Incentive Plans</div>
          <div style="line-height: 1.25;">&#160;
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We maintain (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Plan and (iii) the 2015 Plan, which was assumed by our company from the Subsidiary upon the
              effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of our company (formerly known as Anchiano Therapeutics Ltd.) as was determined based on the exchange ratio in the
              Merger Agreement, with a reciprocal adjustment to exercise price. As of December 31, 2022, a total of 1,422,153 of ADSs were reserved for issuance under the 2015 Plan, of which 172,276 ADSs had been issued pursuant to previous exercises
              options, and 1,173,037 ADSs&#160;were issuable under outstanding options. Of such outstanding options, options to purchase 620,036 ADSs had vested and were exercisable as of that date, with a weighted average exercise price of $5.96 per ADS.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As of December 31, 2022, a total of&#160;625,581 of ADSs were reserved for issuance under the 2017 Plan, of which&#160;586,540 ADSs&#160;were issuable under outstanding options. Of such
              outstanding options, options to purchase 21,377 ADSs had vested and were exercisable as of that date, with a weighted average exercise price of $6.98 per ADS. No ADSs had been issued pursuant to previous exercises options.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">2011 Plan</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On December 19, 2011, our board of directors adopted the 2011 Plan to allocate options to purchase our ordinary shares to our directors, officers, employees and consultants,
            and those of our affiliated companies (as such term is defined under the 2011 Plan), or the Grantees. The 2011 Plan is administered by our board of directors or a committee that was designated by our board of directors for such purpose (the
            &#8220;Administrator&#8221;).</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the 2011 Plan, we may grant options to purchase ordinary shares (&#8220;Options&#8221;), under four tracks: (i) Approved 102 capital gains Options through a trustee, which was
            approved by the Israeli Tax Authority in accordance with Section 102(a) of the Israeli Income Tax Ordinance (&#8220;ITO&#8221;), and granted under the tax track set forth in Section 102(b)(2) of the ITO, or the Approved 102 Capital Gains Options. The
            holding period under this tax track is 24 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment of Section 102 of the ITO, or any applicable tax ruling or guidelines; (ii) Approved 102
            Earned Income Options through a trustee, granted under the tax track set forth is Section 102(b)(1) of the ITO, or the Approved 102 Earned Income Options. The holding period under this tax track is 12 months from the date of allocation of
            Options to the trustee or such period as may be determined in any amendment of Section 102 of the ITO; (iii) Unapproved 102 Options (the Options will not be allocated through a trustee and will not be subject to a holding period), or the
            Unapproved 102 Options; and (iv) 3(i) Options (the Options will not be subject to a holding period). These Options shall be subject to taxation pursuant to Section 3(i) of the ITO, or Section 3(i).</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Options pursuant to the first three tax tracks (under Section 102 of the ITO) can be granted to our employees and directors and the grant of Options under Section 3(i) can be
            granted to our consultants and controlling shareholders (a controlling shareholder is defined under the Section 102 of the ITO is a person who holds, directly or indirectly, alone or together with a &#8220;relative,&#8221; (i) the right to at least 10% of
            the company&#8217;s issued capital or 10% of the voting power; (ii) the right to hold at least 10% of the company&#8217;s issued capital or 10% of the voting power, or the right to purchase such rights; (iii) the right to receive at least 10% of the
            company&#8217;s profits; or (iv) the right to appoint a company&#8217;s director). Grantees who are not Israeli residents may be granted options that are subject to the applicable tax laws in their respective jurisdictions.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">28</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We determine, in our sole discretion, under which of the first three tax tracks above the Options are granted and we notify the Grantee in a grant letter, as to the elected
            tax track. As mentioned above, consultants and controlling shareholders can only be granted Section 3(i) Options.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The number of ordinary shares authorized to be issued under the 2011 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares
            issued as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other capital change), or issuance of rights to purchase ordinary shares or payment of a dividend. We will
            not allocate fractions of ordinary shares and the number of ordinary shares shall be rounded up to the closest number of ordinary shares.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise determined by the Administrator, the exercise price of an Option granted under the 2011 Plan will be the average of the market price of the Company&#8217;s
            ordinary shares during the 22 business days prior to the date on which our board of directors authorized the grant of Options; provided, however, that such exercise price cannot be lower than the market price at the close of the trading day at
            which it was granted by our board of directors. The exercise price will be specified in the grant letter every Grantee received from us in which the Grantee notifies of the decision to grant him/her Options under the 2011 Plan.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise determined by the Administrator, the Options granted under the 2011 Plan will become vested and may be exercised in 16 equal portions of 6.25% of the total
            number of Options, at the end of each quarter following the day the Options were granted. Unless otherwise determined by our board of directors, the Options may be exercised for ten years following the date of grant, unless terminated earlier,
            and as long as the Grantee is employed by the Company (or by an affiliated company), or provides service to the Company (or an affiliated company).</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Administrator may, in its absolute discretion, accelerate the time at which Options granted under the 2011 Plan or any portion of which will vest.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise determined by the Administrator, in the event that the Grantee&#8217;s employment was terminated, not for Cause (as defined in the 2011 Plan), the Grantee may
            exercise that portion of the Options that had vested as of the date of such termination until the end of the specified term in the grant letter or the 2011 Plan. The portion of the Options that had not vested at such date, will be forfeited and
            can be re-granted according to the terms of the 2011 Plan.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">2015 Plan</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In November 2015, the Subsidiary&#8217;s board of directors adopted, and its shareholders subsequently approved, the 2015 Plan. The 2015 Plan provides for the grant of options,
            restricted shares, restricted share units and other share-based awards to the Subsidiary&#8217;s (following the Merger, the Company&#8217;s) and its subsidiaries&#8217; and affiliates&#8217; directors, employees, officers, consultants, advisors, and any other person
            whose services are considered valuable to Chemomab or its affiliates. Any such grants are intended to incentivize the foregoing persons to continue as service providers, to increase their efforts on Chemomab&#8217;s behalf or on behalf of its
            subsidiaries or affiliates, and to promote the success of its business.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The 2015 Plan is administered by Chemomab&#8217;s board of directors or by a committee designated by the board of directors, which determines, subject to Israeli law, the grantees
            of awards and the terms of the grant, including, exercise prices, vesting schedules, acceleration of vesting and the other matters necessary in the administration of the 2015 Plan. The 2015 Plan enables Chemomab to issue awards under various
            tax regimes, including, without limitation, pursuant to Section 102 of the Israeli Income Tax Ordinance, or the Ordinance, and under Section 3(i) of the Ordinance and Section 422 of the United States Internal Revenue Code of 1986, as amended,
            or the Code.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The 2015 Plan provides that options granted to Chemomab&#8217;s employees, directors and officers who are not controlling shareholders and who are considered Israeli residents are
            intended to qualify for special tax treatment under the &#8220;capital gain track&#8221; provisions of Section 102(b) of the Ordinance. Chemomab&#8217;s Israeli non-employee service providers and controlling shareholders may only be granted options under Section
            3(i) of the Ordinance, which does not provide for similar tax benefits.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Options granted under the 2015 Plan to U.S. residents may qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code, or may be non-qualified. The
            exercise price for &#8220;incentive stock options&#8221; must not be less than the fair market value on the date on which an option is granted, or 110% of the fair market value if the option holder holds more than 10% of Chemomab&#8217;s share capital.&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Options and other awards granted under the 2015 Plan generally vest over four years commencing on the date of grant, such that 25% vests on the first anniversary of the date
            of grant and an additional 6.25% vests at the end of each subsequent calendar quarter over the course of the next three years, provided that the participant remains continuously employed or engaged by Chemomab.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">29</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Options, other than certain incentive share options, that are not exercised within ten years from the grant date expire, unless otherwise determined by Chemomab&#8217;s board of
            directors or its designated committee, as applicable. Share options that qualify as &#8220;incentive stock options&#8221; and are granted to a person holding more than 10% of Chemomab&#8217;s voting power will expire within five years from the date of the grant.
            In the event of the death of a grantee while employed by or performing service for Chemomab or its subsidiary or within three months after the date of the employee&#8217;s termination, or the termination of a grantee&#8217;s employment or services for
            reasons of disability, the grantee, or in the case of death, his or her legal successor, may exercise options or other awards that have vested prior to termination within a period of one year from the date of disability or death. If Chemomab
            terminates a grantee&#8217;s employment or service for cause, all of the grantee&#8217;s vested and unvested options or other awards will expire on the date of termination. If a grantee&#8217;s employment or service is terminated for any other reason, the
            grantee may generally exercise his or her vested options or other award within three months of the date of termination. Any expired or unvested options return to the pool and become available for reissuance. From time to time, Chemomab may
            consider issuing options with slightly different terms or accelerating, extending or otherwise modifying options in accordance with applicable law and regulation and the terms of the 2015 Plan.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event of a merger or consolidation of Chemomab, or a sale of all, or substantially all, of Chemomab&#8217;s shares or assets or other transaction having a similar effect on
            Chemomab, then without the consent of the option holder, Chemomab&#8217;s board of directors or its designated committee, as applicable, may, but is not required, to (i) cause any outstanding award to be assumed or an equivalent award to be
            substituted by such successor corporation, or (ii) in case the successor corporation does not assume or substitute the award (a) provide the grantee with the option to exercise the award as to all or part of the shares or (b) cancel the options
            and pay in cash an amount determined by the board of directors or the committee as fair in the circumstances. Notwithstanding the foregoing, Chemomab&#8217;s board of directors or its designated committee may upon such event amend, modify or
            terminate the terms of any award, including conferring the right to purchase any other security or asset that the board of directors or the committee shall deem, in good faith, appropriate.&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The 2015 plan was assumed by our company from the Subsidiary upon the effectiveness of the Merger.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">2017 Plan</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 22, 2017, our board of directors adopted the 2017 Plan to allocate a variety of share-based awards to our directors, officers, employees, consultants, advisors
            and service providers, and those of our affiliates (companies that control us, are controlled by us or are under common control with us) (the &#8220;Participants&#8221;). The 2017 Plan is currently administered by our board of directors, and may be
            administered by a committee designated by our board of directors for such purpose.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the 2017 Plan, we may grant options to purchase ordinary shares or ADSs, restricted shares or ADSs, restricted share units and other awards based on our ordinary
            shares, all of which are referred to as Awards. We may grant Awards under the same four tracks as described above with respect to the 2011 Plan, subject to the same conditions as apply for the 2011 Plan. In addition, we may grant incentive
            stock options and nonqualified stock options to Participants who are residents of the United States, and we may grant awards to Participants who are residents of other countries that comply with the laws of those jurisdictions.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The number of ordinary shares authorized to be issued under the 2017 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares
            issued as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other capital change), issuance of rights to purchase ordinary shares or payment of a dividend. We will
            not allocate fractions of ordinary shares and the number of ordinary shares shall be rounded down to the closest number of ordinary shares.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">30</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="SECURITY"><!--Anchor--></a>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-indent: 36pt; line-height: 1.25;">The following table sets forth information, as of March 16, 2023, regarding beneficial ownership of our ordinary shares represented by ADSs:</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z34fbbb47a476482499fba2f48d25dfc1">

              <tr>
                <td style="width: 5%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;">each person who is known by us to own beneficially more than 5% of our ordinary shares;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;">each director;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;">each executive officer; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;">all of our directors and executive officers collectively.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The percentages of ordinary shares beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities.
            Under the rules of the SEC, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the
            power to dispose of or to direct the disposition of the security.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise noted, the address of each director and current and former executive officer of Chemomab is Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z17aced2cae31403aa4eddb1f0e18bfa4" class="cfttable">

                <tr>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="line-height: 1.25; font-weight: bold;">NAME OF BENEFICIAL OWNER</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total</div>
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Beneficial</div>
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ownership (ADSs)</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Percentage of</div>
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ADSs Beneficially</div>
                    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Owned</font>&#8224;</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;">
                    <div style="line-height: 1.25; font-style: italic;">5% and Greater Shareholders</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%;">
                    <div style="line-height: 1.25;">OrbiMed Israel (1)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">2,270,091</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">20.5</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25;">The Centillion Fund(2)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">661,370</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">6.0</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%;">
                    <div style="line-height: 1.25;">Rivendell Investments 2017-9(3)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">1,131,563</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">10.2</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25;">Kobi George(4)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">747,445</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">6.7</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%;">
                    <div style="line-height: 1.25;">Apeiron Group(5)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">770,388</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">6.9</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25; font-style: italic;">Directors and Executive Officers</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                    <div style="line-height: 1.25;">Dale Pfost (6)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">174,757</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">1.6</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25;">Donald Marvin (7)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">75,828</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                    <div style="line-height: 1.25;">Adi Mor (8)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">747,445</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">6.7</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25;">Neil Cohen (9)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">25,702</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                    <div style="line-height: 1.25;">Nissim Darvish (10)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">26,395</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25;">Alan Moses (11)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">15,072</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                    <div style="line-height: 1.25;">Claude Nicaise (12)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">15,072</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25;">Jill Quigley (13)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">3,788</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                    <div style="line-height: 1.25;">Matthew Frankel</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
                    <div style="line-height: 1.25; font-weight: bold;">All current executive officers and directors as a group (9 persons)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">1,084,059</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
                  <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                    <div style="line-height: 1.25;">9.40</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"> </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#8224; Percentage ownership based on 11,049,812 ADSs outstanding as of March 16, 2023</div>
          </div>
          <div style="line-height: 1.25;">* Less than one percent (1%)</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" id="zbf63ffb5f1d54fa38060c81f601e51fd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">(1)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Pursuant to a Schedule 13D/A filed with the SEC by OrbiMed Israel BioFund GP Limited Partnership (&#8220;OrbiMed BioFund&#8221;) and OrbiMed Israel GP Ltd. (&#8220;OrbiMed GP&#8221;, and together with OrbiMed BioFund, &#8220;OrbiMed Israel&#8221;) on January 5, 2023,
                      such amount consists of (i) 2,241,274 ADSs and (ii) 28,817 ADSs issuable upon the exercise of warrants to purchase ADSs. OrbiMed GP, a company that acts as general partner of certain limited partnerships, is the general partner of
                      OrbiMed BioFund, which is the general partner of OrbiMed Israel Partners Limited Partnership, which is the entity that holds the foregoing securities. The address of OrbiMed Israel is 89 Medinat HaYehudim St., Build E, 11th Floor,
                      Herzliya 46766 Israel.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z3a09ddafb6ca4ce9a6250002f60ec4db" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">(2)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>The address of Centillion Fund, Inc. is 10 Manoel Street, Castries, Saint Lucia.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z5a639a21918b49a2ba601dfee2dbcd24" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">(3)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Represents 1,108,509 ADSs, representing 22,170,180 ordinary shares, held by Rivendell Investments 2017-9 LLC, or Rivendell, as reported by Rivendell on Schedule 13G filed with the SEC on March 26, 2021, and 23,054 ADSs,
                      representing 461,080 Ordinary Shares, issuable upon the exercise of warrants. Rivendell is the shareholder of record. Peter Thiel is the beneficial owner of Rivendell and has sole voting and investment power over the securities held
                      by Rivendell. The address of Rivendell is 1209 Orange Street, Wilmington, Delaware 19801.</div>
                  </td>
                </tr>

            </table>
            <br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">31</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" id="z5b6a89ffd4414bf6ace72991b2a000be" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">(4)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Consists of (i) 257,247 ADSs owned directly by Dr. George, (ii) 324,775 ADSs owned by Dr. Adi Mor (Dr. George&#8217;s spouse), (iii) 33,725 options to purchase 33,725 ADSs issued directly to Dr. George, issuable upon the exercise of
                      options, and (iv) 131,698 options to purchase 131,698 ADSs, issued to Dr. Mor, (Dr. George&#8217;s spouse), as reported by Dr. Adi Mor on Schedule 13D/A filed with the SEC on November 17, 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z0462c906a6a646c9957776b757009f73" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">(5)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>The Apeiron Group consists of (i) Apeiron SICAV Ltd. - Presight Capital Fund One, of which owns 438,993 ADSs, (ii) Apeiron Presight Capital Fund II, LP, of which owns 288,170 ADSs and 28,817 ADSs issuable upon the exercise of
                      warrants and (iii) Apeiron Investment Group Ltd., of which owns 14,408 ADSs issuable upon the exercise of warrants. Each of Fabian Hansen and Christian Angermayer may be deemed to share voting and investment power with respect to the
                      ADSs held by the Apeiron Group.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z4822bf711c35451d887fa2aea836431e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">(6)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Includes 2,500 ADSs and 172,257&#160; ADSs issuable upon the exercise of options within 60 days of the date hereof as reported by Dr. Dale Pfost on Form 4 filed with the SEC on March 15, 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="zbfa1ed27386e4c8786cae8101dac25db" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">(7)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Includes 2,000 ADSs and 73,828&#160; ADSs issuable upon the exercise of options within 60 days of the date hereof as reported by Mr. Donald Marvin on Form 4 filed with the SEC on June 21, 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z0fb51c9a1ad949c685c20eace4cb997c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">(8)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Consists of (i) 324,775 ADSs owned directly by Dr. Mor, (ii) 257,247 ADSs owned by Dr. George, (Dr. Mor&#8217;s spouse), (iii) 131,698 ADSs issued to Dr. Mor, issuable upon the exercise of options within 60 days of the date hereof, and
                      (iv) 33,725 options to purchase 33,725 ADSs issued to Dr. George, (Dr. Mor&#8217;s spouse) issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Adi Mor on Schedule 13D/A filed with the SEC on November
                      17, 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z156030dfcb5b478db71e2d8435660cc4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">(9)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Includes 10,000 ADSs, and 15,702 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on November 11, 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="zb64736d4533d4cde996898b7f976aa7b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">(10)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Includes 1,200 ADSs, and 25,195 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Nissim Darvish on Form 4 filed with the SEC on March 14, 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z19570b3c93e84c64b3dc3f4bf3495eec" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">(11)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Represents 15,072 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Alan Moses on Form 4 filed with the SEC on March 9, 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="zbc8d778423534df787dc85d6e901d41d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">(12)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Represents 15,072 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Claude Nicaise on Form 4 filed with the SEC on March 9, 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z8f708b4e3740480e8da58a544d46f662" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">(13)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Represents 3,788 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Ms. Jill Quigley on Form 4 filed with the SEC on June 16, 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">32</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">DESCRIPTION OF <a name="SHARECAPITAL"><!--Anchor--></a>SHARE CAPITAL</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and are qualified by reference to our amended
            and restated articles of association, a copy of which is filed as Exhibit 3.1 hereto.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Registration Number and Purposes of the Company</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are registered with the Israeli Registrar of Companies. Our registration number is 51-4672625.&#160;Our affairs are governed by our amended and restated articles of
            association, applicable Israeli law and the Companies Law. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful act or activity.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Voting Rights</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All ordinary shares have identical voting and other rights in all respects.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Transfer of Shares</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer is
            restricted or prohibited by another instrument, applicable law or the rules&#160;of Nasdaq. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and restated articles of association or
            the laws of the State of Israel, except for ownership by nationals of some countries that are, have been, or will be, in a state of war with Israel.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Election of Directors</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under our amended and restated articles of association, our board of directors must consist of not less than three (3)&#160;but no more than eleven (11) directors. Pursuant to our
            amended and restated articles of association, each of our directors will be appointed by a simple majority vote of holders of our ordinary shares, participating and voting at an annual general meeting of our shareholders, provided that (i)&#160;in
            the event of a contested election, the method of calculation of the votes and the manner in which the resolutions will be presented to our shareholders at the general meeting shall be determined by our board of directors in its discretion, and
            (ii)&#160;in the event that our board of directors does not or is unable to make a determination on such matter, then the directors will be elected by a majority of the voting power represented at the general meeting in person or by proxy and voting
            on the election of directors, provided that if the number of such nominees exceeds the number of directors to be elected, then as among such nominees the election shall be by a plurality of the votes cast. In addition, our directors are divided
            into three classes, one class being elected each year at the annual general meeting of our shareholders, and shall serve on our board of directors until the third annual general meeting following such election or re-election or until they are
            removed by a vote of 65% of the total voting power of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance with the Companies Law and our amended and restated articles of association.
            In addition, our amended and restated articles of association provide that vacancies on our board of directors may be filled by a vote of a simple majority of directors then in office. Any director so appointed will hold office until the next
            annual general meeting of our shareholders for the election of the class of directors in respect of which the vacancy was created, or in the case of a vacancy due to the number of directors being less than the maximum number of directors stated
            in our amended and restated articles of association, until the next annual general meeting of our shareholders for the election of the class of directors to which such director was assigned by our board of directors.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Dividend and Liquidation Rights</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions
            are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our amended and restated articles of association do not require
            shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to our then
            last reviewed or audited financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the end of the period to which the financial statements relate is not more than six months
            prior to the date of the distribution. If we do not meet such criteria, then we may distribute dividends only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors and, if applicable, the
            court determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">33</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their
            shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the
            future.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Exchange Controls</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the ordinary shares or interest or
            other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, have been, or will be, in a state of war with Israel.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Shareholder Meetings</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year and no later than 15 months after the date of the previous
            annual general meeting. All meetings other than the annual general meeting of shareholders are referred to in our amended and restated articles of association as special general meetings. Our board of directors may call special general meetings
            of our shareholders whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene a special general meeting of our
            shareholders upon the written request of (i)&#160;any two or more of our directors, (ii)&#160;one-quarter or more of the serving members of our board of directors or (iii)&#160;one or more shareholders holding, in the aggregate, either (a)&#160;5% or more of our
            outstanding issued shares and 1% or more of our outstanding voting power or (b)&#160;5% or more of our outstanding voting power.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting of the shareholders may request that the board of directors
            include a matter in the agenda of a general meeting of the shareholders to be convened in the future, provided that it is appropriate to discuss such a matter at the general meeting. Our amended and restated articles of association contain
            procedural guidelines and disclosure items with respect to the submission of shareholder proposals for general meetings.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings of shareholders
            are the shareholders of record on a date to be decided by the board of directors, which, as a company listed on an exchange outside Israel, may be between four and 40 days prior to the date of the meeting. Furthermore, the Companies Law
            requires that resolutions regarding the following matters must be passed at a general meeting of shareholders:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb26e087711bf418cada5b0bc566da711">

              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.18%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">amendments to our amended and restated articles of association;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z04da4c947a0e44f1ac3e2952dcc79833">

              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.18%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">appointment, terms of service or and termination of service of our auditors;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf0856c811083471b91a10c4fc648ddbb">

              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.18%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">appointment of directors, including external directors (if applicable);</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1dd7ed268c644d1db584ee1f525cd9c1">

              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.18%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">approval of certain related party transactions;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z5bfbbe2194a247fe9122796e88b13758">

              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.18%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">increases or reductions of our authorized share capital;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: center; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z97fb93b9333a413a9b3192a11a3a36bf">

              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.18%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">a merger; and</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za1aefc4bae4f434b8a119d926c05595e">

              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.18%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">the exercise of our board of directors&#8217; powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our
                    proper management.</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the
            agenda of the meeting includes, among other things, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be provided at least 35 days
            prior to the meeting. Under the Companies Law, shareholders are not permitted to take action by way of written consent in lieu of a meeting.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">34</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Quorum</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote
            before the shareholders at a general meeting of shareholders. The quorum required for our general meetings of shareholders consists of at least two shareholders present in person or by proxy who hold or represent between them at least 33&#8531;% of
            the total outstanding voting rights, provided, however, that with respect to any general meeting that was convened pursuant to a resolution adopted by the board of directors and which at the time of such general meeting we qualify as a &#8220;foreign
            private issuer,&#8221; the requisite quorum shall consist of two or more shareholders present in person or by proxy who hold or represent between them at least 25% of the total outstanding voting rights. The requisite quorum shall be present within
            half an hour of the time fixed for the commencement of the general meeting. A general meeting adjourned for lack of a quorum shall be adjourned either to the same day in the next week, at the same time and place, to such day and at such time
            and place as indicated in the notice to such meeting, or to such day and at such time and place as the chairperson of the meeting shall determine. At the reconvened meeting, any number of shareholders present in person or by proxy shall
            constitute a quorum, unless a meeting was called pursuant to a request by our shareholders, in which case the quorum required is one or more shareholders, present in person or by proxy and holding the number of shares required to call the
            meeting as described above.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Vote Requirements</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies
            Law or by our amended and restated articles of association. Under the Companies Law, certain actions require the approval of a special majority, including: (i)&#160;an extraordinary transaction with a controlling shareholder or in which the
            controlling shareholder has a personal interest, (ii)&#160;the terms of employment or other engagement of a controlling shareholder of the company or a controlling shareholder&#8217;s relative (even if such terms are not extraordinary) and (iii)&#160;certain
            compensation-related matters described above under &#8220;Management&#8212;Compensation Committee&#8212;Compensation Policy under the Companies Law.&#8221; Under our amended and restated articles of association, the alteration of the rights, privileges, preferences or
            obligations of any class of our shares (to the extent there are classes other than ordinary shares) requires the approval of a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the
            governing documents relevant to such class), in addition to a majority of all classes of shares voting together as a single class at a shareholder meeting.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under our amended and restated articles of association, the approval of the holders of at least 65% of the total voting power of our shareholders is generally required to
            remove any of our directors from office, to amend the provision requiring the approval of at least 65% of the total voting power of our shareholders to remove any of our directors from office, or certain other provisions regarding our staggered
            board, shareholder proposals, the size of our board and plurality voting in contested elections. Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement
            or reorganization, of the company pursuant to Section&#160;350 of the Companies Law, which requires the approval of holders holding at least 75% of the voting rights represented at the meeting and voting on the resolution.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Access to Corporate Records</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, all shareholders generally have the right to review minutes of our general meetings, our shareholder register (including with respect to material
            shareholders), our articles of association, our financial statements, other documents as provided in the Companies Law and any document we are required by law to file publicly with the Israeli Registrar of Companies or the Israeli Securities
            Authority. Any shareholder who specifies the purpose of its request may request to review any document in our possession that relates to any action or transaction with a related party which requires shareholder approval under the Companies Law.
            We may deny a request to review a document if we determine that the request was not made in good faith, that the document contains a trade secret or a patent or that the document&#8217;s disclosure may otherwise impair our interests.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Acquisitions under Israeli Law</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Full Tender Offer</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A person wishing to acquire shares of a public Israeli company who would, as a result, hold over 90% of the target company&#8217;s voting rights or the target company&#8217;s issued and
            outstanding share capital (or of a class thereof), is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company (or the applicable
            class). In general, if (a)&#160;the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company (or the applicable class) and the shareholders who accept the offer constitute a majority of
            the offerees that do not have a personal interest in the acceptance of the tender offer or (b)&#160;the shareholders who did not accept the tender offer hold less than 2% of the issued and outstanding share capital of the company (or of the
            applicable class), all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. A shareholder who had its shares so transferred may petition an Israeli court within six months from the date of
            acceptance of the full tender offer, regardless of whether such shareholder agreed to the offer, to determine whether the tender offer was for less than fair value and whether the fair value should be paid as determined by the court. However,
            an offeror may provide in the offer that a shareholder who accepted the offer will not be entitled to petition the court for appraisal rights as described in the preceding sentence, as long as the offeror and the company disclosed the
            information required by law in connection with the full tender offer. If the full tender offer was not accepted, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s voting rights
            or the company&#8217;s issued and outstanding share capital (or of the applicable class) from shareholders who accepted the tender offer. Shares purchased in contradiction to the full tender offer rules&#160;under the Companies Law will have no rights and
            will become dormant shares.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">35</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Special Tender Offer</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law provides that, subject to certain exceptions, an acquisition of shares of an Israeli public company must be made by means of a special tender offer if, as a
            result of the acquisition, the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly,
            the Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if, as a result of the acquisition, the purchaser would become a holder of more than 45% of the voting rights
            in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company. These requirements do not apply if (i)&#160;the acquisition occurs in the context of a private placement by the company that
            received shareholder approval as a private placement whose purpose is to give the purchaser 25% or more of the voting rights in the company, if there is no person who holds 25% or more of the voting rights in the company or as a private
            placement whose purpose is to give the purchaser 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company, (ii)&#160;the acquisition was from a shareholder holding 25% or more of the voting
            rights in the company and resulted in the purchaser becoming a holder of 25% or more of the voting rights in the company, or (iii)&#160;the acquisition was from a shareholder holding more than 45% of the voting rights in the company and resulted in
            the purchaser becoming a holder of more than 45% of the voting rights in the company. in general, a special tender offer must be extended to all shareholders of a company. A special tender offer may be consummated only if (i)&#160;at least 5% of the
            voting power attached to the company&#8217;s outstanding shares will be acquired by the offeror and (ii)&#160;the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser, its
            controlling shareholders, holders of 25% or more of the voting rights in the company and any person having a personal interest in the acceptance of the tender offer, or anyone on their behalf, including any such person&#8217;s relatives and entities
            under their control).</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event that a special tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer, or may abstain from
            expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. The board of directors shall also disclose any personal interest that any of the directors has with respect to the special tender offer or
            in connection therewith. An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or foreseeable special tender offer or to impair the
            chances of its acceptance, is liable to the potential purchaser and shareholders for damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit of the company. However,
            office holders of the target company may negotiate with the potential purchaser in order to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the offer within four days of the last day set for
            the acceptance of the offer and they will be considered to have accepted the offer from the first day it was made.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling
            person or entity at the time of the offer may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer,
            unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.&#160;Shares purchased in contradiction to the special tender offer rules&#160;under the Companies Law will have no rights and
            will become dormant shares.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Merger</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain conditions described under the Companies Law are met, a
            simple majority of the outstanding shares of each party to the merger that are represented and voting on the merger. The board of directors of a merging company is required pursuant to the Companies Law to discuss and determine whether in its
            opinion there exists a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial condition of the
            merging companies. If the board of directors determines that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of the merging companies, the boards of directors must jointly
            prepare a merger proposal for submission to the Israeli Registrar of Companies.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">36</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For purposes of the shareholder vote of a merging company whose shares are held by the other merging company, or by a person or entity holding 25% or more of the voting
            rights at the general meeting of shareholders of the other merging company, or by a person or entity holding the right to appoint 25% or more of the directors of the other merging company, unless a court rules&#160;otherwise, the merger will not be
            deemed approved if a majority of the shares voted on the matter at the general meeting of shareholders (excluding abstentions) that are held by shareholders other than the other party to the merger, or by any person or entity who holds 25% or
            more of the voting rights of the other party or the right to appoint 25% or more of the directors of the other party, or any one on their behalf including their relatives or corporations controlled by any of them, vote against the merger. In
            addition, if the non-surviving entity of the merger has more than one class of shares, the merger must be approved by each class of shareholders. If the transaction would have been approved but for the separate approval of each class or the
            exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable,
            taking into account the valuation of the merging companies and the consideration offered to the shareholders. If a merger is with a company&#8217;s controlling shareholder or if the controlling shareholder has a personal interest in the merger, then
            the merger is instead subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, each merging company must deliver to its secured creditors the merger proposal and inform its unsecured creditors of the merger proposal and its
            content. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be
            unable to satisfy the obligations of the surviving company, and may further give instructions to secure the rights of creditors.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger is filed with the Israeli Registrar of
            Companies and 30 days from the date that shareholder approval of both merging companies is obtained.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Anti-Takeover Measures</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights
            with respect to voting, distributions or other matters and shares having preemptive rights. As of the date of this prospectus, no preferred shares are authorized under our amended and restated articles of association. In the future, if we do
            authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders
            from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and restated articles of association, which requires
            the prior approval of the holders of a majority of the voting power attached to our issued and outstanding shares at a general meeting of our shareholders. The convening of the meeting, the shareholders entitled to participate and the vote
            required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law and our amended articles of association, as described above in &#8220;&#8212;Shareholder Meetings.&#8221; In addition, as disclosed under &#8220;&#8212;Election of
            Directors,&#8221; we have a classified board structure, which effectively limits the ability of any investor or potential investor or group of investors or potential investors to gain immediate control of our board of directors.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Borrowing Powers</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take all actions that are not required
            under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Changes in Capital</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to Israeli law and must be approved by a
            resolution duly passed by our shareholders at a general meeting of shareholders. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings
            or profits, require the approval of both our board of directors and an Israeli court.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Exclusive Forum</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the
            Southern District of New York shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act and/or the Exchange Act. Our amended and restated articles of association also provide
            that unless we consent in writing to the selection of an alternative forum, the competent courts in Tel Aviv,&#160;Israel shall be the exclusive forum for any derivative action or proceeding brought on behalf of the Company, any action asserting a
            breach of a fiduciary duty owed by any of our directors, officers or other employees to the Company or our shareholders or any action asserting a claim arising pursuant to any provision of the Companies Law or the Israeli Securities Law.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Transfer Agent and Registrar</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The transfer agent and registrar for our ordinary shares and ADSs is Computershare. Its address is 1290 Avenue of the Americas, 9th Floor, New York, NY 10104, and its
            telephone number is (212) 805-7100.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Listing</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The ADSs are listed on Nasdaq under the symbol &#8220;CMMB.&#8221;</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">37</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFSECURITIES"><!--Anchor--></a>DESCRIPTION OF SECURITIES WE ARE OFFERING</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; font-weight: bold;">Units</div>
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each unit consists of one ADS and a warrant to purchase one ADS at an exercise price equal to $1.52. The ADSs and Warrants may be transferred separately immediately upon
                issuance. This prospectus also relates to the offering of ADSs issuable upon exercise, if any, of the Warrants issued in this offering.</div>
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
              <div style="line-height: 1.25; font-weight: bold;">Pre-funded Units</div>
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are offering the Pre-funded Units at a price equal to the price per Unit, minus $0.001, and the exercise price of each Pre-Funded Warrant included in the Pre-Funded
                Unit will be $0.001 per ADS. Each Pre-Funded Unit consists of one Pre-Funded Warrant to purchase one ADS and one Warrant to purchase one ADS. The Pre-Funded Warrants and Warrants may be transferred separately immediately upon issuance. This
                prospectus also relates to the offering of ADSs issuable upon exercise, if any, of the Pre-funded Warrants issued in this offering.</div>
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
              </div>
            </div>
          </div>
          <div style="line-height: 1.25; font-weight: bold;">ADSs</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Bank of New York Mellon, as depositary, will register and deliver the ADSs. Each ADS represents twenty (20) ordinary shares (or a right to receive twenty (20) ordinary
              shares). Each ADS will also represent any other securities, cash or other property which may be held by the depositary. The depositary&#8217;s office at which the ADSs will be administered and its principal executive office are located at 240
              Greenwich Street, New York, New&#160;York&#160;10286.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You may hold ADSs either (A)&#160;directly (i)&#160;by having an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name or (ii)&#160;by having
                uncertificated ADSs registered in your name or (B)&#160;indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in DTC. If you hold ADSs directly, you are a
                registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS
                holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder rights. The depositary will
                be the holder of the ordinary shares underlying the ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding
                ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.</div>
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of
            ADR. For directions on how to obtain copies of those documents see &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>.&#8221;</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Dividends and Other Distributions</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">How will you receive dividends and other distributions on the shares?</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities, upon
              payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares the ADSs represent.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Cash.</font>&#160;&#160;&#160;The depositary will convert any cash dividend or other cash distribution we pay on the ordinary shares into U.S. dollars, if
            it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the
            foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of our ADS holders who have not been paid. It will not invest the foreign currency and it will not
            be liable for any interest.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Before making a distribution, any withholding taxes or other governmental charges that must be paid will be deducted. See &#8220;Taxation and Government Programs.&#8221; It will
            distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value
            of the distribution.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Shares.</font>&#160;&#160;&#160;The depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free
            distribution. The depositary will only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fraction of an ADS (or ADSs representing those ordinary shares) and distribute the net proceeds in the same way as it
            does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed ordinary shares (or ADSs representing those ordinary shares)
            sufficient to pay its fees and expenses in connection with that distribution.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Rights to purchase additional shares.</font>&#160;&#160;&#160;If we offer holders of our securities any rights to subscribe for additional ordinary shares
            or any other rights, the depositary may (i)&#160;exercise those rights on behalf of ADS holders, (ii)&#160;distribute those rights to ADS holders or (iii)&#160;sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or
            upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse.&#160;<font style="font-style: italic;">In that case, you will receive no value for them.</font>&#160;The depositary
            will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and
            distribute those securities or, in the case of ordinary shares, new ADSs representing the new ordinary shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict
            the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">38</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Other Distributions.</font>&#160;&#160;&#160;The depositary will send to ADS holders anything else we distribute on deposited securities by any means it
            thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary will have a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may
            decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory
            evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may
            restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register
            ADSs, ordinary shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not
            receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Deposit, Withdrawal and Cancellation</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">How are ADSs issued?</div>
          <div style="text-align: justify; line-height: 1.25;"><br>
            <div style="text-indent: 36pt; line-height: 1.25;">The depositary will deliver ADSs if you or your broker deposits ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of
              any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made
              the deposit.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25; font-style: italic;">How can ADS holders withdraw the deposited securities?</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">You may surrender your ADSs for the purpose of withdrawal of the ordinary shares at the depositary&#8217;s office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp
              taxes or stock transfer taxes or fees, the depositary will deliver the ordinary shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your
              request, risk and expense, the depositary will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a
              deposited share or other securities. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities.</div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">How do ADS holders interchange between certificated ADSs and uncertificated ADSs?</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS
            holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of
            uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Voting Rights</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">How do you vote?</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">ADS holders may instruct the depositary how to vote the number of deposited ordinary shares their ADSs represent. If we request the depositary to solicit your voting
            instructions (and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders
            may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Israel and the provisions of our
            articles of association or similar documents, to vote or to have its agents vote the ordinary shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can
            still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Except by instructing the depositary as described above, you won&#8217;t be able to exercise voting rights unless you surrender the ADSs and withdraw the ordinary
                shares. However, you may not know about the meeting enough in advance to withdraw the ordinary shares.</font>&#160;In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to
              vote as instructed.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">39</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary and
            its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote and there may be nothing you can do if your
            ordinary shares are not voted as you requested.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In order to give you a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary to
            act, we agree to give the Depositary notice of any such meeting and details concerning the matters to be voted upon at least 45&#160;days in advance of the meeting date.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Fees and Expenses</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc1d084e476be4cd8b8a3c3e92c7cfbf9">

              <tr>
                <td style="width: 40.72%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Persons depositing or withdrawing ordinary shares or ADS holders must pay</div>
                </td>
                <td style="width: 4.08%; vertical-align: bottom;">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#8203;</div>
                </td>
                <td style="width: 54.62%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">For</div>
                </td>
                <td style="width: 0.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#8203;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Issuance of ADSs, including issuances resulting from a distribution of ordinary shares or rights or other property </div>
                  <div style="text-align: justify; line-height: 1.25;"> <br>
                  </div>
                  <div style="text-align: justify; line-height: 1.25;">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">$.05 (or less) per ADS</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Any cash distribution to ADS holders</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the ordinary shares had been deposited for issuance of ADSs</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">$.05 (or less) per ADS per calendar year</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Depositary services</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z19ca98092c9b403dbe8fbc38a32ffcc5">

              <tr>
                <td style="width: 40.72%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Persons depositing or withdrawing ordinary shares or ADS holders must pay</div>
                </td>
                <td style="width: 4.08%; vertical-align: bottom;">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#8203;</div>
                </td>
                <td style="width: 54.62%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">For</div>
                </td>
                <td style="width: 0.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                  <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#8203;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Registration or transfer fees</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw ordinary shares</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Expenses of the depositary</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)</div>
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                  <div style="text-align: justify; line-height: 1.25;">Converting foreign currency to U.S. dollars</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or ordinary shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding
                    taxes</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
                <td nowrap="nowrap" style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">As necessary</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td nowrap="nowrap" style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 40.72%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Any charges incurred by the depositary or its agents for servicing the deposited securities</div>
                </td>
                <td style="width: 4.08%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
                <td nowrap="nowrap" style="width: 54.62%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">As necessary</div>
                </td>
                <td style="width: 0.58%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8203;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or
            from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may
            collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by
            deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services
            until its fees for those services are paid.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of our ADS program,
            waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency or
            other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">40</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The depositary may convert foreign currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as an agent, fiduciary
            or broker on behalf of any other person and earns revenue, including, without limitation, fees and spreads that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned
            to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate
            used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be most favorable to ADS holders, subject
            to its obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Payment of Taxes</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">You will be responsible for any taxes or other governmental charges payable on the ADSs or on the deposited securities represented by any of the ADSs. The depositary may refuse to register any
              transfer of the ADSs or allow you to withdraw the deposited securities represented by the ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by the ADSs to pay any taxes
              owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property,
              remaining after it has paid the taxes.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do so by an ADS holder surrendering ADSs and subject to any conditions or
                procedures the depositary may establish.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a
                corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">If there is any change in the deposited securities such as a subdivision, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the
                issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit
                agreement. However, if the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell
                the replacement securities and distribute the net proceeds upon surrender of the ADSs.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new
                deposited securities or ask you to surrender your outstanding ADSs in exchange for new ADSs identifying the new deposited securities.</div>
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become
            apparently worthless, the depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Amendment and Termination</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">How may the deposit agreement be amended?</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;
            <div style="text-indent: 36pt; line-height: 1.25;">We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other
              governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30&#160;days
              after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold the ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as
              amended.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">How may the deposit agreement be terminated?</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd12b6a4123d346daaf3e9fd6eb2a4874">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>90&#160;days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zccf7506513b14201acef559ca11e784b">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="text-align: left; line-height: 1.25;">we delist the ADSs from an exchange on which they were listed and do not list the ADSs on another exchange within a reasonable time;</div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">41</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div>
            <div><br>
            </div>
            <table cellspacing="0" cellpadding="0" id="za551b2937580494d827a268618cc715b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                <tr>
                  <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>
                      <div style="line-height: 1.25;">the depositary has reason to believe that the ADSs have become, or will become, ineligible for registration on Form F-6 under the Securities Act.</div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9732f99dcad94c2494b38ac48b23f5f1">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>we appear to be insolvent or enter insolvency proceedings;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeb1a184cbb3947ca9ed9f73a09b0a97a">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8b89a1d7b6bb4db8884ba760847860c3">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="text-align: left; line-height: 1.25;">there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or</div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcddfd925b1954acd9683293a0cd7e44d">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>there has been a replacement of deposited securities.</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the deposit agreement will terminate, the depositary will notify ADS holders at least 90&#160;days before the termination date. At any time after the termination date, the
            depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the
            pro&#160;rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the
            depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind if it would interfere with the selling process. The depositary may refuse to accept a
            surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not
            required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit
            agreement except as described in this paragraph.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Limitations on Obligations and Liability</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Limits on our obligations and the obligations of the depositary; Limits on liability to holders of ADSs</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the
            depositary:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0b221cb0538d4bc08f0850e19360a4d1">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z96b6eeacabfe461199bae3d7c7b4cf7f">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>are not liable if we are or it is prevented or delayed by law or circumstances beyond our or its control from performing our or its obligations under the deposit agreement;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z66c5077e2ab94b13b323391bd6829b1b">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>are not liable if we exercise or it exercises discretion permitted under the deposit agreement;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z233a77f41ef94598b976a228ad4d7336">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential
                    or punitive damages for any breach of the terms of the deposit agreement;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z886f909bc44040048a6e41a2319f1eb1">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="text-align: left; line-height: 1.25;">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;</div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0a7be97e1a684efba3c286c373e387e1">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>are not liable for the acts or omissions of any securities depository, clearing agency or settlement system;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6f8c7335c666484094c5897ab0baf2dc">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person; and</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcdfe9b436d2f4fa7972c7990b34de3e6">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>the depositary has no duty to make any determinations or provide any information as to our status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or liable for the
                    inability or failure of an ADS holder to obtain the benefit of a foreign tax credit reduced rate of withholdings or refund of amounts withheld in respect of tax or any other tax benefit.</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">42</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Requirements for Depositary Actions</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6cc66cad8574461ea6ac167ad9bf08f6">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any ordinary shares or other deposited securities;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf719ff09d4da41b49b3a5292e6c8e796">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd96c214d64a2433cae118671ab8fa160">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the
            depositary or we think it advisable to do so.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">
            <div style="line-height: 1.25; font-weight: bold;">Your Right to Receive the Ordinary Shares Underlying the ADSs</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time except:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze2d4d80224f94fa08cf592e9c9966cd8">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>when temporary delays arise because: (i)&#160;the depositary has closed its transfer books or we have closed our transfer books; (ii)&#160;the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting; or (iii)&#160;we are
                    paying a dividend on our shares;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e6c67b739a94c29a0e8bb286d2a0a3b">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>when you owe money to pay fees, taxes and similar charges; or</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5125d3c3b11a44648d04abce1f9f7921">

              <tr>
                <td style="width: 27pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This right of withdrawal may not be limited by any other provision of the deposit agreement.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Direct Registration System</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply to the ADSs. DRS
              is a system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC
              participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant
              without receipt by the depositary of prior authorization from the ADS holder to register that transfer.</div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will
            not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS
            holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance on and compliance with instructions received by the depositary through the DRS/Profile
            system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Shareholder Communications; Inspection of Register of Holders of ADSs</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders
              of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose
              of contacting those holders about a matter unrelated to our business or the ADSs.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25; font-weight: bold;">Jury Trial Waiver</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or
              relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was
              enforceable in the facts and circumstances of that case in accordance with applicable case law.</div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">43</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%44%%%-->
          <div style="line-height: 1.25;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Warrants</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following summary of certain terms and provisions of Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the
              provisions of the Warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Warrant for a
              complete description of the terms and conditions of the Warrants.</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Duration and Exercise Price</font>. Each Warrant offered hereby has an assumed initial exercise price per share equal to $1.52, which is
                the assumed offering price of the ADSs in this offering. The Warrants will be immediately exercisable and will have a term of five (5) years.&#160; The exercise price and number of ADSs issuable upon exercise is subject to appropriate adjustment
                in the event of share dividends, share splits, recapitalizations or similar events affecting our ordinary shares and the exercise price.</div>
            </div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
              <div style="line-height: 1.25">&#160;</div>
            </div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Exercisability</font>. The Warrants will be exercisable, at the option of each holder, in whole or in part, by
              delivering to us a duly executed exercise notice accompanied by payment in full for the number of ADSs purchased upon such exercise (except in the case of a cashless exercise, as discussed below). A holder (together with its affiliates) may
              not exercise any portion of the Warrant to the extent that the holder would beneficially own more than 4.99% (or, at the election of the purchaser, 9.99%)&#160;of the outstanding ordinary shares immediately after exercise. No fractional ADSs will
              be issued in connection with the exercise of a Warrant. In lieu of fractional ADSs, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole ADS.</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Cashless Exercise</font>. If, at the time a holder exercises its Warrants, a registration statement registering the
              issuance of the ADS underlying the Warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities Act is not available for the issuance of such shares, then in lieu of making the
              cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of Warrants determined
              according to a formula set forth in the Warrants.</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Transferability</font>. Subject to applicable laws, a Warrant may be transferred at the option of the holder upon
              surrender of the Warrant to us together with the appropriate instruments of transfer.</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Exchange Listing</font>. We do not intend to list the Warrants on Nasdaq or any other national securities exchange or
              nationally recognized trading system. The ADSs issuable upon exercise of the Warrants are currently listed on Nasdaq.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Right as a Shareholder</font>. Except as otherwise provided in the Warrants or by virtue of such holder&#8217;s ownership of
              ADSs, the holders of the Warrants do not have the rights or privileges of holders of our ordinary shares, including any voting rights, until they exercise their Warrants and receive the ordinary shares underlying the Warrant ADSs from our
              depositary.</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Fundamental Transaction</font>. In the event of a fundamental transaction, as described in the Warrants and generally including any
                reorganization, recapitalization or reclassification of our ordinary shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the
                acquisition of more than 50% of our outstanding ordinary shares, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding ordinary shares, the holders of the Warrants will be entitled to
                receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants immediately prior to such fundamental transaction (without regard to any
                beneficial ownership limitations, as described above).</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Share Combination Event Adjustment</font>. If at any time and from time to time on or after the date of issuance there occurs any share
                split, share dividend, share combination recapitalization or other similar transaction involving the Ordinary Shares (each, a &#8220;Share Combination Event&#8221;, and such date thereof, the &#8220;Share Combination Event Date&#8221;) and the lowest daily volume
                weighted average price during the 5 consecutive trading days commencing on the Share Combination Event Date (the &#8220;Event Market Price&#8221;) (provided if the Share Combination Event is effective after close of Trading on the primary trading
                market, then commencing on the next Trading Day which period shall be the &#8220;Share Combination Adjustment Period&#8221;) is less than the exercise price then in effect (after giving effect to the adjustment in the Warrant upon a stock dividend,
                stock split or similar transaction), then at the close of trading on the primary trading market on the last day of the Share Combination Adjustment Period, the exercise price then in effect on such 5th trading Day shall be reduced (but in
                no event increased) to the Event Market Price and the number of Warrant Shares issuable hereunder shall be increased such that the aggregate exercise Price payable hereunder, after taking into account the decrease in the exercise price,
                shall be equal to the aggregate exercise price on the date of issuance. For the avoidance of doubt, if the adjustment in the immediately preceding sentence would otherwise result in an increase in the exercise price hereunder, no adjustment
                shall be made, and if the Warrant is exercised, on any given exercise date during the Share Combination Adjustment Period, solely with respect to such portion of the Warrant exercised on such applicable exercise date, such applicable Share
                Combination Adjustment Period shall be deemed to have ended on, and included, the trading day immediately prior to such exercise date and the Event Market Price on such applicable exercise date will be the lowest daily volume weighted
                average price of the Ordinary Shares immediately prior to the Share Combination Event Date and ending on, and including the Trading Day immediately prior to such exercise date.</div>
              <div style="text-indent: 36pt; line-height: 1.25;"> <br>
              </div>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">44</font></div>
                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="line-height: 1.25; font-weight: bold;">Pre-Funded Warrants</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">The following summary of certain terms and provisions of the Pre-Funded Warrants included in the Pre-Funded Units that are being offered hereby is not complete and is subject to, and
                qualified in its entirety by, the provisions of the Pre-Funded Warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms
                and provisions of the form of Pre-Funded Warrants for a complete description of the terms and conditions of the Pre-Funded Warrants.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">The purpose of the Pre-Funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, upon election of the holder, 9.99%) of our
                outstanding Ordinary Shares following the consummation of this offering the opportunity to make an investment in the Company without triggering their ownership restrictions, by receiving Pre-Funded Warrants in lieu of ADSs which would
                result in such ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their option to purchase the shares underlying the Pre-Funded Warrants at such nominal price at a later date.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Duration and Exercise Price</font>. Each Pre-Funded Warrant included in a Pre-Funded Unit offered hereby has an initial exercise price per
                ADS equal to $0.001. Pre-Funded Warrants are immediately exercisable and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The exercise price and number of ADSs issuable upon exercise is subject to
                appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our Ordinary Shares and the exercise price.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Exercisability</font>. The Pre-Funded Warrants are exercisable, at the option of each holder, in whole or in part, by delivering to us a
                duly executed exercise notice accompanied by payment in full for the number of ADSs purchased upon such exercise (except in the case of a cashless exercise as discussed below). Purchasers of the Pre-Funded Warrants included in the
                Pre-Funded units in this offering may elect to deliver their exercise notice following the pricing of the offering and prior to the issuance of the Pre-Funded Warrants at closing to have their Pre-Funded Warrants exercised immediately upon
                issuance and receive ADSs underlying the Pre-Funded Warrants upon closing of this offering. A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the extent that the holder would own more than
                4.99% of the outstanding Ordinary Shares (or, at the election of the purchaser, 9.99%), except that upon at least 61 days&#8217; prior notice from the holder to us, a holder with a 4.99% ownership blocker may increase the amount of ownership of
                outstanding shares after exercising the holder&#8217;s Pre-Funded Warrants up to 9.99% of our outstanding Ordinary Shares. No fractional ADSs will be issued in connection with the exercise of a Pre-Funded Warrant. In lieu of fractional shares, we
                may, at our election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price of the Pre-Funded Warrant or round up to the next whole ADS.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Cashless Exercise</font>. In lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the
                aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of ADSs determined according to a formula set forth in the Pre-Funded Warrants.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Transferability</font>. Subject to applicable laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of
                the Pre-Funded Warrant to us together with the appropriate instruments of transfer.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Exchange Listing</font>. There is no trading market available for the Pre-Funded Warrants on any securities exchange or nationally
                recognized trading system. We do not intend to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading system, nor do we have any obligation to do so.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Right as a Shareholder</font>. Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder&#8217;s ownership of the ADSs
                or Ordinary Shares, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders of the ADSs or Ordinary Shares, including any voting rights, until they exercise their Pre-Funded Warrants.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Fundamental Transaction</font>. If, at any time while the Pre-Funded Warrants are outstanding, (1) we, directly or indirectly, consolidate
                or merge with or into another person, (2) we, directly or indirectly, sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets, (3) any direct or indirect purchase offer, tender offer or
                exchange offer (whether by us or another person) is completed pursuant to which holders of our Ordinary Shares (including any Ordinary Shares underlying ADSs)&#160; are permitted to sell, tender or exchange their Ordinary Shares for other
                securities, cash or property and has been accepted by the holders of 50% or more of our outstanding Ordinary Shares or 50% or more of the voting power of the common equity of the Company&#160; (including any Ordinary Shares underlying ADSs), (4)
                we, directly or indirectly, effect any reclassification, reorganization or recapitalization of our Ordinary Shares or any compulsory share exchange pursuant to which our Ordinary Shares are converted into or exchanged for other securities,
                cash or property, or (5) we, directly or indirectly, consummate a stock or share purchase agreement or other business combination with another person whereby such other person acquires more than 50% of our outstanding Ordinary Shares
                (including any Ordinary Shares underlying ADSs) or 50% or more of the voting power of the common equity of the Company, each, a &#8220;Fundamental Transaction&#8221;, then upon any subsequent exercise of the Pre-Funded Warrants, a holder thereof will
                have the right to receive the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental
                Transaction, the holder of the number of ADSs then issuable upon exercise of the Pre-funded Warrant, and any additional consideration payable as part of the Fundamental Transaction.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">45</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <a name="MATERIALTAXCONSIDERATIONS"><!--Anchor--></a>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">MATERIAL TAX CONSIDERATIONS</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following is a brief summary of certain material tax consequences concerning the ownership and disposition of our securities by purchasers or holders of our securities.
            Because parts of this discussion are based on new or existing tax or other legislation that has not been subject to judicial or administrative interpretation, there can be no assurance that the views expressed herein will be accepted by the tax
            or other authorities in question. The summary below does not address all of the tax consequences that may be relevant to all purchasers or holders of our securities in light of each purchaser&#8217;s or holder&#8217;s particular circumstances and specific
            tax treatment. For example, the summary below does not address the tax treatment of residents of Israel and traders in securities who are subject to special tax regimes. As individual circumstances may differ, holders of our securities should
            consult their own tax advisors as to United States, Israeli or other tax consequences of the purchase, ownership and disposition of our securities. The discussion below is subject to change, including due to amendments under Israeli law or
            changes to the applicable judicial or administrative interpretations of Israeli law, which change could affect the accuracy of the tax consequences described below. This discussion is not intended, nor should it be construed, as legal or
            professional tax advice and it is not exhaustive of all possible tax considerations. Each investor should consult his or her own tax or legal advisor.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Israeli Taxation</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Taxation of Capital Gains Applicable to Non-Israeli Shareholders</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Israeli Income Tax Ordinance [New Version], 5721-1961 (the &#8220;Tax Ordinance&#8221;) generally imposes a capital gains tax on the sale of capital assets by non-Israeli tax
            residents if those assets (i) are located in Israel, (ii) are shares or a right to shares in an Israeli resident corporation, including securities traded on the Tel Aviv Stock Exchange (the &#8220;TASE&#8221;), on a recognized stock exchange outside Israel
            (such as Nasdaq) or on a regulated market (which includes a system through which securities are traded pursuant to rules prescribed by the competent authority in the relevant jurisdiction) in or outside Israel, or (iii) represent, directly or
            indirectly, rights to assets located in Israel, unless a specific exemption is available or unless a tax treaty between Israel and the shareholder&#8217;s country of residence provides otherwise. The Tax Ordinance distinguishes between real capital
            gain and inflationary surplus. The inflationary surplus is a portion of the total capital gain equivalent to the increase of the relevant asset&#8217;s tax basis attributable to an increase in the Israeli consumer price index or, in certain
            circumstances, a foreign currency exchange rate, between the date of purchase and the date of disposition. Inflationary surplus is not currently subject to tax in Israel. The real capital gain is the excess of the total capital gain over the
            inflationary surplus. The capital gains tax rate applicable to individuals upon the sale of such securities is 25%, or 30% with respect to an individual who meets the definition of a &#8216;Substantial Shareholder&#8217; on the date of the sale of the
            securities or at any time during the 12 month-period preceding such date (or claims a deduction for interest and linkage differences expenses in connection with the purchase and holding of such shares). A &#8216;Substantial Shareholder&#8217; is defined as
            a person who, either alone or together with another person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of a company (including, among other things, the
            right to receive profits of the company, voting rights, the right to receive the company&#8217;s liquidation proceeds and the right to appoint a director). With respect to corporate investors, the capital gains tax rate is equal to the corporate tax
            rate (23% in 2023).</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Notwithstanding the foregoing, dealers in securities in Israel whose gains from selling or otherwise disposing of the shares or ADSs are deemed to be business income are
            taxed at regular tax rates applicable to business income (a corporate tax rate for a corporation and a marginal tax rate of up to 47% for an individual in 2023, excluding excess tax as discussed below) unless contrary provisions in a relevant
            tax treaty applies.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Generally, a non-Israeli resident (whether an individual or a corporation) who derives capital gains from the sale of shares or ADSs in an Israeli resident company purchased
            upon or after the registration of the shares on the TASE or on a regulated market outside of Israel (such as Nasdaq) may be generally be exempt from Israeli capital gains tax, provided, among other things, that the capital gain derived from the
            sale&#160; of shares or ADSs was not attributed to a permanent establishment that the non-Israeli tax resident investor maintains in Israel.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">However, non-Israeli resident &#8220;body of persons&#8221; (as defined under the Tax Ordinance, which includes corporate entities, partnerships and other entities) will not be entitled
            to the foregoing exemption if Israeli residents, whether directly or indirectly: (i) hold more than 25% of any of the means of control in such non-Israeli entity or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues
            or profits of such non-Israeli entity, whether directly or indirectly. Such exemption is not applicable to a person whose gains from selling or otherwise disposing of the shares or ADSs are deemed to be business income. In addition, a sale of
            shares by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, persons paying consideration for shares or ADSs, including purchasers of shares or ADSs, Israeli securities dealers effecting a transaction, or a financial
            institution through which securities being sold are held, are generally required to withhold Israeli tax at source upon the sale of publicly traded securities at a rate of 25% for individuals and at the corporate tax rate (23% in 2023) for
            corporations, regardless of whether such holder is liable for or exempt from Israeli capital gains tax on such sale. Holders may be required to demonstrate that they are exempt from tax on their capital gains by providing a valid certificate
            from the Israel Tax Authority allowing for an exemption from withholding tax at source at the time of sale. Specifically, in transactions involving a sale of all of the shares of an Israeli resident company, in the form of a merger or
            otherwise, the Israel Tax Authority may require from securityholders who are not liable for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the Israel Tax Authority to confirm their
            status as a non-Israeli resident for tax purposes, and, in the absence of such declarations or exemptions, may require the purchaser of the shares to withhold Israeli taxes at source.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">46</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Income Taxes on Dividend Distribution to Non-Israeli Shareholders</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Non-Israeli residents (whether individuals or corporations) are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of
            25%, unless relief is provided under the provisions of an applicable tax treaty between Israel and the shareholder&#8217;s country of residence (provided that a certificate from the Israel Tax Authority allowing for a reduced withholding tax rate or
            a tax exemption is obtained in advance). With respect to a person who is a Substantial Shareholder (as defined above) at the time of receiving the dividend or on any time during the preceding 12 months, the applicable tax rate is 30%.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In principle, non-Israeli residents (whether individuals or corporations) are generally subject to Israeli withholding tax on the receipt of dividends paid on publicly traded
            shares at the rate of 25% and at the rate of 30% on dividends paid to Substantial Shareholders. However, so long as the shares are registered with a Nominee Company, which is a company incorporated to be a holder of record and distribution
            agent of publicly traded or other securities in accordance with the Israeli Securities Law, 5728-1968, the dividends are generally subject to Israeli withholding tax at a rate of 25% (whether or not the recipient is a Substantial Shareholder),
            unless a reduced rate is provided under an applicable tax treaty (provided that a certificate from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance).</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The distribution of dividends to non-Israeli residents (either individuals or corporations) from income derived from a company&#8217;s Approved Enterprises or Benefited Enterprises
            (as such terms are defined under the Israeli Law for the Encouragement of Capital Investments, 5719-1959), during the applicable benefits period is subject to withholding tax at a rate of 15%, and 20% if the dividend is distributed from income
            attributed to a Preferred Enterprise, a Special Preferred Enterprise, Preferred Technological Enterprise or Special Preferred Technological Enterprise (as such terms are defined under the Israeli Law for the Encouragement of Capital
            Investments, 5719-1959),&#160;subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for such reduced tax rates, or such lower rate as may be provided under an applicable tax treaty (provided that a
            certificate from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance). We cannot assure you that we will designate the profits that we may distribute in a way that will reduce shareholders&#8217; tax liability.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A non-resident of Israel who has dividend and/or capital income derived from or accrued in Israel, from which the full amount of tax was withheld, is generally exempt from
            the duty to file tax returns in Israel in respect of such income, provided that: (i) such income was not derived from a business conducted in Israel by the taxpayer; (ii) the taxpayer has no other taxable sources of income in Israel with
            respect to which a tax return is required to be filed; and (iii) the taxpayer is not obligated to pay Excess Tax (as further explained below).</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">U.S.- Israel Tax Treaty</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Convention between the Government of the State of Israel and the Government of the United States of America with Respect to Taxes on Income (the &#8220;Treaty&#8221;) is generally
            effective as of January 1, 1995. Under the Treaty, the maximum Israeli withholding tax on dividends paid to a holder of our ordinary shares who is a Treaty U.S. Resident (as defined below) is generally 25%. However, generally, for dividends not
            generated by an Approved Enterprise, Benefited Enterprise or Preferred Enterprises and paid to a U.S. corporation holding 10% or more of the outstanding voting capital throughout the tax year in which the dividend is distributed as well as
            during the previous tax year, the maximum rate of Israeli withholding tax is generally 12.5%, provided that not more than 25% of the gross income of the Israeli resident paying corporation for such preceding year consists of certain types of
            dividends and interest. Notwithstanding the foregoing, dividends distributed from income attributed to an Approved Enterprise are not entitled to such reduction under such tax treaty but are subject to withholding tax at the rate of 15% for
            such a U.S. corporate shareholder, provided that the conditions related to the holding of 10% of our voting capital and to our gross income for the previous year (as set forth in the previous sentence) are met. The aforementioned rates under
            the Treaty would not apply if the dividend income is derived through a permanent establishment of the Treaty U.S. Resident in Israel.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Treaty, the sale, exchange or disposition of our ordinary shares or ADSs by a person who qualifies as a resident of the United States within the meaning of
            the Treaty that holds the shares or ADSs as a capital asset, and who is entitled to claim the benefits afforded to such residents under the Treaty a (&#8220;Treaty U.S. Resident&#8221;) generally will not be subject to the Israeli capital gains tax
            unless,&#160;<font style="font-style: italic;">inter alia</font>: (i) such Treaty U.S. Resident holds, directly or indirectly, shares or ADSs representing 10% or&#160; more of the voting power of the Company during any part of the 12-month period
            preceding such sale, exchange or disposition subject to certain conditions; (ii) the capital gain arising from such sale, exchange or disposition can be attributable to a permanent establishment of the holder maintained in Israel, under certain
            terms; (iii) such U.S. resident is an individual and was present in Israel for a period or periods aggregating to 183 days or more during the relevant taxable year; (iv) the capital gains arising from such sale, exchange or disposition is
            attributed to real estate located in Israel, or (v) the capital gain arising from such sale, exchange or disposition is attributed to royalties.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">47</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As noted above, a sale, exchange or disposition of our ordinary shares or ADSs by a Treaty U.S. Resident who holds, directly or indirectly, shares representing 10% or more of
            the voting power of the Company at any time during such preceding 12-month period would not be exempt under the Treaty from such Israeli tax; however, under the Treaty, a Treaty U.S. Resident may be permitted to claim a credit for such taxes
            against U.S. federal income tax imposed on any gain from such sale, exchange or disposition, under the circumstances and subject to the limitations specified in the Treaty and U.S. domestic law.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Excess Tax</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Individuals (whether Israeli or non-Israeli tax residents) who are subject to tax in Israel are also subject to an additional tax at a rate of 3% on their annual income
            exceeding NIS 698,280 for 2023, which amount is linked to the annual change in the Israeli Consumer Price Index, including, but not limited to, dividends, interest and capital gain.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Certain Material U.S. Federal Income Tax Consequences</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">General</div>
          <div style="text-align: justify; line-height: 1.25;"><br>
            <div style="text-indent: 36pt; line-height: 1.25;">The following discussion describes the material U.S. federal income tax consequences relating to the ownership and disposition of our ordinary shares or Pre-Funded Warrants by U.S. Holders (as
              defined below). This discussion applies to U.S. Holders that purchase ordinary shares or Pre-Funded Warrants pursuant to this offering and hold such ordinary shares or Pre-Funded Warrants as capital assets within the meaning of Section 1221
              of the Code. This discussion is based on the Code, U.S. Treasury regulations promulgated thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly
              with retroactive effect. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment
              under U.S. federal income tax law (such as banks, financial institutions, insurance companies, broker-dealers and traders in securities, commodities or currencies, persons that generally mark their securities to market for U.S. federal income
              tax purposes, tax-exempt entities, retirement plans, individual retirement accounts or other tax deferred accounts, regulated investment companies, real estate investment trusts, certain former citizens or residents of the United States,
              persons who hold ordinary shares or Pre-Funded Warrants as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion transaction,&#8221; &#8220;synthetic security&#8221; or integrated investment, persons who received their ordinary shares as compensatory payments, persons
              that have a &#8220;functional currency&#8221; other than the U.S. dollar, persons that own or are treated for tax purposes as owning directly, indirectly or through attribution 10% or more of our shares by vote or value, persons who are subject to
              special tax accounting under Section 451(b) of the Code, corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass-through entities and arrangements that are classified as partnerships for U.S.
              federal income tax purposes, and investors in such pass-through entities, holders receiving or holding ordinary shares in connection with the performance of services, and any holders that are not U.S. Holders). This discussion does not
              address any U.S. state or local or non-U.S. tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">As used in this discussion, the term &#8220;U.S. Holder&#8221; means a beneficial owner of ordinary shares or Pre-Funded&#160;Warrants that is, for U.S. federal income tax purposes, (1) an individual who is a
              citizen or resident of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of
              Columbia, (3) an estate the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within the United States is able to exercise primary supervision over its
              administration and one or more United States persons have the authority to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income
              tax purposes.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds ordinary shares or Pre-Funded Warrants, the U.S. federal income tax consequences relating to an
              investment in the ordinary shares or Pre-Funded Warrants will depend in part upon the status and activities of such entity or arrangement and the particular partner. Any such entity or arrangement should consult its own tax advisor regarding
              the U.S. federal income tax consequences applicable to it and its partners of the purchase, ownership and disposition of ordinary shares or Pre-Funded Warrants.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Persons considering an investment in ordinary shares or Pre-Funded Warrants should consult their own tax advisors as to the particular tax consequences applicable to them
              relating to the purchase, ownership and disposition of ordinary shares or Pre-funded Warrants, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">48</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Passive Foreign Investment Company Consequences</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In general, a corporation organized outside the United States will be treated as a PFIC, for any taxable year in which either (1) at least 75% of its gross income is &#8220;passive
            income&#8221;, the PFIC income test, or (2) on average at least 50% of its assets, determined on a quarterly basis, are assets that produce passive income or are held for the production of passive income, the PFIC asset test. Passive income for this
            purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property that gives rise to passive income. Assets that produce or are held for the production of passive income
            generally include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate
            share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets (which may be determined based on the fair market value of each
              asset, with the value of goodwill and going concern value being determined in large part by reference to the market value of the ADSs, which may be volatile). Based upon the value of our assets, including any goodwill and the nature and
              composition of our income, we believe that we were classified as a PFIC for the taxable year ended December 31, 2021. Furthermore, we presently anticipate that we will be classified as a PFIC for the current taxable year ending December 31,
              2022 based upon the expected value of our assets, including goodwill, and the expected nature and composition of our income and assets. Our status as a PFIC is a fact-intensive determination made on an annual basis after the end of each
              taxable year. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with our conclusion and that the IRS would not successfully challenge our position. Our U.S. counsel expresses no
              opinion with respect to our PFIC status for any period</div>
            <div style="line-height: 1.25">&#160;
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to the discussion below relating to the making of a QEF election or a mark-to-market election by a U.S. Holder, if we are a PFIC in any taxable year during which
                a U.S. Holder owns ordinary shares or Pre-Funded&#160;Warrants, the U.S. Holder could be liable for additional taxes and interest charges under the &#8220;PFIC excess distribution regime&#8221; upon (1) a distribution paid during a taxable year that is
                greater than 125% of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder&#8217;s holding period for the ordinary shares or Pre-Funded&#160;Warrants, and (2) any gain recognized on a sale,
                exchange or other disposition, including a pledge, of the ordinary shares or Pre-Funded&#160;Warrants, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined
                by allocating the distribution or gain ratably over the U.S. Holder&#8217;s holding period for ordinary shares or Pre-Funded&#160;Warrants. The amount allocated to the current taxable year (i.e., the year in which the distribution occurs or the gain
                is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates
                in effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="line-height: 1.25">
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we are a PFIC for any year during which a U.S. Holder holds ordinary shares or Pre-Funded&#160;Warrants, we must generally continue to be treated as a PFIC by that holder
                  for all succeeding years during which the U.S. Holder holds the ordinary shares or Pre-Funded&#160;Warrants, unless we cease to meet the requirements for PFIC status and the U.S. Holder makes a &#8220;deemed sale&#8221; election with respect to the
                  ordinary shares or Pre-Funded&#160;Warrants. If the election is made, the U.S. Holder will be deemed to sell the ordinary shares or Pre-Funded&#160;Warrants it holds at their fair market value on the last day of the last taxable year in which we
                  qualified as a PFIC, and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale election, the U.S. Holder&#8217;s ordinary shares or Pre-Funded&#160;Warrants would not be treated as
                  shares or warrants of a PFIC unless we subsequently become a PFIC.</div>
                <div style="line-height: 1.25">&#160;</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we are a PFIC for any taxable year during which a U.S. Holder holds ordinary shares or Pre-Funded&#160;Warrants and one of our non-U.S. corporate subsidiaries is also a
                  PFIC (i.e., a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the
                  lower-tier PFIC and on gain from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Each U.S. Holder is advised to consult its tax advisors
                  regarding the application of the PFIC rules to our non-U.S. subsidiaries.</div>
                <div style="line-height: 1.25">&#160;</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In general, if we are determined to be a PFIC, a U.S. Holder may avoid application of the PFIC tax consequences described above in respect to our ordinary shares or
                  Pre-Funded&#160;Warrants by making a timely QEF election (if eligible to do so) to include in income its pro rata share of our net capital gains (as long-term capital gain) and other earnings and profits (as ordinary income), on a current
                  basis, in each case whether or not distributed, in the taxable year of the U.S. Holder in which or with which our taxable year ends. A U.S. Holder generally may make a separate election to defer the payment of taxes on undistributed
                  income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest charge. It should be noted that dividends paid by a PFIC would generally not qualify for the preferred capital gains rates discussed
                  above. The QEF election is made on a shareholder-by-shareholder basis and, once made, can be revoked only with the consent of the IRS.</div>
              </div>
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A U.S. Holder generally makes a QEF election by attaching a completed IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified
            Electing Fund), including the information provided in a PFIC annual information statement, to a timely filed U.S. federal income tax return for the tax year to which the election relates. Retroactive QEF elections generally may be made only by
            filing a protective statement with such return and if certain other conditions are met or with the consent of the IRS. U.S. Holders should consult their own tax advisors regarding the availability and tax consequences of a retroactive QEF
            election under their particular circumstances.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">49</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In order to comply with the requirements of a QEF election, a U.S. Holder must receive a PFIC annual information statement from us. If we determine we are a PFIC for any
            taxable year, we will endeavor to provide to a U.S. Holder such information as the IRS may require, including a PFIC annual information statement, in order to enable the U.S. Holder to make and maintain a QEF election. However, there is no
            assurance that we will have timely knowledge of our status as a PFIC in the future or of the required information to be provided.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">If a U.S. Holder has made a QEF election with respect to our Class A ordinary shares or Pre-Funded&#160;Warrants, and the special tax and interest charge rules do not apply to such shares (because
              of a timely QEF election for our first taxable year as a PFIC in which the U.S. Holder holds (or is deemed to hold) such shares), any gain recognized on the sale of our Class A ordinary shares or Pre-Funded Warrants generally will be taxable
              as capital gain and no interest charge will be imposed under the PFIC rules. As discussed above, U.S. Holders of a QEF are currently taxed on their pro rata shares of its earnings and profits, whether or not distributed. In such case, a
              subsequent distribution of such earnings and profits that were previously included in income generally should not be taxable as a dividend to such U.S. Holders. The tax basis of a U.S. Holder&#8217;s shares or Pre-Funded Warrants in a QEF will be
              increased by amounts that are included in income, and decreased by amounts distributed but not taxed as dividends, under the above rules.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">Although a determination as to our PFIC status will be made annually, an initial determination that our company is a PFIC will generally apply for subsequent years to a U.S. Holder who held our
              ordinary shares or Pre-Funded Warrants while we were a PFIC, whether or not we meet the test for PFIC status in those subsequent years. A U.S. Holder who makes the QEF election discussed above for our first taxable year as a PFIC in which the
              U.S. Holder holds (or is deemed to hold) our ordinary shares or Pre-Funded Warrants, however, will not be subject to the PFIC tax and interest charge rules discussed above in respect to such shares or Pre-Funded Warrants. In addition, such
              U.S. Holder will not be subject to the QEF inclusion regime with respect to our ordinary shares or Pre-Funded Warrants for any taxable year of us that ends within or with a taxable year of the U.S. Holder and in which we are not a PFIC. On
              the other hand, if the QEF election is not effective for each of our taxable years in which we are a PFIC and the U.S. Holder holds our ordinary shares or Pre-Funded Warrants, the PFIC rules discussed above will continue to apply to such
              ordinary shares or Pre-Funded Warrants unless the holder makes a &#8220;deemed sale&#8221; election under the PFIC rules. If the U.S. Holder makes such a deemed sale election, the U.S. Holder may thereafter make a QEF election. The deemed sale election
              creates a deemed sale of such ordinary shares or Pre-Funded Warrants at their fair market value. The gain recognized by the deemed sale election attributable to the pre-QEF election period will be subject to the special tax and interest
              charge rules treating the gain as an excess distribution under the general PFIC rules described above. As a result of the deemed sale election, the U.S. Holder will have a new basis and holding period in the ordinary shares or Pre-Funded
              Warrants for purposes of the PFIC rules. U.S. Holders are urged to consult their tax advisors as to the application of the rules governing purging elections to their particular circumstances.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">Alternatively, if we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on ordinary shares or Pre-Funded Warrants
              if such U.S. Holder makes a valid &#8220;mark-to-market&#8221; election for our ordinary shares or Pre-Funded warrants. A mark-to-market election is available to a U.S. Holder only for &#8220;marketable stock.&#8221; Our ordinary shares or Pre-Funded Warrants will
              be marketable stock as long as they remain listed on Nasdaq and are regularly traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. If a mark-to-market election is in effect, a U.S. Holder generally
              would take into account, as ordinary income for each taxable year of the U.S. holder, the excess of the fair market value of ordinary shares or Pre-Funded Warrants held at the end of such taxable year over the adjusted tax basis of such
              ordinary shares or Pre-Funded&#160;Warrants. The U.S. Holder would also take into account, as an ordinary loss each year, the excess of the adjusted tax basis of such ordinary shares or Pre-Funded Warrants over their fair market value at the end
              of the taxable year, but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holder&#8217;s tax basis in ordinary shares or Pre-Funded Warrants
              would be adjusted to reflect any income or loss recognized as a result of the mark-to-market election. Any gain from a sale, exchange or other disposition of ordinary shares or Pre-Funded Warrants in any taxable year in which we are a PFIC
              would be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter as capital
              loss.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">A mark-to-market election will not apply to ordinary shares or Pre-Funded Warrants for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent
              taxable year in which we become a PFIC. Such election will not apply to any non-U.S. subsidiaries that we may organize or acquire in the future. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution
              regime with respect to any lower-tier PFICs that we may organize or acquire in the future notwithstanding the U.S. Holder&#8217;s mark-to-market election for the ordinary shares or Pre-Funded Warrants.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">Each U.S. person that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621 containing such information as the U.S. Treasury Department may
              require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">The U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own tax advisors with
                respect to the impact of PFIC status on the purchase, ownership and disposition of ordinary shares or Pre-Funded Warrants, the consequences to them of an investment in a PFIC, any elections available with respect to the ordinary shares or</font>&#160;<font style="font-weight: bold;">Pre-Funded Warrants and the IRS information reporting obligations with respect to the purchase, ownership and disposition of ordinary shares or Pre-Funded Warrants of a PFIC.</font></div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">50</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <div style="text-align: left; line-height: 1.25; font-weight: bold;">General Treatment of&#160;Pre-Funded&#160;Warrants</div>
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Although the law in this area is not completely settled, the&#160;Pre-Funded&#160;Warrants are generally expected to be treated as outstanding
                stock for U.S. federal income tax purposes. Accordingly, upon exercise, no income, gain or loss should be recognized upon the exercise of a Pre-Funded Warrant except to the extent of cash received in exchange for a fractional share, which
                will be treated as a sale subject to the rules described below under &#8220;<font style="font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8212; </font>Sale, Exchange or Other Disposition of Ordinary Shares and Pre-Funded Warrants,&#8221;
                and the holding period of a&#160;pre-funded&#160;warrant should carry over to the share of common stock received. The tax basis of the&#160;Pre-Funded&#160;Warrant should carry over to the share of common stock received upon exercise increased by the exercise
                price. If you are contemplating the acquisition of&#160;Pre-Funded&#160;Warrants, you should discuss with your personal tax advisor the consequences of the purchase, ownership and disposition of the&#160;Pre-Funded&#160;Warrants, as well as the exercise of,
                certain adjustments to, and any payments in respect of the&#160;Pre-Funded&#160;Warrants (including potential alternative characterizations).</div>
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Distributions</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to the discussion above under &#8220;&#8212;Passive Foreign Investment Company Consequences,&#8221; a U.S. Holder that receives a distribution with respect to ordinary shares generally
            will be required to include the gross amount of such distribution (before reduction for any Israeli withholding taxes withheld therefrom) in gross income as a dividend when actually or constructively received to the extent of the U.S. Holder&#8217;s
            pro rata share of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&#8217;s pro
            rata share of our current and accumulated earnings and profits, it will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#8217;s ordinary shares. To the extent the distribution
            exceeds the adjusted tax basis of the U.S. Holder&#8217;s ordinary shares, the remainder will be taxed as capital gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should
            expect all distributions to be reported to them as dividends. Such dividends will not be eligible for the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Dividends paid to non-corporate U.S. Holders by a &#8220;qualified foreign corporation&#8221; are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates
            generally applicable to ordinary income provided that certain requirements are met. However, if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year (see discussion above under &#8220;&#8212;Passive Foreign
            Investment Company Consequences&#8221;), we will not be treated as a qualified foreign corporation, and therefore the reduced capital gains tax rate described above will not apply. Each U.S. Holder is advised to consult its tax advisors regarding the
            availability of the reduced tax rate on dividends with regard to its particular circumstances.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A non-United States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year)
            generally will be considered to be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for
            purposes of this provision and which includes an exchange of information provision, or (b) with respect to any dividend it pays on ordinary shares that are readily tradable on an established securities market in the United States. We believe
            that we qualify as a resident of Israel for purposes of, and are eligible for the benefits of, the Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the Treaty is satisfactory for purposes of the
            qualified dividend rules and that it includes an exchange of information provision. Therefore, subject to the discussion above under &#8220;&#8212;Passive Foreign Investment Company Consequences,&#8221; if the Treaty is applicable, such dividends will generally
            be &#8220;qualified dividend income&#8221; in the hands of individual U.S. Holders, provided that certain conditions are met.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">Distributions on ordinary shares that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and generally will
              constitute passive category income. Subject to applicable limitations, some of which vary depending upon a U.S. Holder&#8217;s particular circumstances, Israeli income taxes withheld from dividends on the ADSs at a rate not exceeding the rate
              provided by the Treaty (assuming such U.S. Holder is eligible for the benefits of the Treaty) will be creditable against the U.S. Holder&#8217;s U.S. federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders
              should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Israeli
              income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable
              year.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25">
              <div style="line-height: 1.25;">
                <div style="text-align: left; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The taxation of a distribution received with respect to a&#160;Pre-funded&#160;Warrant is unclear. It is possible such a distribution would be treated as a distribution as described in
                  this section, although other treatments may also be possible. You should consult your tax advisors regarding the proper treatment of any payments in respect of the&#160;Pre-Funded&#160;Warrants.</div>
                <div style="line-height: 1.25">&#160;</div>
              </div>
              <div style="line-height: 1.25; font-weight: bold;">Sale, Exchange or Other Disposition of Ordinary Shares and Pre-Funded Warrants</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">Subject to the discussion above under &#8220;&#8212;Passive Foreign Investment Company Consequences,&#8221; a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon
                the sale, exchange or other disposition of ordinary shares or Pre-Funded Warrants in an amount equal to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on
                the sale, exchange or other disposition and such U.S. Holder&#8217;s adjusted tax basis in the ordinary shares or Pre-Funded Warrants. Such capital gain or loss generally will be long-term capital gain taxable at a reduced rate for non-corporate
                U.S. Holders or long-term capital loss if, on the date of sale, exchange or other disposition, the ordinary shares or Pre-Funded Warrants were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate U.S. Holder
                that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized from the sale or other disposition of ordinary shares or Pre-Funded Warrants
                will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes.</div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">51</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">&#160;
            <div style="text-align: left; line-height: 1.25; font-weight: bold;">Certain Adjustments to Pre-Funded Warrants</div>
            <div style="text-align: left; line-height: 1.25; font-weight: bold;"> <br>
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="line-height: 1.25;">
              <div style="text-indent: 36pt; line-height: 1.25;">Under Section&#160;305 of the Code, an adjustment to the number of shares of common stock that will be issued on the exercise of the&#160;Pre-Funded&#160;Warrants, or an adjustment to the exercise price of
                the&#160;Pre-Funded&#160;warrants, may be treated as a constructive distribution to you of the&#160;Pre-Funded&#160;Warrants if, and to the extent that, such adjustment has the effect of increasing your proportionate interest in our &#8220;earnings and profits&#8221; or
                assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to our shareholders).</div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
            <div style="line-height: 1.25;">
              <div style="text-align: left; line-height: 1.25; font-weight: bold;">Lapse of&#160;Pre-Funded&#160;Warrants</div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
            <div style="line-height: 1.25;">
              <div style="text-indent: 36pt; line-height: 1.25;">If a U.S. holder allows a&#160;Pre-funded&#160;Warrant to expire unexercised, such U.S. holder will recognize a capital loss in an amount equal to such holder&#8217;s tax basis in&#160;Pre-funded&#160;Warrant. The
                deductibility of capital losses is subject to certain limitations.</div>
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25;"> <br>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Disposition of Foreign Currency</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;
            <div style="text-indent: 36pt; line-height: 1.25;">U.S. Holders are urged to consult their tax advisors regarding the tax consequences of receiving, converting or disposing of any non-U.S. currency received as dividends on ordinary shares or on
              the sale or retirement of ordinary shares or Pre-Funded Warrants.</div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Medicare Tax</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;
            <div style="text-indent: 36pt; line-height: 1.25;">Certain U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income,
              which may include their gross dividend income and net gains from the disposition of ordinary shares or Pre-Funded Warrants. If you are a United States person that is an individual, estate or trust, you are encouraged to consult your tax
              advisors regarding the applicability of this tax to your income and gains in respect of your investment in ordinary shares or Pre-Funded Warrants.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Information Reporting and Backup Withholding</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in ordinary shares or Pre-Funded&#160;Warrants, including, among others,
              IRS Form 8938 (Statement of Specified Foreign Financial Assets). As described above under &#8220;Passive Foreign Investment Company Consequences,&#8221; each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain
              information. U.S. Holders paying more than $100,000 for ordinary shares or Pre-Funded&#160;Warrants may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial
              penalties may be imposed upon a U.S. Holder that fails to comply with the required information reporting.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">Dividends on and proceeds from the sale or other disposition of ordinary shares or Pre-Funded&#160;Warrants may be reported to the IRS unless the U.S. Holder establishes a basis for exemption.
              Backup withholding (currently at a rate of 24%) may apply to amounts subject to reporting if the holder (1) fails to provide an accurate United States taxpayer identification number or otherwise establish a basis for exemption, or (2) is
              described in certain other categories of persons. However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules. Backup withholding is not an additional tax. Any amounts
              withheld under the backup withholding rules generally will be allowed as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">U.S. Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25; font-weight: bold;">EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ORDINARY SHARES AND PRE-FUNDED&#160;WARRANTS IN LIGHT OF THE INVESTOR&#8217;S OWN
              CIRCUMSTANCES.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">52</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div>
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="UNDERWRITINGN"><!--Anchor--></a>UNDERWRITING</div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We entered into an underwriting agreement with Aegis Capital Corp., the underwriter of this offering, on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2023. The underwriting agreement provides for the
              purchase of a specific number of Units and Pre-Funded Units.&#160; Subject to the terms and conditions of the underwriting agreement, the underwriter has agreed to purchase the number of Units and Pre-Funded Units set forth opposite its name
              below:</div>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" border="0" id="z735f55db07764e3883926f51b941ecce" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 75%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="line-height: 1.25; font-weight: bold;">Underwriter</div>
                  </td>
                  <td style="width: 0.62%; vertical-align: bottom; padding-bottom: 2px;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#8203;</div>
                  </td>
                  <td style="width: 9.38%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of<br>
                      Units</div>
                  </td>
                  <td style="width: 2%; vertical-align: top; padding-bottom: 2px;">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of Pre-Funded Units</div>
                  </td>
                  <td style="width: 0.84%; vertical-align: top; padding-bottom: 2px;">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 75%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Aegis Capital Corporation</div>
                  </td>
                  <td style="width: 0.62%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9.38%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 0.84%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: center; line-height: 1.25;">&#8203;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 75%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">Total</div>
                  </td>
                  <td style="width: 0.62%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#8203;</div>
                  </td>
                  <td style="width: 9.38%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#8203;</div>
                  </td>
                  <td style="width: 2%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 0.84%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The underwriter has agreed to purchase all of the Units and Pre-Funded Units offered by this prospectus (other than those covered by the over-allotment option described
              below), if any are purchased.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Units and Pre-Funded Units offered hereby are expected to be ready for delivery on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2023 against payment in immediately available funds.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The underwriter is offering the Units and Pre-Funded Units subject to various conditions and may reject all or part of any order. The underwriter has advised us that the
              underwriter proposes initially to offer the Units and Pre-Funded Units to the public at the public offering price set forth on the cover page of this prospectus and to dealers at a price less a concession not in excess of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per ADS
              and accompanying Warrant (or per Pre-Funded Warrant and accompanying Warrant) to brokers and dealers. After the ADSs and Pre-Funded Warrants are released for sale to the public, the underwriter may change the offering price, the concession,
              and other selling terms at various times.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table provides information regarding the amount of the discounts to be paid to the underwriter by us, before expenses. These amounts are shown assuming both
              no exercise and full exercise of the underwriter&#8217;s option to purchase additional securities.</div>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" border="0" id="z85723ac37ebb41aba767ac0eeeb880f8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 51.33%; vertical-align: bottom; padding-bottom: 2px;">
                    <div style="line-height: 1.25; font-weight: bold;">&#8203;</div>
                  </td>
                  <td style="width: 0.48%; vertical-align: bottom; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Per Unit</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Per Pre-Funded Unit</div>
                  </td>
                  <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Total No Exercise</div>
                  </td>
                  <td style="width: 1%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td style="width: 9%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Total Full Exercise</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 51.33%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">Public offering price</div>
                  </td>
                  <td style="width: 0.48%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: right; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td nowrap="nowrap" style="width: 0.96%; vertical-align: top; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 51.33%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">Underwriting discounts (1)</div>
                  </td>
                  <td style="width: 0.48%; vertical-align: bottom;">
                    <div style="text-align: right; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
                  <td style="width: 1%; vertical-align: bottom;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom;">&#160;</td>
                  <td nowrap="nowrap" style="width: 0.96%; vertical-align: top;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: top;">&#160;</td>
                  <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
                  <td style="width: 9%; vertical-align: top;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 51.33%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">Proceeds, before expenses, to us</div>
                  </td>
                  <td style="width: 0.48%; vertical-align: bottom; background-color: #CCEEFF;">
                    <div style="text-align: right; line-height: 1.25;">&#160;</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td nowrap="nowrap" style="width: 0.96%; vertical-align: top; background-color: #CCEEFF;">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">(1) We have agreed to pay the underwriter a discount of 7.0% of the gross proceeds of this offering.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; line-height: 1.25;">We estimate that our total expenses of the offering, excluding the estimated underwriting discounts, will be approximately $0.5 million, which includes the fees and expenses for which we have
              agreed to reimburse the underwriter, including fees and expenses of their counsel, up to a maximum aggregate amount of $100,000.&#160;</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have agreed to indemnify the underwriter against certain liabilities, including liabilities under the Securities Act.</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
              <div style="line-height: 1.25">&#160;</div>
              <div style="line-height: 1.25; font-weight: bold;">Over-Allotment Option</div>
              <div style="line-height: 1.25">&#160;
                <div style="text-align: left; line-height: 1.25;">
                  <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We have granted the underwriter an option to purchase from us, at the public offering price, less the underwriting discounts , up to
                    986,842 additional ADSs and/or Pre-Funded Warrants, and/or up to 986,842 over-allotment Warrants, within 30 days after the closing of this offering to cover over-allotments, if any. The underwriter may exercise the over-allotment option
                    with respect to ADSs only, Pre-Funded Warrants only, Warrants only, or any combination thereof. The purchase price to be paid per additional Ordinary Share or Pre-Funded Warrant will be equal to the public offering price of one Unit or
                    Pre-Funded Unit (less $0.01 allocated to each Warrant), as applicable, less the underwriting discounts, and the purchase price to be paid per over-allotment Warrant will be $0.01. No underwriting discounts will be paid on any Warrants
                    purchased pursuant to the underwriter&#8217;s over-allotment option.</div>
                </div>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">53<br>
              </div>
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <br>
            <div style="line-height: 1.25; font-weight: bold;">Lock-up</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We and our officers and directors have agreed to a 60-day &#8220;lock-up,&#8221; with respect to our ordinary shares, ADSs and other of our securities that we or they beneficially own,
              including securities that are convertible into ordinary shares or ADSs and securities that are exchangeable for or exercisable into ordinary shares or ADSs. This means that, subject to certain exceptions, for a period of 60 days following the
              date of this prospectus, we and such persons may not offer, sell, pledge or otherwise dispose of these securities without the prior written consent of Aegis Capital Corp.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25;">Rules of the SEC may limit the ability of the underwriter to bid for or purchase ADSs before the distribution of the ADSs is completed. However, the underwriter may
              engage in the following activities in accordance with the rules:</div>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z43d61d4ce29a49a6bae1efeadae50d6f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 4.3%; vertical-align: middle;">&#160;</td>
                  <td style="width: 5.16%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 90.54%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">Stabilizing transactions&#8201;&#8212;&#8201;The underwriter may make bids or purchases for the purpose of pegging, fixing or maintaining the price of the ADSs, so long as stabilizing bids do not
                      exceed a specified maximum.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zd971773a955d4ab0ac5fb039c9ecb3ef" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 4.3%; vertical-align: middle;">&#160;</td>
                  <td style="width: 5.16%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 90.54%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">Syndicate covering transactions&#8201;&#8212;&#8201;The underwriter may sell more ADSs in connection with this offering than the number of ADSs that it has committed to purchase. This over-allotment
                      creates a short position for the underwriter. This short sales position may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221; short sales. Covered short sales are short sales made in an amount not greater than the underwriter&#8217;s
                      over-allotment option to purchase additional ADSs, if applicable. The underwriter may close out any covered short position either by exercising its over-allotment option, if applicable, or by purchasing ADSs in the open market. To
                      determine how they will close the covered short position, the underwriter will consider, among other things, the price of ADSs available for purchase in the open market, as compared to the price at which it may purchase ADSs through
                      the over-allotment option, if applicable. Naked short sales are short sales in excess of the over-allotment option, if applicable. The underwriter must close out any naked short position by purchasing ADSs in the open market. A naked
                      short position is more likely to be created if the underwriter is concerned that, in the open market after pricing, there may be downward pressure on the price of the ADSs that could adversely affect investors who purchase ADSs in
                      this offering.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="zc2b8288e5e5348a68250dfdced429f06" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 4.3%; vertical-align: middle;">&#160;</td>
                  <td style="width: 5.16%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 90.54%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">Penalty bids&#8201;&#8212;&#8201;If the underwriter purchases ADSs in the open market in a stabilizing transaction or syndicate covering transaction, it may reclaim a selling concession from the
                      underwriter and selling group members who sold those ADSs as part of this offering.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" id="z558a03aa21c2492a86d0c1358dcf70b5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 4.3%; vertical-align: middle;">&#160;</td>
                  <td style="width: 5.16%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 90.54%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">Passive market making&#8201;&#8212;&#8201;Market makers in the ADSs who is the underwriter or prospective underwriters may make bids for or purchases of ADSs, subject to limitations, until the time, if
                      ever, at which a stabilizing bid is made.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25;">Similar to other purchase transactions, the underwriter purchases to cover the syndicate short sales or to stabilize the market price of the ADSs may have the effect of
              raising or maintaining the market price of the ADSs or preventing or mitigating a decline in the market price of the ADSs. As a result, the price of the ADSs may be higher than the price that might otherwise exist in the open market. The
              imposition of a penalty bid might also have an effect on the price of the ADSs if it discourages resales of the ADSs.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25;">Neither we nor the underwriter makes any representation or prediction as to the effect that the transactions described above may have on the price of the ADSs. These
              transactions may occur on Nasdaq or otherwise. If such transactions are commenced, they may be discontinued without notice at any time.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25;">The underwriter and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial
              and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriter and certain of their affiliates may in the future engage in investment
              banking and other commercial dealings in the ordinary course of business with us and our affiliates, for which they may in the future receive customary fees, commissions and expenses.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25;">In addition, in the ordinary course of their business activities, the underwriter and its affiliates may make or hold a broad array of investments and actively trade
              debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities
              and/or instruments of ours or our affiliates. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may
              hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25; font-weight: bold;">Electronic Delivery of Prospectus</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A prospectus in electronic format may be delivered to potential investors by the underwriter participating in this offering. The prospectus in electronic format will be
              identical to the paper version of such prospectus. Other than the prospectus in electronic format, the information on the underwriter&#8217;s website and any information contained in any other website maintained by the underwriter is not part of
              this prospectus or the registration statement of which this prospectus forms a part.</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="UNDERWRITING"><!--Anchor--></a></div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">54</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25; font-weight: bold;"> <br>
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Notice to Non-U.S. Investors</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Belgium</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The offering is exclusively conducted under applicable private placement exemptions and therefore it has not been and will not be notified to, and this document or any other
            offering material relating to the securities has not been and will not be approved by, the Belgian Banking, Finance and Insurance Commission (&#8220;Commission bancaire, financi&#232;re et des assurances/Commissie voor het Bank, Financie en
            Assurantiewezen&#8221;). Any representation to the contrary is unlawful.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The underwriter has undertaken not to offer sell, resell, transfer or deliver directly or indirectly, any securities, or to take any steps relating/ancillary thereto, and not
            to distribute or publish this document or any other material relating to the securities or to the offering in a manner which would be construed as: (a)&#160;a public offering under the Belgian Royal Decree of 7 July&#160;1999 on the public character of
            financial transactions; or (b)&#160;an offering of securities to the public under Directive 2003/71/EC which triggers an obligation to publish a prospectus in Belgium. Any action contrary to these restrictions will cause the recipient and the
            company to be in violation of the Belgian securities laws.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Canada</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This document constitutes an &#8220;exempt offering document&#8221; as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been filed with any
            securities commission or similar regulatory authority in Canada in connection with the offer and sale of the securities described herein (the &#8220;Securities&#8221;). No securities commission or similar regulatory authority in Canada has reviewed or in
            any way passed upon this document or on the merits of the Securities and any representation to the contrary is an offence.</div>
          <div style="text-align: justify; line-height: 1.25;">Canadian investors are advised that this document has been prepared in reliance on section 3A.3 of National Instrument 33-105 Underwriting Conflicts (&#8220;NI 33-105&#8221;). Pursuant to section 3A.3 of
            NI 33-105, this document is exempt from the requirement to provide investors with certain conflicts of interest disclosure pertaining to &#8220;connected issuer&#8221; and/or &#8220;related issuer&#8221; relationships as would otherwise be required pursuant to
            subsection 2.1(1) of NI 33-105.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Resale Restrictions</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The offer and sale of the securities in Canada is being made on a private placement basis only and is exempt from the requirement to prepare and file a prospectus under
            applicable Canadian securities laws. Any resale of Securities acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary depending on the relevant jurisdiction, and which
            may require resales to be made in accordance with Canadian prospectus requirements, a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption
            from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the Securities outside of Canada.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Representations of Purchasers</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each Canadian investor who purchases the Securities will be deemed to have represented to the issuer and to each dealer from whom a purchase confirmation is received, as
            applicable, that the investor (i)&#160;is purchasing as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii)&#160;is an
            &#8220;accredited investor&#8221; as such term is defined in section 1.1 of National Instrument 45-106 Prospectus Exemptions (&#8220;NI 45-106&#8221;) or, in Ontario, as such term is defined in section 73.3(1) of the Securities Act (Ontario); and (iii)&#160;is a &#8220;permitted
            client&#8221; as such term is defined in section 1.1 of National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Taxation and Eligibility for Investment</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any discussion of taxation and related matters contained in this document does not purport to be a comprehensive description of all of the tax considerations that may be
            relevant to a Canadian investor when deciding to purchase the Securities and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax consequences to a resident, or deemed
            resident, of Canada of an investment in the Securities or with respect to the eligibility of the Securities for investment by such investor under relevant Canadian federal and provincial legislation and regulations.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Rights of Action for Damages or Rescission</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum, including where the distribution
            involves an &#8220;eligible foreign security&#8221; as such term is defined in Ontario Securities Commission Rule&#160;45-501&#160;<font style="font-style: italic;">Ontario Prospectus and Registration Exemptions</font>&#160;and in Multilateral Instrument 45-107&#160;<font style="font-style: italic;">Listing Representation and Statutory Rights of Action Disclosure Exemptions</font>, as applicable, with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the
            offering memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a &#8220;misrepresentation&#8221; as defined under applicable Canadian securities laws. These remedies, or notice with respect to
            these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and defenses under, applicable Canadian securities legislation. In addition, these
            remedies are in addition to and without derogation from any other right or remedy available at law to the investor.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">55</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Language of Documents</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the
            securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only.&#160;<font style="font-style: italic;">Par la r&#233;ception de ce document, chaque</font>&#160;investisseur&#160;<font style="font-style: italic;">canadien confirme par les pr&#233;sentes qu&#8217;il a express&#233;ment exig&#233; que tous les documents faisant foi ou se rapportant de quelque mani&#232;re que ce soit &#224; la vente des valeurs mobili&#232;res d&#233;crites aux pr&#233;sentes (incluant,
              pour plus de certitude, toute confirmation d&#8217;achat ou tout avis) soient r&#233;dig&#233;s en anglais seulement.</font></div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">France</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Neither this prospectus nor any other offering material relating to the securities has been submitted to the clearance procedures of the Autorit&#233; des march&#233;s financiers in
            France. The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to the securities has been or will be:
            (a)&#160;released, issued, distributed or caused to be released, issued or distributed to the public in France; or (b)&#160;used in connection with any offer for subscription or sale of the securities to the public in France. Such offers, sales and
            distributions will be made in France only: (i)&#160;to qualified investors (investisseurs qualifi&#233;s) and/or to a restricted circle of investors (cercle restreint d&#8217;investisseurs), in each case investing for their own account, all as defined in and
            in accordance with Articles L.411-2, D.411-1, D.411-2, D.734-1, D.744-1, D.754-1 and D.764-1 of the French Code mon&#233;taire et financier; (ii)&#160;to investment services providers authorised to engage in portfolio management on behalf of third
            parties; or (iii)&#160;in a transaction that, in accordance with article L.411-2-II-1&#176; -or-2&#176; -or 3&#176; of the French Code mon&#233;taire et financier and article 211-2 of the General Regulations (R&#232;glement G&#233;n&#233;ral) of the Autorit&#233; des march&#233;s financiers,
            does not constitute a public offer (appel public &#224; l&#8217;&#233;pargne). Such ADSs may be resold only in compliance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 through L.621-8-3 of the French Code mon&#233;taire et financier.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Israel</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The securities offered hereunder may not be offered or sold to the public in Israel absent the publication of a prospectus that has been approved by the Israel Securities
            Authority (the &#8220;ISA&#8221;). This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968 (the &#8220;Israeli Securities Law&#8221;), and has not been filed with or approved by the ISA and the securities offered hereunder have not
            been registered for sale in Israel. In Israel, this document is being distributed only to, and is directed only at, and any offer of the securities hereunder is directed only at, (i) a limited number of persons in accordance with the Israeli
            Securities Law and (ii) investors listed in the first addendum to the Israeli Securities Law (the &#8220;Addendum&#8221;), consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment
            advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as it may be amended from time to time),
            collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are
            required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Italy</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25;">The offering of the securities offered hereby in Italy has not been registered with the Commissione Nazionale per la Societ&#224; e la Borsa (&#8220;CONSOB&#8221;) pursuant to Italian
            securities legislation and, accordingly, the securities offered hereby cannot be offered, sold or delivered in the Republic of Italy (&#8220;Italy&#8221;) nor may any copy of this prospectus or any other document relating to the ADSs offered hereby be
            distributed in Italy other than to professional investors (operatori qualificati) as defined in Article&#160;31, second paragraph, of CONSOB Regulation&#160;No. 11522 of 1 July, 1998 as subsequently amended. Any offer, sale or delivery of the securities
            offered hereby or distribution of copies of this prospectus or any other document relating to the securities offered hereby in Italy must be made:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z91a19ab50a9a41f2b6a89dcdbb5c4565">

              <tr>
                <td style="width: 20.25pt;"><br>
                </td>
                <td style="width: 27pt; vertical-align: top;">(a)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>by an investment firm, bank or intermediary permitted to conduct such activities in Italy in accordance with Legislative Decree No. 58 of 24 February&#160;1998 and Legislative Decree No. 385 of 1 September&#160;1993 (the &#8220;Banking Act&#8221;);</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zde4241360cc940f883041f33fef54c00">

              <tr>
                <td style="width: 20.25pt;"><br>
                </td>
                <td style="width: 27pt; vertical-align: top;">(b)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>in compliance with Article&#160;129 of the Banking Act and the implementing guidelines of the Bank of Italy; and</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z254ab17cd23e4dd3a5fb2791d9b1cd11">

              <tr>
                <td style="width: 20.25pt;"><br>
                </td>
                <td style="width: 27pt; vertical-align: top;">(c)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>in compliance with any other applicable laws and regulations and other possible requirements or limitations which may be imposed by Italian authorities.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Sweden</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus has not been nor will it be registered with or approved by Finansinspektionen (the &#8220;Swedish Financial Supervisory Authority&#8221;). Accordingly, this prospectus
              may not be made available, nor may the securities offered hereunder be marketed and offered for sale in Sweden, other than under circumstances which are deemed not to require a prospectus under the Financial Instruments Trading Act (1991:
              980).</div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">56</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Switzerland</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The securities offered pursuant to this prospectus will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute a public
            offering prospectus as that term is understood pursuant to art. 652a or art. 1156 of the Swiss Federal Code of Obligations. The company has not applied for a listing of the securities being offered pursuant to this prospectus on the SWX Swiss
            Exchange or on any other regulated securities market, and consequently, the information presented in this prospectus does not necessarily comply with the information standards set out in the relevant listing rules. The securities being offered
            pursuant to this prospectus have not been registered with the Swiss Federal Banking Commission as foreign investment funds, and the investor protection afforded to acquirers of investment fund certificates does not extend to acquirers of
            securities.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Investors are advised to contact their legal, financial or tax advisers to obtain an independent assessment of the financial and tax consequences of an investment in
            securities.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">United Kingdom/Germany/Norway/The Netherlands</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25;">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &#8220;Relevant Member State&#8221;) an offer to the public of
            any ADSs which are the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State other than the offers contemplated in this prospectus in name(s) of Member State(s) where prospectus will be approved
            or passported for the purposes of a non-exempt offer once this prospectus has been approved by the competent authority in such Member State and published and passported in accordance with the Prospectus Directive as implemented in name(s) of
            relevant Member State(s) except that an offer to the public in that Relevant Member State of any ADSs may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member
            State:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za2481c474eac4a5b9443951b89a7a593">

              <tr>
                <td style="width: 20.25pt;"><br>
                </td>
                <td style="width: 27pt; vertical-align: top;">(a)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb63b4dba9ab04b3397956be6777e77f6">

              <tr>
                <td style="width: 20.25pt;"><br>
                </td>
                <td style="width: 27pt; vertical-align: top;">(b)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>to any legal entity which has two or more of (1)&#160;an average of at least 250 employees during the last financial year; (2)&#160;a total balance sheet of more than &#8364;43,000,000 and (3)&#160;an annual net turnover of more than &#8364;50,000,000, as
                    shown in its last annual or consolidated accounts;</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbef10a7262c940689ad112672acf7be9">

              <tr>
                <td style="width: 20.25pt;"><br>
                </td>
                <td style="width: 27pt; vertical-align: top;">(c)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>by the representative to fewer than 100 natural or legal persons (other than qualified investors as defined in the Prospectus Directive); or</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6d47abbab23d407d8309e2c7c23ab0e4">

              <tr>
                <td style="width: 20.25pt;"><br>
                </td>
                <td style="width: 27pt; vertical-align: top;">(d)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>in any other circumstances falling within Article&#160;3(2) of the Prospectus Directive, provided that no such offer of ADSs shall result in a requirement for the publication by the company or any underwriter of a prospectus pursuant to
                    Article&#160;3 of the Prospectus Directive.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 20.25pt; line-height: 1.25;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any ADSs in any Relevant Member State means the communication in any form and by
            any means of sufficient information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to purchase any ADSs, as the same may be varied in that Member State by any measure implementing the Prospectus
            Directive in that Member State and the expression &#8220;Prospectus Directive&#8221; means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">Each underwriter has represented, warranted and agreed that:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za456563ca4774dd5a03ec511dc2bca42">

              <tr>
                <td style="width: 20.25pt;"><br>
                </td>
                <td style="width: 27pt; vertical-align: top;">(a)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>it has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and
                    Markets Act 2000 (the FSMA)) received by it in connection with the issue or sale of any ADSs in circumstances in which section 21(1) of the FSMA does not apply to the company; and</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8502ea28e9614e8ab954d6ca61590875">

              <tr>
                <td style="width: 20.25pt;"><br>
                </td>
                <td style="width: 27pt; vertical-align: top;">(b)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>it has complied with and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the ADSs in, from or otherwise involving the United Kingdom.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="LEGALMATTERS"><!--Anchor--></a>LEGAL MATTERS</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Certain legal matters as to United States law in connection with this offering will be passed upon for us by Wilson Sonsini Goodrich&#160;&amp;
              Rosati, P.C., Boulder, Colorado.&#160;The validity of the securities and other matters of Israeli law will be passed upon for us by Meitar | Law Offices, Ramat Gan, Israel. Certain matters of U.S. federal law will be passed upon for the
              underwriter by Kaufman &amp; Canoles, P.C., Richmond, Virginia.</div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPERTS"><!--Anchor--></a>EXPERTS</div>
          <div style="line-height: 1.25;">&#160;
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The consolidated financial statements of Chemomab Therapeutics Ltd. as of December 31, 2022 and 2021, and for each of the years in the two-year period ended December 31,
              2022, have been incorporated by reference herein in reliance upon the report of Somekh Chaikin, a member firm of KPMG International, independent registered public accounting firm incorporated by reference herein, and upon the authority of
              said firm as experts in accounting and auditing&#160;</div>
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">57</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="ENFORCEMENTOFCIVILLIABILI"><!--Anchor--></a>ENFORCEMENT OF CIVIL LIABILITIES</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Chemomab is incorporated under the laws of the State of Israel. Not all of our directors or officers are residents of the United States. Most of our assets and those of
            our&#160;non-U.S.&#160;directors and officers are located outside the United States. Service of process upon us and upon our&#160;non-U.S.&#160;resident directors and officers and the Israeli experts named in this prospectus may be difficult to obtain within the
            United States.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have irrevocably appointed Chemomab Therapeutics, Inc. as our agent to receive service of process in any action against us in any U.S. federal or state court arising out
            of this offering or any purchase or sale of securities in connection with this offering. The address of our agent is One Kendall Square, Building 1400E, Suite 14-105, Cambridge, MA 02139.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have been informed by our legal counsel in Israel, Meitar | Law Offices, that it may be difficult to assert claims under U.S. securities laws in original actions
            instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws against us or
            our&#160;non-U.S.&#160;officers or directors reasoning that Israeli court is not the most appropriate forum to hear such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is
            applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure may also be governed
            by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or
            our&#160;non-U.S.&#160;officers and directors.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to specified time limitations, legal procedures and certain exceptions, Israeli courts may enforce a U.S. judgment in a civil matter which
            is&#160;non-appealable,&#160;including judgements based on the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a&#160;non-civil&#160;matter, provided that, among other things:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z28e643a093ab428cbfe60c60e07616d9">

              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to
                    public policy; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">the judgment is executory in the state in which it was given.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Even if these conditions are met, an Israeli court may not declare a foreign civil judgment enforceable if:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1a42d417bf70413db397c46e2cd4b470">

              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">the judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases);</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">the enforcement of the judgment is likely to prejudice the sovereignty or security of the State of Israel;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">the judgment was obtained by fraud;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">the opportunity given to the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">the judgment was rendered by a court not competent to render it according to the laws of private international law as they apply in Israel;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">the judgment is contradictory to another judgment that was given in the same matter between the same parties and that is still valid; or</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">at the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal in Israel.</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into&#160;non-Israeli&#160;currency and transferred
            out of Israel. The usual practice in an action before an Israeli court to recover an amount in a&#160;non-Israeli&#160;currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on
            the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index
            plus interest at the annual statutory rate set by Israeli regulators prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">58</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="WHERE"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are subject to the informational requirements of the Exchange Act and in accordance therewith file annual, quarterly and current reports, proxy statements and other
            information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the SEC&#8217;s website is www.sec.gov.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">We make available free of charge on or through our website at www.chemomab.com, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to
            those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the SEC.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and
            schedules filed therewith or the documents incorporated by reference herein. For further information about us and the ADSs offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto and to the
            documents incorporated by reference herein. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement or to a document incorporated by
            reference herein are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement or a document incorporated by
            reference herein. You can obtain a copy of the registration statement, at prescribed rates, from the SEC at the address listed above, or for free at www.sec.gov. The registration statement and the documents referred to below under
            &#8220;Incorporation by Reference&#8221; are also available on our website, www.chemomab.com.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The information contained on, or accessible through, our website does not form a part of this prospectus and is not incorporated by reference herein or therein.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="INCORPORATIONBYREFERENCE"><!--Anchor--></a>INCORPORATION BY REFERENCE</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The SEC&#8217;s rules allow us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you by referring you to
            another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information.
            Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a
            subsequently filed document incorporated by reference modifies or replaces that statement.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus incorporates by reference the documents set forth below that have previously been filed with the SEC:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf18997808e7d41479a1e64ae4d305e8b">

              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">
                    <div style="text-align: left; line-height: 1.25;">The Registrant&#8217;s Annual Report on <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/0001178913-23-001041-index.htm">Form 10-K</a> for the fiscal year ended
                      December 31, 2022, filed with the SEC on March 20, 2023 (the &#8220;Annual Report&#8221;);</div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za5b7d7bf1b634b9e90cb3e45452516e5">

              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The Company&#8217;s Current Reports on Form 8-K, as filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/0001178913-23-000010-index.htm">January
                      3, 2023</a>,&#160;<a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000147/0001178913-23-000147-index.htm">January 11, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/0001178913-23-000670-index.htm">February 21, 2023</a> and <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/0001178913-23-000679-index.htm"><u>February 21, 2023</u></a>;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z800315d2f16f42f6958afeee0e3a2f77">

              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">The description of our share capital, which is set forth in exhibit 4.1 of our Annual Report, and as may be further updated or amended in any amendment or report filed for such purpose;
                    and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.99%; vertical-align: middle;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), since the end of the fiscal year covered by the
                    Annual Report.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All filings filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act of 1934 after the date of the initial filing of the registration statement of which
            this prospectus forms a part and prior to the termination of the offering (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) shall also be deemed to be incorporated by reference into this prospectus.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different
            information. Any statement contained in a document incorporated by reference into this prospectus will be deemed to be modified or superseded for the purposes of this prospectus to the extent that a later statement contained in this prospectus
            or in any other document incorporated by reference into this prospectus modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this
            prospectus. You should not assume that the information in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will provide without charge to each person to whom a copy of this prospectus is delivered, upon written or oral request, a copy of any or all of the reports or documents
            that have been incorporated by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this prospectus). Any such request
            should be addressed to us at: Kiryat Atidim, Building 7, Tel Aviv 6158002, Israel, Attention: Donald Marvin, Chief Financial Officer, or made by phone at +972-77-331-0156. You may also access the documents incorporated by reference in this
            prospectus through our website at www.chemomab.com. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration
            statement of which it forms a part. You may also access any of the documents incorporated by reference in this prospectus by visiting <font style="font-style: italic;">www.chemomab.com</font>, or our investor relations website is <font style="font-style: italic;">www.investors.chemomab.com</font>. The information on either of these websites, however, is not, and should not be deemed to be, a part of this prospectus.</div>
          <div style="text-align: center; line-height: 1.25;"><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">59</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
        </div>
        <div> <br>
        </div>
      </div>
      <div><br>
        <div> <br>
        </div>
      </div>
      <div><br>
        <div> <br>
        </div>
      </div>
      <div><br>
        <div> <br>
        </div>
      </div>
      <font style="font-family: 'Times New Roman',Times,serif;"> </font> </div>
    <div> <br>
    </div>
    <div>
      <div style="line-height: 1.25; text-align: center;"><img src="image00003.jpg"></div>
      <div style="text-align: center; line-height: 1.25;"><br>
      </div>
      <br>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Up to 6,578,947&#160;Units Each Consisting of One American Depositary Share and One Warrant to Purchase One American </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Depositary Share</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Up to 6,578,947&#160;Pre-Funded Units Each Consisting of One Pre-Funded Warrant to Purchase One American Depositary </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Share and One Warrant to Purchase One American Depositary Share</div>
      <div style="text-align: center; line-height: 1.25;"><br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROSPECTUS</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">Sole Book-Running Manager</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">
              <div style="text-align: center; line-height: 1.25;">Aegis Capital Corp.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">, 2023</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Through and including &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2023 (the 25th day after the date of this prospectus), all dealers </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">effecting transactions in these securities, whether or not participating in this offering, may be required to </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">deliver a prospectus. This is in addition to a dealer&#8217;s obligation to deliver a prospectus when acting as an </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">underwriter and with respect to an unsold allotment or subscription.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%II - %%-->
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PART II</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Item 13. Other Expenses of Issuance and Distribution.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth the fees and expenses in connection with the issuance and distribution of the securities being registered (excluding the underwriting discount).
        Except for the Securities and Exchange Commission registration fee and the FINRA filing fee, all amounts are estimates.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" class="cfttable" id="z8a3ee83578884f8fb067a59ec6f07203" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

            <tr>
              <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount Paid<br>
                  or to be Paid</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 88%;">
                <div style="line-height: 1.25;">SEC registration fee</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">3,306</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div style="line-height: 1.25;">FINRA filing fee</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">1,050</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 88%;">
                <div style="line-height: 1.25;">Legal fees and expenses&#160;(including underwriters' legal fees)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">300,000</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div style="line-height: 1.25;">Accounting fees and expenses</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">65,710</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 88%;">
                <div style="line-height: 1.25;">Printing expenses</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">15,000</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div style="line-height: 1.25;">Depositary and transfer agent fees and expenses</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">151,312</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 88%; padding-bottom: 2px;">
                <div style="line-height: 1.25;">Miscellaneous</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                <div style="line-height: 1.25;">10,000</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: top; width: 88%;">
                <div style="line-height: 1.25;">Total</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">546,378</div>
              </td>
              <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"> <br>
      </div>
      <div style="line-height: 1.25;"> </div>
      <div style="line-height: 1.25; font-weight: bold;">Item 14. Indemnification of Directors and Officers.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law, 5759-1999, or the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli
        company may exculpate an office holder in advance from liability, in whole or in part, for damages caused as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our
        amended and restated articles of association contain such a provision.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">An Israeli company may indemnify an office holder in respect of certain liabilities either in advance of an event or following an event provided that a provision authorizing such
        indemnification is inserted in its articles of association. Our amended and restated articles of association contain such a provision. An undertaking provided in advance by an Israeli company to indemnify an office holder with respect to a
        financial liability imposed on him or her in favor of another person pursuant to a judgment, settlement or arbitrator&#8217;s award approved by a court must be limited to events which in the opinion of the Board of Directors can be foreseen based on the
        company&#8217;s activities when the undertaking to indemnify is given, and to an amount or a criteria determined by the Board of Directors as reasonable under the circumstances, and such undertaking must detail the abovementioned events and amount or
        criteria.</div>
      <div style="text-align: justify; line-height: 1.25;"><br>
        <div style="text-indent: 36pt; line-height: 1.25;">In addition, a company may indemnify an office holder against the following liabilities incurred for acts performed as an office holder:</div>
        <div style="line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3cfe5d4a343a4ba4b8a942bd151e0879">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or
                  proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty (as defined in the Companies Law), was imposed
                  upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal
                  intent or in connection with a monetary sanction;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9b18cbe65bbf4518aa798d77a6cdaae2">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court (i) in proceedings instituted against him or her by the company, on its behalf or by a third party, or (ii) in connection
                  with criminal proceedings in which the office holder was acquitted, or (iii) as a result of a conviction for a crime that does not require proof of criminal intent;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">II - 1</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze854d0029acc4c25a81e0165889bdc26">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to
                  such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and
                  to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned events and amount or criteria; and</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ff8ce918b47411585cf07ba000da072">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made to an injured
                  party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">An Israeli company may insure a director or officer against the following liabilities incurred for acts performed as a director or officer:</div>
        <div style="text-align: left; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze12e9ac5d8bc4ab29ca17380d88bde9d">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>a breach of duty of care to the company or to a third party, including a breach arising out of the negligent conduct of an office holder;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z953767534ca849e1ae126a9708dfad34">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>a breach of duty of loyalty to the company, provided the director or officer acted in good faith and had a reasonable basis to believe that the act would not prejudice the interests of the company;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7bf1ab0a83eb4d4486a5bb50508384f2">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>financial liabilities imposed on the office holder for the benefit of a third party;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4f2b08d122774450bae46d598e0d02be">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>financial liabilities imposed in an administrative proceeding on the office holder in favor of a third party harmed by a breach, pursuant to certain provisions of the Israeli Securities Law; and</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2ee930dc2b0d499abc7f682cc7c43967">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>expenses, including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain provisions of the Israeli Securities Law.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 36pt; line-height: 1.25;">An Israeli company may not, however, indemnify or insure an office holder against any of the following:</div>
        <div style="text-align: left; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaa739ff72556472baf4dc06514777d59">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>a breach of duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zab0deca0bb6e489eaed45aed09bd1d7b">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za08d4ed45d1d483db851fa23550b1b56">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>an act or omission committed with intent to derive unlawful personal benefit; or</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze64ee1e5a75a4f7c9c851ac20d9cda1c">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>a fine, monetary sanction, penalty or forfeit levied against the office holder.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, exculpation, indemnification and insurance of office holders must be approved by our compensation committee, our Board of Directors and, in certain circumstances, by our
          shareholders. We have obtained directors&#8217; and officers&#8217; liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Companies
          Law. In addition, we have entered into indemnification agreements with each of our directors providing them with indemnification for liabilities or expenses incurred as a result of acts performed by them in their capacity as our, or our
          subsidiaries&#8217;, directors and officers. This indemnification is limited both in terms of amount and coverage and it covers certain amounts regarding administrative proceedings insurable or indemnifiable under the Companies Law and our amended and
          restated articles of association. In the opinion of the U.S. Securities and Exchange Commission, however, indemnification of directors and office holders for liabilities arising under the U.S.&#160;Securities Act of 1933, as amended, or the&#160;Securities
          Act, is against public policy and therefore unenforceable.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">II - 2</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: left; line-height: 1.25; font-weight: bold;">Item 15. Recent Sales of Unregistered Securities</div>
        <div style="text-align: left; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The following is a summary of transactions during the preceding three fiscal years involving sales of our securities that were not registered under the Securities Act:</div>
        <div style="text-align: left; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">In connection with the Merger, on March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately USD
          $45.5 million of its ADSs in a private placement transaction (&#8220;The Private Placement&#8221;). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270 ADSs together with warrants to purchase up to
          261,929 ADSs at an exercise price of USD $17.35088 per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately USD $4.5 million.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: left; line-height: 1.25; font-weight: bold;">Item 16. Exhibits and Financial Statement Schedules.</div>
        <div style="text-align: left; line-height: 1.25;">&#160;</div>
        <div style="text-align: left; line-height: 1.25; font-weight: bold;">(a) Exhibits</div>
        <div style="text-align: left; line-height: 1.25; font-weight: bold;"> </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd08b994d1e6247518d62fe67b30bed38">

            <tr>
              <td style="width: 8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Exhibit No.</div>
              </td>
              <td style="width: 2%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="line-height: 1.25; font-weight: bold;">Description</div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="exhibit_1-1.htm">1.1*</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="exhibit_1-1.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_1-1.htm">Form of Underwriting Agreement</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">3.1</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">Amended and Restated Articles of Association (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s
                    current report on Form 8-K filed with the SEC on March 17, 2021)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">4.1</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">Form of Deposit Agreement between Chemomab Therapeutics Ltd. (f/k/a Anchiano Therapeutics
                    Ltd.), the Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued by the Company, dated February 14, 2019 (incorporated by reference to Exhibit 4.1 to the Registrants registration statement on
                    Form S-1 filed with the SEC on January 13, 2023)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="exhibit_4-2.htm">4.2*</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><a href="exhibit_4-2.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_4-2.htm">Form of Warrant</a></div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 8%; vertical-align: top; text-align: center;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_4-3.htm">4.3*</a></div>
              </td>
              <td rowspan="1" style="width: 2%; vertical-align: top;"><br>
              </td>
              <td rowspan="1" style="width: 90%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="exhibit_4-3.htm">Form of Pre-Funded Warrant</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="exhibit_5-1.htm">5.1*</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="exhibit_5-2.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_5-1.htm">Opinion of Meitar | Law Offices, Israeli counsel to the registrant</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="exhibit_5-2.htm">5.2*</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><br>
              </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_5-2.htm">Opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C., U.S. counsel to the
                    registrant</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#tANF">10.1+</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#tANF"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#tANF">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.7 of the
                    Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">10.2+</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><br>
              </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="line-height: 1.25;">
                  <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">Compensation Policy for Officers and Directors (incorporated by reference to Exhibit 10.2 of the Company&#8217;s
                      Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 30, 2022)</a></div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">10.3+</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">2011 Incentive Plan for Employees, Officers and Consultants (previously filed as Exhibit
                    10.6 of our Registration Statement on Form F-1 (File No. 333-229155) as filed with the SEC on January 7, 2019 and incorporated by reference herein)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">10.4+</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">2017 Equity-Based Incentive Plan (previously filed as Exhibit 10.8 of our Registration
                    Statement on Form F-1 (File No. 333-229155) as filed with the SEC on January 7, 2019 and incorporated by reference herein)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">10.5+</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">Chemomab Ltd. 2015 Share Incentive Plan (incorporated by reference to Exhibit 10.4 to
                    the Registrant&#8217;s registration statement on Form S-4 (SEC file number 333- 252070), filed with the SEC on January 13, 2021)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">10.6&#8734;</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">Tel-Aviv Souraski Medical Center (TASMC) License Agreement between Chemomab Ltd. and the
                    Medical Research, Infrastructure, Health Services Fund of the Tel Aviv Souraski Medical Center., dated December 1, 2011, as amended on May 9, 2013 (incorporated by reference to Exhibit 10.8 of the Company&#8217;s Amendment No. 1 to its
                    Registration Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">10.7&#8734;</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">CMC Collaboration Agreement between Chemomab Ltd. and CMC ICOS Biologics, Inc., dated
                    June 7, 2015 (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm">10.8</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm">Controlled Equity Offering SM Sales Agreement, dated April 30, 2021, by and between the
                    Company and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2 of the Company&#8217;s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on April 30, 2021)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">10.9+</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">Employment Agreement, dated September 1, 2021, by and between Chemomab Therapeutics, Inc. and
                    Dale Pfost (incorporated by reference to Exhibit 10.9 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">10.10+</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">Employment Agreement, dated November 8, 2021, by and between Chemomab Therapeutics, Inc. and
                    Donald Marvin (incorporated by reference to Exhibit 10.10 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">10.11+</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">Consulting Agreement, dated April 18, 2022, by and between Chemomab Ltd. and Dr. Adi Mor (incorporated by
                    reference to Exhibit 10.11 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_21-1.htm">21.1</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_21-1.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_21-1.htm">List of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Registrants
                    registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="exhibit_23-1.htm">23.1*</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_23-1.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_23-1.htm">Consent of Somekh Chaikin, member firm of KPMG International, independent
                    registered public accounting firm</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="exhibit_5-1.htm">23.2*</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-1.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">Consent of Meitar | Law Offices, Israeli counsel to the registrant (included in Exhibit 5.1)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-2.htm">23.3*</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-2.htm"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_5-2.htm">Consent of Opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C., U.S. counsel to the registrant (included in
                    Exhibit 5.2)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><a href="#SIGNATURES">24.1**</a></div>
              </td>
              <td style="width: 2%; vertical-align: top;"><a href="#SIGNATURES"><br>
                </a> </td>
              <td style="width: 90%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#SIGNATURES">Power of Attorney (included in the signature page of the Registration Statement)</a></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_107.htm">107*</a></div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br>
              </td>
              <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000672/exhibit_107.htm">Filing Fee Table</a></div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="3" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td colspan="3" style="vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*&#160;&#160; Filed herewith</div>
              </td>
            </tr>
            <tr>
              <td colspan="3" style="vertical-align: top;">
                <div style="line-height: 1.25;">** Previously filed</div>
              </td>
            </tr>
            <tr>
              <td colspan="3" style="vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">+&#160;&#160; Indicates management contract or compensatory plan</div>
              </td>
            </tr>
            <tr>
              <td colspan="3" style="vertical-align: top;">
                <div style="line-height: 1.25;">&#8734; &#160; Portions of this Exhibit (indicated with [***]) have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause
                  competitive harm to the Registrant if publicly disclosed</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; line-height: 1.25;">&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">II - 3</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: left; line-height: 1.25; font-weight: bold;">(b) Financial Statement Schedules</div>
        <div style="text-align: left; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">All financial statement schedules have been omitted because they are not required or because the required information is given in the financial statements or notes to those statements.</div>
        <div style="text-align: left; line-height: 1.25;">&#160;</div>
        <div style="text-align: left; line-height: 1.25; font-weight: bold;">Item 17. Undertakings.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">Insofar as indemnification for liabilities arising under the&#160;Securities Act&#160;may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the
          registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the&#160;Securities Act&#160;and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
          (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
          controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
          whether such indemnification by it is against public policy as expressed in the&#160;Securities Act&#160;and will be governed by the final adjudication of such issue.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">The undersigned registrant hereby undertakes:</div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z29e66c583fe3497e8c865ddf7fee730f">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">1.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e3ea944563c4471bbb1a26aa798a4f9">

              <tr>
                <td style="width: 40pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">a.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>To include any prospectus required by Section 10(a)(3) of the Securities Act;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z424153074c784ffabaf0512815cb02d2">

              <tr>
                <td style="width: 40pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">b.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
                    change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was
                    registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
                    represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z44987f9cb762497bac87b96e9fc5169f">

              <tr>
                <td style="width: 40pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">c.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;">provided, however, that paragraphs (1)(a), (b) and (c) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or
          furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is
          part of the registration statement.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">II - 4</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6c7a04a129a84f5283a6fd82d6ea369a">

            <tr>
              <td style="width: 20.25pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top;"><br>
              </td>
              <td style="width: auto; vertical-align: top; text-align: justify;"><br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93565f076acc4b13805153f1166aae62">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">2.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>That, for the purpose of determining any liability under the&#160;Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
                    securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4b15951b77fb40428f9b017a9bf02891">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">3.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb719acbdffd24ffc97b8cfa71d6faf0f">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">4.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>That, for the purpose of determining liability under the&#160;Securities Act&#160;to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements
                    relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no
                    statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the
                    registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
                    statement or made in any such document immediately prior to such date of first use.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6c526cdc6e1a4eab8ff0978c63f7db64">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top;">5.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>That, for the purpose of determining liability of the registrant under the&#160;Securities Act&#160;to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities
                    of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the
                    following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;"></div>
        <div style="line-height: 1.25;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd8e231a9a8fa4c93b4d42d03105cd960">

            <tr>
              <td style="width: 20.25pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top;">a.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za2076bfee5d5401991bbad2f7df1d446">

            <tr>
              <td style="width: 20.25pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top;">b.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z85314816d837421db88696f5cd6a93d6">

            <tr>
              <td style="width: 20.25pt;"><br>
              </td>
              <td style="width: 27pt; vertical-align: top;">c.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">II - 5</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>
        <div style="text-align: left; line-height: 1.25;">&#160;
          <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
            authorized, in the City of Tel-Aviv, Israel, on March 21, 2023.</div>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7c59e43e978040acad19f9c4f046dfe1">

            <tr>
              <td style="width: 49.89%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td colspan="2" style="width: 50.11%; vertical-align: top;">
                <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.89%; vertical-align: middle;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.2%; vertical-align: middle;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 46.91%; vertical-align: middle;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.89%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.2%; vertical-align: bottom;">
                <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;">By:</div>
              </td>
              <td style="width: 46.91%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">/s/ Dale Pfost</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.89%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.2%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 46.91%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Dale Pfost</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.89%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.2%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 46.91%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Chairman of the Board,</div>
                <div style="line-height: 1.25;">Chief Executive Officer</div>
              </td>
            </tr>

        </table>
        <div style="text-align: left; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons on behalf of the registrant in the capacities and on the dates
          indicated.</div>
        <div style="line-height: 1.25;"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2be1323de58e402695a15a4fb81c0919">

            <tr>
              <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Signature</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Title</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Date</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">/s/ <font style="font-style: italic;">Dale Pfost</font></div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">Chairman of the Board and</div>
                <div style="text-align: center; line-height: 1.25;">Chief Executive Officer</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">March 21, 2023</div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Dale Pfost</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">(Principal Executive Officer)</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">/s/ <font style="font-style: italic;">Donald Marvin</font></div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">Chief Financial Officer, Executive Vice President and Chief Operating Officer</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">March 21, 2023</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Donald Marvin</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">(Principal Financial and Accounting Officer)</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; text-align: center;">*<font style="font-style: italic;"></font></div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">Director</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">March 21, 2023</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Adi Mor</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; text-align: center;">*<font style="font-style: italic;"></font></div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">Director</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">March 21, 2023</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Nissim Darvish</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; text-align: center;">*<font style="font-style: italic;"></font></div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">Director</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">March 21, 2023</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Alan Moses</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; text-align: center;">*<font style="font-style: italic;"></font></div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">Director</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">March 21, 2023</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Claude Nicaise</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; text-align: center;">*</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">Director</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">March 21, 2023</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Neil Cohen</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; text-align: center;">*<br>
                </div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">Director</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: middle;">
                <div style="text-align: center; line-height: 1.25;">March 21, 2023</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Jill M. Quigley</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2.01%; vertical-align: top;">&#160;</td>
              <td style="width: 32%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2.01%; vertical-align: top;">&#160;</td>
              <td style="width: 32%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">/s/ <font style="font-style: italic;">Dale Pfost</font></div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">&#160;</td>
              <td style="width: 32%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2.01%; vertical-align: top;">&#160;</td>
              <td style="width: 32%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Dale Pfost</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">&#160;</td>
              <td style="width: 32%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2.01%; vertical-align: top;">&#160;</td>
              <td style="width: 32%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Attorney in Fact</div>
              </td>
              <td style="width: 2.01%; vertical-align: top;">&#160;</td>
              <td style="width: 32%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2.01%; vertical-align: top;">&#160;</td>
              <td style="width: 32%; vertical-align: bottom;">&#160;</td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">II - 6</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;AUTHORIZED REPRESENTATIVE</div>
        <div style="text-align: left; line-height: 1.25;">&#160;
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Chemomab Therapeutics
            Ltd., has signed this registration statement on March 21, 2023.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zfb7a2507c3814bc3aef3ebf1c721dd11">

            <tr>
              <td style="width: 49.89%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td colspan="2" style="width: 50.11%; vertical-align: top;">
                <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS, INC.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.89%; vertical-align: middle;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.21%; vertical-align: middle;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 46.9%; vertical-align: middle;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.89%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.21%; vertical-align: bottom;">
                <div style="text-indent: -10pt; margin-left: 10pt; line-height: 1.25;">By:</div>
              </td>
              <td style="width: 46.9%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">/s/ Dale Pfost</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.89%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.21%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 46.9%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Dale Pfost</div>
              </td>
            </tr>
            <tr>
              <td style="width: 49.89%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.21%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 46.9%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Chairman of the Board,</div>
                <div style="line-height: 1.25;">Chief Executive Officer</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25;">
          <div class="BRPFPageNumberArea"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">II - 7<br>
            </font>
            <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
        </div>
        <br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>exhibit_1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> Exhibit 1.1</u><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Up to [&#8226;] American Depositary Shares</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Or [&#8226;] Pre-funded Warrants to Purchase American Depositary Shares</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">And [&#8226;] Warrants to Purchase American Depositary Shares</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>UNDERWRITING AGREEMENT</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: right; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[&#8226;], 2023</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Aegis Capital Corp.</div>
    <div style="line-height: 1.25;">as Representative of the several</div>
    <div style="line-height: 1.25;">Underwriters named in Schedule I hereto</div>
    <div style="line-height: 1.25;">1345 Avenue of the Americas, 27th Floor<br>
      New York, NY 10105</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Ladies and Gentlemen:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">Chemomab Therapeutics Ltd., a company organized and existing under the laws of the State of Israel (the &#8220;Company&#8221;), proposes, subject to the terms and conditions contained herein,
      to sell to you and the other underwriters (the &#8220;Underwriters&#8221;) named on Schedule I to this Underwriting Agreement (this &#8220;Agreement&#8221;), for whom you are acting as Representative, if any (the &#8220;Representative&#8221;), an aggregate of&#160; (A) up to [&#8226;] (i)
      American Depositary Shares, or &#8220;ADS&#8221; (the &#8220;Firm Shares&#8221;), each representing 20 ordinary shares, no par value per share, of the Company (the &#8220;Ordinary Shares&#8221;) or (ii) [&#8226;]&#160; pre-funded warrants to purchase up to [&#8226;]&#160; ADSs at an exercise price of $0.01
      per share, in the form attached hereto as Exhibit A (the &#8220;Pre-Funded Warrants&#8221;) and (B) [&#8226;] warrants, each warrant exercisable for one ADS at an exercise price of $[&#8226;] per ADS with a term of five years, in the form attached hereto as Exhibit B (the
      &#8220;Common Warrants&#8221; and together with the Pre-funded Warrants, the &#8220;Warrants&#8221;).&#160; The Firm Shares and Pre-Funded Warrants and the accompanying Warrants in the transaction will be sold as units (the &#8220;Firm Units&#8221;), with each Firm Unit consisting of (i)
      one Firm Share or one Pre-Funded Warrant to purchase one Warrant Share (as defined below) and (ii) one Common Warrant to purchase one Warrant Share. The Firm Shares and/or Pre-Funded Warrants and Warrants will be issued separately but will be
      purchased together in this offering.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">In addition, the Company proposes to grant to the Representative an option to purchase, in the aggregate, up to [&#8226;] additional ADSs and/or Pre-funded Warrants to purchase ADSs,
      representing 15.0% of the Firm Units, and/or up to [&#8226;]&#160; additional Warrants to purchase an aggregate of an additional [&#8226;] ADSs, representing 15.0% of the Firm Units sold in the offering (the &#8220;Option Units&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">The Firm Units and Option Units are referred to herein as &#8220;Units&#8221;. The ADSs issuable upon exercise of the Warrants are referred to herein as the &#8220;Warrant Shares.&#8221; The Shares, the
      Warrants, the Warrant Shares are collectively called the &#8220;Securities.&#8221;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">The Securities are to be issued pursuant to that certain deposit agreement (the &#8220;Deposit Agreement&#8221;), dated as of February 14, 2019, among the Company, the Bank of New York Mellon
      as depositary (the &#8220;Depositary&#8221;), and the holders and beneficial owners from time to time of the ADSs.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">&#160;The Company has prepared and filed in conformity with the requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the published rules and regulations
      thereunder (the &#8220;Rules&#8221;) adopted by the Securities and Exchange Commission (the &#8220;Commission&#8221;), a Registration Statement (as hereinafter defined) on Form S-1 (No. 333-269218), including a preliminary prospectus, and such amendments thereof as may have
      been required to the date of this Agreement.&#160; Copies of such Registration Statement (including all amendments thereof) and of the related Preliminary Prospectus (as hereinafter defined) have heretofore been delivered by the Company or are otherwise
      available to you.&#160; The term &#8220;Preliminary Prospectus&#8221; means any preliminary prospectus included at any time as a part of the Registration Statement or filed with the Commission by the Company pursuant to Rule 424(a) of the Rules. The term
      &#8220;Registration Statement&#8221; as used in this Agreement means the initial registration statement (including all exhibits and financial schedules and all documents and information deemed to be part of the Registration Statement by incorporation by
      reference or otherwise), as amended at the time and on the date it becomes effective (the &#8220;Effective Date&#8221;), including the information (if any) contained in the form of final prospectus filed with the Commission pursuant to Rule 424(b) of the Rules
      and deemed to be part thereof at the time of effectiveness pursuant to Rule 430A of the Rules.&#160; If the Company has filed an abbreviated registration statement to register additional Securities pursuant to Rule 462(b) under the Rules (the &#8220;462(b)
      Registration Statement&#8221;), then any reference herein to the Registration Statement shall also be deemed to include such 462(b) Registration Statement.&#160; The term &#8220;Prospectus&#8221; as used in this Agreement means the prospectus in the form included in the
      Registration Statement at the time of effectiveness or, if Rule 430A of the Rules is relied on, the term Prospectus shall also include the final prospectus filed with the Commission pursuant to and within the time limits described in Rule 424(b) of
      the Rules.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">The Company understands that the Underwriters propose to make a public offering of the Securities, as set forth in and pursuant to the Statutory Prospectus (as hereinafter defined)
      and the Prospectus, as soon after the Effective Date and the date of this Agreement as the Representative deems advisable.&#160; The Company hereby confirms that the Underwriters and dealers have been authorized to distribute or cause to be distributed
      each Preliminary Prospectus, and, if applicable, each Issuer Free Writing Prospectus (as hereinafter defined) and are authorized to distribute the Prospectus (as from time to time amended or supplemented if the Company furnishes amendments or
      supplements thereto to the Underwriters).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>Sale, Purchase, Delivery and Payment for the Securities</u>.&#160;
        On the basis of the representations, warranties and agreements contained in, and subject to the terms and conditions of, this Agreement:</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, the number of
      Firm Units set forth opposite the name of such Underwriter under the columns &#8220;Number of Firm Units to be Purchased&#8221; on Schedule I to this Agreement. The combined purchase price for one Firm Share and one Common Warrant (each, a &#8220;Common Unit&#8221;) shall
      be $[&#9679;] (93% of the price offered to the public). The combined purchase price for one Pre-Funded Warrant and one Common Warrant (each , a &#8220;Pre-Funded Unit&#8221; shall be $[&#9679;] (93% of the price offered to the public minus $0.001).</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Delivery of certificates for the Firm Shares shall be made through the facilities of the Depository Trust Company (&#8220;DTC&#8221;), New York, New York, at the offices of Aegis Capital Corp., 1345 Avenue of
      the Americas, 27th Floor, New York, New York 10105, at 10:00 a.m., New York City time, on the second business day following the date of this Agreement or at such time on such other date, not later than ten (10) business days after the date of this
      Agreement, as shall be agreed upon by the Company and the Representative (such time and date of delivery and payment are called the &#8220;Firm Units Closing Date&#8221;). The Firm UnitsClosing Date and any Additional Closing Date (as defined below) are called,
      individually, a &#8220;Closing Date&#8221; and, together, the &#8220;Closing Dates.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payment for the Firm Units shall be made to the Company by wire transfer of immediately available funds or by certified or official bank check or checks payable in New York
      Clearing House (same day) funds drawn to the order of the Company, against delivery of the respective certificates to the Representative for the respective accounts of the Underwriters of certificates for the Shares and/or Warrants to be purchased by
      them.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Two (2) business days prior to any Closing Date, the Representative shall provide the Company with a list of investors to which the Underwriters allocated Securities (the
      &#8220;Investor List&#8221;). The Investor List shall specify the name, address and number of Securities to be sold to each such investor. The Firm Shares shall be registered in such names and shall be in such denominations as the Representative shall request
      before the Firm Units Closing Date or, in the case of Option Shares (as defined below), on the day of the Over-Allotment Exercise Notice as described in Section 1(e) and shall be delivered by or on behalf of the Company to the Representative through
      the facilities of the DTC for the account of the Representative. Prior to the Closing Date, the Company shall provide drafts of the Warrants to the Representative for review. On the Closing Date, the Company shall deliver the Warrants by mailing such
      instruments to each investor in accordance with the Investor List through a U.S. nationally recognized overnight courier service.</div>
    <div style="line-height: 1.25">&#160;</div>
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representative is hereby granted an option (the &#8220;Over-Allotment Option&#8221;) to purchase, in the aggregate, up to [&#9679;] additional ADSs and/or Pre-funded Warrants to purchase Warrant Shares, representing 15.0% of the Firm Units
    sold in the offering from the Company (the &#8220;Option Shares&#8221; or &#8220;Option Pre-funded Warrants,&#8221; as applicable) and/or up to [&#9679;] additional Warrants to purchase an aggregate of an additional [&#9679;] Warrant Shares, representing 15.0% of the Firm Units sold in
    the offering from the Company (the &#8220;Option Warrants&#8221;). The purchase price to be paid per Option Share or Option Pre-funded Unit shall be equal to the price per Common Unit or Pre-funded Unit set forth in Section 1(a) hereof minus $0.01 and the purchase
    price to be paid per Option Warrant shall be equal to $0.01 per Option Warrant. The Over-allotment Option is, at the Representative&#8217;s sole discretion, for Option Shares and Option Warrants together, Option Pre-funded Warrants and Option Warrants
    together, solely Option Shares, solely Option Pre-funded Warrants, solely Option Warrants, or any combination thereof (each, an &#8220;Option Security&#8221; and collectively, the &#8220;Option Securities&#8221;). The Representative may cancel any exercise of the
    Over-Allotment Option at any time prior to the Closing Date or the applicable Additional Closing Date, as the case may be, by giving written notice of such cancellation to the Company.
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">The Over-Allotment Exercise Notice shall set forth:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(A) the aggregate number of Option Units as to which the Over-Allotment Option is being exercised;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(B) the purchase price for the Option Units;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(C) the names and denominations in which the Option Units are to be registered; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(D) the applicable Additional Closing Date, which may be the same date and time as the Closing Date but shall not be
      earlier than the Closing Date nor later than the thirtieth (30th) day following the Closing Date.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Payment for the Option Units (the &#8220;Option Securities Payment&#8221;) shall be made by wire transfer in immediately available funds to the accounts specified by the Company to the Representative at the offices of Aegis Capital
      Corp., 1345 Avenue of the Americas, 27th Floor, New York, New York 10105, at 10:00 a.m., New York City time on the date specified in the corresponding Over-Allotment Exercise Notice, or at such other place on the same or such other date and time, not
      later than the fifth business day thereafter, as the Representative and the Company may agree upon in writing (an &#8220;Additional Closing Date&#8221;). The Option Securities Payment shall be made against delivery to the Representative for its account of the
      Option Units to be purchased on any Additional Closing Date, with any transfer taxes, stamp duties and other similar taxes payable in connection with the sale of the Option Securities duly paid by the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>Representations and Warranties of the Company</u>.&#160; The
        Company represents and warrants to each Underwriter as of the date hereof and as of the Closing Date, as follows:</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On the Effective Date, the Registration Statement complied, and on the date of the&#160; Prospectus, the date any post-effective amendment to the Registration Statement becomes
      effective, the date any supplement or amendment to the Prospectus is filed with the Commission, the Registration Statement and the Prospectus (and any amendment thereof or supplement thereto) will comply, in all material respects, with the
      requirements of the Securities Act and the Rules and the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and the rules and regulations of the Commission thereunder.&#160; Neither the Registration Statement nor any amendments thereto
      as of the times they became effective, contained any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading; and on the Effective Date
      and the other dates referred to above neither the Registration Statement nor the Prospectus, nor any amendment or supplement of either of the foregoing, will contain any untrue statement of a material fact or will omit to state any material fact
      required to be stated therein or necessary in order to make the statements therein not misleading.&#160; When any Preliminary Prospectus was first filed with the Commission (whether filed as part of the Registration Statement or any amendment thereto or
      pursuant to Rule 424(a) of the Rules) and when any amendment thereof or supplement thereto was first filed with the Commission, such Preliminary Prospectus as amended or supplemented complied in all material respects with the applicable provisions of
      the Securities Act and the Rules and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading.&#160; If applicable, each
      Preliminary Prospectus and the Prospectus delivered to the Underwriters for use in connection with this offering was identical to the electronically transmitted copies thereof filed with the Commission pursuant to the Commission&#8217;s Electronic Data
      Gathering, Analysis and Retrieval system (&#8220;EDGAR&#8221;), except to the extent permitted by Regulation S-T.&#160; Notwithstanding the foregoing, none of the representations and warranties in this Section 2(a) shall apply to statements in, or omissions from, the
      Registration Statement, any Preliminary Prospectus or the Prospectus made in reliance upon, and in conformity with, information herein or otherwise furnished in writing by the Representative on behalf of the several Underwriters specifically for use
      in the Registration Statement, any Preliminary Prospectus or the Prospectus, as the case may be.&#160; With respect to the preceding sentence, the Company acknowledges that the only information furnished in writing by the Representative on behalf of the
      several Underwriters for use in the Registration Statement, any Preliminary Prospectus or the Prospectus is the statements contained in the [&#8226;] and [&#8226;] paragraphs under the caption &#8220;Underwriting&#8221; in the Prospectus (collectively, the &#8220;Underwriter
      Information&#8221;).</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of the Applicable Time (as hereinafter defined), none of (i) the price to the public and the number of Securities offered and sold, as indicated on the cover page
      of the Prospectus<font style="font-weight: bold; font-style: italic;">&#160;</font>and the Statutory Prospectus (as hereinafter defined), all considered together (collectively, the &#8220;General Disclosure Package&#8221;), (ii)&#160;any individual Issuer Free Writing
      Prospectus when considered together with the General Disclosure Package, and (iii) any individual Written Testing-the Waters Communication (as defined herein), when considered together with the General Disclosure Package, included, includes or will
      include any untrue statement of a material fact or omitted, omits or will omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were
      made, not misleading; provided, however, that this representation and warranty shall not apply to statements in or omissions in the General Disclosure Package made in reliance upon and in conformity with the Underwriter Information.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Each Issuer Free Writing Prospectus (as hereinafter defined), including any electronic road show (including without limitation any &#8220;bona fide electronic road show&#8221; as defined in Rule 433(h)(5) under
      the Securities Act) (each, a &#8220;Road Show&#8221;) (i) is identified in Schedule III hereto and (ii) complied when issued, and complies, in all material respects with the requirements of the Securities Act and the Rules and the Exchange Act and the rules and
      regulations of the Commission thereunder. The Company has made at least one version of the Road Show available without restriction by means of graphic communication to any person, including any potential investor in the Securities (and if there is
      more than one version of a Road Show for the offering that is a written communication, the version available without restriction was made available no later than the other versions).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 36pt; line-height: 1.25;">As used in this Section and elsewhere in this Agreement:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 36pt; line-height: 1.25;">&#8220;Applicable Time&#8221; means [&#8226;] [a.m.][p.m.] (Eastern time) on the date of this Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 36pt; line-height: 1.25;">&#8220;Statutory Prospectus&#8221; as of any time means the Preliminary Prospectus relating to the Securities that is included in the Registration Statement immediately prior to the Applicable Time.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 36pt; line-height: 1.25;">&#8220;Issuer Free Writing Prospectus&#8221; means each &#8220;free writing prospectus&#8221; (as defined in Rule 405 of the Rules) prepared by or on behalf of the Company or used or referred to by the Company in connection
      with the offering of the Securities, including, without limitation, each Road Show.</div>
    <div style="margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160; &#160;&#160; &#160; &#160; &#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
      preventing the use of any Preliminary Prospectus, the Prospectus or any &#8220;free writing prospectus,&#8221; as defined in Rule 405 under the Rules, has been issued by the Commission and no proceedings for that purpose have been instituted or, to the Company&#8217;s
      knowledge, have been threatened under the Securities Act. Any required filing of any Preliminary Prospectus and/or the Prospectus and any supplement thereto pursuant to Rule 424(b) of the Rules has been or will be made in the manner and within the
      time period required by such Rule 424(b).&#160; Any material required to be filed by the Company pursuant to Rule 433(d) or Rule 163(b)(2) of the Rules has been or will be made in the manner and within the time period required by such Rules.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; (d)&#160; &#160; &#160; &#160; &#160; &#160; Each Issuer Free Writing Prospectus, if any, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Securities or
      until any earlier date that the Company notified or notifies the Representative as described in the next sentence, did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in
      the Registration Statement, the Statutory Prospectus or the Prospectus.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 54pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing
      Prospectus conflicted or would conflict with the information contained in the Registration Statement, the Statutory Prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a
      material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances prevailing at the subsequent time, not misleading, the Company has promptly notified or will promptly notify the
      Representative and has promptly amended or will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160; &#160;&#160; &#160; &#160;&#160; (e)&#160; &#160; &#160; &#160; &#160;&#160; The financial statements of the Company (including all notes and schedules thereto) included in the Registration Statement, the Statutory Prospectus and Prospectus present
      fairly, in all material respects, the financial condition of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, shareholders&#8217; equity and cash flows of the Company and its consolidated subsidiaries
      for the periods specified; and such financial statements and related schedules and notes thereto, and the unaudited financial information filed with the Commission as part of the Registration Statement, have been prepared in conformity with&#160;
      generally accepted accounting principles, consistently applied throughout the periods involved, except as may be expressly stated in the related notes thereto.&#160; The summary and selected financial data included in the Statutory Prospectus and
      Prospectus present fairly the information shown therein as of the respective dates and for the respective periods specified and have been presented on a basis consistent with the consolidated financial statements set forth in the Prospectus.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Somekh Chaikin, a member firm of KPMG International (the &#8220;Auditor&#8221;), whose reports are filed with the Commission as a part of the Registration Statement, are and,
      during the periods covered by their reports, were independent public accountants as required by the Securities Act and the Rules.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and each of its subsidiaries, including each entity (corporation, partnership, joint
        venture, association or other business organization) controlled directly or indirectly by the Company (each, a &#8220;subsidiary&#8221;), is duly organized, validly existing and in good standing under the laws of their respective jurisdictions of incorporation
        or organization and each such entity has all requisite power and authority to carry on its business as is currently being conducted as described in the Statutory Prospectus and the Prospectus, and to own, lease and operate its properties and to
        enter into and perform its obligations pursuant to the public offer and sale of Securities and this Agreement.&#160; All of the issued shares of capital stock of, or other ownership interests in, each subsidiary of the Company have been duly and validly
        authorized and issued and are fully paid and non-assessable and are owned, directly or indirectly, by the Company, free and clear of any lien, charge, mortgage, pledge, security interest, claim, limitation on voting rights, equity, trust or other
        encumbrance, preferential arrangement, defect or restriction of any kind whatsoever. The Company and each of its subsidiaries is duly qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the nature
        of the business conducted by it or location of the assets or properties owned, leased or licensed by it requires such qualification, except for such jurisdictions where the failure to so qualify individually or in the aggregate would not have a
        material adverse effect on the assets, properties, condition, financial or otherwise, or in the results of operations, business affairs or business prospects of the Company and its subsidiaries considered as a whole or in the context of the public
        offer and sale of the Securities or underwriting of the Securities (a &#8220;Material Adverse Effect&#8221;); and to the Company&#8217;s knowledge, no proceeding has been instituted or, to the knowledge of the Company, is threatened in any such jurisdiction
        revoking, limiting or curtailing, or seeking to revoke, limit or curtail, such power and authority or qualification or taken against it for its winding-up, liquidation or dissolution or for any similar or analogous proceeding in any jurisdiction,
        or for it to enter into any arrangement or composition for the benefit of creditors, or for the appointment of a receiver, administrative receiver, trustee or similar officer. None of the Company nor any of its Israeli subsidiaries is designated as
        a &#8220;breaching company&#8221; (within the meaning of the Israeli Companies Law, 5759-1999 (together with the regulations promulgated thereunder, the &#8220;Israeli Companies Law&#8221;)) by the registrar of companies of the State of Israel (the &#8220;Registrar of
        Companies&#8221;), nor has a proceeding been instituted in Israel by the Registrar of Companies of the State of Israel for the dissolution of the Company or any of its Israeli subsidiaries, and other than with respect to that certain notices to Chemomab
        Ltd. and Chemomab Therapeutics Israel Ltd. received in March 2023, there is no basis for such designation.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; (h)&#160; &#160; &#160; &#160; &#160;&#160; (i) At the time of filing the Registration Statement and (ii) on the date hereof, the Company was not and is not an &#8220;ineligible issuer,&#8221; as defined in Rule&#160;405 of the
      Rules, including (but not limited to) the Company or any other subsidiary in the preceding three (3) years not having been convicted of a felony or misdemeanor or having been made the subject of a judicial or administrative decree or order as
      described in Rule&#160;405 of the Rules.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; (i)&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; Except as described in the Statutory Prospectus and the Prospectus, and as would not reasonably be expected, singly or in the aggregate, to have a Material Adverse Effect,
      the Company and each of its subsidiaries (i) owns or possesses, or can promptly acquire on reasonable terms, adequate rights to use all patents, patent rights, inventions, trademarks, trademark applications, trade names, service marks, copyrights,
      copyright applications, licenses, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems, processes or procedures) and other similar rights and proprietary knowledge (in each case,
      whether registered or not and including applications for registration) (collectively, &#8220;Intellectual Property&#8221;) necessary for the conduct of its business as currently conducted and as proposed to be conducted in the Statutory Prospectus and the
      Prospectus.&#160; Neither the Company nor any of its subsidiaries has received any notice of, or is not aware of, any infringement of or conflict with asserted rights of others with respect to any Intellectual Property and neither the Company nor any of
      its subsidiaries has knowledge of any infringement of or conflict with asserted rights of others or of any infringement of, or conflict with the Company and its subsidiaries&#8217; rights with respect to any Intellectual Property, (ii) the Company and each
      of its subsidiaries processes employed and the products and services dealt in by the Company or any of its subsidiaries do not, to its knowledge, infringe Intellectual Property of a third party and neither of the Company nor any of its subsidiaries
      has received any notice of infringement of or conflict with, and neither of the Company nor any of its subsidiaries has knowledge of any infringement of or conflict with, asserted rights of a third party with respect to any Intellectual Property,
      except for or in respect of any such infringements or conflicts that would not, individually or in the aggregate, have a Material Adverse Effect, (iii) except as described in the Statutory Prospectus and the Prospectus, neither the Company nor any of
      its subsidiaries is obligated to pay a royalty, grant a license or provide other consideration to any third party in connection with its Intellectual Property, and the public offer and sale of Securities will not trigger such payment, except for any
      such obligations that would not, individually or in the aggregate, have a Material Adverse Effect.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; (j)&#160; &#160; &#160; &#160; &#160; &#160; The Company and each of its subsidiaries has good and marketable title in fee simple to all real property, and good and marketable title to all other property owned by it,
      in each case free and clear of all liens, encumbrances, claims, security interests and defects, except such as do not materially affect the value of such property and do not materially interfere with the use made or proposed to be made of such
      property by the Company and its subsidiaries.&#160; All property held under lease by the Company and its subsidiaries is held by them under valid, existing and enforceable leases, free and clear of all liens, encumbrances, claims, security interests and
      defects, except such as are not material and do not materially interfere with the use made or proposed to be made of such property by the Company and its subsidiaries.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act,
      including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto
      and documents incorporated by reference therein, together with the Prospectus, being collectively referred to herein as the &#8220;SEC Reports&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports
      prior to the expiration of any such extension.&#160; As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed,
      contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.&#160;
      The Company has never been an issuer subject to Rule 144(i) under the Securities Act.&#160; The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and
      regulations of the Commission with respect thereto as in effect at the time of filing.&#160; Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the
      periods involved (&#8220;GAAP&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material
      respects the financial position of the Company and its consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal,
      immaterial, year-end audit adjustments.&#160; The agreements and documents described in the Registration Statement, the Preliminary Prospectus, the General Disclosure Package, the Prospectus, and the SEC Reports conform in all material aspects to the
      descriptions thereof contained therein and there are no agreements or other documents required by the Securities Act and the Rules to be described in the Registration Statement, the Preliminary Prospectus, the General Disclosure Package, the
      Prospectus or the SEC Reports or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company is a
      party or by which it is or may be bound or affected that has been filed or incorporated by reference as an exhibit pursuant to Item 601(b)(4) or (10) of Regulation S-K to the Registration Statement or identified in a Current Report on Form 8-K filed
      by the Company pursuant to Item 1.01 or 2.03 of such Form 8-K since December 31, 2020 (each, a &#8220;Material Contract&#8221;), is in full force and effect in all material respects and is enforceable against the Company in accordance with its terms. To the best
      of the Company&#8217;s knowledge, performance by the Company of the material provisions of such Material Contracts will not result in a material violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental
      agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses, including, without limitation, those relating to environmental laws and regulations.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; Subsequent to the respective dates as of which information is given in the Registration Statement, the Statutory Prospectus and the Prospectus, (i) there has not been
      any event which could have a Material Adverse Effect; (ii) neither the Company nor any of its subsidiaries has sustained any loss or interference with its assets, businesses or properties (whether owned or leased) from fire, explosion, earthquake,
      flood or other calamity, whether or not covered by insurance, or from any labor dispute or any court or legislative or other governmental action, order or decree which would have a Material Adverse Effect; and (iii) since the date of the latest
      balance sheet included in the Registration Statement and the Prospectus, as described in the Statutory Prospectus and the Prospectus, neither the Company nor its subsidiaries has (A) issued any securities (other than securities issued pursuant to
      employee benefit plans, qualified stock option plans or other employee compensation plans, or pursuant to outstanding options, rights or warrants) or incurred any liability or obligation, direct or contingent, for borrowed money, except such
      liabilities or obligations incurred in the ordinary course of business, (B) entered into any transaction not in the ordinary course of business or (C) declared or paid any dividend or made any distribution on any shares of its stock or redeemed,
      purchased or otherwise acquired or agreed to redeem, purchase or otherwise acquire any shares of its capital stock.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; (m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is no document, contract or other agreement required to be described in the Registration Statement, the Statutory Prospectus or the Prospectus or to be filed as an
      exhibit to the Registration Statement which is not described or filed as required by the Securities Act or Rules.&#160; Each description of a contract, document or other agreement in the Registration Statement, the Statutory Prospectus or the Prospectus
      accurately reflects in all material respects the terms of the underlying contract, document or other agreement.&#160; Each contract, document or other agreement described in the Registration Statement, the Statutory Prospectus or the Prospectus or listed
      in the exhibits to the Registration Statement is in full force and effect and is valid and enforceable by and against the Company or its subsidiary, as the case may be, in accordance with its terms.&#160; Neither the Company nor any of its subsidiaries,
      if a subsidiary is a party, nor to the Company&#8217;s knowledge, any other party, is in default in the observance or performance of any term or obligation to be performed by it under any such agreement, and, to the Company&#8217;s knowledge, no event has
      occurred which with notice or lapse of time or both would constitute such a default, in any such case which default or event, individually or in the aggregate, would have a Material Adverse Effect.&#160; No default exists, and no event has occurred which
      with notice or lapse of time or both would constitute a default, in the due performance and observance of any term, covenant or condition, by the Company or its subsidiary, if a subsidiary is a party thereto, of any other agreement or instrument to
      which the Company or any of its subsidiaries is a party or by which Company or its properties or business or a subsidiary or its properties or business may be bound or affected which default or event, individually or in the aggregate, would have a
      Material Adverse Effect.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160; &#160; (n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The statistical and market related data included in the Registration Statement, the Statutory Prospectus or the Prospectus are based on or derived from sources that the
      Company believes to be reliable and accurate.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as would not reasonably be expected to have a Material Adverse Effect, neither<font style="font-weight: bold;">&#160;</font>the Company nor any subsidiary of the Company (i) is in violation of its certificate or articles of
    incorporation, articles of association, bylaws, certificate of formation, limited liability company agreement, partnership agreement or any other organizational documents, (ii) is in default under, and no event has occurred which, with notice or lapse
    of time, or both, would constitute a default under, or result in the creation or imposition of any lien, charge, mortgage, pledge, security interest, claim, limitation on voting rights, equity, trust or other encumbrance, preferential arrangement,
    defect or restriction of any kind whatsoever, upon, any property or assets of the Company or any subsidiary pursuant to, any bond, debenture, note, indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which it is a
    party or by which it is bound or to which any of its properties or assets is subject, including any instrument of approval granted to any of them by the Israel Innovation Authority of the Israeli Ministry of Economy and Industry (the &#8220;Innovation
    Authority&#8221;), or (iii) is in violation of any applicable statute, law, rule, regulation, ordinance, directive, judgment, decree or order of any judicial, regulatory or other legal or governmental agency or body, foreign or domestic.
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Agreement and the Warrants have been duly authorized, executed and delivered by the Company and each, assuming the due authorization, execution and delivery by the
      other parties hereto, constitutes a valid and legally binding agreement of the Company, enforceable in accordance with its terms, except as (i) the enforcement hereof may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization,
      moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles (whether considered in a proceeding at law or in equity) relating to enforceability and (ii) rights to indemnification
      and contribution hereunder may be limited by applicable law and public policy considerations.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All necessary corporate action has been duly and validly taken by the Company, including, to the extent applicable, under Chapter 5 of Part VI of the Israeli Companies
      Law, for the offer, issuance and sale of the Securities (including the issuance of the Ordinary Shares underlying the Firm Shares, Option Shares and Warrant Shares and the Warrant Shares underlying the Warrants) and the execution, delivery and
      performance of its obligations under this Agreement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company is in compliance in all material respects with the Israeli Companies Law and the Israeli Securities Law, 5728-1968, as amended, and the regulations
      promulgated thereunder (the &#8220;Israeli Securities Law&#8221;). Neither the Company nor any of its subsidiaries has received or claimed any tax benefits under the Israeli Law for the Encouragement of Capital Investments, 5719&#8211;1959.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (s)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; Neither the execution, delivery and performance of this Agreement by the Company nor the consummation of any of the transactions contemplated hereby (including, without
      limitation, the issuance and sale by the Company of the Securities and the issuance of the Ordinary Shares underlying the Securities) will give rise to a right to terminate or accelerate the due date of any payment due under, or conflict with or
      result in the breach of any term or provision of, or constitute a default (or an event which with notice or lapse of time or both would constitute a default) under, or require any consent or waiver under, or result in the execution or imposition of
      any lien, charge or encumbrance upon any properties or assets of the Company or its subsidiaries pursuant to the terms of, any indenture, mortgage, deed of trust or other agreement or instrument to which the Company or any of its subsidiaries is a
      party or by which either the Company or its subsidiaries or any of their properties or businesses is bound, or any franchise, license, permit, judgment, decree, order, statute, rule or regulation applicable to the Company or any of its subsidiaries
      or violate any provision of the articles of association, charter or bylaws or other organizational documents of the Company or any of its subsidiaries, except for such consents or waivers which have already been obtained and are in full force and
      effect.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has authorized and outstanding share capital as set forth under the caption &#8220;Capitalization&#8221; in the Statutory Prospectus and the Prospectus.&#160; All of
      the issued and outstanding shares of the Company have been duly and validly issued and are fully paid and nonassessable under Israeli law and have been issued in compliance with the Israeli Securities Law and all federal, state and local laws of the
      United States.&#160; There are no statutory preemptive rights, rights of first refusal or other similar rights to subscribe for or to purchase or acquire any securities of the Company or any of its subsidiaries, or any such rights pursuant to its articles
      of association, charter, certificate of incorporation or bylaws or any other applicable organizational documents or any agreement or instrument to or by which the Company or any of its subsidiaries is a party or bound.&#160; The Securities and the
      Ordinary Shares underlying the Securities have been duly authorized for issuance and sale, as applicable, pursuant to this Agreement. When issued and sold, as applicable, pursuant to this Agreement, the Shares and the Ordinary Shares underlying the
      Shares will be duly and validly issued, fully paid and nonassessable and none of them will be issued in violation of any preemptive or other similar right.&#160; When paid for and issued in accordance with the Warrants, the Warrant Shares (including the
      Ordinary Shares underlying the Warrant Shares) will be validly issued, fully paid and non-assessable and none of them will be issued in violation of any preemptive or other similar right. Except as disclosed in the Registration Statement, the
      Statutory Prospectus and the Prospectus, there is no outstanding option, warrant or other right calling for the issuance of, and there is no commitment, plan or arrangement to issue, any shares of the Company or any of its subsidiaries or any
      security convertible into, or exercisable or exchangeable for, such shares. The exercise price of each option to acquire Ordinary Shares or ADSs (each, a &#8220;Company Stock Option&#8221;) is no less than the fair market value of an Ordinary Share or ADS as
      determined on the date of grant of such Company Stock Option.&#160; All grants of Company Stock Options were validly issued and properly approved by the Board of Directors of the Company (and, if required, by a committee of the Board of Directors of the
      Company and/or the shareholders of the Company) in material compliance with all applicable laws and the terms of the plans under which such Company Stock Options were issued and were recorded on the Company&#8217;s financial statements, in accordance with
      GAAP, and no such grants involved any &#8220;back dating,&#8221; &#8220;forward dating,&#8221; &#8220;spring loading&#8221; or similar practices with respect to the effective date of grant.<u> Each Company Stock Option </u>that was intended to qualify for either the &#8220;capital gains
      track&#8221; or the &#8220;employment income track&#8221; of Section 102 of the Israeli Income Tax Ordinance (New Version), 5721-1961, and the rules and regulations promulgated thereunder, so qualifies as was indicated with respect to each such <u>Company Stock
        Option </u>at the date that such <u>Company Stock Option </u>was granted.<u>&#160;</u>The Securities conform in all material respects to all statements in relation thereto contained in the Registration Statement and the Statutory Prospectus and the
      Prospectus.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; (u)&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times from its duly authorized share capital, free of
      preemptive rights, a sufficient number of Ordinary Shares for the purpose of enabling the Company to issue Warrant Shares issuable upon exercise of outstanding Warrants.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; (v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; No holder of any security of the Company has any right, which has not been waived, to have any security owned by such holder included in the Registration Statement or to
      demand registration of any security owned by such holder for a period of one hundred and eighty (180) days after the date of this Agreement.&#160; Each director and executive officer of the Company and each shareholder of the Company or ADS holder listed
      on Schedule II hereto has delivered to the Representative his or her enforceable written lock-up agreement in the form attached to this Agreement as Exhibit C hereto (&#8220;Lock-Up Agreement&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no legal or governmental proceedings pending to which the Company or any of its subsidiaries is a party or of which any property of the Company or any of its
      subsidiaries is the subject which, if determined adversely to the Company or any of its subsidiaries could individually or in the aggregate have a Material Adverse Effect; and, to the knowledge of the Company, no such proceedings are threatened or
      contemplated by governmental authorities or threatened by others.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; (x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All obligations of the Company and its Israeli subsidiaries to provide statutory severance pay to all its currently engaged employees in Israel (&#8220;Israeli
      Employees&#8221;) are, with such exceptions as are not material, in accordance with Section 14 of the Israeli Severance Pay Law, 5723-1963 (the &#8220;Severance Pay Law&#8221;) and are fully funded or, if not required to be funded, are accrued on the Company&#8217;s
      financial statements, and all such employees have been subject to the provisions of Section 14 of the Severance Pay Law with respect to their entire salary, as defined under the Severance Pay Law, from the date of commencement of their employment
      with the Company or its Israeli subsidiaries, and the Company and its Israeli subsidiaries have been, with such exceptions as are not material, in full compliance with the technical and substantive requirements for a Section 14 Arrangement with
      respect to severance pay with respect to 100% of such salary for which severance pay is due under the Severance Pay Law; and all amounts that the Company and its Israeli subsidiaries are required by contract or applicable law either (A) to deduct
      from Israeli Employees&#8217; salaries or to transfer to such Israeli Employees&#8217; pension or provident, life insurance, incapacity insurance, advance study fund or other similar funds or (B) to withhold from their Israeli Employees&#8217; salaries and benefits
      and to pay to any Israeli governmental authority as required by applicable Israeli tax law, have, in each case, been duly and timely deducted, transferred, withheld and paid, and the Company and its Israeli subsidiaries have no outstanding obligation
      to make any such deduction, transfer, withholding or payment.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Company nor any of its subsidiaries is involved in any labor dispute nor, to the knowledge of the Company, is any such dispute threatened, which
      dispute would have a Material Adverse Effect.&#160; The Company is not aware of any existing or imminent labor disturbance by the employees of any of its principal suppliers or contractors which would have a Material Adverse Effect.&#160; The Company is not
      aware of any threatened or pending litigation between the Company or its subsidiaries and any of its executive officers which, if adversely determined, could have a Material Adverse Effect and has no reason to believe that such executive officers
      will not remain in the employment of the Company or its subsidiaries.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No transaction has occurred between or among the Company and any of its officers or directors, shareholders or any affiliate or affiliates of any such officer or
      director or shareholder that is required to be described in and is not described in the Registration Statement, the Statutory Prospectus and the Prospectus.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has not taken, nor will it take, directly or indirectly, any action designed to, or which might reasonably be expected to cause or result in, or
      which has constituted or which might reasonably be expected to constitute, the stabilization or manipulation of the price of the ADSs, Ordinary Shares or any security of the Company to facilitate the sale or resale of any of the Securities.&#160; In
      addition, neither the Company nor any of its subsidiaries has engaged in any form of solicitation, advertising or any other action constituting an offer or sale under the Israeli Securities Law in connection with the transactions contemplated hereby
      which would require the publication of a prospectus in the State of Israel under the laws of the State of Israel.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(bb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and each of its subsidiaries has duly paid all national, including Israeli, regional and local taxes of any kind (including but not limited to,
      income taxes, capital gain taxes, withholding taxes, sales and transfer taxes, energy and real estate taxes, labor market and social contribution taxes, customs duties, value added tax, registration fees and similar levies, duties, charges, stamps
      and imposts of whatever nature as well as any penalty, fine, surcharge or interest relating thereto) which have become due and payable with regard to the period up to and including the date of this Agreement (other than tax deficiencies which the
      Company or any of its subsidiaries is contesting in good faith and for which the Company or any of its subsidiaries have provided adequate provisions if required by GAAP), except for such failures that would not, individually or in the aggregate,
      have a Material Adverse Effect. The Company and each of its subsidiaries has filed all federal, state, local and foreign, including Israeli, tax returns which are required to be filed through the date hereof, which returns are true and correct in all
      material respects or has received timely extensions thereof, and has paid all taxes shown on such returns and all assessments received by it to the extent that the same are material and have become due. There are no tax audits or investigations
      pending, which if adversely determined would have a Material Adverse Effect; nor are there any material proposed additional tax assessments against the Company or any of its subsidiaries nor have any written claims been made by any governmental
      authority that the Company or its subsidiaries are or may be subject to tax or required to file a tax return in a jurisdiction where it does not file tax returns.</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Firm Shares, Option Shares, and the Warrant Shares have been duly authorized for quotation on The Nasdaq Capital Market, subject to official Notice of
      Issuance. A registration statement has been filed on Form 8-A pursuant to Section 12 of the Exchange Act, which registration statement complies in all material respects with the Exchange Act.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the ADSs under the Exchange Act or the quotation
      of the ADSs on the Nasdaq Capital Market, nor has the Company received any notification that the Commission or the Nasdaq Capital Market is contemplating terminating such registration or quotation.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The books, records and accounts of the Company and its subsidiaries accurately and fairly reflect the transactions in, and dispositions of, the assets of, and
      the results of operations of, the Company and its subsidiaries.&#160; The Company and each of its subsidiaries maintains a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance
      with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in
      accordance with management&#8217;s general or specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(ff)&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; Except as may be disclosed in the Registration Statement, the Statutory Prospectus and the Prospectus, the Company has established and maintains disclosure
      controls and procedures (as such term is defined in Rule 13a-15 under the Exchange Act) and such disclosure controls and procedures are effective in all material respects to perform the functions for which they were established.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as disclosed in the Registration Statement, the Statutory Prospectus and the Prospectus, based on a reasonable evaluation of its disclosure controls and
      procedures, the Company is not aware of (i) any material weakness or significant deficiency in the design or operation of internal controls which could adversely affect the Company&#8217;s ability to record, process, summarize and report financial data or
      any material weaknesses in internal controls; or (ii) any fraud, whether or not material, that involves management or other employees who have a role in the Company&#8217;s internal controls.</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(hh)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as described in the Statutory Prospectus and the Prospectus and as preapproved in accordance with the requirements set forth in Section 10A of the
      Exchange Act, the Auditor has not been engaged by the Company to perform any &#8220;prohibited activities&#8221; (as defined in Section 10A of the Exchange Act).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160; (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as described in the Statutory Prospectus and the Prospectus, there are no material off-balance sheet arrangements (as defined in Item 303 of Regulation
      S-K) that have or are reasonably likely to have a material current or future effect on the Company&#8217;s financial condition, revenues or expenses, changes in financial condition, results of operations, liquidity, capital expenditures or capital
      resources.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(jj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company&#8217;s Board of Directors has validly appointed an audit committee whose composition satisfies the requirements of Rule 5605 of the Nasdaq Stock Market
      and the Israeli Companies Law, and the Board of Directors and/or the audit committee has adopted a charter that satisfies the requirements of Rule 5605 of the Nasdaq Stock Market.&#160; The audit committee has reviewed the adequacy of its charter within
      the past twelve (12) months.</div>
    <div style="line-height: 1.25">&#160;</div>
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (kk)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company is in compliance with all applicable provisions of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), any related rules and regulations promulgated by the Commission and corporate governance
    requirements under applicable Nasdaq regulations upon the effectiveness of such provisions and has no reason to believe that it will not be able to comply with such provisions at the time of effectiveness. There is and has been no failure on the part
    of the Company or any of its directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act, including, without limitation, Section 402 related to loans and Sections 302 and 906 related to certifications.
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160; &#160; &#160; (ll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; The Company and its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are
      customary in the businesses in which they are engaged or propose to engage after giving effect to the transactions described in the Statutory Prospectus and the Prospectus; all policies of insurance insuring the Company or any of its subsidiaries or
      the Company&#8217;s or its subsidiaries&#8217; respective businesses, assets, employees, officers and directors are in full force and effect; the Company and each of its subsidiaries are in compliance with the terms of such policies and instruments in all
      material respects; and neither the Company nor any subsidiary of the Company has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
      insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(mm)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assuming that the Underwriters have not offered the Securities or otherwise engaged in solicitation, advertising or any other action constituting an offer to
      the public of the Securities under the Israeli Securities Law in Israel, no consent, approval, authorization, or order of, or filing or registration with, any person (including any governmental agency or body or any court),&#160; is required to be
      obtained or made by or on behalf of the Company for the consummation of the transactions contemplated by this Agreement, including in connection with the offering, issuance and sale of the Securities, including the Ordinary Shares underlying the
      Shares and the Warrant Shares, by the Company, except for (i) the obligation to file certain information with the Israel Registrar of Companies, (ii) the obligation to obtain the consent of the Innovation Authority, which the Company has obtained,
      (iii) such approvals as have been obtained or made, or as may be required by Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;) and as may be required under state securities laws and the securities laws of any jurisdiction outside the United
      States, and (iv) the approval by the Nasdaq Capital Market for the listing of the Firm Shares, Option Shares and Warrant Shares.</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(nn)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There are no affiliations with FINRA among the Company&#8217;s officers, directors or, to the knowledge of the Company, any five percent or greater shareholder of the
      Company, except as set forth in the Registration Statement or otherwise disclosed in writing to the Representative.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(oo)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assuming that (A) the Underwriters are not otherwise subject to taxation in Israel due to Israeli tax residence or the existence of a permanent establishment of such
      Underwriters in Israel or due to any other present or former connection between the Underwriters and Israel, and (B) the Underwriters&#8217; services under this Agreement will be performed entirely outside of Israel by the Underwriters, no capital gain,
      income, withholding or other taxes are payable in the State of Israel by or on behalf of the Underwriters to any taxing authority thereof or therein in connection with (i) the issuance, sale and delivery of the Securities as contemplated by this
      Agreement; (ii) the purchase from the Company, and the initial resale and delivery by the Underwriters of the Securities to purchasers thereof as contemplated by this Agreement; or (iii) the execution, delivery and performance of this Agreement or
      any other document to be furnished hereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160; (pp)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) Each of the Company and each of its subsidiaries is in compliance in all material respects with all rules, laws and regulation relating to the use,
      treatment, storage and disposal of toxic substances and protection of health or the environment (each such law, an &#8220;Environmental Law&#8221;) which are applicable to its business; (ii) neither the Company nor its subsidiaries has received any notice from
      any governmental authority or third party of an asserted claim under Environmental Laws; (iii) each of the Company and each of its subsidiaries has received all permits, licenses or other approvals required of it under applicable Environmental Laws
      to conduct its business and is in compliance with all terms and conditions of any such permit, license or approval; (iv) to the Company&#8217;s knowledge, no facts currently exist that will require the Company or any of its subsidiaries to make future
      material capital expenditures to comply with Environmental Laws; and (v) no property which is or has been owned, leased or occupied by the Company or its subsidiaries has been designated as a Superfund site pursuant to the Comprehensive Environmental
      Response, Compensation of Liability Act of 1980, as amended (42 U.S.C. Section 9601, et. seq.) (&#8220;CERCLA 1980&#8221;) or otherwise designated as a contaminated site under other applicable Environmental Laws.&#160; Neither the Company nor any of its subsidiaries
      has been named as a &#8220;potentially responsible party&#8221; under CERCLA 1980 or under other applicable Environmental Laws.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(qq)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries possess, and are in compliance with the terms of, all applicable certificates, authorizations, consents, franchises, licenses and
      permits (&#8220;Licenses&#8221;), including, without limitation, any licenses issued by the European Medicines Agency (&#8220;EMA&#8221;), the Israeli Ministry of Health (the &#8220;MOH&#8221;) or the U.S. Food and Drug Administration (&#8220;FDA&#8221;), necessary to the conduct of the business
      now conducted or proposed in the Prospectus to be conducted by them, except where the failure to possess or be in compliance with any such Licenses would not, individually or in the aggregate, have a Material Adverse Effect, and neither the Company
      nor any of its subsidiaries has received any notice relating to the revocation or modification of any Licenses (or non-compliance therewith) that, if determined adversely to the Company or any of its subsidiaries, would individually or in the
      aggregate have a Material Adverse Effect. The Company and its subsidiaries are, and at all times have been, in compliance with all applicable statutes, rules and regulations of the FDA, the EMA, the MOH and other federal, state, local or foreign
      governmental and regulatory authorities applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product
      or pipeline product manufactured or distributed by the Company or its subsidiaries, except where such noncompliance would not, individually or in the aggregate, have a Material Adverse Effect. The disclosures in the Registration Statement concerning
      the effects of federal, state, local and all foreign regulation on the Company&#8217;s business as currently contemplated are correct in all material respects.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160; (rr)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company is not and, after giving effect to the offering and sale of the Securities and the application of proceeds thereof as described in the Statutory
      Prospectus and the Prospectus, will not be an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(ss)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the qualifications and assumptions set forth in the Registration Statement and the Prospectus, and based on current estimates of the Company&#8217;s gross income
      and gross assets, its intended use of the proceeds of the offering and sale of the Securities and the nature of its business, the Company does not expect that it will be classified as a &#8220;passive foreign investment company&#8221; (&#8220;PFIC&#8221;) as defined in
      Section 1297 of the United States Internal Revenue Code of 1986, as amended, for the taxable year ending December 31, 2022 or December 31, 2023.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(tt)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Company nor any of its properties or assets has any immunity from the jurisdiction of any court or from any legal process (whether through service of
      notice, attachment prior to judgment, attachment in aid of execution or otherwise) under the laws of the State of Israel or U.S. federal or New York state law and, to the extent that the Company may have or may hereafter become entitled to any such
      right of immunity in any such court in which proceedings arising out of, or relating to the transactions contemplated by this Agreement, may at any time be commenced, the Company has, pursuant to Section 9 of this Agreement, waived, and it will waive
      such right to the extent permitted by law.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(uu)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Company, its subsidiaries, its controlled affiliates nor any of their respective officers or directors nor, to the Company&#8217;s knowledge, any of their
      respective employees or agents or other persons associated with or acting on behalf of the Company or any of its subsidiaries has (a) violated, and the Company and its subsidiaries have instituted and maintain policies and procedures designed to
      ensure continued compliance with, anti-bribery laws to which they are subject, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement
      the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December 17, 1997, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010, or any other law, rule or
      regulation of similar purpose and scope, including Sections 291 and 291A of the Israeli Penal Law, 5737-1977, and the rules and regulations thereunder; or (b) (i) used any corporate funds for any unlawful contribution, gift, entertainment or other
      unlawful expense relating to political activity; (ii) made, offered, promised, or authorized any payment or gift of money or anything of value, directly or indirectly, to any employee or official of a foreign or domestic government or government
      owned or controlled entity, or public international organization, political party or official thereof, or candidate for political office; or (iii) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(vv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with all applicable anti-money laundering laws, including
      but not limited to, applicable federal, state, international, foreign, including Israeli, or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 U.S. Code section 1956 and 1957, the
      USA PATRIOT Act, the Bank Secrecy Act, the Currency and Foreign Transactions Reporting Act of 1970, Israel Prohibition on Money Laundering Law, 5760-2000, Israel Prohibition on Money Laundering Order, 5761-2001, and the Israel Prohibition on
      Terrorist Financing Law, 5765-2005, all as amended, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder (collectively, the &#8220;Money Laundering Laws&#8221;) and no
      action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the Company&#8217;s knowledge,
      threatened.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(ww)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on
      behalf of the Company or any of its subsidiaries (i) has violated, nor shall the Company&#8217;s participation in the offering violate, and the Company and its subsidiaries have instituted and maintain policies and procedures designed to ensure continued
      compliance with all applicable laws and regulations imposing economic sanctions measures, including, but not limited to, the International Emergency Economic Powers Act, the Trading with the Enemy Act, the United Nations Participation Act, and the
      Syria Accountability and Lebanese Sovereignty Act, all as amended, the Israeli Trade with the Enemy Ordinance, 1939, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, including the regulations of the
      United States Government, including, without limitation, the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury, the Israeli Ministry of Defense, or
      other relevant sanctions authority (collectively, &#8220;Sanctions&#8221;) or (ii) is currently the subject or target of any Sanctions. Neither the Company nor any of its subsidiaries is located, organized or resident in a country or territory that is the
      subject of Sanctions including, without limitation, Cuba, Iran, North Korea, Syria, and the Crimea Region of the Ukraine; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise
      make available such proceeds to any subsidiaries, joint venture partners or other person, to fund or facilitate any activities of or business with any person, or in any country or territory, that, at the time of such funding or facilitation, is the
      subject or target of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years,
      the Company has not engaged in, is not currently engaged in, and will not engage in, any dealings or transactions with any person, or with any country or territory, that at the time of the dealing or transaction is or was the subject or target of
      Sanctions.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; (xx)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Company nor, to the knowledge of the Company, any other person associated with or acting on behalf of the Company including, without limitation, any director,
      officer, agent or employee of the Company or its subsidiaries, has, directly or indirectly, while acting on behalf of the Company or its subsidiaries (i) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful
      expenses relating to political activity; (ii)&#160;made any direct or indirect unlawful payment or unlawful benefit to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns from corporate funds;
      (iii) violated or is in violation of, or engaged in any activity or conduct which would constitute an offense under, any provision of the&#160; Foreign Corrupt Practices Act of 1977, as amended, or any provision of any applicable non-U.S. anti-bribery or
      anti-corruption law or regulation (&#8220;Anti-Corruption Laws&#8221;); or (iv) made any other unlawful payment. Neither the Company nor its subsidiaries will directly or indirectly use the proceeds of the public offer and sale of Securities or lend, contribute
      or otherwise make available such proceeds to any subsidiary, affiliate, joint venture partner or any other person or entity for the purpose of financing or facilitating any activity in violation of applicable Anti-Corruption Laws.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160; (yy)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The operations of the Company and its subsidiaries are and have been conducted at all times in compliance, in all material respects with applicable financial
      recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules,
      regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;Money Laundering Laws&#8221;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
      involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending, or to the knowledge of the Company, threatened.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160; (zz)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any
      of its subsidiaries, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;OFAC&#8221;); and the Company will not directly or indirectly use the proceeds of the offering, or lend,
      contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160; (aaa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as described in the Statutory Prospectus and the Prospectus, the Company has not sold or issued any shares during the six-month period preceding the
      date of the Prospectus, including any sales pursuant to Rule 144A under, or Regulations D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified stock options plans or other employee compensation plans or
      pursuant to outstanding options, rights or warrants.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;(bbb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has fulfilled its obligations, if any, under the minimum funding standards of Section 302 of the U.S. Employee Retirement Income Security Act of
      1974 (&#8220;ERISA&#8221;) and the regulations and published interpretations thereunder with respect to each &#8220;plan&#8221; as defined in Section 3(3) of ERISA and such regulations and published interpretations in which its employees are eligible to participate and each
      such plan is in compliance in all material respects with the presently applicable provisions of ERISA and such regulations and published interpretations. No &#8220;Reportable Event&#8221; (as defined in 12 ERISA) has occurred with respect to any &#8220;Pension Plan&#8221;
      (as defined in ERISA) for which the Company could have any liability.</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; (ccc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as described in the Statutory Prospectus and the Prospectus, the clinical studies intended to support a regulatory filing and conducted by or, to the knowledge of the Company, on behalf
      of or sponsored by the Company or its subsidiaries, or in which the Company or its subsidiaries have participated, that are described in the Statutory Prospectus and the Prospectus, or the results of which are referred to in the Statutory Prospectus
      and the Prospectus, as applicable, were, and if still pending are, being conducted in all material respects in accordance with standard medical and scientific research standards and procedures for products or product candidates comparable to those
      being developed by the Company and all applicable statutes and all applicable rules and regulations of the FDA and comparable regulatory agencies outside of the United States to which they are subject, including the EMA (collectively, the &#8220;Regulatory
      Authorities&#8221;) and current Good Clinical Practices and Good Laboratory Practices; (ii) the descriptions in the Statutory Prospectus and the Prospectus of the results of such studies are accurate descriptions in all material respects and fairly present
      the data derived therefrom in all material respects; (iii) the Company has no knowledge of any other clinical studies not described in the Statutory Prospectus and the Prospectus, the results of which are inconsistent with or call into question the
      results described or referred to in the Statutory Prospectus and the Prospectus; (iv) the Company and its subsidiaries have operated at all times and are currently in compliance in all material respects with all applicable statutes, rules and
      regulations of the Regulatory Authorities; and (v) neither the Company nor any of its subsidiaries have received any written notices, correspondence or other communications from the Regulatory Authorities or any other governmental agency requiring or
      threatening the termination, material modification or suspension of any clinical studies that are described in the Statutory Prospectus and the Prospectus or the results of which are referred to in the Statutory Prospectus and the Prospectus, other
      than ordinary course communications with respect to modifications in connection with the design and implementation of such studies, and, to the Company&#8217;s best knowledge, there are no reasonable grounds for the same.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160; (ddd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Company, its directors or its officers has distributed nor will distribute prior to the later of (i) the Closing Date and (ii) completion of the
      distribution of the Securities, any offering material in connection with the offering and sale of the Securities other than any Preliminary Prospectus, the Prospectus, the Registration Statement and other materials, if any, permitted by the
      Securities Act and consistent with the terms of this Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(eee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since the date of the preliminary prospectus included in the Registration Statement filed with the Commission on [&#8226;], 2023 (or, if earlier, the first date on which
      the Company engaged directly or through any Person authorized to act on its behalf in any Testing-the-Waters Communication (as defined herein)) through the date hereof, the Company has been and is an &#8220;emerging growth company,&#8221; as defined in Section
      2(a) of the Securities Act (an &#8220;Emerging Growth Company&#8221;). &#8220;Testing-the-Waters Communication&#8221; means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(fff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company (a) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent of the Representative
      with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act, and (b) has not authorized anyone
      other than the Representative to engage in Testing-the-Waters Communications.&#160; The Company reconfirms that the Representative has been authorized to act on its behalf in undertaking Testing-the-Waters Communications.&#160; The Company has not distributed
      any Written Testing-the-Waters Communications (as defined below) other than those listed on Schedule IV hereto.&#160; &#8220;Written Testing-the-Waters Communication&#8221; means any Testing-the-Waters Communication that is a written communication within the meaning
      of Rule 405 under the Securities Act.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(ggg)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has the power to submit, and pursuant to Section 9 of this Agreement, has legally, validly, effectively and irrevocably submitted, to the personal
      jurisdiction of each United States federal court and New York state court located in the Borough of Manhattan, in the City of New York, New York, U.S.A. (each, a &#8220;New York Court&#8221;), and the Company has the power to designate, appoint and authorize,
      and pursuant to Section 9 of this Agreement, has legally, validly, effectively and irrevocably designated, appointed and authorized an agent for service of process in any action arising out of or relating to this Agreement in any New York Court, and
      service of process effected on such authorized agent will be effective to confer valid personal jurisdiction over the Company as provided in Section 9 hereof.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(hhh)&#160; &#160; &#160;&#160; The Deposit Agreement has been duly authorized by the Company and delivered in accordance with its terms by each of the parties thereto, and constitutes a valid and
      legally binding agreement of the Company enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting the enforcement of
      creditors&#8217; rights generally or by equitable principles relating to enforceability.&#160; Upon the issuance, sale and payment for the underlying Ordinary Shares in accordance with the terms hereof and the due issuance by the Depositary of the ADSs against
      the deposit of the underlying Ordinary Shares in respect thereof in accordance with the provisions of the Deposit Agreement, such Ordinary Shares will be duly and validly issued, and the persons in whose names the ADSs are registered will be entitled
      to the rights specified in the Deposit Agreement; and the Deposit Agreement and the ADSs conform in all material respects to the descriptions thereof contained in the Registration Statement and the Prospectus.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No transaction, stamp or other issuance or transfer taxes or duties is payable on behalf of the Underwriters to any taxing authority or therein in connection with
      (i) the issuance, sale and delivery of the Securities by the Company; (ii) the purchase from the Company, and the initial sale and delivery by the Underwriters of the Securities to purchasers thereof; (iii) the holding or transfer of the Securities;
      or (iv) the execution and delivery of this Agreement or any other document to be furnished hereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(jjj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any certificate signed by an officer or board member of the Company in their capacity as such and delivered to the Underwriters or to counsel for the Underwriters
      pursuant to the terms of this Agreement shall be deemed a representation and warranty by the Company, as appropriate, to the Underwriters as to matters covered thereby.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(kkk)&#160;&#160;&#160;&#160;&#160;&#160; Without limiting the Company&#8217;s representation and warranty under (a) above, all forward-looking statements, forecasts, estimates, targets and predictions and
      expressions of opinion, belief, intention and expectation made by the Company expressed in or included in the Registration Statement and in the General Disclosure Package, are truly and honestly held, are not misleading and have been made on
      reasonable grounds after due and careful consideration of such relevant circumstances and assumptions reasonably deemed relevant and there are no facts which have not been disclosed which by their omission make any such estimates materially
      misleading or which are material for disclosure. Each of the assumptions used in the preparation of the forward-looking statements, forecasts, estimates, targets and predictions are reasonable and, to the Company&#8217;s knowledge, there are no other
      material assumptions that should reasonably be taken into account in the preparation of such information and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(lll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (i) No outstanding indebtedness of the Company or any of its subsidiaries has become repayable before its stated maturity, nor has any security in respect of such
      indebtedness become enforceable by reason of default by the Company or any of its subsidiaries, and no event has occurred or is, the Company&#8217;s knowledge, impending which, with the lapse of time or the fulfilment of any condition or the giving of
      notice or the compliance with any other formality, may reasonably be expected to result in any such indebtedness becoming so repayable or any such security becoming enforceable and neither the Company nor any of its subsidiaries has received notice
      from any person to whom any indebtedness of the Company or any of its subsidiaries which is repayable on demand is owed, demanding or, to the Company&#8217;s knowledge, threatening to demand repayment of, or to take any steps to enforce any security for,
      the same; (ii) the amounts borrowed by the Company or any of its subsidiaries do not exceed any limitation (A) on borrowing contained in its articles of association, charter or bylaws or other organizational documents, any debenture or other deed or
      document binding upon them, and neither the Company nor any of its subsidiaries has outstanding any loan capital, or is or has engaged in a financing of a type which would not be required to be shown or reflected in its audited accounts, except in
      any such case as would not, individually or in the aggregate, have a Material Adverse Effect; and (B) all borrowing facilities of each of the Company and each of its subsidiaries have been duly executed by the Company and its relevant subsidiaries
      and are in full force and effect and are in compliance with all covenants and undertakings contained therein, except as may terminate in accordance with their terms.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(mmm)&#160;&#160;&#160;&#160; The Company and its subsidiaries have no pending insolvency, bankruptcy, composition or similar proceedings pending against them and have no reason to believe that any
      such proceeding may be brought and are not in liquidation or receivership.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(nnn)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as disclosed in the Registration Statement, the Statutory Prospectus and the Prospectus, (i) all the information and communications technologies required for
      use in the business of the Company and its subsidiaries, including, without limitation, hardware, proprietary and third party software, networks, peripherals and associated documentation and any IT systems currently being implemented by the Company
      and its subsidiaries (&#8220;IT Systems&#8221;) used in connection with the businesses of the Company and its subsidiaries: (A) are owned by, or properly licensed or leased to, the Company or its subsidiaries, as applicable, and are not dependent on any
      facilities or systems which are not under the ownership or control of the Company and its subsidiaries and the Company and its subsidiaries do not share any user rights with any other person; and (B) are all the IT Systems required for the present
      needs of the business of the Company and its subsidiaries, and the Company has taken reasonable steps to ensure system capacity and ability to process current peak volumes and anticipated volumes in a timely manner; (ii) in relation to the IT
      Systems, there has not been any act or default by the Company or any of its subsidiaries or their sub-lessees, sub-licensees, sub-contractors nor any other person, and there is no breach of any lease, license, support, maintenance service agreement,
      understanding or other arrangement (together, &#8220;IT Contracts&#8221;) granted or provided by a third party in favor of the Company or any of its subsidiaries which may in any way, in the reasonable opinion of the Company, result in any IT Contract being
      terminated. There is no reason to believe that any IT Contract granted or provided by a third party will not be renewed when it expires on the same or substantially the same terms (including as regards pricing and any other commercial details); (iii)
      there are no circumstances in which the ownership, benefit or right to use the IT Systems may be lost or rendered liable to termination, by virtue of the making of the public offer and sale of Securities as contemplated by this Agreement (and the
      Registration Statement and the General Disclosure Package), the entry into and performance of this Agreement and each agreement referred to in it, or the offering and sale of the Securities, except for any such losses or terminations that would not,
      individually or in the aggregate, have a Material Adverse Effect or otherwise be material in the context of the offering of Securities.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(ooo)&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries comply in all material respects with all applicable data protection laws, guidelines and industry standards and of any privacy policies
      of its own (including, but not limited to, the Israeli Privacy Protection Regulations, Information Security, 2017). Neither the Company nor any of its subsidiaries has received any notice from a competent authority (including any information or
      enforcement notice, or any transfer prohibition notice) alleging that the Company or any of its subsidiaries has not complied with applicable data protection laws, guidelines and industry standards. None of the Company or any of its subsidiaries has
      received any material unresolved written claim from an individual for compensation for breaches of applicable data protection laws or for loss or unauthorized disclosure of personal data.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(ppp) &#160; &#160; &#160; Neither the Company nor any of its subsidiaries has engaged in price exchange, price fixing or other comparable anti-competitive practices. Neither the Company nor any
      of its subsidiaries is a party to any agreement, arrangement or concerted practice or is carrying on any practice which in whole or in part contravenes or is invalidated by any applicable anti-trust, anti-monopoly, competition, fair trading, consumer
      protection or similar legislation in any jurisdiction in which the Company or any of its subsidiaries is established or operating or in respect of which any filing, registration or notification is required or is advisable pursuant to such legislation
      (whether or not the same has in fact been made), except for any such contraventions or invalidations, or any such failures to make a filing, registration or notification, that would not, individually or in the aggregate, have a Material Adverse
      Effect or otherwise be material in the context of the public offer and sale of Securities.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(qqq)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither the Company, nor to the knowledge of the Company, any person acting on its behalf has, directly or indirectly, made any offers or sales of any security or
      solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any trading market
      on which any of the securities of the Company are listed or designated.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>Conditions of the Underwriters&#8217; Obligations</u>.&#160; The
        obligations of the Underwriters under this Agreement are several and not joint.&#160; The respective obligations of the Underwriters to purchase the Securities are subject to each of the following terms and conditions:</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notification that the Registration Statement has become effective shall have been received by the Representative and the Prospectus shall have been timely filed with
      the Commission in accordance with Section 4(a) of this Agreement and any material required to be filed by the Company pursuant to Rule 433(d) of the Rules shall have been timely filed with the Commission in accordance with such rule.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No order preventing or suspending the use of any Preliminary Prospectus, the Prospectus or any &#8220;free writing prospectus&#8221; (as defined in Rule 405 of the Rules), shall
      have been or shall be in effect and no order suspending the effectiveness of the Registration Statement shall be in effect and no proceedings for such purpose shall be pending before or threatened by the Commission, and any requests for additional
      information on the part of the Commission (to be included in the Registration Statement or the Prospectus or otherwise) shall have been complied with to the satisfaction of the Commission and the Representative.&#160; If the Company has elected to rely
      upon Rule 430A, Rule 430A information previously omitted from the effective Registration Statement pursuant to Rule 430A shall have been transmitted to the Commission for filing pursuant to Rule 424(b) within the prescribed time period and the
      Company shall have provided evidence satisfactory to the Underwriters of such timely filing, or a post-effective amendment providing such information shall have been promptly filed and declared effective in accordance with the requirements of Rule
      430A.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The representations and warranties of the Company contained in this Agreement and in the certificates delivered pursuant to Section 3(d) shall be true and correct when
      made and on and as of the Closing Date as if made on such date. The Company shall have performed all covenants and agreements and satisfied all the conditions contained in this Agreement required to be performed or satisfied by it at or before such
      Closing Date.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representative shall have received on the Closing Date a certificate, addressed to the Representative and dated the Closing Date, of the chief executive or chief
      operating officer and the chief financial officer or chief accounting officer of the Company, in their capacity as such officers, to the effect that: (i) the representations, warranties and agreements of the Company in this Agreement were true and
      correct when made and are true and correct as of the Closing Date; (ii) the Company has performed all covenants and agreements and satisfied all conditions contained herein; (iii) they have carefully examined the Registration Statement, the
      Prospectus, the General Disclosure Package, and any individual Issuer Free Writing Prospectus and, in their opinion (A) as of the Effective Date, the Registration Statement and Prospectus did not include, and as of the Applicable Time, neither
      (i)&#160;the General Disclosure Package, nor (ii)&#160;any individual Issuer Free Writing Prospectus, when considered together with the General Disclosure Package, included any untrue statement of a material fact and did not omit to state a material fact
      required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (B) since the Effective Date, no event has occurred which should have been set forth in a
      supplement or otherwise required an amendment to the Registration Statement, the Statutory Prospectus or the Prospectus; (iv) no stop order suspending the effectiveness of the Registration Statement has been issued and, to their knowledge, no
      proceedings for that purpose have been instituted or are pending under the Securities Act and (v) there has not occurred any Material Adverse Effect.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representative shall have received: (i) simultaneously with the execution of this Agreement, a signed letter from the Auditor addressed to the Representative and
      dated the date of this Agreement, in form and substance reasonably satisfactory to the Representative, containing statements and information of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the
      financial statements and certain financial information contained in the Registration Statement and the General Disclosure Package, and (ii) on the Closing Date, a signed letter from the Auditor addressed to the Representative and dated the date of
      the Closing Date, in form and substance reasonably satisfactory to the Representative containing statements and information of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the financial statements and
      certain financial information contained in the Registration Statement and the Prospectus.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representative shall have received on the Closing Date from Wilson Sonsini Goodrich &amp; Rosati, P.C., U.S. counsel for the Company, an opinion and negative
      assurance statement, addressed to the Representative and dated the Closing Date, in form and substance reasonably satisfactory to the Representative.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representative shall have received on the Closing Date from Meitar Law Offices, Israeli counsel for the Company, an opinion and negative assurance statement,
      addressed to the Representative and dated the Closing Date, in form and substance reasonably satisfactory to the Representative.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representative shall have received on the Closing Date from Emmet, Marvin &amp; Martin, LLP, counsel for the Depositary, an opinion, addressed to the
      Representative and dated the Closing Date, in form and substance reasonably satisfactory to the Representative.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representative shall have received on the Closing Date from Cohn, de Vries, Stadler &amp; Co., intellectual property counsel for the Company, an opinion and
      written negative assurance statement, addressed to the Representative and dated the Closing Date, in form and substance reasonably satisfactory to the Representative.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reserved.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All proceedings taken in connection with the sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Representative
      and its counsel. &#160;The Shares shall have been delivered via the DTC system to the accounts of the Underwriters, and the Representative shall have received electronic copies of the Warrants executed by the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representative shall have received copies of the Lock-up Agreements executed by each entity or person listed on Schedule II hereto.&#160; In the event that Aegis
      Capital Corp., in its sole discretion, agrees to release or waive any restriction set forth in a Lock-Up Agreement for an officer or director of the Company, and provides the Company with notice of the impending release or waiver at least three (3)
      business days before the effective date of such release or waiver (which release or waiver shall be substantially in the Form found at Exhibit C-1 attached hereto), the Company agrees to announce the impending release or waiver by a press release
      substantially in the form of Exhibit C-2 attached hereto through a major news service at least two (2) business days before the effective date of the release or waiver<font style="font-style: italic;">.</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall not have taken any action to, or likely to have the effect of, delisting the ADSs, nor shall the Company have received any notification that the
      Nasdaq Capital Market is contemplating terminating such listing.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representative shall be reasonably satisfied that since the respective dates as of which information is given in the Registration Statement, the Statutory
      Prospectus, the General Disclosure Package and the Prospectus, (i) there shall not have been any material change in the share capital of the Company or any material change in the indebtedness (other than in the ordinary course of business) of the
      Company, (ii) except as set forth or contemplated by the Registration Statement, the Statutory Prospectus, the General Disclosure Package or the Prospectus, no material oral or written agreement or other transaction shall have been entered into by
      the Company that is not in the ordinary course of business or that could reasonably be expected to result in a material reduction in the future earnings of the Company, (iii) no loss or damage (whether or not insured) to the property of the Company
      shall have been sustained that had or could reasonably be expected to have a Material Adverse Effect, (iv) no legal or governmental action, suit or proceeding affecting the Company or any of its properties that is material to the Company or that
      affects or could reasonably be expected to affect the transactions contemplated by this Agreement shall have been instituted or threatened and (v) there shall not have been any material change in the assets, properties, condition (financial or
      otherwise), or in the results of operations, business affairs or business prospects of the Company or its subsidiaries considered as a whole that makes it impractical or inadvisable in the Representative&#8217;s reasonable judgment to proceed with the
      purchase or offering of the Securities as contemplated hereby.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINRA shall have confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting terms and agreements in connection
      with the offering of the Securities.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall have furnished or caused to be furnished to the Representative such further certificates or documents as the Representative shall have reasonably
      requested.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">4. &#160; &#160; &#160; &#160; &#160; <u>Covenants and other Agreements of the Company and the Underwriters</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company covenants and agrees as follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will use its reasonable best efforts to cause the Registration Statement, if not effective at the time of execution of this Agreement,
      and any amendments thereto, to become effective as promptly as possible.&#160; The Company shall prepare the Prospectus in a form approved by the Representative and file such Prospectus pursuant to Rule 424(b) under the Securities Act not later than the
      Commission&#8217;s close of business on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier time as may be required by the Rules. The Company will file with the Commission all Issuer Free Writing
      Prospectuses in the time and manner required under Rules 433(d) or 163(b)(2), as the case may be.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall promptly advise the Representative in writing (A) when any post-effective amendment to the Registration Statement shall have
      become effective or any supplement to the Prospectus shall have been filed, (B) of any request by the Commission for any amendment of the Registration Statement or the Prospectus or for any additional information, (C) of the issuance by the
      Commission of any stop order suspending the effectiveness of the Registration Statement or of any order preventing or suspending the use of any preliminary prospectus or any &#8220;free writing prospectus,&#8221; as defined in Rule 405 of the Rules, or the
      institution or threatening of any proceeding for that purpose and (D) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Securities for sale in any jurisdiction or the initiation or
      threatening of any proceeding for such purpose.&#160; The Company shall not file any amendment of the Registration Statement or supplement to the Prospectus or any Issuer Free Writing Prospectus unless the Company has furnished the Representative a copy
      for its review and obtained the Representative&#8217;s consent (not to be unreasonably withheld) prior to filing and shall not file any such proposed amendment or supplement to which the Representative reasonably objects.&#160; The Company shall use its
      reasonable best efforts to prevent the issuance of any such stop order and, if issued, to obtain as soon as reasonably possible the withdrawal thereof.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If, at any time when a prospectus relating to the Securities (or, in lieu thereof, the notice referred to in Rule 173(a) of the Rules) is required
      to be delivered under the Securities Act, any event occurs as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary to make the statements
      therein in the light of the circumstances under which they were made not misleading, or if it shall be necessary to amend or supplement the Prospectus to comply with the Securities Act or the Rules, the Company promptly shall prepare and file with
      the Commission, subject to the second sentence of paragraph (ii) of this Section 4(a), an amendment or supplement which shall correct such statement or omission or an amendment which shall effect such compliance.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If at any time following issuance of an Issuer Free Writing Prospectus there occurs an event or development as a result of which such Issuer Free
      Writing Prospectus would conflict with the information contained in the Registration Statement or would include an untrue statement of a material fact or would omit to state a material fact required to be stated therein or necessary in order to make
      the statements therein, in the light of the circumstances prevailing at the subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Issuer Free Writing
      Prospectus to eliminate or correct such conflict, untrue statement or omission.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall make generally available to its security holders and to the Representative as soon as practicable, but not later than forty-five
      (45) days after the end of the 12-month period beginning at the end of the fiscal quarter of the Company during which the Effective Date occurs (or ninety (90) days if such 12-month period coincides with the Company&#8217;s fiscal year), an earning
      statement (which need not be audited) of the Company, covering such 12-month period, which shall satisfy the provisions of Section 11(a) of the Securities Act or Rule 158 of the Rules.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall furnish to the Representative and counsel for the Underwriters, without charge, signed copies of the Registration Statement
      (including all exhibits thereto and amendments thereof) and to each other Underwriter a copy of the Registration Statement (without exhibits thereto) and all amendments thereof and, so long as delivery of a prospectus by an Underwriter or dealer may
      be required by the Securities Act or the Rules, as many copies of any Preliminary Prospectus, any Issuer Free Writing Prospectus and the Prospectus and any amendments thereof and supplements thereto as the Representative may reasonably request.&#160; If
      applicable, the copies of the Registration Statement, Preliminary Prospectus, any Issuer Free Writing Prospectus and Prospectus and each amendment and supplement thereto furnished to the Underwriters will be identical to the electronically
      transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(vii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall cooperate with the Representative and its counsel in endeavoring to qualify the Securities for offer and sale in connection with
      the offering under the laws of such jurisdictions as the Representative may designate and shall maintain such qualifications in effect so long as required for the distribution of the Securities; provided, however, that the Company shall not be
      required in connection therewith, as a condition thereof, to qualify as a foreign corporation or to execute a general consent to service of process in any jurisdiction or subject itself to taxation as doing business in any jurisdiction.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(viii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company, during the period when the Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules) is required to be
      delivered under the Securities Act and the Rules or the Exchange Act, will file all reports and other documents required to be filed with the Commission pursuant to Section 13, 14 or 15 of the Exchange Act within the time periods required by the
      Exchange Act and the regulations promulgated thereunder.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(ix)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without the prior written consent of the Representative, for a period of sixty (60) days after the date of this Agreement, the Company shall not
      issue, sell or register with the Commission (other than on Form S-8 or on any successor form), or otherwise dispose of, directly or indirectly, any equity securities of the Company (or any securities convertible into, exercisable for or exchangeable
      for equity securities of the Company), except for (i) the issuance of the Shares and the issuance of the Warrants and the issuance of any Warrant Shares upon exercise of the Warrants and Ordinary Shares underlying such Warrant Shares pursuant to the
      Registration Statement and the issuance of the Ordinary Shares underlying such Shares, (ii) the issuance of securities pursuant to the Company&#8217;s existing stock option plan or bonus plan as described in the Registration Statement and the Prospectus,
      (iii) the issuance of equity securities pursuant to the conversion of securities or the exercise of warrants, which securities or warrants are outstanding on the date hereof and described in the Registration Statement and the Prospectus or (iv) the
      issuance of equity securities or any securities convertible into, or exercisable for, or exchangeable for equity securities, or the entry into an agreement to issue equity securities, or any securities convertible into or exercisable or exchangeable
      for equity securities, in connection with any merger, joint venture, strategic alliance, commercial or other collaborative transaction, or the acquisition or license of the business, property, technology or other assets of another individual or
      entity, or the assumption of an employee benefit plan in connection with such a merger or acquisition, provided, however, that (x) the aggregate number of equity securities, or securities convertible into or exercisable or exchangeable for equity
      securities, that the Company may issue or agree to issue pursuant to this clause (iv) shall not exceed 10.0% of the total outstanding shares of the Company immediately following the issuance of the Shares, and (y) the recipients of any such
      securities used pursuant to this clause (iv) shall promptly provide to the Representatives a signed lockup letter in the form attached as <u>Exhibit C</u> hereto.&#160; For the avoidance of doubt, the Company shall not sell ADSs pursuant to the
      Controlled Equity Offering Sales Agreement with Cantor Fitzgerald &amp; Co., dated April 30, 2021, during the 60-day period following the date of this Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On or before completion of this offering, the Company shall make all filings required under applicable securities laws and by the Nasdaq Capital
      Market (including any required registration under the Exchange Act).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(xi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to the Closing Date, the Company will issue no press release or other communications directly or indirectly and hold no press conference with
      respect to the Company, the condition, financial or otherwise, or the earnings, business affairs or business prospects of any of them, or the offering of the Securities without the prior written consent of the Representative unless in the judgment of
      the Company and its counsel, and after notification to the Representative, such press release or communication is required by law.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(xii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will apply the net proceeds from the offering of the Securities in the manner set forth under &#8220;Use of Proceeds&#8221; in the Prospectus.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(xiii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will promptly notify the Representative if the Company ceases to be an Emerging Growth Company at any time prior to the later of
      (a)&#160;completion of the distribution of the Securities within the meaning of the Securities Act and (b)&#160;completion of the 60-day restricted period referred to in Section 4(a)(ix) hereof.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 90pt; line-height: 1.25;">(xiv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a
      result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the
      circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such&#160;
      untrue statement or omission.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company agrees to pay, or reimburse if paid by the Representative, whether or not the transactions contemplated hereby are consummated or this Agreement is terminated,
      all costs and expenses incident to the public offering of the Securities and the performance of the obligations of the Company under this Agreement including those relating to: (i) the preparation, printing, reproduction filing and distribution of
      the Registration Statement, including all exhibits thereto, each Preliminary Prospectus, the Prospectus, any Issuer Free Writing Prospectus, all amendments and supplements thereto, and the printing, filing and distribution of this Agreement; (ii) the
      preparation and delivery of certificates for the Securities to the Underwriters, if applicable; (iii) the registration or qualification of the Securities for offer and sale under the securities or Blue Sky laws of the various jurisdictions referred
      to in Section 4(a)(vii), including the reasonable fees and disbursements of counsel for the Underwriters in connection with such registration and qualification and the preparation, printing, distribution and shipment of preliminary and supplementary
      Blue Sky memoranda; (iv) the furnishing (including costs of shipping and mailing) to the Representative and to the Underwriters of copies of each Preliminary Prospectus, the Prospectus and all amendments or supplements to the Prospectus, any Issuer
      Free Writing Prospectus, and of the several documents required by this Section to be so furnished, as may be reasonably requested for use in connection with the offering and sale of the Securities by the Underwriters or by dealers to whom Securities
      may be sold; (v) the filing fees of FINRA in connection with its review of the terms of the public offering and reasonable fees and disbursements of counsel for the Underwriters in connection with such review; (vi) inclusion of the Firm Shares,
      Option Shares and Warrant Shares for quotation on the Nasdaq Capital Market; (vii) all transfer taxes, if any, with respect to the sale and delivery of the Securities by the Company to the Underwriters; and (viii) all costs and expenses incident to
      the offering and the performance of the obligations of the Company under this Agreement, and all reasonable out-of-pocket costs and expenses incident to the performance of the obligations of the Underwriters under this Agreement (including, without
      limitation, the fees and expenses of Underwriters&#8217; outside attorneys), provided that any such out-of-pocket costs and expenses to be reimbursed or paid by the Company shall not exceed $100,000 (without the Company&#8217;s prior approval).</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160;&#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company acknowledges and agrees that each of the Underwriters has acted and is acting solely in the capacity of a principal in an arm&#8217;s length transaction between the
      Company, on the one hand, and the Underwriters, on the other hand, with respect to the offering of Securities contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor, agent or fiduciary
      to the Company or any other person, and that the Underwriters may have interests that differ from those of the Company.&#160; Additionally, the Company acknowledges and agrees that the Underwriters have not and will not advise the Company or any other
      person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction.&#160; The Company has consulted with its own advisors concerning such matters and shall be responsible for making its own independent investigation and
      appraisal of the transactions contemplated hereby, and the Underwriters shall have no responsibility or liability to the Company or any other person with respect thereto, whether arising prior to or after the date hereof.&#160; Any review by the
      Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions have been and will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company.&#160; The Company agrees
      that it will not claim that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a fiduciary duty to the Company or any other person in connection with any such transaction or the process leading thereto.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 27pt; line-height: 1.25;">&#160; (d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company represents and agrees that, unless it obtains the prior consent of the Representative, and each Underwriter represents and agrees that, unless it obtains
      the prior consent of the Company and the Representative, it has not made and will not make any offer relating to the Securities that would constitute an &#8220;issuer free writing prospectus,&#8221; as defined in Rule&#160;433, or that would otherwise constitute a
      &#8220;free writing prospectus,&#8221; as defined in Rule&#160;405, required to be filed with the Commission.&#160; The Company has complied and will comply with the requirements of Rule 433 under the Securities Act applicable to any Issuer Free Writing Prospectus,
      including timely filing with the Commission where required, legending and record keeping.&#160; The Company represents that it has satisfied and agrees that it will satisfy the conditions set forth in Rule 433 of the Rules to avoid a requirement to file
      with the Commission any Road Show.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 27pt; line-height: 1.25;">&#160; (e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall ensure that: (i) the qualifications of the persons serving as board members and the overall composition of the Board of Directors comply with the
      Sarbanes-Oxley Act and with the listing requirements of the Nasdaq Capital Market and (ii) if applicable, at least one member of the Board of Directors qualifies as a &#8220;financial expert&#8221; as such term is defined under the Sarbanes-Oxley Act.</div>
    <div style="text-align: justify; text-indent: 27pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">5. &#160; &#160; &#160; &#160; &#160; <u>Indemnification</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company agrees to indemnify and hold harmless each Underwriter, its officers and employees and each person, if any, who controls any Underwriter within the meaning
      of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all losses, claims, damages and liabilities, joint or several (including any reasonable investigation, legal and other expenses incurred in connection with, and any
      amount paid in settlement of, any action, suit or proceeding or any claim asserted), to which they, or any of them, may become subject under the Securities Act, the Exchange Act or other federal or state law or regulation, at common law or otherwise,
      insofar as such losses, claims, damages or liabilities arise, directly or indirectly, in connection with, out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus, the
      Registration Statement, the Statutory Prospectus, the Prospectus, any Issuer Free Writing Prospectus<font style="font-weight: bold;">&#160;</font>or any &#8220;issuer-information&#8221; filed or required to be filed pursuant to Rule 433(d) of the Rules, any amendment
      thereof or supplement thereto, any Written Testing-the-Waters Communication, or in any Blue Sky application or other information or other documents executed by the Company filed in any state or other jurisdiction to qualify any or all of the
      Securities under the securities laws thereof (any such application, document or information being hereinafter referred to as a &#8220;Blue Sky Application&#8221;), (ii) arise out of or are based upon any omission or alleged omission to state therein a material
      fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any actual or alleged breach by the Company of any of its obligations, or of any of its representations, warranties and undertakings, set out in
      this Agreement; provided, however, that such indemnity shall not inure to the benefit of any Underwriter (or any person controlling such Underwriter) on account of any losses, claims, damages or liabilities arising from the sale of the Securities to
      any person by such Underwriter if such untrue statement or omission or alleged untrue statement or omission was made in such preliminary prospectus, the Registration Statement, the Prospectus, the Statutory Prospectus, any Issuer Free Writing
      Prospectus or such amendment or supplement thereto, any Written Testing-the-Waters Communication, or in any Blue Sky Application in reliance upon and in conformity with the Underwriter Information, or if any such losses, claims, damages or
      liabilities have arisen from (i) the fraud, gross negligence, willful misconduct or bad faith of, or material breach of the Agreement by the person entitled to indemnification to the extent finally judicially determined by a court of competent
      jurisdiction or by a regulatory authority (as appropriate) or (ii) a breach of the duties owed by an person to indemnification under relevant regulatory rules to the extent finally judicially determined by a court of competent jurisdiction or by a
      regulatory authority (as appropriate). This indemnity agreement will be in addition to any liability which the Company may otherwise have.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160; (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, and each person, if any, who controls the Company within the meaning of
      Section 15 of the Securities Act or Section 20 of the Exchange Act, each director of the Company, and each officer of the Company who signs the Registration Statement, against any losses, claims, damages or liabilities to which such party may become
      subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in any
      preliminary prospectus, the Registration Statement or the Prospectus, or any amendment or supplement thereto, or arise, directly or indirectly, in connection with, out of or are based upon the omission or alleged omission to state therein a material
      fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in any
      Preliminary Prospectus, the Registration Statement, the Statutory Prospectus or the Prospectus or any such amendment or supplement in reliance upon and in conformity with the Underwriter Information; provided, however, that the obligation of each
      Underwriter to indemnify the Company (including any controlling person, director or officer thereof) shall be limited to the amount of the underwriting discount and commissions applicable to the Securities to be purchased by such Underwriter
      hereunder, and that that such indemnity shall not inure to the benefit of the Company (or any person controlling such Company) on account of any losses, claims, damages or liabilities arising from (i) the fraud, gross negligence, willful misconduct
      or bad faith of, or material breach of the Agreement by the person entitled to indemnification to the extent finally judicially determined by a court of competent jurisdiction or by a regulatory authority (as appropriate) or (ii) a breach of the
      duties owed by an person to indemnification under relevant regulatory rules to the extent finally judicially determined by a court of competent jurisdiction or by a regulatory authority (as appropriate).</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160;&#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any party that proposes to assert the right to be indemnified under this Section will, promptly after receipt of notice of commencement of any action, suit or proceeding
      against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section, notify each such indemnifying party of the commencement of such action, suit or proceeding, enclosing a copy of all papers
      served.&#160; No indemnification provided for in Section 5(a) or 5(b) shall be available to any party who shall fail to give notice as provided in this Section 5(c) if the party to whom notice was not given was unaware of the proceeding to which such
      notice would have related and was prejudiced by the failure to give such notice but the omission so to notify such indemnifying party of any such action, suit or proceeding shall not relieve it from any liability that it may have to any indemnified
      party for contribution or otherwise than under this Section.&#160; In case any such action, suit or proceeding shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party
      shall be entitled to participate in, and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party, and after notice
      from the indemnifying party to such indemnified party of its election so to assume the defense thereof and the approval by the indemnified party of such counsel, the indemnifying party shall not be liable to such indemnified party for any legal or
      other expenses, except as provided below and except for the reasonable costs of investigation subsequently incurred by such indemnified party in connection with the defense thereof.&#160; The indemnified party shall have the right to employ its counsel in
      any such action, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the employment of counsel by such indemnified party has been authorized in writing by the indemnifying parties, (ii) the
      indemnified party shall have been advised by counsel that there may be one or more legal defenses available to it which are different from or in addition to those available to the indemnifying party (in which case the indemnifying parties shall not
      have the right to direct the defense of such action on behalf of the indemnified party) or (iii) the indemnifying parties shall not have employed counsel to assume the defense of such action within a reasonable time after notice of the commencement
      thereof, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying parties.&#160; An indemnifying party shall not be liable for any settlement of any action, suit, and proceeding or claim effected without its
      written consent, which consent shall not be unreasonably withheld or delayed. No indemnifying party shall settle any action, suit or proceeding for which indemnification or contribution is or would have been available hereunder to an indemnified
      person that was or could have been made party thereto without obtaining a release in favor of each such indemnified person from all claims brought in or arising from such action, suit or proceeding.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><u>Contribution</u>.&#160; In order to provide for just and
        equitable contribution in circumstances in which the indemnification provided for in Section 5(a) or 5(b) is due in accordance with its terms but for any reason is unavailable to or insufficient to hold harmless an indemnified party in respect to
        any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate losses, liabilities, claims, damages and expenses (including any investigation, legal and other expenses
        reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claims asserted, but after deducting any contribution received by any person entitled hereunder to contribution from any person who
        may be liable for contribution) incurred by such indemnified party, as incurred, in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering
        of the Securities pursuant to this Agreement or, if such allocation is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to above but also the relative fault of the Company on
        the one hand and the Underwriters on the other hand in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations.&#160; The Company and the
        Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 6 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
        which does not take account of the equitable considerations referred to above.&#160; The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above shall be deemed to include any legal or
        other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever
        based upon any such untrue or alleged untrue statement or omission or alleged omission.&#160; Notwithstanding the provisions of this Section 6, no Underwriter (except as may be provided in the Agreement Among Underwriters) shall be required to
        contribute any amount in excess of the underwriting discounts and commissions applicable to the Securities purchased by such Underwriter.&#160; No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act)
        shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.&#160; For purposes of this Section 6, each person, if any, who controls an Underwriter within the meaning of Section 15 of the Securities Act or
        Section 20 of the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, including any person who, with his or her consent, is named in the Registration Statement as about to become a director
        of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Section 15 of the Securities Act or Section 20 of the Exchange Act, shall have the same
        rights to contribution as the Company.&#160; Any party entitled to contribution will, promptly after receipt of notice of commencement of any action, suit or proceeding against such party in respect of which a claim for contribution may be made against
        another party or parties under this Section 6, notify such party or parties from whom contribution may be sought, but the omission so to notify such party or parties from whom contribution may be sought shall not relieve the party or parties from
        whom contribution may be sought from any other obligation it or they may have hereunder or otherwise than under this Section 6.&#160; No party shall be liable for contribution with respect to any action, suit, proceeding or claim settled without its
        written consent.&#160; The Underwriters&#8217; obligations to contribute pursuant to this Section 6 are several in proportion to their respective underwriting commitments and not joint.</font></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>Termination</u>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement may be terminated with respect to the Securities to be purchased on the Closing Date by the Representative by notifying the Company at any time at or before the
      Closing Date in the absolute discretion of the Representative if: (i) there has occurred any material adverse change in the securities markets or any event, act or occurrence that has materially disrupted, or in the opinion of the Representative,
      will in the future materially disrupt, the securities markets or there shall be such a material adverse change in general financial, political or economic conditions or the effect of international conditions on the financial markets in Israel or the
      United States is such as to make it, in the judgment of the Representative, inadvisable or impracticable to market the Securities or enforce contracts for the sale of the Securities; (ii) there has occurred any outbreak or material escalation of
      hostilities or acts of terrorism or other calamity or crisis the effect of which on the financial markets of Israel or the United States is such as to make it, in the judgment of the Representative, inadvisable or impracticable to market the
      Securities or enforce contracts for the sale of the Securities; (iii) trading in the Shares or any securities of the Company has been suspended or materially limited by the Commission or trading generally on the New York Stock Exchange, Inc. or the
      Nasdaq Stock Market has been suspended or materially limited, or minimum or maximum ranges for prices for securities shall have been fixed, or maximum ranges for prices for securities have been required, by any of said exchanges or by such system or
      by order of the Commission, FINRA, or any other governmental or regulatory authority; (iv) a banking moratorium has been declared by any state, federal or Israeli authority; (v) in the judgment of the Representative, there has been, since the time of
      execution of this Agreement or since the respective dates as of which information is given in the Prospectus, any material adverse change in the assets, properties, condition, financial or otherwise, or in the results of operations, business affairs
      or business prospects of the Company and its subsidiaries considered as a whole, whether or not arising in the ordinary course of business; (vi) the representations and warranties given by the Company in this Agreement have ceased to be true and
      accurate in all material respects; or (vii) there has been a material breach by the Company of any of the covenants contained in this Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If this Agreement is terminated pursuant to any of its provisions, the Company shall not be under any liability to any Underwriter, and no Underwriter shall be under any
      liability to the Company, except that (y) if this Agreement is terminated by the Representative or the Underwriters because of any failure, refusal or inability on the part of the Company to comply with the terms or to fulfill any of the conditions
      of this Agreement, the Company will reimburse the Underwriters for all out-of-pocket expenses (including the reasonable fees and disbursements of their counsel) incurred by them in connection with the proposed purchase and sale of the Securities or
      in contemplation of performing their obligations hereunder and (z) no Underwriter who shall have failed or refused to purchase the Securities agreed to be purchased by it under this Agreement, without some reason sufficient hereunder to justify
      cancellation or termination of its obligations under this Agreement, shall be relieved of liability to the Company or to the other Underwriters for damages occasioned by its failure or refusal.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Reserved.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9. &#160; &#160; &#160; &#160; <u>Miscellaneous</u>.&#160; The respective agreements, representations, warranties, indemnities and other statements of the Company and the several
      Underwriters, as set forth in this Agreement or made by or on behalf of them pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any
      Underwriter or the Company or any of their respective officers, directors or controlling persons referred to in Sections 5 and 6 hereof, and shall survive delivery of and payment for the Securities.&#160; In addition, the provisions of Sections 4(b), 5, 6
      and 7 shall survive the termination or cancellation of this Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">This Agreement has been and is made for the benefit of the Underwriters, the Company, and their respective successors and assigns, and, to the extent expressed herein, for the
      benefit of persons controlling any of the Underwriters, or the Company, and directors and officers of the Company, and their respective successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement.&#160;
      The term &#8220;successors and assigns&#8221; shall not include any purchaser of Securities from any Underwriter merely because of such purchase.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">All notices and communications hereunder shall be in writing and mailed or delivered or by telephone or facsimile if subsequently confirmed in writing, (a) if to the
      Representative, c/o Aegis Capital Corp., 1345 Avenue of the Americas, 27th Floor, New York, NY 10105 Attention:&#160; Robert Eide, with a copy to Kaufman &amp; Canoles, P.C., Two James Center, 14th Floor, 1021 E. Cary St., Richmond, VA 23219, Attention:
      Anthony W. Basch, Esq.,<font style="font-style: italic;">&#160;</font>and (b) if to the Company, to its agent for service as such agent&#8217;s address appears on the cover page of the Registration Statement, with a copy to (i) Wilson Sonsini Goodrich &amp;
      Rosati, P.C., 1881 9th Street, Suite 110, Boulder, CO 80302, Attention: Brent Fassett and (ii) Meitar Law Offices, 16 Abba Hillel Silver Road, Ramat Gan 5250608, Israel, Attention: David S. Glatt and Ronen Bezalel.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;"><font style="font-weight: bold;">This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and
        to be performed in such state. </font>Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (&#8220;Related Proceedings&#8221;) may be instituted in the federal courts of the United States of
      America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#8220;Specified Courts&#8221;), and each party irrevocably
      submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a &#8220;Related Judgment&#8221;), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or
      proceeding. Service of any process, summons, notice or document by mail to such party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and
      unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other
      proceeding brought in any such court has been brought in an inconvenient forum. The Company has irrevocably appointed Chemomab Therapeutics, Inc., which currently maintains an office at One Kendall Square, Building 1400E, Suite 14-105, Cambridge, MA
      02139, United States of America, as its agent to receive service of process or other legal summons for purposes of any such suit, action or proceeding that may be instituted in any Specified Court.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity (whether on the basis of sovereignty or
      otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related Judgment, each party waives any such immunity
      in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including, without limitation, any
      immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The obligations of the Company pursuant to this Agreement in respect of any sum due to the Underwriters shall, notwithstanding any judgment in a currency other than United States
      dollars, not be discharged until the first business day, following receipt by the Underwriters of any sum adjudged to be so due in such other currency, on which the Underwriters may in accordance with normal banking procedures purchase United States
      dollars with such other currency. If the United States dollars so purchased are less than the sum originally due to the Underwriters in United States dollars hereunder, the Company agrees as a separate obligation and notwithstanding any such
      judgment, to indemnify the Underwriters against such loss. If the United States dollars so purchased are greater than the sum originally due to the Underwriters hereunder, the Underwriters agree to pay to the Company an amount equal to the excess of
      the dollars so purchased over the sum originally due to the Underwriters hereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All payments made or deemed to be made by or on behalf of the Company to any Underwriter, its officers and employees, and each person controlling any Underwriter under this
      Agreement, if any, will be made without withholding or deduction for or on account of any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income or similar taxes) imposed or levied by
      or on behalf of the State of Israel or any political subdivision or any taxing authority thereof or therein or any other jurisdiction in which the Company is organized or incorporated, engaged in business for tax purposes or is otherwise resident for
      tax purposes or has a permanent establishment, any jurisdiction from or through which payment is made by or on behalf of the Company, or any political subdivision, authority or agency in or of any of the foregoing having power to tax, unless the
      Company is or becomes required by law to withhold or deduct such taxes, duties, assessments or other governmental charges.&#160; In such event, the Company will pay such additional amounts as will result, after such withholding or deduction, in the
      receipt by each Underwriter, its officers and employees, and each person controlling any Underwriter, as the case may be, of the amounts that would otherwise have been receivable in respect thereof had such deduction or withholding not been required.
      Notwithstanding anything to the contrary herein, in no event shall the Company be liable to pay (or pay additional amounts with respect to) any taxes, duties, assessments, governmental charges, withholding or deduction imposed on an Underwriter as a
      result of the Underwriter being (currently or in the past) a tax resident of, or having a permanent establishment in, the jurisdiction imposing the tax or as a result of any present or former connection (other than as a result of entering into this
      Agreement or any connection resulting from the transactions contemplated by this Agreement) between the Underwriter and the jurisdiction imposing such tax, withholding or deduction or, to the extent resulting from the Underwriter&#8217;s services under
      this Agreement having been performed by or on behalf of the Underwriter inside the State of Israel. If timely requested by the Company, the Underwriters shall reasonably cooperate with the Company, by providing reasonably required information for the
      Company to obtain an exemption certificate from withholding or deduction in connection with the payments under this Agreement, if any. All sums payable, paid or deemed payable under this Agreement shall be considered exclusive of value added tax,
      sales tax or other similar taxes which, to the extent applicable, shall be borne by, paid, collected and remitted by the Company in accordance with applicable law.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph,
      clause or provision. If any section, paragraph, clause or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to
      make it valid and enforceable.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-style: italic;">[Remainder of Page Intentionally Left Blank. Signature Page Follows.]</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same
      instrument.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">Please confirm that the foregoing correctly sets forth the agreement among us.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z20311d46f6fd44399edbce7b45ef44b7">

          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50.00%;">
              <div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Very truly yours,</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">CHEMOMAB THERAPEUTICS LTD.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By: ________________________________</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name:</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title:</div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="line-height: 1.25;">Confirmed:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">AEGIS CAPITAL CORP.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">By: ________________________________</div>
    <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name: Robert Eide</div>
    <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title: Chief Executive Officer</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Acting severally on behalf of itself</div>
    <div style="line-height: 1.25;">and as representative of the several</div>
    <div style="line-height: 1.25;">Underwriters named in Schedule I annexed</div>
    <div style="line-height: 1.25;">hereto.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; text-align: center;">
      <div style="line-height: 1.25; font-style: italic;">[Signature Page to Underwriting Agreement]</div>
      <div style="line-height: 1.25; font-style: italic;"> <br>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">SCHEDULE I</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z70affff4471c496390e3e3aa90040a41" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 32.01%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-weight: bold;">Underwriter</div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of Firm Units to Be<br>
              Purchased</div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of Option Securities<br>
              to Be Purchased if the<br>
              Maximum Over-Allotment<br>
              Option Is Exercised</div>
          </td>
        </tr>
        <tr>
          <td style="width: 32.01%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Aegis Capital Corp.</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">Common Units: &#160;&#160;&#160;[NUMBER]</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">[NUMBER]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 32.01%; vertical-align: bottom; background-color: #D9EEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 35.99%; vertical-align: bottom; background-color: #D9EEFF;" colspan="3">
            <div style="text-align: center; line-height: 1.25;">Pre-funded Units: [NUMBER]</div>
          </td>
          <td style="width: 32%; vertical-align: bottom; background-color: #D9EEFF;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 32.01%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">Total:</div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">[NUMBER]</div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">[NUMBER]</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25;">SCHEDULE II</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Lock-up Signatories</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Nissim Darvish</div>
    <div style="line-height: 1.25;">Jill Quigley</div>
    <div style="line-height: 1.25;">Neil Cohen</div>
    <div style="line-height: 1.25;">Claude Nicais</div>
    <div style="line-height: 1.25;">Adi Mor</div>
    <div style="line-height: 1.25;">Alan Moses</div>
    <div style="line-height: 1.25;">Dale Pfost</div>
    <div style="line-height: 1.25;">Donald Marvin</div>
    <div style="line-height: 1.25;">Dr. Matthew B. Frankel</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">SCHEDULE III</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Issuer Free Writing Prospectuses</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">[None.]</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">SCHEDULE IV</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Testing-the-Waters Communications</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">[None.]</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: right; text-indent: 324pt; line-height: 1.25;">Exhibit A</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">[TO COME]</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: right; text-indent: 324pt; line-height: 1.25;">Exhibit B</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">[TO COME]</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: right; text-indent: 72pt; line-height: 1.25;">Exhibit C</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">[TO COME]</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: right; text-indent: 72pt; line-height: 1.25;">Exhibit C-1</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">[TO COME]</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: right; text-indent: 72pt; line-height: 1.25;">Exhibit C-2</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">[TO COME]</div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>exhibit_4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">

  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> Exhibit 4.2</u><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6a5144c4f3964092a836f092948acbfb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Warrant ADSs: [&#9679;]</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25;">Initial Exercise Date: [&#9679;], 2023</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25;">Issue Date: [&#9679;], 2023</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [&#9679;] or its assigns (the &#8220;<u>Holder</u>&#8221;) is
      entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and on or prior to 5:00 p.m. (New York City time) on [&#9679;], 2028 (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Chemomab Therapeutics Ltd., a company organized and existing under the laws of the State
      of Israel (the &#8220;<u>Company</u>&#8221;), up to [&#9679;] Ordinary Shares, represented by [&#9679;] American Depositary Shares (&#8220;<u>ADSs</u>&#8221;), each ADS representing twenty (20) Ordinary Shares, as subject to adjustment hereunder (the ADSs issuable hereunder, the &#8220;<u>Warrant
          ADSs</u>&#8221;). The purchase price of one (1) ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 1</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant or in the
        Underwriting Agreement dated [&#9679;], 2023, the following terms have the meanings indicated in this Section 1:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>ADS</u>&#8221;
      means the American Depositary Shares of the Company, each to purchase 20 Ordinary Shares, without par value per share (subject to adjustment), and any other class of securities into which such securities may hereafter be reclassified or changed.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Affiliate</u>&#8221;
      means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Bid Price</u>&#8221;
      means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then listed or quoted on a Trading Market, the bid price of the ADSs for the time in question (or the nearest preceding date) on the
      Trading Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume
      weighted average price of the ADSs for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the ADSs are then reported on the Pink
      Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported, or (d)&#160;in all other cases, the fair market value of an ADS as determined by an independent appraiser
      selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Board of
          Directors</u>&#8221; means the board of directors of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Business Day</u>&#8221;
      means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>,
      <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;,
      &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for
      wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Commission</u>&#8221;
      means the United States Securities and Exchange Commission.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Depositary</u>&#8221;
      means The Bank of New York Mellon, the current depositary bank of the Company&#8217;s ADSs, with a mailing address of 240 Greenwich Street, New York, New York 10286 and an email address of [&#9679;], and any successor depositary bank of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Exchange Act</u>&#8221;
      means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Ordinary Share</u>&#8221;
      means the ordinary shares of the Company, without par value per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Ordinary Share
          Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Ordinary Shares or ADSs, including, without limitation, any debt, preferred stock, right, option,
      warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Ordinary Shares or ADSs.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Person</u>&#8221;
      means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Registration
          Statement</u>&#8221; means the Company&#8217;s registration statement on Form S-1, as amended (File No. 333&#8209;269218).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Securities Act</u>&#8221;
      means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Subsidiary</u>&#8221;
      means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Trading Day</u>&#8221;
      means a day on which the ADSs are traded on a Trading Market.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Trading Market</u>&#8221;
      means any of the following markets or exchanges on which the ADSs are listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
      Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Underwriting
          Agreement</u>&#8221; means the underwriting agreement, dated as of [&#9679;], 2023, between the Company and Aegis Capital Corp., as amended, modified or supplemented from time to time in accordance with its terms.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>VWAP</u>&#8221;
      means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then listed or quoted on a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding
      date) on the Trading Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160;if OTCQB or OTCQX is not a Trading Market, the
      volume weighted average price of the ADSs for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the ADSs are then reported on the
      Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported, or (d)&#160;in all other cases, the fair market value of an ADS as determined by an independent
      appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Warrants</u>&#8221;
      means this Warrant and other ADSs purchase warrants issued by the Company pursuant to the Registration Statement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 2</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
        after the Initial Exercise Date and on or before the Termination Date by delivery to the Company and the Depositary of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise substantially in the form attached
        hereto as <u>Exhibit A</u> (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the
        earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
        Price for the Warrant ADSs specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice
        of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder
        shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
        to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs
        available hereunder shall have the effect of lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant ADSs purchased. The Holder and the Company shall maintain records showing the
        number of Warrant ADSs purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <font style="font-weight: bold;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant ADSs hereunder, the number
          of Warrant ADSs available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-weight: bold;"> <br>
        </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise Price</u>. The exercise price per Warrant ADS shall be $[&#9679;], subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
        therein is not available for the issuance of the Warrant ADSs to the Holder or the resale of the Warrant ADSs by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the
        Holder shall be entitled to receive a number of Warrant ADSs equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z5beebf0d131f42d6bb048d480fd53253" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">(A) =</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and
              delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of
              Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid
              Price of the ADSs on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading
              Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of
              Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z667c299822914b66893e7ce7e7bd34f2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">(B) =</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Exercise Price of this Warrant, as adjusted hereunder; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zfcc236699a36478eba71fd633c5aa9b1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">(X) =</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the number of Warrant ADSs that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash
              exercise rather than a cashless exercise.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">If Warrant ADSs are issued in such a cashless exercise, the parties acknowledge and agree that in
      accordance with Section 3(a)(9) of the Securities Act, the Warrant ADSs shall take on the registered characteristics of the Warrants being exercised, and the holding period of the Warrant ADSs being issued may be tacked on to the holding period of
      this Warrant. Assuming (i) the Holder is not an Affiliate of the Company, and (ii) all of the applicable conditions of Rule 144 promulgated under the Securities Act with respect to Holder and the Warrant ADSs are met in the case of such a cashless
      exercise, the Company agrees that the Company will cause the removal of the legend from such Warrant ADSs (including by delivering an opinion of the Company&#8217;s counsel to the Company&#8217;s Depositary at its own expense to ensure the foregoing), and the
      Company agrees that the Holder is under no obligation to sell the Warrant ADSs issuable upon the exercise of the Warrant prior to removing the legend.. The Company agrees not to take any position contrary to this Section 2(c).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be
      automatically exercised via cashless exercise pursuant to this Section 2(c).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Mechanics of Exercise</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery of Warrant ADSs upon Exercise</u>. The Company shall cause its registrar to deposit the Warrant ADSs subject to such exercise with the
        Depositary and instruct the Depositary to credit the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Depositary is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant ADSs to or resale of the Warrant ADSs
        by Holder or (B) the Warrant ADSs are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, for the
        number of Warrant ADSs to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the
        Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise
        (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become
        the holder of record of the Warrant ADSs with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant ADSs, provided that payment of the aggregate Exercise Price (other than in the case of a cashless
        exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. Notwithstanding anything herein to the contrary, upon
        delivery of the Notice of Exercise, the Holder shall be deemed for purposes of Regulation SHO under the Exchange Act to have become the holder of the Warrant ADSs irrespective of the date of delivery of the Warrant ADSs. If the Company fails for
        any reason to deliver to the Holder the Warrant ADSs subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant ADSs
        subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3rd) Trading Day after the Warrant Share Delivery Date) for each Trading
        Day after such Warrant Share Delivery Date until such Warrant ADSs are delivered or Holder rescinds such exercise. The Company agrees to maintain a Depositary that is a participant in the FAST program so long as this Warrant remains outstanding and
        exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s
        primary Trading Market with respect to the ADSs as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the
        Initial Exercise Date, which may be delivered at any time after the time of execution of the Underwriting Agreement, the Company agrees to deliver the Warrant ADSs subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise
        Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery
        Date.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
        upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for by this Warrant, which new Warrant
        shall in all other respects be identical with this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">iii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Rescission Rights</u>. If the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs pursuant to Section 2(d)(i) by the
        Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise in respect to the untransmitted Warrant ADSs (with the effect that the Holder&#8217;s rights to acquire such untransmitted Warrant ADSs pursuant to this Warrant
        shall be restored) and the Company shall return to the Holder the portion of the aggregate Exercise Price paid to the Company for such untransmitted Warrant ADSs.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">iv.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant ADSs upon Exercise</u>. In addition to any other rights available to the Holder, if
        the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
        is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, ADSs to deliver in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated
        receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase
        price (including brokerage commissions, if any) for the ADSs so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant ADSs that the Company was required to deliver to the Holder in connection with the exercise at issue
        times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant ADSs for which such exercise was not
        honored and return any amount received by the Company in respect of the Exercise Price for those Warrant ADSs (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that would have been issued had the
        Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases ADSs having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of ADSs with an aggregate sale
        price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts
        payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including,
        without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver ADSs upon exercise of the Warrant as required pursuant to the terms hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">v.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Fractional ADSs or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.
        As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
        multiplied by the Exercise Price or round up to the next whole ADS.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">vi.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other
        incidental expense in respect of the issuance of such Warrant ADSs, all of which taxes and expenses shall be paid by the Company, and such Warrant ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the
        Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant ADSs
        are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <u>Exhibit
            B</u> duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Depositary fees required for
        same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant ADSs. The Company will
        pay all applicable fees and expenses of the Depositary in connection with the issuance of the Warrant ADSs hereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">vii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing of Books</u>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this
        Warrant, pursuant to the terms hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
        any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any
        other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in
        excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Ordinary Shares or ADSs beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of
        Ordinary Shares or ADSs issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of ADSs which would be issuable upon (i) exercise of the remaining, unexercised portion of this
        Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any other
        Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding
        sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is
        not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
        contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
        exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
        together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of
        such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this
        Section 2(e), in determining the number of outstanding Ordinary Shares or ADSs, a Holder may rely on the number of outstanding Ordinary Shares and ADSs as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the
        Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Depositary setting forth the number of Ordinary Shares and ADSs outstanding. Upon the written or oral
        request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of Ordinary Shares and ADSs then outstanding. In any case, the number of outstanding Ordinary Shares and ADSs shall be
        determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Ordinary Shares or ADSs
        was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number
        of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares underlying the ADSs issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
        Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares underlying ADSs
        upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day after such notice is delivered
        to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or
        inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a
        successor holder of this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 3</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Certain Adjustments</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Share and ADS Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a share or ADS dividend or
        otherwise makes a distribution or distributions on ADSs or any other equity or equity equivalent securities payable in Ordinary Shares or ADSs (which, for avoidance of doubt, shall not include any ADSs issued by the Company upon exercise of this
        Warrant), (ii) subdivides outstanding Ordinary Shares&#160; into a larger number of shares or ADSs, (iii) combines (including by way of reverse stock split or ADR ratio change) outstanding Ordinary Shares or ADSs into a smaller number of shares or ADSs,
        or (iv) issues by reclassification of Ordinary Shares, ADSs any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of ADSs (excluding treasury
        shares, if any) outstanding immediately before such event and of which the denominator shall be the number of ADSs outstanding immediately after such event, and the number of ADSs issuable upon exercise of this Warrant shall be proportionately
        adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to
        receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Reserved</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Subsequent Rights Offerings</u>. In addition to any adjustments
          pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Ordinary Share Equivalents or rights to purchase stock, warrants,
          securities or other property pro rata to all (or substantially all) of the record holders of any class of Ordinary Shares or ADSs (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the
          Holder had held the number of Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
          on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Ordinary Shares or ADSs are to be determined for the grant, issue or sale of such
          Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
          participate in such Purchase Right to such extent (or beneficial ownership of such ADSs as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever,
          as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
        distribution of its assets (or rights to acquire its assets) to all (or substantially all) holders of Ordinary Shares or ADSs, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other
        securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;),
        at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of
        Ordinary Shares or ADSs acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is
        taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Ordinary Shares or ADSs are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Distribution would result
        in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Ordinary Shares or ADSs as a result of such Distribution to
        such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent
        that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">10</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
        transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all
        or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of
        Ordinary Shares (including any Ordinary Shares underling ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares or
        50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares or ADSs or
        any compulsory share exchange pursuant to which the Ordinary Shares or ADSs are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
        consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other
        Person or group acquires 50% or more of the outstanding Ordinary Shares or 50% or more of the voting power of the common equity of the Company (each a &#8220;<u>Fundamental
            Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Ordinary Share represented by each Warrant ADS that would have been issuable upon such exercise immediately prior
        to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of capital stock (or its equivalent) of the successor or acquiring
        corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of
        such Fundamental Transaction by a holder of the number of Ordinary Shares represented by each Warrant ADS for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on
        the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
        one Ordinary Share or ADS, as applicable, in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the
        Alternate Consideration. If holders of Ordinary Shares or ADSs are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
        it receives upon any exercise of this Warrant following such Fundamental Transaction.&#160; The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in
        form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a
        security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant that is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
        equivalent to the Ordinary Shares or ADSs acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
        the Exercise Price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares prior to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
        stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
        Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision
        of this Warrant referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company,
        may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such
        Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the
        Company has sufficient authorized Ordinary Shares or ADSs for the issuance of Warrant ADSs and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">11</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be.
        For purposes of this Section 3, the number of Ordinary Shares or ADSs, as applicable, deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares or ADSs, as applicable, (excluding treasury shares, if
        any) issued and outstanding.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notice to Holder</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
        deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Ordinary
        Shares or ADSs, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares or ADSs, (C) the Company shall authorize the granting to all holders of the ADS rights or warrants to subscribe for or
        purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which
        the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Ordinary Shares or ADSs are converted into other securities, cash or property, or (E)
        the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
        appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
        distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be
        determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Ordinary Shares or ADSs of
        record shall be entitled to exchange their Ordinary Shares or ADSs for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such
        notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
        non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant
        during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">12</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Share Combination Event Adjustment.</u>&#160;In addition to the
          adjustments set forth in Section 3(a) above, if at any time and from time to time on or after the Issuance Date there occurs any share split, share dividend, share combination recapitalization or other similar transaction involving the ADSs
          (each, a &#8220;<u>Share Combination Event</u>&#8221;, and such date thereof, the &#8220;<u>Share Combination Event Date</u>&#8221;) and the lowest VWAP during the 5 consecutive Trading
          Days commencing on the Share Combination Event Date (the &#8220;<u>Event Market Price</u>&#8221;) (provided if the Share Combination Event is effective after close of Trading on the primary Trading Market, then commencing on the next Trading Day, which period shall be the &#8220;<u>Share Combination Adjustment Period</u>&#8221;) is less than the Exercise Price then in effect (after giving effect to the adjustment in
          clause 3(a) above), then at the close of trading on the primary Trading Market on the last day of the Share Combination Adjustment Period, the Exercise Price then in effect on such fifth (5th) Trading Day shall be reduced (but in no event
          increased) to the Event Market Price and the number of Warrant ADSs issuable hereunder shall be increased such that the aggregate Exercise Price payable
          hereunder, after taking into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price on the Issuance Date. For the avoidance of doubt, if the adjustment in the immediately preceding sentence would otherwise
          result in an increase in the Exercise Price hereunder, no adjustment shall be made, and if this Warrant is exercised on any given Exercise Date during the Share Combination Adjustment Period, solely with respect to such portion of this Warrant
          exercised on such applicable Exercise Date, such applicable Share Combination Adjustment Period shall be deemed to have ended on, and included, the Trading Day immediately prior to such Exercise Date and the Event Market Price on such applicable
          Exercise Date will be the lowest VWAP of the ADSs immediately during such the Share Combination Adjustment Period prior to such Exercise Date and ending on, and including the Trading Day immediately prior to such Exercise Date.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Voluntary Adjustment by Company</u>. Subject to the rules and regulations of the Trading Market and the consent of the Holder, the Company may at
        any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">13</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 4</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transfer of Warrant</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transferability</u>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or
        in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto as <u>Exhibit B</u> duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such
        payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a
        new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
        unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this
        Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant ADSs without having a new Warrant issued.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>New Warrants</u>. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined
        with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.
        Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
        accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
        absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">14</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 5</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Miscellaneous</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Rights as Shareholder until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or
        other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant ADSs on a &#8220;cashless exercise&#8221; pursuant
        to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
        to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the
        Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
        cancellation, in lieu of such Warrant or stock certificate.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or
        granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Authorized Shares</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 72pt; line-height: 1.25;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its
      authorized and unissued ADSs a sufficient number of ADSs to provide for the issuance of the Warrant ADSs and underlying Ordinary Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of
      this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant ADSs upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be
      necessary to assure that such Warrant ADSs may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Ordinary Shares and ADSs may be listed. The Company
      covenants that all Warrant ADSs which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant ADSs in accordance herewith,
      be duly authorized, validly issued, fully paid and nonassessable (which means that no further sums are required to be paid by the holders thereof in connection with the issue thereof) and free from all taxes, liens and charges created by the Company
      in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 72pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">15</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any
      action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid
      the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of
      Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant ADSs above the amount payable therefor upon such exercise immediately prior to
      such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant ADSs upon the exercise of this Warrant and (iii) use commercially
      reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25;">Before taking any action that would result in an adjustment in the number of Warrant ADSs for
      which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Governing Law</u>. All questions concerning the construction,
          validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party
          agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
          partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in
          the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
          suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives
          personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in
          effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
          other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their
          reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Notwithstanding the foregoing, nothing in this paragraph shall limit or restrict the federal
        district court in which a Holder may bring a claim under the federal securities laws.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">16</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Restrictions</u>. The Holder acknowledges that the Warrant ADSs acquired upon the exercise of this Warrant, if not registered, and the Holder does
        not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a
        waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. No provision of this Warrant shall be construed as a waiver by the Holder of any rights which the Holder may have under the federal securities laws and the rules
        and regulations of the Commission thereunder. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the
        Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any
        amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any
        Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at Kiryat Atidim, Building 7 , Tel Aviv, 6158002, Israel, Attention:<font style="font-weight: bold;">&#160;</font>Dale Pfost, Chief Executive Officer, email address: dale.pfost@chemomab.com, or such other email address or address as the Company may specify for
        such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier
        service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of
        transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or
        communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if
        sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public
        information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 6-K.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">17</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
        Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Ordinary Shares or ADSs or as a shareholder of the Company, whether such liability is
        asserted by the Company or by creditors of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to
        specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and
        not to assert the defense in any action for specific performance that a remedy at law would be adequate.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
        benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
        and shall be enforceable by the Holder or holder of Warrant ADSs.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the other hand.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under
        applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
        or the remaining provisions of this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
        Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">********************</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">[CMMB Warrant Signature Page Follows]</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">18</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">[CMMB Warrant Signature Page]</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of
      the date first above indicated.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z87ec5e86bf284043b7b37160a6f9dd3d">

          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50.00%;">
              <div>
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">By:</font>&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">______________________________</font></div>
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Name:</font>&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Dale
                    Pfost</font></div>
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Its:</font> <font style="font-family: 'Times New Roman',Times,serif;">Chief
                    Executive Officer</font></div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
              </div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
      <br>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit A</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">NOTICE OF EXERCISE</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">TO:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CHEMOMAB THERAPEUTICS
          LTD.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
          undersigned hereby elects to purchase ________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable
          transfer taxes, if any.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payment
          shall take the form of (check applicable box):</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 108pt; line-height: 1.25;">&#9744; in lawful money of the United States; or</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 108pt; line-height: 1.25;">&#9744; if permitted the cancellation of such number of Warrant ADSs as is necessary, in accordance with the formula set
        forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant ADSs purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Please
          issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Warrant ADSs shall be delivered to the following DWAC Account Number:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 108pt; line-height: 1.25;">_______________________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 108pt; line-height: 1.25;">_______________________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 108pt; line-height: 1.25;">_______________________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">[SIGNATURE OF HOLDER]</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z9fbd93a4eab0419a98bd4da9ddfe1fb7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Name of Investing Entity:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">Signature of Authorized
                  Signatory of Investing Entity</font>:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Name of Authorized Signatory:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Title of Authorized Signatory:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Date:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit B</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">ASSIGNMENT FORM</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 10.5pt; line-height: 1.25; font-style: italic;">(To assign the foregoing Warrant, execute this form and supply required information. Do not
        use this form to exercise the Warrant to purchase shares.)</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 10.5pt; line-height: 1.25;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z4c49de89930444fca99806aa6e767ce6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Name:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">(Please Print)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Address:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>
                <div>
                  <div style="text-align: justify; line-height: 1.25;"> <br>
                  </div>
                  <div style="text-align: justify; line-height: 1.25;">Phone Number:</div>
                  <div style="text-align: justify; line-height: 1.25;">Email Address:</div>
                </div>
              </div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">(Please Print)</div>
              <div style="text-align: justify; line-height: 1.25;">______________________________________</div>
              <div style="text-align: justify; line-height: 1.25;">______________________________________</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Dated: _______________ __, ______</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Holder&#8217;s Signature:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Holder&#8217;s Address:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>exhibit_4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> Exhibit 4.3</u><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6a5144c4f3964092a836f092948acbfb">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Warrant ADSs: [&#9679;]</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25;">Initial Exercise Date: [&#9679;], 2023</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25;">Issue Date: [&#9679;], 2023</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">THIS PRE-FUNDED<font style="font-weight: bold;">&#160;</font>WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [&#9679;] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the
        limitations on exercise and the conditions hereinafter set forth, at any time until this Warrant is exercised in full (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Chemomab Therapeutics Ltd., a company organized and existing under the laws of the State of Israel (the &#8220;<u>Company</u>&#8221;), up to [&#9679;] Ordinary Shares, represented by [&#9679;] American Depositary Shares (&#8220;<u>ADSs</u>&#8221;), each ADS representing twenty (20) Ordinary Shares, as subject to adjustment hereunder (the ADSs issuable hereunder, the &#8220;<u>Warrant ADSs</u>&#8221;).
        The purchase price of one (1) ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 1</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant or in the Underwriting Agreement dated [&#9679;], 2023, the following terms have
      the meanings indicated in this Section 1:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>ADS</u>&#8221; means the American Depositary Shares of the Company, each to purchase 20 Ordinary Shares, without par value per share (subject to adjustment), and
      any other class of securities into which such securities may hereafter be reclassified or changed.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with
      a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then listed or quoted on a
      Trading Market, the bid price of the ADSs for the time in question (or the nearest preceding date) on the Trading Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City
      time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the ADSs for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed
      or quoted for trading on OTCQB or OTCQX and if prices for the ADSs are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported, or
      (d)&#160;in all other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and
      expenses of which shall be paid by the Company.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law
      to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221; or any other similar
      orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York
      generally are open for use by customers on such day.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Depositary</u>&#8221; means The Bank of New York Mellon, the current depositary bank of the Company&#8217;s ADSs, with a mailing address of 240 Greenwich Street, New
      York, New York 10286 and an email address of [&#9679;], and any successor depositary bank of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Ordinary Share</u>&#8221; means the ordinary shares of the Company, without par value per share, and any other class of securities into which such securities may
      hereafter be reclassified or changed.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Ordinary Share Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time
      Ordinary Shares or ADSs, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to
      receive, Ordinary Shares or ADSs.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
      joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Registration Statement</u>&#8221; means the Company&#8217;s registration statement on Form S-1, as amended (File No. 333&#8209;269218).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or
      acquired after the date hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Trading Day</u>&#8221; means a day on which the ADSs are traded on a Trading Market.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the ADSs are listed or quoted for trading on the date in question: the NYSE
      American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Underwriting Agreement</u>&#8221; means the underwriting agreement, dated as of [&#9679;], 2023, between the Company and Aegis Capital Corp., as amended, modified or
      supplemented from time to time in accordance with its terms.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then listed or quoted on a
      Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding date) on the Trading Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
      (New York City time) to 4:02 p.m. (New York City time)), (b)&#160;if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the ADSs for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are
      not then listed or quoted for trading on OTCQB or OTCQX and if prices for the ADSs are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so
      reported, or (d)&#160;in all other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
      the fees and expenses of which shall be paid by the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">&#8220;<u>Warrants</u>&#8221; means this Warrant and other ADSs purchase warrants issued by the Company pursuant to the Registration Statement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 2</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
      after the Initial Exercise Date and on or before the Termination Date by delivery to the Company and the Depositary of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise substantially in the form attached
      hereto as <u>Exhibit A</u> (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of
      exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant ADSs specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure
      specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be
      required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant ADSs available hereunder and the Warrant has been
      exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
      resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect of lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant ADSs
      purchased. The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such
      notice. <font style="font-weight: bold;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant ADSs hereunder, the
        number of Warrant ADSs available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise Price</u>. The aggregate exercise price of this
              Warrant, except for a nominal exercise price of $0.001 per Warrant ADS, was pre-funded to the Company on or prior to the Initial Exercise Date
              and, consequently, no additional consideration (other than the nominal exercise price of $0.001 per Warrant ADS) shall be required to be paid by
              the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever,
              including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid exercise price per ADS under this
              Warrant shall be $0.001<u style="border-bottom: 1px solid;">,</u>
          subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Cashless Exercise</u>. This Warrant may also be exercised,
          in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant ADSs equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5beebf0d131f42d6bb048d480fd53253">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">(A) =</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading
              Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such
              Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the ADSs on the principal Trading Market as reported by
              Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including
              until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and
              such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z667c299822914b66893e7ce7e7bd34f2">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">(B) =</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Exercise Price of this Warrant, as adjusted hereunder; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfcc236699a36478eba71fd633c5aa9b1">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">(X) =</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the number of Warrant ADSs that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">If Warrant ADSs are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the
      Warrant ADSs shall take on the registered characteristics of the Warrants being exercised, and the holding period of the Warrant ADSs being issued may be tacked on to the holding period of this Warrant. Assuming (i) the Holder is not an Affiliate of
      the Company, and (ii) all of the applicable conditions of Rule 144 promulgated under the Securities Act with respect to Holder and the Warrant ADSs are met in the case of such a cashless exercise, the Company agrees that the Company will cause the
      removal of the legend from such Warrant ADSs (including by delivering an opinion of the Company&#8217;s counsel to the Company&#8217;s Depositary at its own expense to ensure the foregoing), and the Company agrees that the Holder is under no obligation to sell
      the Warrant ADSs issuable upon the exercise of the Warrant prior to removing the legend.. The Company agrees not to take any position contrary to this Section 2(c).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Mechanics of Exercise</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery of Warrant ADSs upon Exercise</u>. The Company shall cause its registrar to deposit the Warrant ADSs subject to such exercise with the
      Depositary and instruct the Depositary to credit the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Depositary is then a
      participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant ADSs to or resale of the Warrant ADSs by Holder or (B) the Warrant ADSs are eligible for resale by the Holder without volume
      or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, for the number of Warrant ADSs to which the Holder is entitled pursuant to such exercise to the
      address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise
      Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of
      Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant ADSs with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant ADSs, provided that
      payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the
      Notice of Exercise. Notwithstanding anything herein to the contrary, upon delivery of the Notice of Exercise, the Holder shall be deemed for purposes of Regulation SHO under the Exchange Act to have become the holder of the Warrant ADSs irrespective
      of the date of delivery of the Warrant ADSs. If the Company fails for any reason to deliver to the Holder the Warrant ADSs subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
      damages and not as a penalty, for each $1,000 of Warrant ADSs subject to such exercise (based on the VWAP of the ADSs on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3rd) Trading
      Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant ADSs are delivered or Holder rescinds such exercise. The Company agrees to maintain a Depositary that is a participant in the
      FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with
      respect to the ADSs as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which
      may be delivered at any time after the time of execution of the Underwriting Agreement, the Company agrees to deliver the Warrant ADSs subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise
      Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
      upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for by this Warrant, which new Warrant
      shall in all other respects be identical with this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">iii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Rescission Rights</u>. If the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs pursuant to Section 2(d)(i) by
      the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise in respect to the untransmitted Warrant ADSs (with the effect that the Holder&#8217;s rights to acquire such untransmitted Warrant ADSs pursuant to this Warrant
      shall be restored) and the Company shall return to the Holder the portion of the aggregate Exercise Price paid to the Company for such untransmitted Warrant ADSs.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">iv.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant ADSs upon Exercise</u>. In addition to any other rights available to the Holder, if
      the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is
      required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, ADSs to deliver in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving
      upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the ADSs so purchased exceeds (y) the amount
      obtained by multiplying (1) the number of Warrant ADSs that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed,
      and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant ADSs for which such exercise was not honored and return any amount received by the Company in respect of the Exercise Price for those
      Warrant ADSs (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
      Holder purchases ADSs having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of ADSs with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
      preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the
      amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
      Company&#8217;s failure to timely deliver ADSs upon exercise of the Warrant as required pursuant to the terms hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">v.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Fractional ADSs or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.
      As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
      multiplied by the Exercise Price or round up to the next whole ADS.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">vi.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other
      incidental expense in respect of the issuance of such Warrant ADSs, all of which taxes and expenses shall be paid by the Company, and such Warrant ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the
      Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <u>Exhibit

        B</u> duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Depositary fees required for same-day
      processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant ADSs. The Company will pay all
      applicable fees and expenses of the Depositary in connection with the issuance of the Warrant ADSs hereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">vii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing of Books</u>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this
      Warrant, pursuant to the terms hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
      any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any
      other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
      foregoing sentence, the number of Ordinary Shares or ADSs beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Ordinary Shares or ADSs issuable upon exercise of this Warrant with respect to which
      such determination is being made, but shall exclude the number of ADSs which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties
      and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any other Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the
      limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
      with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the
      Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
      relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
      be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each
      case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in
      accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding Ordinary Shares or ADSs, a Holder may rely on the number of
      outstanding Ordinary Shares and ADSs as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
      the Company or the Depositary setting forth the number of Ordinary Shares and ADSs outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of
      Ordinary Shares and ADSs then outstanding. In any case, the number of outstanding Ordinary Shares and ADSs shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or
      its Affiliates or Attribution Parties since the date as of which such number of outstanding Ordinary Shares or ADSs was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, upon election by a Holder prior to the issuance of any
      Warrants, 9.99%) of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares underlying the ADSs issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or
      decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of
      Ordinary Shares underlying ADSs upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
      with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
      to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 3</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Certain Adjustments</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Share and ADS Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a share or ADS dividend or
      otherwise makes a distribution or distributions on ADSs or any other equity or equity equivalent securities payable in Ordinary Shares or ADSs (which, for avoidance of doubt, shall not include any ADSs issued by the Company upon exercise of this
      Warrant), (ii) subdivides outstanding Ordinary Shares&#160; into a larger number of shares or ADSs, (iii) combines (including by way of reverse stock split or ADR ratio change) outstanding Ordinary Shares or ADSs into a smaller number of shares or ADSs,
      or (iv) issues by reclassification of Ordinary Shares, ADSs any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of ADSs (excluding treasury
      shares, if any) outstanding immediately before such event and of which the denominator shall be the number of ADSs outstanding immediately after such event, and the number of ADSs issuable upon exercise of this Warrant shall be proportionately
      adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to
      receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Reserved</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
      any Ordinary Share Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all (or substantially all) of the record holders of any class of Ordinary Shares or ADSs (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder
      will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of Ordinary Shares acquirable upon complete exercise of this Warrant
      (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such
      record is taken, the date as of which the record holders of Ordinary Shares or ADSs are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such
      Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such ADSs as a result of such Purchase
      Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
      distribution of its assets (or rights to acquire its assets) to all (or substantially all) holders of Ordinary Shares or ADSs, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other
      securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each
      such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of Ordinary Shares or ADSs acquirable upon complete exercise of this
      Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date
      as of which the record holders of Ordinary Shares or ADSs are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Distribution would
      result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Ordinary Shares or ADSs as a result of such
      Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To
      the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
      transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
      substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary
      Shares (including any Ordinary Shares underling ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares or 50% or more
      of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares or ADSs or any compulsory
      share exchange pursuant to which the Ordinary Shares or ADSs are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or
      share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires
      50% or more of the outstanding Ordinary Shares or 50% or more of the voting power of the common equity of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to
      receive, for each Ordinary Share represented by each Warrant ADS that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
      Section 2(e) on the exercise of this Warrant), the number of capital stock (or its equivalent) of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate
        Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares represented by each Warrant ADS for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without
      regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
      Alternate Consideration issuable in respect of one Ordinary Share or ADS, as applicable, in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
      relative value of any different components of the Alternate Consideration. If holders of Ordinary Shares or ADSs are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given
      the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.&#160; The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the
      survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory
      to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a
      written instrument substantially similar in form and substance to this Warrant that is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Ordinary Shares or ADSs
      acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the Exercise Price hereunder to such shares of
      capital stock (but taking into account the relative value of the Ordinary Shares prior to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose
      of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental
      Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant referring to the &#8220;Company&#8221;
      shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the
      Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities, jointly
      and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized Ordinary Shares or
      ADSs for the issuance of Warrant ADSs and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be.
      For purposes of this Section 3, the number of Ordinary Shares or ADSs, as applicable, deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares or ADSs, as applicable, (excluding treasury shares, if any)
      issued and outstanding.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notice to Holder</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
      deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Ordinary
      Shares or ADSs, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares or ADSs, (C) the Company shall authorize the granting to all holders of the ADS rights or warrants to subscribe for or
      purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which the
      Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Ordinary Shares or ADSs are converted into other securities, cash or property, or (E) the
      Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear
      upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
      redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Ordinary Shares or ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)
      the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Ordinary Shares or ADSs of record shall be entitled
      to exchange their Ordinary Shares or ADSs for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein
      or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the
      Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of
      such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%13%%%-->
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 4</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transfer of Warrant</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transferability</u>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or
      in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto as <u>Exhibit B</u> duly executed by the Holder or
      its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
      assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall
      promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
      surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
      by a new holder for the purchase of Warrant ADSs without having a new Warrant issued.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>New Warrants</u>. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined
      with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject
      to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
      with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant
        Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
      and for all other purposes, absent actual notice to the contrary.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">13</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><u>Section 5</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Miscellaneous</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Rights as Shareholder until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or
      other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant ADSs on a &#8220;cashless exercise&#8221; pursuant
      to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
      to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the
      Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
      cancellation, in lieu of such Warrant or stock certificate.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or
      granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Authorized Shares</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 72pt; line-height: 1.25;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued ADSs a sufficient number of ADSs to
      provide for the issuance of the Warrant ADSs and underlying Ordinary Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
      who are charged with the duty of issuing the necessary Warrant ADSs upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant ADSs may be issued as
      provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Ordinary Shares and ADSs may be listed. The Company covenants that all Warrant ADSs which may be issued upon the
      exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant ADSs in accordance herewith, be duly authorized, validly issued, fully paid and
      nonassessable (which means that no further sums are required to be paid by the holders thereof in connection with the issue thereof) and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes
      in respect of any transfer occurring contemporaneously with such issue).</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 72pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">14</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
      incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
      but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
      limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant ADSs above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be
      necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant ADSs upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
      or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25;">Before taking any action that would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise Price, the
      Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
      construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
      of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and
      federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
      in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any
      such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
      by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
      service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any
      provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution
      of such action or proceeding. Notwithstanding the foregoing, nothing in this paragraph shall limit or restrict the federal district court in which a Holder may bring a claim under the federal securities laws.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">15</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Restrictions</u>. The Holder acknowledges that the Warrant ADSs acquired upon the exercise of this Warrant, if not registered, and the Holder does
      not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a
      waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. No provision of this Warrant shall be construed as a waiver by the Holder of any rights which the Holder may have under the federal securities laws and the rules and
      regulations of the Commission thereunder. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the
      Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
      due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any
      Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at Kiryat Atidim, Building 7 , Tel Aviv, 6158002, Israel, Attention:<font style="font-weight: bold;">&#160;</font>Dale Pfost, Chief Executive Officer, email address: dale.pfost@chemomab.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or
      other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address
      of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via
      e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set
      forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or
      (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
      shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">16</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
      Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Ordinary Shares or ADSs or as a shareholder of the Company, whether such liability is
      asserted by the Company or by creditors of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to
      specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not
      to assert the defense in any action for specific performance that a remedy at law would be adequate.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
      benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
      and shall be enforceable by the Holder or holder of Warrant ADSs.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand,
      and the Holder, on the other hand.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under
      applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or
      the remaining provisions of this Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
      Warrant.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">********************</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">
      <div style="line-height: 1.25; font-style: italic;">[CMMB Pre-Funded Warrant
        Signature Page Follows]</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">17</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">
      <div style="line-height: 1.25; font-style: italic;">[CMMB sWarrant Signature Page]</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" border="0" id="z87ec5e86bf284043b7b37160a6f9dd3d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50.00%;">
              <div>
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">By:</font>&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">______________________________</font></div>
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Name:</font>&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Dale Pfost</font></div>
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Its:</font> <font style="font-family: 'Times New Roman',Times,serif;">Chief Executive Officer</font></div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
              </div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
      <br>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit A</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">NOTICE OF EXERCISE</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">TO:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CHEMOMAB THERAPEUTICS LTD.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned hereby elects to purchase ________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
        herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payment shall take the form of (check applicable box):</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 108pt; line-height: 1.25;">&#9744; in lawful money of the United States; or</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 108pt; line-height: 1.25;">&#9744; if permitted the cancellation of such number of Warrant ADSs as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with
        respect to the maximum number of Warrant ADSs purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Please issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Warrant ADSs shall be delivered to the following DWAC Account Number:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 108pt; line-height: 1.25;">_______________________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 108pt; line-height: 1.25;">_______________________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 108pt; line-height: 1.25;">_______________________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">[SIGNATURE OF HOLDER]</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9fbd93a4eab0419a98bd4da9ddfe1fb7">

          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Name of Investing Entity:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">Signature of Authorized Signatory of Investing Entity</font>:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Name of Authorized Signatory:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Title of Authorized Signatory:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 75.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Date:</div>
            </td>
            <td style="width: 24.72%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit B</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">ASSIGNMENT FORM</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 10.5pt; line-height: 1.25; font-style: italic;">(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 10.5pt; line-height: 1.25;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4c49de89930444fca99806aa6e767ce6">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Name:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">(Please Print)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Address:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>
                <div>
                  <div style="text-align: justify; line-height: 1.25;"> <br>
                  </div>
                  <div style="text-align: justify; line-height: 1.25;">Phone Number:</div>
                  <div style="text-align: justify; line-height: 1.25;">Email Address:</div>
                </div>
              </div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">(Please Print)</div>
              <div style="text-align: justify; line-height: 1.25;">______________________________________</div>
              <div style="text-align: justify; line-height: 1.25;">______________________________________</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Dated: _______________ __, ______</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Holder&#8217;s Signature:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Holder&#8217;s Address:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>exhibit_5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 5.1</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;"><img width="576" height="88" src="image00005.jpg"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: right; line-height: 1.25;">March 21, 2023</div>
      <div style="line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
      <div style="line-height: 1.25;">Kiryat Atidim, Building 7</div>
      <div style="line-height: 1.25;">Tel Aviv, Israel, 6158002</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Re:&#160;<u>Registration Statement on Form S-1</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Ladies and Gentlemen:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">We have acted as Israeli counsel to Chemomab Therapeutics Ltd., a company organized under the laws of the State
        of Israel (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), in connection with its registration statement on Form S-1 (the &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;) filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;) on the
        date hereof under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;) relating to the issuance and sale of the Company of up to
        6,578,947 units (&#8220;<font style="font-weight: bold;">Units</font>&#8221;), with each Unit consisting of (a) (i) one American Depositary Share (the &#8220;<font style="font-weight: bold;">ADS</font>&#8221;), each representing twenty (20) ordinary shares of the Company, no par value (the &#8220;<font style="font-weight: bold;">Ordinary
          Shares</font>&#8221;) or (ii) one pre-funded warrant to purchase one ADS (the &#8220;<font style="font-weight: bold;">Pre-funded Warrants</font>&#8221;) and (b) one accompanying immediately exercisable
        warrant to purchase one ADS (the &#8220;<font style="font-weight: bold;">Common Warrants</font>&#8221;, and together with the Pre-funded Warrants, the &#8220;<font style="font-weight: bold;">Warrants</font>&#8221;),&#160;each as further described in the Registration Statement. The ADSs underlying the Warrants are referred to herein as the &#8220;<font style="font-weight: bold;">Warrant Shares</font>&#8221;.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5)
        of Regulation S-K under the Securities Act, in connection with the filing of the Registration Statement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified
        to our satisfaction, of: (i) the form of the Registration Statement, to which this opinion letter is attached as an exhibit; (ii) the articles of association of the Company, as currently in effect (the &#8220;<font style="font-weight: bold;">Articles</font>&#8221;); (iii) minutes of a meeting of the board of directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;)
        at which the filing of the Registration Statement and the actions to be taken in connection therewith were approved; and (iv) such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents
        of public officials and of officers and representatives of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. We have also made inquiries of such officers and representatives as we have deemed
        relevant and necessary as a basis for the opinions hereafter set forth.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons,
        the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed as photostatic copies and the authenticity of the originals of such latter documents. We
        have also assumed the truth of all facts communicated to us by the Company and that all minutes of meetings of the Board and the shareholders of the Company that have been provided to us are true and accurate and have been properly prepared in
        accordance with the Articles and all applicable laws.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On the basis of the foregoing, and in reliance thereon, we are of the opinion that (i) upon payment to the Company
        of the consideration in such amount and form as shall be determined by the Board, the Ordinary Shares underlying the ADSs, when issued and sold in the offering as described in the Registration Statement, will be duly validly issued, fully paid and
        non-assessable and (ii) the Ordinary Shares underlying the Warrant Shares, when issued and sold by the Company and delivered by the Company against receipt of the exercise price therefor as shall be determined by the Board, in accordance with and
        in the manner described in the Registration Statement, will be validly issued, fully paid and non-assessable.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have further assumed that, at the time of issuance and to the extent any such issuance would exceed the maximum
        share capital of the Company currently authorized, the number of Ordinary Shares that the Company is authorized to issue shall have been increased in accordance with the Company&#8217;s Articles such that a sufficient number of Ordinary Shares is
        authorized and available for issuance under the Articles.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Members of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the
        laws of any other jurisdiction. This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our
        firm appearing under the caption &#8220;Legal Matters&#8221; and, if applicable, &#8220;Enforceability of Civil Liabilities&#8221; in the prospectus forming part of the Registration Statement. In giving this consent, we do not thereby admit that we are within the category
        of persons whose consent is required under Section 7 of the Securities Act, the rules and regulations of the SEC promulgated thereunder or Item 509 of the SEC&#8217;s Regulation S-K under the Securities Act.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts,
        circumstances, events or developments that may be brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z736f01f079b34f8186157d8e56877445" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.7%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 50.3%; vertical-align: top;">
              <div style="line-height: 1.25;">Very truly yours,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.7%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 50.3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.7%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 50.3%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">/s/ Meitar Law Offices</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.7%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 50.3%; vertical-align: top;">
              <div style="line-height: 1.25;">Meitar Law Offices</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>6
<FILENAME>exhibit_5-2.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 5.2</font></u><br>
    </div>
    <div style="text-align: right;"><u><font style="font-weight: bold;"> <br>
        </font></u></div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" border="0" id="zdde7cd8833a54968828bfd10d440cf01" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 80%; vertical-align: top;">
                  <div style="margin-right: 12.95pt; line-height: 1.25;"><img width="120" height="45" src="image0.jpg"></div>
                </td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 9pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Wilson

                    Sonsini Goodrich &amp; Rosati<br>
                    Professional Corporation</div>
                  <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-style: normal; font-variant: normal; text-transform: none;"><font style="line-height: 1.25;">&#160;</font></div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 9pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">1881

                    9th Street, Suite 110</div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 9pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Boulder,

                    CO 80302</div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 9pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br>
                  </div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 9pt; font-variant: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; text-transform: none;">O: 303-256-5900<br>
                      F: 866.974.7329</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25;">March 21, 2023</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
      <div style="line-height: 1.25;">Kiryat Atidim, Building 7</div>
      <div style="line-height: 1.25;">Tel Aviv, 6158002,</div>
      <div style="line-height: 1.25;">Israel</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">Re:</font>&#160;<font style="font-weight: bold;">&#160; &#160; <u>Registration Statement on Form S-1</u></font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Ladies and Gentlemen:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This opinion is furnished to you in connection with the Registration Statement on Form S-1, as amended (the &#8220;<u>Registration Statement</u>&#8221;), filed by Chemomab Therapeutics Ltd.
        (the &#8220;<u>Company</u>&#8221;) with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) on the date hereof in connection with the registration under the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), of the offering and sale
        of up to 7,565,789 &#8220;<u>Units</u>&#8221;, with each Unit consisting of (A) (i) one American Depositary Share (the &#8220;<u>ADSs</u>&#8221;), each representing twenty (20) of the Company&#8217;s ordinary shares (the <u>&#8220;Shares</u>&#8221;), no par value per share, or (ii) one
        pre-funded warrant to purchase one ADS (the &#8220;<u>Prefunded Warrants</u>&#8221;), and (B) one accompanying immediately exercisable warrant to purchase one ADS (&#8220;<u>Warrants</u>&#8221;). The ADSs issuable upon the exercise of the of the Prefunded Warrants and
        Warrants are referred to as the &#8220;<u>Warrant ADSs</u>&#8221;, and together with the ADSs, Prefunded Warrants and Warrants as the &#8220;<u>Securities</u>&#8221;.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are acting as counsel for the Company in connection with the registration of the Securities for offer and sale. As such counsel, we have made such legal and factual
        examinations and inquiries as we have deemed necessary or advisable for the purpose of rendering the opinions and statements set forth below. In rendering the opinions and statements expressed below, we have examined originals or copies, certified
        or otherwise identified to our satisfaction, of such documents, corporate records, certificates of public officials and other instruments as we have deemed necessary for the purposes of rendering this opinion.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, we have reviewed originals or copies of such corporate records of the Company, certificates of public officials, a certificate of an officer of the Company as to
        factual matters and such other documents which we consider necessary or advisable for the purpose of rendering the opinions set forth below. We have not independently established the facts stated therein.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In our examination, we have assumed the genuineness of all signatures, the authenticity and completeness of all documents submitted to us as originals, the conformity with the
        originals of all documents submitted to us as copies, the authenticity of the originals of such documents and the legal competence of all signatories to such documents. We have also assumed the authority of such persons signing on behalf of the
        parties thereto other than the Company and the due authorization, execution and delivery of all documents by the parties thereto other than the Company. We have also assumed<font style="font-style: italic;">&#160;</font>the conformity of the documents
        filed with the Commission via the Electronic Data Gathering, Analysis and Retrieval System (&#8220;<u>EDGAR</u>&#8221;), except for required EDGAR formatting changes, to physical copies submitted for our examination and the absence of any evidence extrinsic to
        the provisions of the written agreements between the parties that the parties intended a meaning contrary to that expressed by those provisions.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;<br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On the basis of the foregoing, we are of the opinion that the Securities are duly authorized, validly issued, fully paid and nonassessable. It is understood that this opinion is
        to be used only in connection with the offer and resale of the Securities while the Registration Statement is in effect. We assume no obligation to supplement this opinion if any applicable law changes after the date hereof or if we become aware of
        any fact that might change the opinion expressed herein after the date hereof.&#160; We express no opinion as to the laws of any other jurisdiction, other than the federal laws of the United States of America and the General Corporation Law of the State
        of Delaware.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We consent to the use of this opinion as an exhibit to the Registration Statement, and we consent to the reference of our name under the caption &#8220;Legal Matters&#8221; in the prospectus
        forming part of the Registration Statement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="zc5b7adf5e2364a49b821387885c3e97a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -11pt; margin-left: 11pt; line-height: 1.25;">Very truly yours,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25;">/s/ Wilson Sonsini Goodrich &amp; Rosati</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">WILSON SONSINI GOODRICH &amp; ROSATI</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">Professional Corporation</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 8pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">AUSTIN&#160; &#160; &#160; &#160; BEIJING&#160; &#160; &#160; &#160; BOSTON&#160; &#160; &#160;&#160; BOULDER&#160;&#160; BRUSSELS&#160; &#160; &#160; &#160; HONG KONG&#160; &#160; &#160; &#160; LONDON&#160; &#160; &#160; &#160; LOS ANGELES&#160; &#160; &#160; &#160; NEW YORK&#160; &#160; &#160; &#160; PALO ALTO<br>
          SALT LAKE CITY&#160; &#160; SAN DIEGO&#160; &#160; &#160; &#160; SAN FRANCISCO&#160; &#160; &#160; &#160; SEATTLE&#160; &#160; &#160; &#160; SHANGHAI&#160; &#160; &#160; &#160; WASHINGTON, DC&#160; &#160; &#160; &#160; WILMINGTON, DE</div>
        <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>exhibit_23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Exhibit 23.1</u></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Board of Directors<br>
      Chemomab Therapeutics Ltd.:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">We consent to the use of our report dated February 20, 2023, with respect to the consolidated financial statements of Chemomab
      Therapeutics Ltd., incorporated herein by reference and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z5589b365ab844401bf33b49220ff5719" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0); font-style: italic;">/s/ Somekh Chaikin</div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 100%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Member Firm of KPMG International</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Tel Aviv, Israel<br>
      <br style="line-height: 1.25;">
      </font></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">March 21, 2023</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 11pt;"> <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font></div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <font style="font-family: 'Times New Roman',Times,serif;"><br>
    </font></div>
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>8
<FILENAME>exhibit_107.htm
<DESCRIPTION>FILING FEES TABLE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 107</u></div>
    <div style="text-align: right; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Calculation of Filing Fee Tables</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd9e0b67aa5004565982341f79a483f3e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 42.57%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.88%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">Form S-1</div>
          </td>
          <td style="width: 41.56%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 42.57%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.88%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">(Form Type)</div>
          </td>
          <td style="width: 41.56%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb7d05c240f78412dadc1406cfb76b85f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 29.26%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 41.48%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
          <td style="width: 29.26%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 29.26%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 41.48%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">(Exact Name of Registrant as Specified in its Charter)</div>
          </td>
          <td style="width: 29.26%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>Table 1: Newly Registered and Carry Forward Securities</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z707aef95addd4e77b4b0de71196f4978" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Security<br>
              Type</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Security<br>
              Class<br>
              Title</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fee<br>
              Calculation<br>
              or Carry<br>
              Forward Rule</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Maximum<br>
              Aggregate<br>
              Offering<br>
              Price<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)</sup></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fee<br>
              Rate</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;"> </div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount of<br>
              Registration<br>
              Fee</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="18">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Newly Registered Securities</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: middle; background-color: #CCEEFF; width: 17.333333333333333333333333333%;" colspan="1">
            <div style="text-align: center; line-height: 1.25;">Fees to be Paid</div>
          </td>
          <td valign="bottom" style="vertical-align: middle; background-color: #CCEEFF; width: 17.333333333333333333333333333%;">
            <div style="text-align: center; line-height: 1.25;">Equity</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 17.333333333333333333333333333%;">
            <div style="text-align: center; line-height: 1.25;">Units consisting of (i) either one American Depositary Share or one Pre-Funded Warrant to purchase one American Depositary Share
              and (ii) one Warrant to Purchase one American Depositary Share (2)(3)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(1</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">11,500,000.00</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">.0001102</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">1,267.30</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; padding-left: 9pt; width: 17.3333%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: top; width: 17.3333%;">&#160;</td>
          <td valign="bottom" style="vertical-align: top; width: 17.3333%;">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: middle; background-color: #CCEEFF; width: 17.333333333333333333333333333%;" colspan="1">
            <div style="text-align: center; line-height: 1.25;">Fees to be Paid</div>
          </td>
          <td valign="bottom" style="vertical-align: middle; background-color: #CCEEFF; width: 17.333333333333333333333333333%;">
            <div style="text-align: center; line-height: 1.25;">Equity</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 17.333333333333333333333333333%;">
            <div style="text-align: center; line-height: 1.25;">American Depositary Shares issuable upon exercise of Pre-Funded Warrants and Warrants (2)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(1</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">11,500,000.00</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">.0001102</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">1,267.30</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; padding-left: 9pt; width: 17.3333%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: top; width: 17.3333%;">&#160;</td>
          <td valign="bottom" style="vertical-align: top; width: 17.3333%;">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-left: 14%; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="3">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total Offering Amounts</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">23,000,000.00</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">2,534.60</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-left: 14%; width: 52%; padding-bottom: 2px;" colspan="3">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total Fees Previously Paid</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">3,306.00</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-left: 14%; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="3">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total Fee Offsets</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-left: 14%; width: 52%; padding-bottom: 4px;" colspan="3">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Net Fee Due</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">0.00</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z09ca5b61b77c439d9560a06568aee4c1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.55%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(1)</div>
          </td>
          <td style="width: 96.74%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities
              Act of 1933, as amended.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.55%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 96.74%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.55%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(2)</div>
          </td>
          <td style="width: 96.74%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Each ADS represents twenty (20) ordinary shares of the registrant. ADSs issuable upon deposit of the ordinary shares registered
              hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-229522).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.55%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 96.74%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.55%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(3)</div>
          </td>
          <td style="width: 96.74%; vertical-align: top;">
            <div style="line-height: 1.25;">Calculated in accordance with Rule 457(g) under the Securities Act, because the ADSs of the registrant underlying the warrants are
              registered hereby.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.55%; vertical-align: top;">&#160;</td>
          <td style="width: 2.7%; vertical-align: top;">&#160;</td>
          <td style="width: 96.74%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0!"HH# 2(  A$! Q$!_\0
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MQ/<Y\WQ!J9!ZJ+IU'Y XJD^MZM(Q9]4O68]2UPY/\ZH455D0Y-]2[_;&J?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+_H%:E^2?_%52A)JZ1G*K"+LV>K45Y3_ ,+XT+_H%:E^2?\ Q5'_  OC0O\
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M%?'UQ;RVEU+;3*4EB<QNI[,#@C\ZZ:,KJQPXN%I<W<CHHHK8Y HHHH ****
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M1110 4444 %%%% !1110 4444 %%%% !7BWQ_P#^9=_[>?\ VE7M->+?'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"_Z_8O\ T(4I;,J'Q(^LJ***X#V@HHHH **** "BBB@ HHHH **** "BBB@
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MI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;H>WI7IE<LHN+LST83C-7B%%%%(L**** "BBB@ HHHH **** "BBB@ HHHH
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SSXRZS_9O@62T1\3:A*L(
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M]>7_ +.U>4UVT_A1Y&(_B,****LR"BBB@ HHHH **** .U^$O_)3M'_[;?\
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MN;E7/N%%%%2:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJNU^+7_)3M8_[8_^B4KBJ[H?"CQJO\27J%%%%40%%%% !1110 4444 %%%%
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MJNFWT6IZ7:7\'^JN84F3GLP!_K5JN ]K<**** "BBB@ HHHH **** "BBB@
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M_"3W8#\Q]#7J]<<HN+LSUJ<U./,@HHHJ2PHHHH **** "BBB@ HHHH ****
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MB/4("%&>LB?,/_'=]?0M<=56D>KAY\U-!11169N%%%% !1110 4444 %%%%
M!1110 5X=\>-8\R_TS18WXB1KF4 \9;Y5_$ -_WU7N-?)OCG6/[=\:ZI?AMT
M33&.(]MB?*OY@9_&MJ*O*YRXN=H6[G/4445U'FA1110 4444 %%%% !1110
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MU]GUS?BKP/HOBZV*W]N$N@N([N( 2)^/<>Q_2MH5G]HY*N$3U@?*%%=7XQ\
M:OX.GW7"?:+!FQ'=QCY3Z!A_"?;\B:Y2NA--71P2BXNS"BBBF(*]4^%/PZ_M
MF>/7]7ASIT39MX7'$[ ]2/[H/YGV!K&^&W@"7Q=J?VJ[1DTBV8>:W3S6_N*?
MYGL/J*^E888K:"."&-8XHU"(BC 4#@ 5A5J6T1UX:AS>_+8?1117,>B%%%%
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MY*=K'_;'_P!$I7%5VOQ:_P"2G:Q_VQ_]$I7%5W0^%'C5?XDO4****H@****
M"BBB@ HHHH **** "BBB@ HHHH Z3P1XNN?!VOQWL>Y[63"74(/^L3_$=1_@
M37U/8WUMJ5A!>V<JRV\Z"2-U[@U\:5ZE\(O'G]C7RZ!J4N-/N7_<2,>(9#V]
ME;]#SW)K&K"ZNCJPU;E?*]CZ!HHHKE/2"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#RGX\?\BMIO_7[_ .R-7@5>^_'C_D5M-_Z_?_9&KP*NNC\)Y>*_
MB!1116ISA1110 4444 %%%% &IX;_P"1ITC_ *_8?_0Q7U_7R!X;_P"1ITC_
M *_8?_0Q7U_7-7W1WX+9A1116!VA5'6M,BUK1+W3)L;+J%HB2/NDC@_@>?PJ
M]10#5U8^,+BWEM+J6VF4I+$YC=3V8'!'YU'7>?%[1/[(\>7$R+B&_07*X_O'
MA_QW G\:X.N^+NKGBSCRR<0HHHIDA1110 4444 %%%% &AH.J/HFOV&IQYS;
M3K(0.X!Y'XC(_&OL"*5)H4EB8-&ZAE8="#T-?%]?4'PLUG^V?A_I[,VZ6T!M
M)/;9]W_QPK6%=:)G;@Y:N)V=%%%<QWA1110 4444 %%%% !1110 4444 8'C
M;6/[!\&:IJ"MMD2 I$<_QM\J_J0?PKY+KW/X\:QY6FZ9HR-\T\AN)0#_  J,
M+^98_P#?->&5U45:-SS<7*\[=@HHHK8Y0HHHH **** "BBB@ HHHH **** "
MBBB@ KV/X#:QLO-4T5VXD1;J(>X^5OS!7\J\<KH_ >L?V%XWTJ^9ML0F$4I/
M38_RDGZ Y_"HFKQ:-*,N6:9]84445Q'L!1110 4444 %%%% !1110 4444 %
M>%?'?6?-U33=&C;Y8(S<2 ?WF.!GZ!3_ -]5[K7R5XTUC^WO&.J:BK;HY)RL
M1S_ ORK^@%;45>5SEQ<[0MW,&BBBNH\T**** "BBB@ HHHH **** /:_@-HN
M$U37)%ZD6L1Q]&?_ -DKVBN=\"Z)_P (_P""],L&7;,(A),#UWO\S#\"<?A7
M15Q3E>39Z]&')!(****@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\6^/_\ S+O_ &\_^TJ]IKQ;X_\ _,N_]O/_ +2K2E\:,,3_  F>*T44
M5V'E!1110 4444 %%%% !70^!/\ D?="_P"OV+_T(5SU=#X$_P"1]T+_ *_8
MO_0A2ELRH?$CZRHHHK@/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** / OCQ_R-.F_]>7_ +.U>4UZM\>/^1ITW_KR_P#9VKRFNVG\*/(Q
M'\1A1115F04444 %%%% !1110!VOPE_Y*=H__;;_ -$O7T]7S#\)?^2G:/\
M]MO_ $2]?3U<M?XCT<'_  WZA1116)UA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E>)
M]0_LKPMJM\#AH+61T_WMIV_KBOD&OISXMW7V;X;ZD <-,8HA^,BD_H#7S'73
M06ESSL8_>2"BBBMSD"BBB@ HHHH **** "M/P]HL_B+7[/2;?A[F0*6QG8O5
MF_  G\*S*]B^ ^C"2]U/6I$_U*K;0GW;EOT"_G4SERQN:4H<\U$]GTW3K;2=
M-M]/LXQ';V\8CC4>@]?<]2?6K5%%<)["T"BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH **** "BBB@ KA/BCXT_X17P_]GM),:G>@I#CK&O\
M$_X9P/?Z&NSOKVWTZQGO;N01V\"&21SV &37R?XL\1W'BKQ'=:K/E5<[88S_
M ,LXQ]U?\?<FM:4.9W9SXFKR1LMV8A))R3DFBBBNL\L**** "BBB@ HHHH *
M*** "BBNN\$> -2\9WF8\V^G1MB:Z9>/]U?[S?R[^Z;25V.,7)V1@Z/HFHZ_
MJ"6.F6LEQ._91PH]6/0#W->Z^#O@[IFC".[USR]1OASY1&8(S]#]_P#'CVKM
M_#WAK2_"^FK9:7;"-.KR'EY#ZL>Y_P BM>N:=5O1'HTL-&.LM6(JJBA5 "@8
M  X I:**Q.H**** "BBB@ HHHH **** "BBB@ HHHH *BN+:"[MY+>YACFAD
M&UXY%#*P]"#UJ6B@#QWQE\%89Q)>^&&$,O+-92M\C?[C'I]#Q[BO%;RRN=/N
MY+2\@D@N(CM>.1<,I^E?9E<SXO\  ^D^,;+R[R/RKM!B&[C7YT]C_>7V/X8Z
MUM"LUI(Y*N%4M8;GRE16YXI\)ZIX2U,V>HQ?*V3#.GW)5]0?YCJ*PZZ4[ZH\
M]IIV84444Q!1110 4444 %%%% !1110![1\$_&!#/X7O).#F6R+'\63^;#_@
M5>UU\:6-[<:=?V][:R&.X@D$D;#LP.17UIX8U^#Q-X=L]5@P/.3]X@/W''#+
M^!_3%<M:%G='HX2KS1Y7T->BBBL3K"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /F'XM?\E.UC_MC_ .B4KBJ[7XM?\E.UC_MC_P"B4KBJ
M[H?"CQJO\27J%%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% 'T3\)
M_'G_  D.F_V/J,N=4M$^5V/,\8[^[#H?P/K7I5?&^F:E=:/J=OJ%C*8KFW<.
MC#U_P/0CWKZI\'^*;3Q=H$6HV^$E'R7$.>8I.X^G<'TKEJPL[H]+#5N=<KW-
M^BBBL3J"BBB@ HHHH **** "BBB@ HHHH **** /*?CQ_P BMIO_ %^_^R-7
M@5>^_'C_ )%;3?\ K]_]D:O JZZ/PGEXK^(%%%%:G.%%%% !1110 4444 :G
MAO\ Y&G2/^OV'_T,5]?U\@>&_P#D:=(_Z_8?_0Q7U_7-7W1WX+9A1116!VA1
M110!Y?\ '#1/MOA6WU6-<R:?-AS_ -,WP#_X\$_6OGROL76M,BUK1+W3)L;+
MJ%HB2/NDC@_@>?PKX^N+>6TNI;:92DL3F-U/9@<$?G751E=6/.Q<+2YNY'11
M16QR!1110 4444 %%%% !7L'P'UCRM2U/1G;Y9XQ<1 G^)3AOS##_OFO'ZW_
M  3K']@^,]+U!FVQI.$E.?X&^5OT)/X5,U>+1I1ERS3/K2BBBN$]@**** "B
MBB@ HHHH **** "BBL_7=431- O]3DQMMH&D /<@<#\3@?C0)NRN?-_Q3UG^
MV?B!J#*VZ*T(M(_;9][_ ,?+5QE/EE>:9Y96+2.Q9F/4D]33*[TK*QXLI<TF
MPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ZU\%ZQ_;W@[2]1+;
MI)( LIS_ !K\K?J#6]7D/P(UCSM*U+1G;YK>43Q@_P!UA@X^A4?]]5Z]7#-6
MDT>Q2ES03"BBBI- HHHH **** "BBB@ HHHH YSQYK']A>"=5O@VV40F*(CK
MO?Y5(^A.?PKY/KW#X\ZQLL]+T5&YD<W,H'H/E7\R6_*O#ZZZ*M&YYF+E>=NP
M4445J<P4444 %%%% !1110 5T7@71/\ A(/&FF6#+NA,HDF!Z;$^9A^(&/QK
MG:]H^ VBY?5-<D7H!:Q''T9__9*B<K1;-*,.>:1[71117$>P%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>+?'_\ YEW_ +>?_:5>TUXM
M\?\ _F7?^WG_ -I5I2^-&&)_A,\5HHHKL/*"BBB@ HHHH **** "NA\"?\C[
MH7_7[%_Z$*YZNA\"?\C[H7_7[%_Z$*4MF5#XD?65%%%<![04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!X%\>/^1ITW_KR_P#9VKRFO5OC
MQ_R-.F_]>7_L[5Y37;3^%'D8C^(PHHHJS(**** "BBB@ HHHH [7X2_\E.T?
M_MM_Z)>OIZOF'X2_\E.T?_MM_P"B7KZ>KEK_ !'HX/\ AOU"BBBL3K"BBB@
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MV-MIMC#96<*PVT"!(XU'  JQ7'.;DSU:-%4UYA1114&P4444 %%%% !1110
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MQ:?"L/MO/S,?U _"M*2O(PQ,N6F_,\[HHHKL/*"BBB@ HHHH **** "BBB@
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M/SQY;_*2?IG/X5]7UR5HVE<]/"SYH6[!11161TA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?,/Q:_Y*=K'_;'_ -$I7%5VOQ:_Y*=K'_;'_P!$
MI7%5W0^%'C5?XDO4****H@**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KZ/^%7CL>)M)_LR_ESJUFG+,>9X^@?ZC@'\#WKYPJ[I.JWFAZK;ZE82
MF.YMWW(>Q]0?4$<$>]1.',K&M&JZ<KGV-16)X4\36?BS08-3M"%+?+-%GF)Q
MU4_T]016W7&U;0]9--704444AA1110 4444 %%%% !1110!Y3\>/^16TW_K]
M_P#9&KP*O??CQ_R*VF_]?O\ [(U>!5UT?A/+Q7\0****U.<**** "BBB@ HH
MHH U/#?_ "-.D?\ 7[#_ .ABOK^OD#PW_P C3I'_ %^P_P#H8KZ_KFK[H[\%
MLPHHHK [0HHHH *HZUID6M:)>Z9-C9=0M$21]TD<'\#S^%7J* :NK'QA<6\M
MI=2VTRE)8G,;J>S X(_.HZ[SXO:)_9'CRXF1<0WZ"Y7']X\/^.X$_C7!UWQ=
MU<\6<>63B%%%%,D**** "BBB@ HHHH ['X7:Q_8WC_3G9L173&UDYZA^!_X]
MM/X5]15\71R/%(LD;%70AE([$5]?^']536_#VGZFF/\ 28$D('9B.1^!R*YJ
MZU3._!RT<32HHHK [0HHHH **** "BBB@"&[NHK&RGNYVVPP1M+(WHJC)_05
M\>:E?2ZIJEW?S?ZVYF>9^>[$G^M?1GQ?UC^RO -S"C[9KYUMEP><'EOPVJ1^
M-?--=-!:7//QDKR40HHHK<XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "OH?X(ZS]N\'S:<[9DT^<J!_TS?YA^N_\ *OGBO1O@OK/]G>-_L3MB
M+4(6BYZ;U^9?Y$?C6=57B;8>?+41]&T445QGK!1110 4444 %%%% !7EWQRU
MC['X5M=+1L/?SY8>J1X)_P#'BGY5ZC7S;\9-9_M/QW+;(V8;")8!@\;OO,?K
MEL?\!K2DKR.?$RY:;\SSZBBBNP\L**** "BBB@ HHHH **** /9/@/HF^ZU/
M7)%XC46L)]SAG_0+^=>WUROPXT4Z%X$TVV==LTL?VB7(YW/\V#]!@?A755Q5
M)7DV>O0ARTT@HHHJ#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *\6^/_ /S+O_;S_P"TJ]IKQ;X__P#,N_\ ;S_[2K2E\:,,3_"9XK11
M178>4%%%% !1110 4444 %=#X$_Y'W0O^OV+_P!"%<]70^!/^1]T+_K]B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ_?_ &1J\"KWWX\?\BMIO_7[_P"R-7@5=='X3R\5_$"BBBM3G"BBB@ HHHH
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M5[37BWQ__P"9=_[>?_:5:4OC1AB?X3/%:***[#R@HHHH **** "BBB@ KH?
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M7(^.?"%QX.U][-]SV<N7M9B/OIZ'_:'0_GWJ5)<W*:.FU!3.8HHHJC,****
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M*M,U/)"P3J9,?W#PP_[Y)KZZ!# $$$'D$5RUE:5STL)*\+=A:***Q.H****
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M?H!77UP25G8]J#O%,****104444 %%%% !1110 4444 %%%% !1110 4444
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MQ_\ ^9=_[>?_ &E7M->+?'__ )EW_MY_]I5I2^-&&)_A,\5HHHKL/*"BBB@
MHHHH **** "NA\"?\C[H7_7[%_Z$*YZNA\"?\C[H7_7[%_Z$*4MF5#XD?65%
M%%<![04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X%\>/^
M1ITW_KR_]G:O*:]6^/'_ "-.F_\ 7E_[.U>4UVT_A1Y&(_B,****LR"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]%!'_ JF<N6-RZ4.>:B>\HBQQK&BA44!5 Z "G445PGLA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>+?'_P#YEW_MY_\
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M***X3V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>!5UT?A/+Q7\0****U.<**** "BBB@ HHHH U/#?_(TZ1_U^P_\ H8KZ_KY
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M5W'C!1110 4444 %%%% !1110!L^$]'.O^*]-TS:2D\ZB3']P<N?^^0:^N0
MH    X %>$_ G1O/UC4-9D3*VT0@B)_OOR<?0#_QZO=ZY:SO*QZ6$A:%^X44
M45B=05%<6\5U;2VTR!XI4,;J>ZD8(_*I:* /CG6--DT?6KW39<[[69XB?7!Q
MG\>M4J]+^-NC?8/&,>HHN(]0A#$X_P"6B?*WZ;#^->:5W1=U<\:I'DFXA111
M5$!1110 4444 %%%% 'O?P*UG[1H%_I#M\]I,)8P?[C_ .#*?^^J]8KYF^$>
ML_V3X^M8W;$-\K6K\]SRO_CP _&OIFN2JK2/4PL^:GZ!11161T'D7QWUGR=)
MTW1HV^:XE,\@!_A08 /L2V?^ UX37:_%;6?[8\?WP5]T-GBUC]MOWO\ QXM7
M%5VTU:*/(KRYJC844459D%%%% !1110 4444 %?3OPIT3^QO -D77;->YNY/
M^!?=_P#'0M?.GA_2GUSQ#I^F)G-S.L9([*3\Q_ 9/X5]?1QI#$D4:A8T4*JC
MH .@K"N]+'9@X:N0^BBBN8] **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KQ;X__P#,N_\ ;S_[2KVFO%OC_P#\R[_V\_\
MM*M*7QHPQ/\ "9XK11178>4%%%% !1110 4444 %=#X$_P"1]T+_ *_8O_0A
M7/5T/@3_ )'W0O\ K]B_]"%*6S*A\2/K*BBBN ]H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \"^/'_(TZ;_UY?\ L[5Y37JWQX_Y&G3?
M^O+_ -G:O*:[:?PH\C$?Q&%%%%69!1110 4444 %%%% ':_"7_DIVC_]MO\
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M  D%%%%0;!1110 4444 %%%% !1110 4444 %%%% !1110!\P_%K_DIVL?\
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M'*[K8]/#UN>-GNC1HHHK(Z3RGX\?\BMIO_7[_P"R-7@5>^_'C_D5M-_Z_?\
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MJX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<9.T5'N4Z***Z3SPHHHH **** "BBB@ K0T/2Y-;UVQTR+(:ZG6+(_A!/)_
M9/X5GUZA\#]$^V^*KC59%S'I\.$/_31\@?\ CH?]*F3M&Y=.//-1/?X(8[:W
MC@A4+%$H1%'8 8 J2BBN$]D**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\6^/_P#S+O\ V\_^TJ]IKQ;X_P#_ #+O
M_;S_ .TJTI?&C#$_PF>*T445V'E!1110 4444 %%%% !70^!/^1]T+_K]B_]
M"%<]70^!/^1]T+_K]B_]"%*6S*A\2/K*BBBN ]H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \"^/'_(TZ;_UY?^SM7E->K?'C_D:=-_Z\
MO_9VKRFNVG\*/(Q'\1A1115F04444 %%%% !1110!VOPE_Y*=H__ &V_]$O7
MT]7S#\)?^2G:/_VV_P#1+U]/5RU_B/1P?\-^H4445B=84444 %%%% !1110
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M_L;Q_J 52L-V1=1^^_[W_CP:N,KO3NKGBRCRR:"BBBF(**** "BBB@ HHHH
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MP2?O;IO/N #TC4_*#]6Y_P" 5X3751C97/-Q<[RY5T"BBBMCE"BBB@ HHHH
M**** "O7?@/I7FZOJFK.ORP0K A(_B<Y./H%'_?5>15]-_"71O[(\ 6;LN);
MTFZ?CLW"_P#CH4_C659VB=&%CS5+]CN****Y#U HHHH **** "BBB@ HHHH
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M1UWGQ>T3^R/'EQ,BXAOT%RN/[QX?\=P)_&N#KOB[JYXLX\LG$****9(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%7-*TZ75M7L].@'[VZF6)?;<<9
M_"@$KGT3\']%_LGP)!<.N)K]S<-D<[>B_A@9_P"!5WU0VEK%96<%I NV&"-8
MT'HJC _05-7!)W=SVH1Y8J(4444B@HHHH **** "BBB@#R+X[Z-YVDZ;K,:_
M-;RF"0@?PN,@GZ%<?\"KPFOKCQAHW]O^$=3TT+NDF@)B'_31?F7_ ,> KY'K
MJHN\;'FXN%IW[A1116QRA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >F_!'1C?>+YM2=<Q:?"2#C_EH^5'Z;_RKZ&KS[X.:)_97@:*Z=<3:A(9S
MZ[/NJ/R&?^!5Z#7'5=Y'JX>'+304445F;A1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUVXTN]7YHSF.0#B1#T8?7^>1772GS*S/,Q-'D?,MF9%%%%:G,%%%% !1110
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M86]G NV&WB6*,>BJ,#]!4]%%<)[04444 %%%% !1110 4444 %%%% !1110
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MAHGVWPK;ZK&N9-/FPY_Z9O@'_P >"?K6E*5I'/B8<U-^1\^4445V'EA1110
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M !7T=\&-$_LSP2+V1,3:C*9>1SL'RJ/T)_X%7SS864VHZC;6-N,S7$JQ(/\
M:8X'\Z^P["RAT[3K:QMUVPV\2Q(/]E1@?RK"O+2QUX.%Y.78L4445S'HA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKZ>KEK_$>C@_X;]0HHHK$ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/7D/P%TTQZ3JVIL/]?,D"$_[ R?_ $,?E7KU<=5WD>IAHVIH****S.@****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A_BEX2/B?PL[VT>[4+',T
M Y<?Q)^(Y'N!7S)7VG7SA\6_!O\ PCOB#^TK2/&G:@Q< #B.7JR^P/4?B.U=
M%&?V6<.+I?;1YW11170<(4444 %%%% !1110 4444 >C_#3XDOX7F72]49GT
M>1LAL$M;L>X'=3W'XCN#]$6]Q#=V\=Q;RI+#*H=)$.0P/0@U\85W/@+XD7WA
M"86MQONM)=OF@S\T6>K)G^70^W6L:E*^J.NAB.7W9;'TU15#1]:T_7].CO\
M3+I+BW?^)>JGT(Z@^QJ_7*>BFGJ@HHHH **** "BBB@ HHHH **** "BBB@
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M<U:=WRH]#"4K+G?4****P.P**** "BBB@ HHHH **** "BBB@ HHHH ****
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MFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVW_HEZ^GJY:_Q'HX/^&_4****Q.L**** "BBB@ HHHH **** "BBB@ HHHH
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MEKL=#9V=OI]E#9VL2Q6\"".-%Z*H& *GHHKC/5"BBB@ HHHH **** "BBB@
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M$\BYAL(VN6R."W1?QR<_\!K@:^@_@?HOV+PK<:JZXDU";"G_ *9ID#_Q[?\
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KQ;X_P#_ #+O_;S_ .TJ]IKQ;X__ /,N_P#;S_[2K2E\
M:,,3_"9XK11178>4%%%% !1110 4444 %=#X$_Y'W0O^OV+_ -"%<]70^!/^
M1]T+_K]B_P#0A2ELRH?$CZRHHHK@/:"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** / OCQ_R-.F_P#7E_[.U>4UZM\>/^1ITW_KR_\ 9VKR
MFNVG\*/(Q'\1A1115F04444 %%%% !1110!J>'==NO#.NVVKV4<,EQ;[MBS
ME#N4J<@$'HQ[UW?_  O;Q/\ \^&D?]^9?_CE>845+C%[EQJ3BK19Z?\ \+V\
M3_\ /AI'_?F7_P".4?\ "]O$_P#SX:1_WYE_^.5YA12]G'L5[>IW/3_^%[>)
M_P#GPTC_ +\R_P#QRC_A>WB?_GPTC_OS+_\ '*\PHH]G'L'MZG<]/_X7MXG_
M .?#2/\ OS+_ /'*/^%[>)_^?#2/^_,O_P <KS"BCV<>P>WJ=ST__A>WB?\
MY\-(_P"_,O\ \<H_X7MXG_Y\-(_[\R__ !RO,**/9Q[![>IW/3_^%[>)_P#G
MPTC_ +\R_P#QRC_A>WB?_GPTC_OS+_\ '*\PHH]G'L'MZG<]/_X7MXG_ .?#
M2/\ OS+_ /'*/^%[>)_^?#2/^_,O_P <KS"BCV<>P>WJ=ST__A>WB?\ Y\-(
M_P"_,O\ \<H_X7MXG_Y\-(_[\R__ !RO,**/9Q[![>IW/3_^%[>)_P#GPTC_
M +\R_P#QRC_A>WB?_GPTC_OS+_\ '*\PHH]G'L'MZG<]/_X7MXG_ .?#2/\
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M )*=K'_;'_T2E<57:_%K_DIVL?\ ;'_T2E<57=#X4>-5_B2]0HHHJB HHHH
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MQ/C.BK6I6,NF:I=6$_\ K;:9HGX[J2/Z55KO/%"BBB@ HHHH **** "BBB@
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M^0WJ_P#U[)_Z%7N]<=7XSU,+_"04445F= 4444 %%%% !1110 4444 %%%%
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MWX0:-_:OCRWG= T-@C7+9'&X<+^.X@_A7TM7E_P/T3[%X5N-5D7$FH380_\
M3-,@?^/%_P!*]0KCJRO(]3#0Y::\PHHHK,Z HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O%OC_ /\
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MUA7:B+_/W/N:MUQSFY,]6C15->84445!L%%%% !1110 4444 %%%% !1110
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M]\"?!R:Z,6I>)T:&#ADL<X=_]\_PCVZ^N*]O@@BMH(X((DBAC4*B(H"J!T
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M% !1110 4444 %%%% !1110 4444 %%:^A^%];\23^5I6G37&#AI ,1K]6/
M_.O7?#'P.M+<I<>([K[4XY^RVY*Q_P# FZG\,5$IQCN:4Z,Y[(\AT+PUJ_B6
M[^S:58R7# _,X&$3_>8\"O;_  ?\&]+T?R[O7&34KT<B+'[A#]#]_P#'CVKT
M:QL+33+1+2QMHK:W3[L<2!5'X"K%<\ZK>QWTL+&&KU8@ 50J@  8 ':EHHK(
MZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/3;:\,61&9HPVW.,XS]!5TY\KN8UJ7M(V/CVBOK+_A!/"G_0O:;_ . ZT?\
M"">%/^A>TW_P'6MO;KL<OU.7<^3:*^LO^$$\*?\ 0O:;_P" ZT?\()X4_P"A
M>TW_ ,!UH]NNP?4Y=SY-HKZR_P"$$\*?]"]IO_@.M'_"">%/^A>TW_P'6CVZ
M[!]3EW/DVBOK+_A!/"G_ $+VF_\ @.M'_"">%/\ H7M-_P# =:/;KL'U.7<^
M3@"Q  ))X %?7/A/1QH'A33-,VA7@@428_YZ'E__ !XFH8O!'A>&5)8] T]9
M$8,K"!<@CH:WZSJ5.;8WH4'3;;"BBBLCI"BBB@ HHHH **** "BBB@ HHHH
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MW_X$37HE%8RJR9U4\-"&NXBJJ(J(H55&  , "EHHK,Z HHHH **** "BBB@
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MT5E*K)G3##TX]+D<,$-M"L,$211(,*D:A54>P%2445F;A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!\P_%K_ )*=K'_;'_T2E<57UU?>$_#VIWDEY?:-97%S)C?++"&9
ML  9/T %5_\ A!/"G_0O:;_X#K71&LDK'#/"2E)NY\FT5]9?\()X4_Z%[3?_
M  '6C_A!/"G_ $+VF_\ @.M/VZ[$_4Y=SY-HKZR_X03PI_T+VF_^ ZT?\()X
M4_Z%[3?_  '6CVZ[!]3EW/DVBOK+_A!/"G_0O:;_ . ZT?\ "">%/^A>TW_P
M'6CVZ[!]3EW/DVBOK+_A!/"G_0O:;_X#K1_P@GA3_H7M-_\  =:/;KL'U.7<
M\I^ G_(;U?\ Z]D_]"KW>LS3/#VCZ+)))IFF6MH\@VNT,84L/0XK3K&<N:5S
MKHP<(<K"BBBH-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ J*ZMH+VUEM;F)98)D*21L,AE(P0:EHH ^5_'W@V;P=X@:W 9["?+VDI_B7
MNI_VEZ'\#WKE*^N/%?A>Q\6Z')IM[E<G?%,HRT3CHP_D1W!KS?\ X4%:_P#0
MP3?^ H_^*KJA65O>/.JX67-[FQX?17N'_"@K7_H8)O\ P%'_ ,51_P *"M?^
MA@F_\!1_\55>UAW,_JU7L>'T5[A_PH*U_P"A@F_\!1_\51_PH*U_Z&";_P !
M1_\ %4>UAW#ZM5['A]%>X?\ "@K7_H8)O_ 4?_%4?\*"M?\ H8)O_ 4?_%4>
MUAW#ZM5['A]%>X?\*"M?^A@F_P# 4?\ Q5'_  H*U_Z&";_P%'_Q5'M8=P^K
M5>QY'X;_ .1ITC_K]A_]#%?7]>2Z=\#K;3]3M+T:[*YMYDE"&V W;6!Q][VK
MUJL*LE)JQV8:G*"?,%%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !00",$9!HHH J2:9I\IS)8VSD< M
M"I_I5=O#NANQ9M&T]F/4FU0D_I6G13NQ61G)X?T6)MT>D:>C=,K;(#_*K$6G
MV4'^IL[>/G/R1*.?RJS11=A9!1112&%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 456NM0LK(9N[RWMQZRRA/YFL:X\>^$[8D2>(=/./^><X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBJ]Y?V>GQ>;>W<%M'_ 'YI @_,T 6*
M*Y"_^*'@[3\A]:BF8?PVZ-+G\5&/UKG;OXZ>'8B5MK'4;@CN41%/YMG]*I0D
M^AFZU-;L]1HKQ:?X_#)%OX=)]&DN_P"@3^M49/CWJAW>7HEFO]W=*QQ]>F:K
MV4^QF\32[GN]%>!?\+XU[_H%:;^3_P#Q53I\>]3&WS-$M&_O;96&?IUQ3]C,
M/K5+N>[45XM!\?ATN/#O_ H[O^A3^M:]I\=?#TI N;#48">ZJC@?^/ _I2]E
M/L4L12?4]2HKCK#XI>#;\A5UF.%S_#<1M'C\2,?K746>HV.HQ^98WEO=)UW0
M2JX_,&H::W-%.,MF6:***104444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%<=XG^)GASPP7AEN3=WJ\?9
MK7#,I_VCT7\3GVKR'Q#\8_$FK[XK%DTNV/ $',A'NY_]E K2-.4C&IB(0/?]
M5UW2M$A\W4]0M[13T\UP"WT'4_A7G^L?''0+,LFF6MUJ#CHV/*C/XGYO_':\
M GN)KJ9IKB:2:5SEGD8LS'W)J.ME12W.2>+F_AT/2]3^-WB:[)6QBL[!.Q2/
MS''XMD?I7(7_ (S\2ZID7>N7SJ>J"8JO_?*X%8=%:*$5LCGE5G+=BLS.Q9B2
MQY))Y-)115$!1110 4444 %6K/4K[3WWV5[<6S9SF&5D/Z&JM% '8Z=\4O&&
MFX"ZN]P@_@N463/XD;OUKL]*^/5RNU=7T:*0=Y+20J?^^6S_ #KQNBH=.+Z&
ML:U2.S/J'1OBEX2UG:BZD+28_P#+.\'E'_OK[OZUV".LB*Z,&1AD,IR"*^+J
MV-%\5:[X=<-I6IW%NN<F,-NC/U0Y!_*LY4.QT0QC^TCZ[HKQ;P[\= 2D'B*P
MQV-S:#^:$_R/X5ZQH^OZ5K]K]HTJ_ANH_P"+RV^9?]Y>JGZBL)0E'<ZX583^
M%FC1114F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%4-3UO2]&
MA\W4M0MK1<9'G2!2?H.I_"N$U?XV^&K'<EA'=:C(.A1/+3\VY_0U2BWL1*I"
M/Q,]*HKY^U/XYZ_<[ET^QL[)#T9@97'XG _\=KD=0\?^+-3S]IUZ\ /587\H
M'\$P*T5&74PEBX+;4^JI[F"U3?<3QPI_>D<*/UK%N?&_A:T.)O$&G9[A+A7(
M_!2:^3I9I9Y#)-(\CGJSL2?S-,JU075F3QKZ(^GIOBSX*AS_ ,3G>WHEO*?U
MVXJF_P 9_!ZD@7%V^.A6W//YU\VT4_8Q(^N5/(^BO^%W^%/^>>I?]^%_^*J2
M/XU^$7SN-]'C^];]?R)KYQHI^QB+ZW4/IB+XP^"Y,;]1FBS_ '[:3C\@:TK?
MXD>#KG_5Z_:C_KINC_\ 0@*^5:*7L(C6,GV1]B6FN:3J! LM4LKDG@>3<(^?
MR-7Z^+*T[#Q%K6EX^P:M>VP'18IV5?RSBI=#LS18WNC[ HKYITWXP^+[#:);
MN"]0?PW,(_FN#^9KM-*^/5JY5-6T:6+UDM9 X_[Y;&/S-0Z,D;1Q5-^1[%17
M,:/\0O"VN;5M-7@69ND,Y\I\^@#8S^&:Z>LVFMS=24M4PHHHI#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBOG_ ,5?%+Q9I?BS5;"TOHDM[>Z>.-3;H2%!P.2*J,'+8SJ5
M8TU=GT!17S/_ ,+A\:?]!&'_ ,!H_P#"C_A</C3_ *",/_@-'_A6GL9&/URG
MYGTQ17S/_P +A\:?]!&'_P !H_\ "C_A</C3_H(P_P#@-'_A1[&0?7*?F?3%
M%?,__"X?&G_01A_\!H_\*/\ A</C3_H(P_\ @-'_ (4>QD'URGYGTQ17S/\
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M%?,__"X?&G_01A_\!H_\*/\ A</C3_H(P_\ @-'_ (4>QD'URGYGTQ17S/\
M\+A\:?\ 01A_\!H_\*/^%P^-/^@C#_X#1_X4>QD'URGYGTQ17S/_ ,+A\:?]
M!&'_ ,!H_P#"C_A</C3_ *",/_@-'_A1[&0?7*?F?3%%?,__  N'QI_T$8?_
M  &C_P *]'^$OC/6_%=UJB:O<I,MND9CVQ*F"2V>@]A4RI2BKLJ&)A.7*CU&
MBBBLSH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ1<)"UP\@DW1J^0 N.H]S3BG)V1,YJ$>9GH]%?,__"X?&G_01A_\!H_\*/\
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M%8?@W4KK6/!^EZA>N'N;B$/(P4*"<GL*W*R:L['2G=7"BBBD,**** "BBB@
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M?==_Z_9?_0C7UE7R9XY97\>:\5.1]NE'XAB#6]#=G'C/A1S]%%%=)YX4444
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M]#D8_P"L0?P?4=O;Z5Z[7QC;7,UG=17-M*T4\3AXW4X*L.017U'X \90>,=
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M:-X>F9++E)[M3@S>RGLOOW^G7R6BBNR,5%61Y52I*;NPHHHJB HHHH ****
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MQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*L65]=Z;=QW5E<2V]Q&<K)$Q4C\15>B@#VOP=\; ?+LO%" =A?1+_P"AJ/YK
M^7>O8[6ZM[VUCN;6:.>"5=R21L&5AZ@BOC&ND\)^-]8\(76^PFWVSG,MK+DQ
MO^'8^X_6L)T4]8G72Q36D]3ZOHKF/"'CK2/&-KNLY/*O$7,MI(?G3W']X>X_
M'%=/7.TT[,]",E)704444AA1110 4444 %%%% !1110 4444 %%%% !1110
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M$D,G!!^\C=U8=B/\\5IUR['HIIJZ"BBB@84444 %%%% !1110 4444 %%%%
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD;QC_ ,COK_\
MV$KC_P!&-7US7R-XQ_Y'?7_^PE<?^C&K>ANSCQGPHQ:***Z3SPHHHH ****
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MQCX?2[7:EY%B.ZA!^X_J/]D]1^([5T]<333LSUXR4E=!1112&%%%% !1110
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MY/\ (5]5U\J?$7_DH>M_]?)_D*VH?$<>,^!'+T445U'GA1110 4444 %%%%
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M5['\ O\ C^US_KG#_-ZSJ_ S;#?Q4>X4445QGK!1110 4444 %%%% !1110
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M&^<*^JW*@W$@YV#KY:GT'?U/X5@?"?X>?V-;)KVK0_\ $QF7_1XG',"'N?\
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M)5W0))YTH/0J@W8/L2 /QKZKKGKR^R=N#I[S84445SG>%%%% !1110 4444
M%%%% !1110 4444 >9?$+X56^OK+JFBHEOJG+/%]U+C_  ;W[]_6OGVXMYK2
MXDM[B)XIHF*/&XPRD=017V?7G_Q)^'<7BRS-_IZ)'K,*_*W03J/X&]_0_ATZ
M;TZMM&<=?#\WO1W/GC2M+O-:U.WTZPA,MS.VU%'ZD^@ Y)KZE\&>$;/P=H:6
M-OB2=\/<SXP97_P'8?\ UZQ/AGX!C\):7]LO45M8ND'FGKY*]?+']3Z^PKO:
M56IS.RV*P]#D7-+<****Q.H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M)&/$,A[>RM^AY[FOH&N.<7%V/6I5%4C<****@U"BBB@ HHHH **** "BBB@
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M 4444 %%%% !1110 5\=:TQ;7M19B2QNI"2>_P QK[%KXYUC_D.:A_U\R?\
MH1K>ANSBQNR*5%%%=)P!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >B?"OQW_PC.J_V;?RXTJ\<;F)X@DZ!_H>A_ ]J^CP01D'(-?%E>]?![QW_
M &C:)X;U*7_3+=/]$D8_ZV,?P?51T]OI7/6A]I';A:WV)'K-%%%<YWA1110
M4444 %%%% !1110 4444 %?*GQ%_Y*'K?_7R?Y"OJNOE3XB_\E#UO_KY/\A6
MU#XCCQGP(Y>BBBNH\\**** "BBB@ HHHH *]C^ 7_']KG_7.'^;UXY7L?P"_
MX_M<_P"N</\ -ZSJ_ S;#?Q4>X4445QGK!1110 4444 %%%% !1110 4444
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M^)&.(_AL\"HHHKM/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*^B/A-X[_P"$@TP:-J,N=3M$^1V/,\0Z'W8=#Z\'UKYWJUIFI76D:E;ZA8RF
M*YMW#QN.Q_J#T(]#43AS*QK1JNG*Y]DT5@>#_%-KXNT"'4;?"RCY+B'/,<@Z
MCZ=Q[5OUQM6=F>LFFKH****0PHHHH **** "BBB@ HHHH *Y[QW_ ,B%KO\
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M/[7/^N</\WKQRO8_@%_Q_:Y_USA_F]9U?@9MAOXJ/<****XSU@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH X/XQ0F7X;WS\_NI87Z_[87_V:OFBOJ[X@
MVAOOA_KD(&2+5I<?[GS_ /LM?*-=5!^Z>=C%[Z84445L<@4444 %%%% !111
M0 5]>>%=075?">DWP8$S6L9;!_BV@,/P(-?(=>^? [Q"MWH5SH,KCSK)S+""
M>L3'G'T;/_?0K&LKQN=6$E:=NYZO1117*>D%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX_M<_P"N</\ -ZSJ_ S;#?Q4>X4445QGK!1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 0W=S'9V<]U,<10QM(Y] !D_RKXZO[R74=1N;Z<YEN)6E?ZL23_.OIOX
MH:D=-^'>JNK8>=!;K[[R%8?]\EJ^7*Z:"T;//QDM5$****W.,**** "BBB@
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M:&S//QNZ"BBBMSC"BBB@ HHHH **** "NNL_^/&W_P"N:_RKD:ZZS_X\;?\
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MQ5E=%=&#*PR"#D$5DTUN=$91DKIBT444B@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y'XH?\DWUK_KFG_HQ
M:^6J^I?BA_R3?6O^N:?^C%KY:KJH?">=C/C7H%%%%;'(%%%% !1110 4444
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M]>4O_H)KH:Y[QW_R(6N_]>4O_H)IQW1,_A9\FT445WGBA1110 4444 %%%%
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M/\WK.K\#-L-_%1[A1117&>L%%%% !1110 4444 %%%% !1110 4444 %%%%
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M'/'?DNGA?4Y?D<_Z#(QZ,>L?X]1[Y'<5A5A?WD=F%K6?(SV^BBBN8] ****
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MC%'\Q^7>O989HKF!)H)$EBD4,CHV58'N#7-*+B]3T*=2-17B/HHHJ30****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y0\?R&3Q_KC$ 8NW7CV./Z
M5S==#X[_ .1]UW_K]E_]"-<]7?'9'BS^)A1113)"BBB@ HHHH **** /JSX=
M?\D\T3_KV'\S73USG@",1^ -#49P;-&Y]QG^M='7!+=GLT_@04444BPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /+OCLBGP78OCYAJ* 'V,<G^ KY]KZ!^.\@'@ZPCQRVH*V?I&_\
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M\<KV/X!?\?VN?]<X?YO6=7X&;8;^*CW"BBBN,]8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *R/$?AG2_%.F-8ZI!O3K'(O#Q-ZJ>Q_0]
M\UKT4)V$TFK,^6O&GP^U7P=<%Y%-SIK-B.[1>/8./X3^A[5R-?9\\$-U \%Q
M$DL,B[7C=0RL/0@]:\=\9_!99#)?>%R$8_,UC(W!_P!QCT^A_/M73"LGI(X*
MV%:U@>)45/>65UIUW):WMO+;W$9P\<JE6'X&H*W.,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH WO#OC'7?"TV[2[YTB)RUN_S1/\ 53_,
M8/O7M/A/XR:1K)2UUA1IEX> Y;,+G_>_A_'CWKYXHJ)4XRW-:=>=/8^TE971
M71@RL,@@Y!%+7RYX0^(VM^$I$BCD-WIV?FM)FX _V#U4_I[&OH+PKXST?Q?9
M>=I\^)T ,UM)Q)'^'<>XXKFG3<3T*5>-33J=#11169N%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <C\4/^2;ZU_US3_T8M?+5?4OQ0_Y)
MOK7_ %S3_P!&+7RU750^$\[&?&O0****V.0**** "BBB@ HHHH *^N?!W_(D
M:!_V#;?_ -%K7R-7USX._P"1(T#_ +!MO_Z+6L*^R.S!_$S:HHHKF/0"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KS;XW_\B%'_ -?L?_H+UZ37GOQH
M /P]EXZ7,6/S-7#XD95OX;/FZBBBNT\@**** "BBB@ HHHH **** /K+P)_R
M(6A?]>47_H(KH:Y[P)_R(6A?]>47_H(KH:X);L]J'PH****11XM\8O ?W_%&
MF1?]?T:C_P B#^OY^M>*U]HR1I-$\4B*\;J596&00>H-?,OQ*\#OX1UOS;9&
M.E73%K=NOEGO&?IV]1]#731G?W6>?BJ-GSQ.(HHHK<XPHHHH **** "BBB@
MHHHH *<CM&ZNC%64Y5@<$'UIM% 'TS\,O'"^+=%^SW<@_M:S4+.#UE7H)!]>
M_H?J*[JOC[0=<O?#FM6^J6#[9H6SM/1U[J?8BOJSP[K]EXFT2WU2Q;,<H^9"
M?FC;NI]Q_P#7KDJPY7=;'IX:MSJSW1JT445D=(5SWCO_ )$+7?\ KRE_]!-=
M#7/>._\ D0M=_P"O*7_T$TX[HF?PL^3:***[SQ0HHHH **** "BBB@ HHHH
M^K/AU_R3S1/^O8?S-=/7,?#K_DGFB?\ 7L/YFNGK@ENSV:?P(****184444
M%%%% !1110 4444 %%%% !1110 4444 9?B3_D5M7_Z\IO\ T U\@5]?^)/^
M16U?_KRF_P#0#7R!730V9Y^-W04445N<84444 %%%% !1110 5UUG_QXV_\
MUS7^5<C776?_ !XV_P#US7^53(N!]2T445PGLA1110 4444 %%%% !7+^*_
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MGM9A_!,A4GW'J/<53K4YFK!1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#7R?Y"OJNOE3XB_P#)0];_ .OD_P A4T/B'C/@1R]%%%=1YX4444 %%%%
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M-O\ ]<U_E4R+@?4M%%%<)[(4444 %%%% !1110 4444 %%%% !1110 4444
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M*^7LI?,C!_YYOV'T8-_WU6-:-U<Z\).TN7N>K4445RGHA1110 4444 %%%%
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M8I()GAE1HY(V*NC#!4C@@CUKMISYD>57I.G+R&44459B%%%% !1110 4444
M%%%% !5[1M7O-!U>WU.PD\NX@?<I[$=P?4$<'ZU1HH!.SNCZZ\+>)+/Q7H$&
MJ6AQO&V6+.3%(.JG_/((-?-OQ%_Y*'K?_7R?Y"I_A[XUE\':\))"SZ;<$)=1
M#T[./<?J,BJGCZ>*Z\=ZO<02+)#+-O1U.0RD @BL80Y9LZJM7VE)=SFZ***V
M.4**** "BBB@ HHHH *]C^ 7_']KG_7.'^;UXY7L?P"_X_M<_P"N</\ -ZSJ
M_ S;#?Q4>X4445QGK!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !)_R*VK_P#7E-_Z :^0*Z:&S//QNZ"BBBMSC"BBB@ HHHH **** "NNL_\
MCQM_^N:_RKD:ZZS_ ./&W_ZYK_*ID7 ^I:***X3V0HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSXN> TU?3Y/$&G
M18U"U3-PJC_71@=?]Y1^8X]*^?Z^TR 1@C(-?*?Q!T!?#?C2_L8DVVS-YT
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M\96R2IFSM,7-QD<$*>%_$X'TS7U#7#?"OPI_PC7A..6>,K?W^)Y]PY4?P)^
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M_F]9U?@9MAOXJ/<****XSU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH7_7E%_Z"*Z&N"6[/:A\*"BBBD4%%%% !1110 4444 %%%% !7BWQB\!_?\
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MHPU+GE=[(WZ***Y#U HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-]:_ZYI_Z,6OEJOJ7XH?\DWUK_KFG_HQ:^6JZJ'PGG8SXUZ!1116QR!1110
M4444 %%%% !7USX._P"1(T#_ +!MO_Z+6OD:OKGP=_R)&@?]@VW_ /1:UA7V
M1V8/XF;5%%%<QZ 4444 %%%% !1110 4444 %%%% !1110 4444 %<5\6O\
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MM#>\FVR74F4MK?/,C_\ Q(ZD_P!2*^6]3U.[UC4KC4+Z8RW,[[G<_P AZ =
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MTY;Z'J=%8^E^*] UH+_9VKV<[-TC$H#_ /?)Y_2MBLVK&Z:>P4444#"BBB@
MHHJM>ZA9:; 9[Z[@M8A_'-($'YF@"S39)$BC:21U1%&69C@ >I-><:_\:/#N
MF*T>FB35+@<#RP4C!]V(Y_ &O'O%7Q U[Q:QCO+@0V><K:096/VSW8_7\,5K
M&E)G/4Q,([:L[[XB_%M9HYM'\-3$JV4GOE[CH5C_ /BOR]:\8HHKIC%15D>=
M4J2J.["BBBJ("BBB@ HHHH **** "I;:WEN[J&VA4M+,XC11W8G %15WOPAT
M,ZOXZMYW3,&GJ;ESVW#A!]=Q!_X":4G97*A'FDHGT9IEC'IFE6=A%_J[:%(5
M^B@#^E6J**X#VM@HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y'XH?\DW
MUK_KFG_HQ:^6J^I?BA_R3?6O^N:?^C%KY:KJH?">=C/C7H%%%%;'(%%%% !1
M110 4444 %?7/@[_ )$C0/\ L&V__HM:^1J^N?!W_(D:!_V#;?\ ]%K6%?9'
M9@_B9M4445S'H!1110 4444 %%%% !1110 4444 %%%% !1110 5QOQ6C,GP
MSUA1C(6)N?:5#_2NRKD?BA_R3?6O^N:?^C%JH?$B*OP/T/EJBBBNX\8****
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M+_KRB_\ 0170USW@3_D0M"_Z\HO_ $$5T-<$MV>U#X4%%%%(H**** "BBB@
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MXY%P5-5ZZ3SPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KUOX->"3>WH\2W\7^C6[8M%8??D'
M5_HO;W^E<AX"\%7/C+6Q#AH]/@(:ZG Z#^Z/]H_XGM7U!9V=OI]E#9VD2Q6\
M*!(T4<*!TK&K.RY4=>%H\SYWL3T445RGHA1110 4444 %%%% !1110 4444
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M?(%=-#9GGXW=!1116YQA1110 4444 %%%% !776?_'C;_P#7-?Y5R-==9_\
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M6T=M:PQPP1+M2.-0JJ/0 5+116!V!1110 4444 %%%% !1110 4444 %%%%
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M#^-G3T445S'HA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK_DGFB?]>P_F:Z>N8^'7_)/-$_Z]A_,UT]<$MV>S3^!!1112+"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#+\2?\BMJ__7E-_P"@&OD"OK_Q)_R*VK_]
M>4W_ * :^0*Z:&S//QNZ"BBBMSC"BBB@ HHHH **** "NNL_^/&W_P"N:_RK
MD:ZZS_X\;?\ ZYK_ "J9%P/J6BBBN$]D**** "BBB@ HHHH *Y+Q!\-O#'B+
M<]QIZV]RW6XM<1OGU/8_B#76T4TVMB914E9H\#USX&:M:[Y-&OH;Z,<B*7]U
M)],_=/YBO.]6\.ZSH4FS5--N;7G :2,[3]&Z'\#7V!371)$9)%5T88*L,@BM
M8UI+<YIX2#^'0^+J*^I]5^&OA+5RS3:/##(?^6EKF$Y]<+@'\0:XO4O@+8R$
MMIFM7$/HES$)!^8VX_(UJJT7N<\L)46VIX917I-_\$O%-J2;5[&\7MY<VQC^
M# #]:YR[^'GB^R)$OA^];'_/%/-_] S5J<7U,72FMT<S15RXTK4;3_CYT^ZA
MQ_STA9?YBJ=41:P4444 %%%3P65W='%O:S39Z>7&6_E0!!16_:>!_%-Z1Y'A
M_4<'HSP,@/XM@5T-C\&O&%WCS;:ULP>]Q< _^@;JERBNI:IS>R//Z*]JT[X"
M#*MJFN?6.UA_]F8_TKM-*^%'A#2BK?V:;R0?QWCF3/\ P'A?TJ'6BC6.%J/?
M0^;M-TC4M8G\G3;&XNY.XAC+8^N.GXUZ+H/P0UN^*2ZQ<PZ=">3&I\V7\A\H
M_,_2O?+>V@M(5AMH8X8EX5(T"J/H!4M92K-['3#"17Q:G)^'/ASX:\,E9+6R
M$]TO(N;K$C@^W&%_ "NLHHK)MO<ZHQ459!1112&%%%% !1110 4444 %%%%
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MT+VF_P#@.M:^W78Y_J<NY\FT5]9?\()X4_Z%[3?_  '6C_A!/"G_ $+VF_\
M@.M'MUV#ZG+N?)M%?67_  @GA3_H7M-_\!UH_P"$$\*?]"]IO_@.M'MUV#ZG
M+N?)M%?67_"">%/^A>TW_P !UH_X03PI_P!"]IO_ (#K1[==@^IR[GR;7L?P
M"_X_M<_ZYP_S>O3_ /A!/"G_ $+VF_\ @.M:&F:!I&BM(VF:;;6;2@!S#&%W
M8Z9Q]:F=52C8NEAI0FI-FC1116!VA1110 4444 %%%% !1110 4444 %%%%
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M!@ #T K.I44D;T*#IMMLDHHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *YCXB_\D]US_KV/\Q73U%<VT%Y:RVUS$DL$JE)(W&58'J"*:=G<4E=-
M'QC17UE_P@GA3_H7M-_\!UH_X03PI_T+VF_^ ZUT>W78X/J<NY\FT5]9?\()
MX4_Z%[3?_ =:/^$$\*?]"]IO_@.M'MUV#ZG+N?)M%?67_"">%/\ H7M-_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SCQ)]S_ML?ZUR]W_ ,>Y
M_P!Y?_0A116\=CCGN35WWA7_ )8_]</\***4]BJ7Q'5T445B=04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !' 04# 2(  A$! Q$!_\0
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MI0E!VDK&B:>P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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4(P1XU**X]0I^[]****F6XUL?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image00005.jpg
<TEXT>
begin 644 image00005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0L!WT# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M .X_M_YB=WZT#7^#\U</YTGJ:/.D]30!W']O?+C=0=?X'S5P_G2>IH\Z3U-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBD,'3BCH!G^3\W2CRLDC%:/D\YQ2"'D\4,#/$/&<4>3QG%:/D<=*/(XQBGU
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M@48%+10 F!1@4M% "8%&!2T4 )@48%+10 F!1@4M% "8%&!2T4 )@48%+10
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_%35ZFE[9H_K0 G\!H_A%*>N*7VH'U&G[PIW\5)UH[9H$(O4T?P&E_K0>N*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWS1_6@ ]Z/>CMBCVHZ &.U&.<49[T9YS0P#^E'O1_6CMBCJ =/QHQVHHSWH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJ.?_ %#_ $J2HY_]0_TH P]/&+K\:Z"L'3^;C/O6]0!R7CS_ ) -Q_NU\ZI_
MKV^M?17COG0[C_=KYV4?Z2P]Z!HDDZ5H6G_'B:H'D'VK1M!_Q+F- +<S7_UI
MIW\%)*/GS2GTH 0_<%!_AI^/EQ3>OX4"$_CH'WC2^]'OZT#L(/NFC^ 4OM1C
MM0 A_AH_CI>OX4>] 6$'WC0/NFE_K1[4!80_<%!ZK2X[4=?PH /XZ0=32^]'
M]: L(/NF@_<%+CM1CM0 AZBC^.EZ_A1[T!80=6H'W#2_UHQVH"PA^X*#U%+C
MM1UH 3^.@=32^]']: L(/N&@_=%+CM1CM0 AZBE_CHZT>] 6$'\5 ^X:7^M'
MM0 A^Z*#U%+CM1[T '\=(/XJ7WH_K0%A!]PT'[HI<=J,=J $/WA1_'2^]'O0
M%A!_%1_ :7^M'M0 A^Z*#]X4N.U'7F@+!_'2#^*E]Z/ZT )_ :#]T4N.U&.U
M "'[PH_CI>O-'O0%A!_%1_!2_P!:,=J $/W10?O"EQVHZ\T!80??- _BI?>C
M^M "?P4'H*7':C'Z4 (?O"@??-+UYH]Z L(/XJ/X*7I^-&.U "'H*#]X4N/T
MH]Z $'WS0.C4OO1T_&@!/X*#T%+CM1C]* $/WA0/OFEZ\T>] 6$'1J/X*7I^
M-'M0 AZ"E/WQ1C]*/>@!!]\T#H:7WH_K0 G\%!Z"EQVH_I0 A^^*4??-'O1[
MT!80=#1_!2X_6C':@!#T6@_?%+U_"CWH"P@^\:!T-+TYHQ^M "?P4'HM+CM1
MU_"@!#]\4#[QI?>CIS0%A!T-'\%+C]:,=J L(?X:#]\4O7\*/>@!!]XT#H:7
MIS1C]: $_@H/\-+CM1_2@!#]\4#[QI?>CIS0%A!]TT?P4N.U&.U "'^&C^.E
M_I1[T (/O&@?=-+TYHQVH 3^ 4'^&EQVH_I0 ?QT@^\:7WI#Q^- AB_ZX'WK
MZ+\ '_BE[?Z5\[8Q*M?0WP_/_%-0#VH ZRBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP'_R+-O]*!'44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5'/_ *A_I4E1S_ZA_I0!B:=Q<$>]
M;]8&G\W&?>M^@#DO'G_(!N/]VOG5/]>WUKZ*\=\Z%<?[M?.RC_26'O0-$LG2
MK]I_QXFJ#<@^U:-H/^)<QH#J9K_ZTT[^"DE&'S2GIB@!#]R@]J=CY<4G7\*!
M"?QT#[QI?>CW]:!B#[IH/W!2X[48[4 (>U'\=+U_"CWH 0?>- ^Z:7^M&.U
M"'[@H/44N.,4=?PH /XZ0=32^]']: $'W30?N"EQVHQVH 0]11_'2]?PH]Z
M$'4T#[AI?ZT8[4 (?N"@]12X[4=?PH /XZ0=32^]']: $'W#0?NBEQVHQVH
M0]12_P ='7\*/>@+"#O0/N&E_K1CM0 A^Z*#U%+CM1UH /XZ0=Z7WH_K0 @^
MX:#]T4N.U&.U "'[PH_CI>O-'O0%A!WH'W#2_P!:,=J $/W10?O"EQVHZ\T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG/K2]L4AY HZ@,'%R@]:^C/ 7'ABW'M7SG_R](:^C/ ?_(LV_P!*!'44444
M%%%% !1110 4444 %%%% !1129YQ0 M%%% !1110 4444 %%%(: %HHI,\XH
M 6BBD/ H 6BD'(I: "BBB@ HHHH **K3SB.55SUJ=3E<T .HHHH #TIJ'.:4
M]*:@ZT /HHHH **0\"D4YH =37.!3J:_2@!1TI:0<+0#F@!:*** "BBCM0 4
M4@.:6@ HI <TM "'I2(<BE;I34Z4 /HI"<4M !110>E !12 Y% /- "T444
M%%%% !1110 4444 ,S\]/IF/GI] !1110 4444 %%%% !1110 4444 %%%%
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M'WS0.AI?>CI^- "?P4'H*,=J7'Z4 (?O"@??-+U.:/>@!!T-'\%+T_&DQVH
M#T%*?O"C'Z4=3F@!!]\T#H:7WH_K0 G\%!Z"C':E_I0(0_?%*/O&CWHZ'- Q
M!T-'\%+C]:3':@ /04'[XI>OX4>] "#[QH'0TO0YHQ^M "?P4'H*,=J7K^%
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MHL<,* ''@YIHD!.,TV9PJ$UFV]V'N&7/0T :]%(.E+0 4444 %%%% !1110
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M]10%Q>V*/2D_CH'>@+B]\TO>FC[AH/W10%Q1TH[8I#]X4?QT!<6COFD'>C^
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M= #'&*3':G=\TG?-# /Z4=\T=J.V*.H!T_&C'&*#VI>^:$ W':E_I1WS1VH
M.^:.GXT=L4&CH 8XQ28[4[OFD[YH8![^E'?-':CMBCJ =/QHQQB@]J7OF@!N
M.U+[^E'?-':CH =\T=/QH[8H/:CH 8XQ28[4[OFD'7- ![^E'?-':CMBCJ =
M/QHQQB@]J7OFA -QVI??TH'7-':CH =\T=/QH[8H/:CH 8XQ28SQ3N^:0=:
M#WH[YH[4=L4=0#I^-&.,4'M2]\T -QGBE]Z!UH[8HZ '?-'3\:.V*#VHZ &.
M,4F,\>E.[YI!UH />CWH[8H[8HZ@'3\:,<8H/:E[YH ;U_"E]Z!UH[4= #WI
M.GXTO;%![4= #'&*3K^%.[YI!U- ![T>]':CMBGU .GXT8XQ0>U+WS20#>OX
M4O?- ZFCM1T />DZ?C2]L4'J*.@!CC%)U_"G=\T@ZF@ ]Z.^:.V*.U/J G3\
M:7'&*#U%+WS20"=?PH]Z!WH[8HZ 'O2=/QI>U!ZBCH 8XQ1U_"E[YI!WH />
MCWH[8H[8I]0$QCCUI<<8H/6E[YI )U_"CWH'>CMBCH >])C''K2]L4'K0 8X
MQ1U_"E[YI!WH .^:/>CMBCMBCJ F,<4N.,4'K2]\T )U_"COF@=Z.V*.@![^
MM)C'%+VH/7-'0 QQBCK^%+WS2#O0 =\TG3GUI>V*0]!1U 8.+E!ZFOHSP%QX
M8MQ[5\Y_\O4=?1G@/_D6;?Z4".HHHHH **** "BBB@ KFO&G_(#N/^N9KI:Y
M?QNV-%F'JAH ^;_ 5P4\<JN?^6Q_G7U!?/\ \29V_P!@_P J^4_"F;?QNC_]
M-3_.OIR\N@?#)DSU0_RH ^:KB<R?$"$9Z3_UKZIT$YTV/Z"ODV(%_'0D])_Z
MU]6^&GWZ5&?:@#%^(;[=$E_W#7SYX6TDZB;@XS^\->^_$EMNC./537FOPHL!
M/%.Q7/[TT ;GP]T0V.O.=N.*]C9?W./:N:T;3UM]6=PN.*Z@]* /FOQJ3'\2
MR*]^\/\ S>'K;W05X)X^7_BY9/TKWSPU_P @"U_W!0!Y?\2])\Z1GQVKQRTL
MS)J+08Z5]*^-;)9K5VV]J\*TBU#>+YH\=#0!ZQ\+],^Q6[G&,FNB^(<GE^&Y
M#5KPQ9BWM5P,9%8WQ1GV>')%S0!X%X5N"GB[.?O2BOK2R.;*$_[ KY&T>(V_
MB"WE_O2 U]9:3+YNG0G_ &!0!5\1_P#(*F/HAKYAM;<W^OSKUQ*17T_XC_Y!
M$_\ N'^5?/7@JT^T>([HD9Q,?YT 5G4Z1K:]N17TCX=E\[0K63U05\\?$2+[
M+K(*\?,*]\\&-N\*V!_Z9B@#?HHHH \\\8IN\1V1]Z[?31BS7Z5QGB__ )&&
MS^M=IIW_ !Z+]* +=(WW3]*6D;[I^E 'BWBZ;;XA4?\ 34?SKU_3#G3;<_[
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M=\31NN%'J* .<\,^'//T>*7;UKTOPII?V%6XQFH?!-DA\,6^5%==#"L:\#%
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M$T'[HH[8I<<8H 0]12_QXH[YH[YH 0=Z/X#2]/QI.V*  _=%!ZBEQQBCOF@
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M?O0!YG/:&V?39L8W,#7T7X4F\[28SGH!7BGB*R\G2M)DQZ&O7? 4OF:*#Z4
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M!Q7Q &=/'TJA\,YTBTN8$@?/6KX\3.EL?137FGA#7?LEM.F['SF@#W:-@_S
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M^'%'84?QXI!U/M1U"XO\5+WIO\)-!^Z* %'0T=L4AZBE_CQ1T"X>E'\5(.]
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MI#]TTM(?NF@#QKQ><:\G_74?SKUO3/\ D&V_^X*\@\:MC78_^NH_G7KVE_\
M(+M_]P4 7*X/XBS>5!'SU%=Y7F?Q7F\NVB]Q0!D1W"MX#N#Q]ZN@^'5R)8%4
M'HM>?V]TW_" W YSNKIOA-<F60H3T6@#U#55W:?*/:O(M!/D>.[C/]TU['>+
MNM7'M7C1/V7QO<-T^6@#45!<R:@>N,T[2)_*\/RQY[FG^'5^TIJC=>M92S^1
M!)"3C)- &OX 3_B?W+^M>HUYOX!CQJ4K^HKTB@ K&\5?\BW>_P#7,ULUC>*O
M^1;O?^N9H \V^%?+,?\ ;->JW_\ QX7'^X:\G^%C8E*_[9KUK4!C3[@_[!H
M\=\,''B<C_IJ?YU[/(?]'8?[->*^&N?%/'_/4_SKVB0_NF_W: / ?%Y*^)(\
M?\]*Z+1'?^VH<DXQ6!XK0OXEBX_Y:5U>D6I748GQV% 'J-KS;I]*\T^*;8A;
M_=KTNT_X]D^E>7_%4_*1_LT <;HDCG38,$_>KW#PZQ;3X\_W17C?ARU+Z7"<
M=Z]C\/ K:*#V% %;QK_R 9*Y#X;_ /(0N*Z_QK_R 9*X[X:G.IW(H [?Q+QH
M5Q]*\[^'H_XJF8^U>C>)Q_Q(I_I7G?P]_P"1FE^E 'K]%%% ')^.C_Q*)/\
M<->$Z'#*Z3E<_P"L->Y>/6QI;#U4UYMX+TT7%G.VW/SF@#U#P4C)H\6[TKJ"
M,C%96@V_V?3XUQC K6H \3^).F.VI/*@/X5:^'6I&WD\EVYZ<UVOBK2!=PO)
MMSQ7DMA<-IOB,1<@&0"@#Z%0[D!]13J@LWWVD3>JBIZ "BBB@ HHHH ****
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M+IO$Y'O6]6!8?\?/XUO]J .2\>?\@&X_W:^=4_U[?6OHKQWSH5Q_NU\[*/\
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M\"@#S[QA_P C'9?6NWT[_CT7Z5P_C(X\0V9]Z[;2SFR0^U %VD/W32TA^Z:
M/%?&WRZXI_Z:"O0M.OE%I;+N'W!7G7Q"/EZB']'J6PU_F!-W0 4 >Q1N&MRP
M]*\;\4DW?B>V0\[9:]4T>X^T:7OSU%>;7MMYGBA&QTEH ]!33 U@HV_P?TKR
M[3 ;+QO<@<9?%>U1*/LBC_8KR&2#;XSG;'5Z /7[<[K=#ZK7@7Q=!74V8?WQ
M7O=K_P >D?\ NBO%_BK9^;<[L?QB@#M_ATA_L*(GN@KS#XL9C\4KCTKU[P-!
MY.@V_'_+,5YG\4+,S^)%;% 'HWP_)/AVV)_N5U]<QX'A\KP_;#T6NGH 0]*H
MW*^;:3IZBKYZ57*?(X]: /$9P;#QJ@Z"NL\6:GC04VMRRXK#\7VOV?7_ +0!
MTK+U#4#?V\,&<X.* .E^%$!-M<2,.KYKU"X_X]Y/]TUR?@/3?L.GMQC=S76S
M\P2?[IH \.+EO&2#_IM_6O<8?]0G^Z*\9-J1XM5L?\M:]GA_U*?04 /KRGXF
M9^WI]*]6KS/XAP>9>H<=J .G\"_\BU!]*Z6N>\%IL\/0CVKH: .9\<?\B_)7
M'?#$8U.X-=MXQ3?H<@KE/AW#Y>H3T >B7*>9&5]17A&ILVG^/)W&0"U>^,,F
MO'O'&F&'5GNP.K=: .Q?4Q_9*MNYV5K^&)S<:;O)[UY2-;W6Z0;NV*]-\%?\
M@9?K0!G_ !"S_9GX&N8^&=TL.GS@G'SFNN\=Q>9I;>RFO(O#NK_V=%,F<?.:
M /;;*\$MZ0#6O,V(2?:O._"FJ?:[S.<Y%>@S\VA/M0!DF^592I:O)?&4YO?$
M%JH.0LP_G70ZQK?V75VBW5S]M"=3UN.3KAP: /:M'C\O381_L"K]06:[+2-?
M114] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !45Q_J'^E2U'<?ZA_I0!BZ9S*3_ +5;U8.F\3D>];U ')^.
MO^0'<?[M?.P_X^F^M?1'CS_D!7'^[7SL/]>WUH&D2=FK3M?^0:WUK+;@5I6I
M_P! (H"Q0E^]0>HIK_?-*/NDT 2=J8.]!/R4A[4 +_#1V%'\>*0=31U"XIZT
MO>FC[I-&?DS0%Q1WH_AI#VI?X\4= N'84'[U(.IH'W2: N.'WJ<>E1Y^4&G$
M]* (S4H'RTPCYZDZ"A@QI^8;13%7RVP:DM09+I5]:DU&,POTQS0%AO1?K42\
M/FI)#@)[TQA@9IA?09_RTS[U+)\TBFHNV:DB.Y2: L,8>8Q441KY$;J>]3Z;
M$9[]DQFG:Y";6>)<8W4@*Z<04@I>D5(G0T#N._BI>]-_A)H)^4&@5Q1T-'\-
M(>HI?X\4= N'84?Q4@[T?PDT!<=WI.QI#]T4O<4 @_AIK] *=_'BF=90/>@!
MWV-I(MP%.6P?R^AKJ],TOSK'=MK031OD'R?I0(\[33I Q&#R:9+I\A.,&O19
M-#VR+\G7VIHT+=/C9^E-#1P$.G2#'!J5K)D?.*[[^PMI^Y^E5+_2?+A+;>E(
M'N<>.!BD'2B?Y;AE]Z0]10%Q>U'I1_'BD'>CJ%Q?XJ7O3?X<T'[HH"XHZ&FI
M]^G?Q"D'^MH"X3)OD0>]22VC*-V*EMT\VYC'O72WNF;;$OM[4 SD$X)%.'2F
MR?+.P]Z4_>% "GI1Z4?Q$4@[T!<7^*E]:;_!F@]!0%Q1TIL@^04I^\!3R,B@
M+BNX$:CVIIMC-;[@*@F?H*ZG1K W&E;MN>:?0.AS36#M$.*C73W'&#7>PZ-N
M7&S]*631=K_<_2@:.%:P?9T-1_V<^X'!KO/[&YQM_2GMHGR9V?I0(X=+!@^<
M4L?RR.I[5VG]D8@+;:XNY!COI%]Z0,CQ^\S3WI/XA1U<T,.H>E'\5(.AH_@S
M0%QW<T@Z4A/ I?X@* N!Z44?Q$4@Z&@+CX_];3"?WC#UIT?K4)/^D*/4T")O
M**0EJ:#E!6M?6ICTXOCM6/ <H*!CF'(J3M36'%)G]W0(!WH'2D/04?Q 4#N*
M>E+W%-'WC0.AH"XO\5 [TG\&:#VH"X'[AJ2"V,HR!4,AQQ74:!8>?&#M[4PN
M<T^G/YG0T#3W\SH:[XZ+DYV?I2?V+SG9^E(#SLVS0LV:GMW B(KH-;TPP+D+
MUKEF)B?:>* N6E.9*2X'[U#383DYJ20;AGTH#J-_BH]:3^#-![4!<4=*#TH_
MB I!]XBCH%QW<4G\5(/NFC^'- 7%]:!TI#VI?XL4=0N!Z"E[TT?>- ^Z: N+
M_%1ZTG\.:#VH"XO\-(W04O\ 'BD')- !_P M5KZ$^'__ "+<'TKYY4YE'UKZ
M)^'X_P"*8MS[4".JHHHH **** "BBB@ KAOB%9&[A@ &<-7<UF:M8B\101G%
M '-Z'9>7X<FBQU%<1I.BE/&$LNWBO6K.S$=FT>.M4+?15CU%IMO6@#F/'>G&
MY@MP!T6M[P%;&UT-4([UJ:IIPNT4$9P*LZ3:BTM0@&* ,GQ=;FXL"N.QKPR\
MT"07#X4\FOHR_MA<1;2.U<S)X:1W)V#KZ4 >=_#[29+;7&=@>E>XH/W 'M7-
MZ5H2V=SY@7%=.!\F* /&_$ND--XU\[::]4TI#'I=NOHM9]YHZS:EYY6MR",1
MPHOH* *^J)YE@Z^HKRS2M)*>+)I=O4UZ[,GF1%?6L.#2%COVEV]: +>IQEM!
ME0?W*\X\(Z48O$_G,M>J7$7F6C1^HQ61INE+;W?F[<4 7]8B\W2;A/5#7F7@
MW2FMM:+XQ\YKUBX3S('3U%8NG:2MO<^8%QSF@"[K,?F:?(OJIKS7PCI1M]9E
M<CK)FO5KB/S8BOJ*Q['25M[AG"XR<T <K\3--^V:6,#)R*W? \!M]&@0]D%:
MFLZ>+ZWV$9J72;86T(C Q@4 :5%%% 'G7C4XU^S^M=IHQS8)7%^-@3K]GCUK
ML]&_X\4H TJ0]#2T4 >0?$'3GGF+*/XJY.TTZX6XCZ\5[1K6DB[.2N>:ST\-
MHI5MG3VH TO#$;)HRJW7%<^VGEM;\S'\>:[33[<06H3%5_L ^T[\=\T :2#$
M '^S7G<NG'_A(Y)<=6KT8#Y<>U9+:<#=F7'4T :, Q;H/:O/?'>FFZ((&?F%
M>C*,(!63JNGBZ'(SS0 [P]!Y&CVZ8Z(*XCQIIAN=9#XS7HUI%Y5NB>@K-U+3
MA<3;RN: '>'8?(TF%,=%K7JO9Q>5;*GH*L4 %)BEHH \[\<:<9F9U'.*X72M
M+E;44# X#"O:-4L!=@@C.:RK;P^L4X?9WH W].MU@M(P!CY15F49B8>U+&NV
M-1Z"E;E2* /.)=./]O))C^/->BQ?ZI?I61+IX^U"3'?-:\?W!0 ^N)\86OGW
M"G':NVK%U:U\^4'% #O#47E:/$OI6Q533HO)M%3TJW0!D>(X_-TMUKG_  =:
M>1>3''6NLU&/S;4K5'2+002L<=: -@]:XWQUIXGT[<J_-FNP8_.*IZI:"[M]
MA&: /!(=,G^W*.<;J]K\*0F#254UG+X;03!M@Z^E=):0?9K8(!B@#,\40?:-
M-D7'\)KP6XTB>.67:",L:^CKR'S[<J1G(KE)/#".S'8.3Z4 <KX#M)8IUWYZ
M5ZLXS9D>U86D:0MG-PN,5T*C*%: /#_%5A._B)F7.*W?!VEL+G<X[UUVH: M
MQ>F4IFKVF:4MJV0N* -N,8C4>U.I!P*6@ HHHH **** "BBB@ HHHH ****
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M#44V:G*OH:A/7-6M48-K$Y'K57L: #OFDZ9]Z7M0>U'0!,?+BC'&*=WI!U-
M >N:4C"[J3L:>Y_T;WH86+>B#S=3A7U:O5-5TO;HQ;;_  UY9X5._7( ?[XK
MWS7H$7P^3C^&@&?.UVNV_D7T--/7-2WQ']KSCWJ+L:86#OFDZ9]Z7M0>HI=
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M4 (R@X-.48%"\BG4 %5YX]S9JQ2$9H ;$-J 4^BB@".5=R8ID";34Q&: ,4
M-(^:G8SUI:3/- !M'I2,/EIU% #<<4;!Z4ZB@"%4 D)Q3U&":=CFEH :5!/2
ME  H[TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 R/O3Z8@P33Z "BBB@ HHHH **** "F _/3Z8!\^: 'T444 %%%% !1110
MS/ST^F8^>GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.:7L: #^+-)TS[TO\-![4= L)CY<4=@*=WI!UH #U!H Y)H[4J]* +?AP?\
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M-)T.?6E_AI&Z"@!@XN%'J:^C/ /'ABW^E?.G_+U'7T9X#_Y%FW^E CIZ***
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M?)BE7TH$,88D%.)^?%*XYS3>^:  <Y]J,_+F@=_>CMB@ [ TKGI2$<8H;F@
M0\XIL?\ R$(?]ZG+US2)Q?P?[U#'U/H/PH<>'C]*\.\7R;?%%U[M7N'A7_D7
M3]*\'\:-CQ/<?[U (J \9IZG=Q5<-^ZS[4V.;!I#ZDKMM-/C;,6:IR2;FJQ$
M<1XIB' _-4AZBFA>,TO4B@!?XL4@[^U+_%FD'?WH ,_+F@] :/X<4'H!Z4"%
M/4"@'YB*3J0:.Y- S0\,\Z_!_P!=!7O?B,_\4NW^[7@GACC7K?WD%>]^(Q_Q
M3##_ &10(^=;L_\ $UF^M!^\!1=C_B:S?6@\G-  /O8I!SGVI?XLT@[^] PS
M\N:#T!HQ\N*".!0(4_> I!][%+U(-'\6:!B#O[49^3- '7WH_AQ0 -_JR?:N
MH^'1_P")W#_O5R[?ZLCVKJ/AT/\ B=P_[U ,]-^)W_(O+]:\&C^_)]:]Y^)W
M_(O+]:\(B'SR?6@!V?DS0>@/K1CY<4$<#VH$!^\!2C[V*3J<T?Q9H& YS[49
M^7- [^]'\.*!"]A1T84=OI0.6S0,4\G%(I^4TIX-(HX- ,@F.Y5'O7OW@6'R
M=!C?'6.O T3?<*GO7T5X=C\CPK&W3$5 @MK_ ':LL>>IKDOBG!NL@V/XJ?I.
MH>;XH1,_Q5H?$N#=I(.*;&SQ"(Y5O:I2/W.ZH(?O2#WJSC]QBD(83\JT'[V*
M3KCVH_BS0 H^\12#H31T.: .#[T##/RYI?2D_AQ2]A[4 B*>O;OAT^=)5?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %17'^H?Z5+45Q_J'^E &-IG,Q/O6]6#IO$Q'^U6]0
M!R?CK_D!W'^[7SLO_'TWUKZ(\=_\@*X_W:^=A_KV/O0-(E[-6E:_\@UOK663
M@&M*U/\ H!% 6*$OWJ#U%(YRYH'W<T 2=J8.]!/R4AXQ[T +_#1V%'\6*!U-
M'4+@?O4O>F]B:,_+F@!1WH_AI#QCWI?XL4= N'84'[U ZFD[$T!<=WI8ON/3
M,_+FG9VPM]*!#]*3S=34>]>Q6X%MHP/3Y*\H\+1>=JZ<5ZCK$GV;2 .GRT%'
ME/B"8S:F?3-5]-?R;U3[TR[?SKIF]Z9GRV5O>FA;'M%BXNM(QU^2O+/$D/D:
MJU>A^$+C[18E<]JX[QS!Y5^[8I/<=S)\/6QNM6AP,X<5]'Q[;31U/3""O#/A
MK9_:]19B,[3FO9O$=Q]E\.R-G&U:"3Y]\8SFY\4W&#D9J/09C;:W:^F\56OI
M/M6L2RGG)IJ/Y.H0OZ&@$?3EBZW>E9Z_+7SMXKMC!XAN3C@R&O=?!=U]JT!6
MSGBO)_B%9^3J3R8^\] UN<HO04WH]$9RM-E.,'WH!$C?<)J,?<I__+/\*C7K
MB@!W84?Q4@[T?PYH =WI.QI"?E!H/44P%_AI%_X_;?\ WJ7^+%)%SJ$ _P!J
MD!]!>%1_Q3I^E>'>,[-V\27# ?Q5[OX47.A >U>>^)M'\W5Y7V]6I,<3SD6C
M^3C':JWV.3T-=V=(P -M._L/C[M,1P:6,C...]6)83"1FNVM-#W.WR=*Q/$=
ME]F)XQ@4",<8V"FCH:8C9C6G'J*"F*?NT=A1_%BD'?VHZBN+_%2]S3?X<T'H
M#0 HZ4?PT=Q1_$10@N7_  U_R'K;_KH*]^\1_P#(LM_N"O ?#'.O6_M(*][\
M1G_BEV_W:!'SO=?\A6?ZTT=*+L_\36;ZT'A@*!@>E'I1_%BD'?VHZA<7^*E[
MFF_PYH/04!<4=#0>E'<"C^+%'0+AZ4?Q4@[^U'\.: N*>C?2NI^'/_(9B_WJ
MY1SB/-=3\.C_ ,3N'_>H$>F_$_\ Y%Y?K7A4?WV^M>Z_$[_D7E^M>#Q'YI/K
M0!)_%2]S3<_+F@G@4#N*.AH/2D_B I?XL4= N'I1_%2#H?:C^'- 7'>M)'2$
M_**1#\V*8#I*<.E-/+$4JG@T@'Z='YNK(OO7T1;#R/" ]H:\#\-1>=KR"O?;
MP^3X58>D1_E0!Y-X:O2WC2,$_P 9KTCQ]%YVB BO'/#%S_Q6J'/_ "T/\Z]N
M\1I]IT'U^6@1\YK\MU*O^U5G/RU!=#R]1F7_ &S0[82@:'+U-*.E-'W0?6G?
MQ8H #T%+W%-_B(H'0T=0N'\=+ZTS/.:<QP!3 BD^Y^->]_#_ !_PCT?KLKP2
M3[M>Z?#U\Z(B^B4 SSOXER8UN+ZUQ3/FZ]JZSXHDC68S[UR$*EFW4@:)HXS-
M?P*/[U?1/@V'[)H'/'%>%>&+0W6K(",X<5] ,HT_P^>WRT"/"_&\OG>)+C']
M^L=A]SZ5;UV7[1K]PW7YJJ=OI0,/XJ/6DS\N:#V]Z N*.E!Z4?Q8I.I(HZ!<
M=W%)_%2#H31_#FA@+ZT#I2'M[TO\6*.H7 ]!2]Q3>YH'W2: N+_%1V-)_#F@
M]O>@!?X:1N@I?XL4G4GVH /^6JU]"?#_ /Y%N#Z5\\@YE'UKZ(^'X_XIBW/M
M0(ZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "HY_]2WTJ2HKC_4/]* ,6P_X^?QK?[5@Z9S,3
M[UO4 <EX[_Y 5Q_NU\[#_7L/>OHKQU_R [C_ ':^=E_X^F^M TQS#BM*U'_$
MO)K//1JTK7_D&M]: 9FN,.: /EQ2R_>I>XI@-Q\N*#V]J=WI/6@ _BS2=":7
M^&@]*70+" ?*11_#BG=Q2?Q4!80]O:E_BS1V-'\-'4+"="?>@#Y2*4]!2]Z
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MS?I3^7J)?_;KZ.\.,+CPNF>Z4"/GK7HO(UEU]7-5IA@8K8\:P^5X@7W<UE7
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M?V->\_$[_D7E^M>#Q#YI/K0 _/RYHZ >]&/EQ01P*!"GJ!0/O8I/X@:7^+-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUKZ(^'X_XIFW/M0(ZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBC- !1129H 6BBB@ HI,TM !1129!H 6BBB@
MHHHH **** "BBB@ HHI,XH 6BD!!I: "BBB@ HHHH **** "BBB@ HI,@4N<
MT %%%% !1110 4444 %%%% !1110 44A(%&<T +1110 4444 %%%% !1110
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MHFEV0;_:J>KN56/']ZF:G-Y>EEO]F@"_:2^= &JQ63X>E\W35;WK6H ****
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MQ9H& YS[49^7- [T?PXH </N&ND^'_'B" ?[5<UG"5TW@$?\5! ?]J@1Z?\
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MZM74ZU&7L0!7 )"T.K1^[4 =YJMSY6E>9FN/TG5&DU(KG^*M[Q#(5\/9KF-
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M_0U[IX&U#S[5%S02<#\1; P7+N!U:N*LR#$V:]?^)6G[K4R =Z\9MW*.Z^]
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M_M5UFB3^=9 Y[4 9>IS;;P _WJMZ\N_0)#_L5A>(Y_)O8_=Q6]JOS^'3[QT
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M-]P_2@#R^[G^SZY<-G'S5IZ=_IFIPS#G;7.>)',>JSD?WJZ7P*/M%H\AZJ:
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MNL\:=!_NT :7ALYL/QK:K!\+'_B7_C6]0 4444 %%%% !1110 4444 %%%%
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M/QKW?X?8&@QG_8KPF89&:];\':NMOHR(6QA:8')_$U]VLQ?6N3+X2M_QQ/\
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M*X_U+?2@#B?":_\ $_U _P"T:;J(_P"*VM\>E6/#2;-8OF]33;E/,\60OZ4
M'B9=TL7^^*T-83.AK[1U4\1+F6/_ 'Q6EJB9T'_MG0!6\.#_ (I[\ZI:&O\
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MN*YCPZNS5IZ -S5%1X&SZ5Q>AEAXGE4?=VFNBUZ],*,,]:S?#=KYEXUWCJ*
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M?X<TC=!0 Q?]>H]Z^B_  QX7M_I7SI_R]1U]&> _^19M_I0(ZBBBB@ HHHH
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MTIXS6GX=M?)TT9'.*T;JS68\BIK: 0P[!0!C6UMMOG;'5JH>)K0ROD#M73K
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M_I1_$32#H: %SQFCI^-)_!B@]!0 O?% ZXI/XP:!]XT +G]*">,T@Z&C^#%
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MRHZ@'?%+3<\9I<_K0 #I0>F:.^*.^*.@!1_%B@?RI,\9H =2#IFC^M'?%'4
M/3-%'?%']*.H!WQ129XS2_UH !TS0>F:.^*.^*.@"TG?%&?TI,\9H 6@=,T'
M^='?%'4 /2EI.^*,_I1U .^**3/&:4_SH !TS0>E'?%'?%'0!>])WQ1GO29X
MS0 M Z9HZ?C1WQ1U #THH]J,\4=0#OBCUI,\9I>GXT  Z9H/2COBCVHZ +2=
M\49XS2=LT,!:.V:.GXT=\4=0 ]*7O2=\49XS1U .^*/6D[9I>GXT ';-(W:E
M[XI.O'I0##_EJM?0GP__ .1;@^E?/(.95KZ(^'X_XIFW/M0(ZNBBB@ HHHH
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MEN3"B<_Q4 =#&^^$'VIZ?=JGIC^9:(?:KH&!0 $XIA^^*5SR*7'.: '4444
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MTO\ 6D/W10>HH 7OBCK^%)_'0.IH 7/&:3/>@?<-!^Z* %]O6COBD/44?QT
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M>-+VS1VS1U"P@^Z:/X*7O1WQ0%A#VH_CI1WH[9H"P@^\:!]TTO:@]<4!83^
M4'^&E[XH'>@+!_'2#[QI>V:0\ 4 ,7_7 >]?1?@ 8\+V_P!*^=/^7I!7T9X#
M_P"19M_I0(ZBBBB@ HHHH **** "L7Q#_P >OX5M5CZ^,VA^E '-0,?^$9N_
MK7/G]YI\0[[JW[3GPW=CW-8%@IE98_0T =?"N/#DP_Z9U+X+.-,Q_M4_9LT&
M<?[%0>#SBTQ[T =;45RVV%C4M5K\XM'/M0!P%S>_\3MESWKT"S.;6,_[->17
M$S?\)*P_VJ]<L/\ CRB_W10!B^)XB]F?K7$ZK)@6:'L17HVL0^;:D8KS/7 5
MOK9?1Q0!W2'R_#['VK#\*Q%]=ED/<5MW7R>&S_NBJWA2##^;CJ* .BU*3RK.
M0^U<;HD1FU_SNU=)XBF\NRD&>U9WA2WWP"<CG- '41C!-<=XYA>6S<+Z5V@&
M#63K=F+FV;(SQ0!B>"FVV$<1Z@5J>)AG3)1_LUC>&#Y>K20=E%;OB)<Z=+_N
MT >=Z? R0!^V:]$TYMVE_P# *Y6WM0NB"3'\5=-IA_XEI_W: ,*R'_%0)]:O
M>+_FC@ _OBJEC_R'5/O5_P 2C?Y0_P!H4 9^N#(M/]T5J(A.@8'I5#65R]J/
M]D5NV,._3 F* .#\/QM!K4Q?N]=IXIY\/OCTK#N;86>J1D#&YZW_ ! -VA-]
M!0!'X?/_ !(%'^Q6?H__ !^2?[YJ]H1QI6WT6J>DC%X_^]0!4<?\55+_ +M+
MH8/G:C^-/*Y\42_[M.T==LU_[YH ;HC?\3( ^M=K7!Z0Q&N*/>N\H Q_$Y_X
MD=Q_NUYAX8AD.I[N=N:].\3?\@:<?[-<UX2TT-"LVWO0!U-TXCL%#?W:XJPD
M#>+(P*Z3Q'/Y,"*#VKCM"D+^+(LT :7C]O(AB8<;FK6\#+_H!)[UB_%#Y;:U
MQW<5T7@Q-NF+[@4 =/37^X:=3)?]4WTH X+Q#=[-2VYKL-&??IT1]J\V\43,
M-< KT/P\<Z5#_NT ,\01[[&3Z5P5_(8M,1#_ 'J])U./S+5Q[5YEXD!BB5?]
MJ@#K/#Y*Z3(W^S61IBF;Q.K]16SI0V>'6;_IG53PU#YEYYV.] '87)V6K^RU
MYY:AKKQ%&_4*U=[JD@2QE/\ LFN0\(0?:)I9B/NN: .Z0;4 ]JY[Q:C/ILH7
M^[71]JS]5MQ/:.I':@#D/ 7[J#RV^]FNWOO^/*;_ '37%Z$/LNLK .!7:7O_
M !Y2_P"Z: /,DMR\%PWHQKJ/#+G[-Y9[+5#3K8/87)Q_$:M>'SMO'C]!0!1E
MRNNQY_OUN^+/^0+@>U8U^NW7(,=WK:\3\Z5CZ4 9=]G^P[3_ ':O:5EM&E J
MI?K_ ,22U_W:O^'%\S3G7WH XK3XWA\52N_0FO1M0YT.0C^Y7)ZM:BSOQ,!C
M+5U-R=WA]CZQT 9?A3_4?C6AX@_X]_PJAX7XA'UJ]XA_X]OPH C\+'-F_P#O
M4GBG_CTC_P!ZF^$S_H<G^]2^*S_HL7^]0!<T0$6P^E:M4=+7;:)[K5Z@#GO$
MRDQ*1VKB!DW8->@:]'NMB?05PL*AG9O0T :&BJ6O9O\ =JE>,4CN%]<UJ>'U
M#7TO^[65K/R7A3^\: &:;G[$J^];NK1G[';'T%9%BNTK'[UTFK1C^S(CZ+0!
MR+'=K$;]@*Z3PXI_M>5^Q%<W'R3+Z&NN\.1C/F^HH N^)P3H\X']VN)MK;'A
MQ3CG=7>:\N[3)1_LUS,< 'AQ/]Z@#-FMRL$#8[5K7C%?"<I-.OH ME;GU%1Z
MM\OA";% &!)\^F6I']X5U%PN-%.>NRN7M%,NF6H_VA77:FGEZ4H]4H RKD;O
M"<8/]ZNA\/Q+%IRG'5:P+KCPK'_O5T.FMLT0-_L4 <UXK==K$58N,OX4@QW6
ML37YS+ YSWK?A7?X8M1ZB@"+X?6QCAN"PZM7<2?ZIOI6#X8MA;P/@=36]+_J
MG^E '&:7&)]6N,\X>M7Q.OE:"^.*H^'0&U6\]FK0\6_\@.04 8IB!\/P/CG%
M5T+/X7O1[5?Q_P 4W!_NU6L4W>'[Q?6@#%M;?_BF(R1SNI5@^5#Z5J^0$\,Q
M\?Q4V.$?9=WM0!U'ATYL!6S6)X:.;#\:VZ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "HKC_ %#_ $J6HY_]0_TH Q=+_P!:?]ZMZL#3
M^+G'O6_0!R7COC0KC_=KYV4_Z2Q]Z^B?'G_(!N/]VOG5/]>WUH&B9N :T;0_
M\2XBLV3I6A:?\>)H#J4)#\^*7MFFO_K33OX*$ 9[T=/QI"/D%![4"%]J.O%)
M_'0.IH&+GO1[T@^Z:/X!0 O]:/:D/:C^.@!>O'I1GO2#J:!]TT +GO1_6D/W
M!0>U "^U'7CTH_CI!U- "Y[T9[T@^Z:#]P4 +_6CVI#U%+_'0 =?PHSQFD'4
MT#[AH 7/>C^M(?N"@]10 OM1U_"C^.D'4T +GC-&>](/N&@_=% "^WK1[4AZ
MBE_CH .OX49XS2#J:!]PT +GO1[>M(?NB@]10 OM1U_"C^.D'>@!<\9HSWI!
M]PT'[HH 7V]:/:D/WA1_'0 O7\*,\9I!WH_@H 7/>CV]:0_=%!^\* %]J.OX
M4?QT@_BH 7/&:.G-)_!0?NB@!?:CVI#]X4O\= !U_"C/&:0=Z/X* %Z<T>U(
M?NB@_>% "^U'7\*/XS2#O0 N>,T9QSZTG\%!^Z* %]J/:D/WA1_&: %Z_A1G
MC-(.]'\% "YQ^-'M2'H*#]X4 +[4=?PI/XS0.AH 7/&:.GXTG\%!Z"@!?:CV
MI#]X4?QF@!>OX49XS2#H:/X* %Z?C1[4AZ"@_>% "^U']*0??- Z&@!<\9HZ
M?C2?P4'H* %]J/:D/WQ0/O&@!>OX49XS2#H:/X* %Z?C1[4AZ"C^,4 +[4=?
MPI!]XT#H: %SQFCI^-)_!0>@H 7VH]J3^,4#[QH 7.>?2C/&:0?=-'\% "]/
MQH]J0]J/XQ0 OM1G//I2#[QH'W30 N>,T=/QI/X*#_#0 OM1[4?QBD'WC0 O
M7FC/&:0?=-'\% "]/QH]J0]J7^.@ ]O2CKS2#[QH'W30 N>,T=/QI/X*#_#0
M OM2=>/2E_CI!]XT"&#FY0^AKZ,\!<^&+<^U?.:_ZX?6OHKP ?\ BF+?Z4 =
M51110 4444 %%%% !67K"[[5_I6I69J9 MWSZ4 <O;+M\/78]S530;+>X;%:
M-NN[0KH#UH\/2(@"GK0!K:@ODZ/./]FJ/@[FSS[UI:YSI$Q']VLKP@X33<GU
MH ZU3EC4=VN^W8>U0VUP))6 JXPRN* /++G3B/$#/C^*O2K3Y;6(?[(KGKJS
M#:FS =ZZ.)<1QCT% "W2;X2*X'7]/_TV%L='KT&9@L>37*:I)'/<HHQD-0!+
MJ+8\/LO^R*M>&(\:>C>U5M40C17'M6AX<&-*C^E &3XJN,.L6?O5J>&8O*TQ
M17-^,'*:G;^F:Z+1+I?LBJ* -P]*J7;#[*YJRQ_=D^U8.IZ@L5NZ$\T 9/AX
M?\5%.U;OB _Z%(/:L;PR-^IO+ZBMG7U)M'^E '/H<>'%'^U6YIO&ED_[%<T9
MQ_9 B_VJZ6T/EZ*3_L4 8>FMG7%^M:7B/CRC_M"L'1K@/KZKGO6_XH&(HV_V
MJ *&KOF>T'^R*Z?3.+(?2N*N[@3WMJH/0 5U\<HM; $^E &!K3@ZG !V>M?Q
M VW0&/L*YR:?[7JJ$=GK:\52^7X>8>PH =H'.EY_V:I:<^V\?_>J7PM.)=)"
MC^[6>9OLMXV>[4 3Q'?XGD_W:6S;RYKWWS3-,_?:X\O8K5::<0W%R,]30!8T
M2/?JBR>]=Q7(>&5WG?[UUP- &3XC&='G_P!VJ/A)0-'4_6M#Q%_R!I_]VJ'A
M1O\ B2J/K0!GZV_VF?9Z&L'2H/(\7PCVK5NI/+U%MW3=52V=6\90E?2@!_Q+
M3S8+8>CBM_P:<Z:!Z 5B>,L71"#G8U:7@R8"S9?0T =?39!E"*KQW(:X*5:/
M2@#S/Q)8E]8#8KN=#39ID0]JRM8LQ)>;L5O:>FRSC7T% #[@;D*^M<%XLLOW
M2MC^*N]G.T9-<GXDF2:%4'7=0!;LAM\-N/\ IG3?"<?^CEO]JIHEV: _^Y3O
M"0_XEY/^U0 _Q-<^1:[<_>&*K>#8/*M)2?XFS53QW*8XK?!ZM5WP[<HMJJCO
M0!TU07)'V=_I4JMN3-9>I7BPPN">HH YJR_Y&53797A_T&4_[)KC=+_>ZPL@
MKLKGYK*0?[)H X_2Y<6%R/\ :-2Z <ZA(?:LN*0VZ31'^)C6OX?C(D>3U6@"
MG>MOUV'V>MKQ0=NDY^E<Q/<C_A(8E)_Y:5U'BA?,T3CVH H7GS:';'_9J_X8
MXM&'O6)+=J=+MX<\@8K:T?\ T:Q9S0!F^*6_>(!_?%;LYQX<)_Z9UR^L3?:[
MI0/[U=+?-Y?AMO:.@#.\*OF,?6KWB1L6XK#\'7(=@N>]:OBR3R[=30 OA0XM
M7'^U3_%?_'I%_O56\'RB6T8CLU/\7S!+2//]Z@#8TI]UHGL*OUB>'YA):CZ5
MMT 9FM_\>,A]%->>6<FZWE;T:O1-;&=-F_W#7FNG G3+AO1S0!O>%I-]_-_N
MUEZZ<ZU$OJU7?!V3?2G_ &:I:TI_X2*W'JU $D3;-5$==-K;[=)3_=KEI 5\
M3!/:ND\0Y_LF/_=H Y*-L:1-)Z-79>$V\RPC;VKC%4_\(M<-_M5U7@^39I,3
M'TH W-?;;I$[>BUS-M+O\+HW^U6WK\XET.YQ_=KG-.S_ ,(C'G^]0!?U63;8
MVGN*;?KYWA25?6H-9)^Q6?TJYC/AJ3- %/2-/W:=;\=#6YK<>-.^BU%HLL?V
M.->.*MZ]C^SW_P!V@#GKH9\+1_[U:EE-_P 20CT2LV<9\+)_O4MC/_Q+)%ST
M6@#"U"+S-*ED_P!JNA@.WPS:_2L.XD7^P)@>NZME/^19M?I0!O: ^ZW:M:4_
MN7^E87AYMMI(36DMT) Z ]J .8\-2XU>\'^W6KXL;.D.M<YI,WV76KG)^\];
MGB!_/TIB* (,?\4Y /\ 9JM8_+H-V:0W:C1X8L\@4^%2OAZZ/J* ()Y,>%8C
M_M4QI=EBGNM176?^$1A_WJ9=Y%A;^ZT =7X7.=/S[UNU@^%?^0;^-;U !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<_^H?Z5)45Q_J'
M^E &-IW,Y/O6]6#I?^M/^]6]0!R7CO\ Y =Q_NU\[J/]);ZU]$>._P#D!W'^
M[7SN#_I+'WH&2'D-6C:#_B7,:S,X!]ZT[4_\2YA0(SY?O9H/84DARU&<\T#0
M_'%-'-.S\N:;T_&@ [9H[4>U'MZ4=0#OBCOBC/>C/>@ %';-'3\:/:CH =J.
M^*/Z49[T '?% HSWHZ?C0 =LT=J/:C^E'4 [XH]J,]Z,]Z$ #FCMFCI^-'M1
MT *.^*/Z49[T 'M0.:,]Z.E !VS11[4?THZ@&.<4>U&>]&>]  *.V:*/:CH
M?UHQSBC^E&>] ![4"C/>B@ [9HH]J/Z4=0#OBCVHSWHSWH0 *.V:/:CVHZ %
M&.<4?THSWH ,=J!1GO1TXHZ@';-']:/:C^E'4 QSBBC/>C/>A  Z9H[9H]J/
M:CH ?UH[XH_I1GO0 4#IFC/>CVH #TS11[4=?PHZ@'?%&*,]Z,]_6A  Z9H/
M3-'M1[4= "COBCK^%&>] !0.F:,_K1[4=0 ],T4>U'7\*.H!WQ11GO1G]:
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MQU-=3':;-&@CQ]T4 +IO[O3935/2KII=3>,GM6K:0_Z#(OK6=IEF8M59L=J
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M[4?THZ@&.<48[49[T9[T %';-'3BCVHZ ']:,<XH_I1GG- !CM11GO1TX]:
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M6&::3A@*4'YJ1A\PH ?1110 5&W!J2F.,XH >.E% Z44 ,7DFG 8%-08)I]
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M;-!XQ[T '\!H/W12XYQ2#DX]*  _>%'\=';/I0.F:!]0'\5'\%!XQ[TN.<4
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MN ]Z^B_  QX7M_I7SITND'K7T9X"X\,V_P!*!'44444 %%%% !1110 4444
M%%%% !1110!&OWC4E- YIU !1110 4444 %%%% $;_>%2#I32.:=0 AZ4V/I
M3STI%&* #'.:8X^85)2$<T ,_CJ2FX^:G4 %%%% !1110!&GWC4E- P:=0 5
M&WWQ4E-(YH =1110 4444 %%%% !1110 4444 %%%% !1110 4=J** &)U-/
MI ,4M !1110 4444 )CFEHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I&^Z:6D/2@!$^[3J0# I: "BBB@ HHHH *2EHH C7[YI^*0#FG4
M%%%% !1110 4444 )BEHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?-(.IH_AI>PHZC$[8H_AQ0?O4O>@!IY(]J=WS2#O1_#1T !U/O1VQ1V%'\5
M@_AQ2'DBG=Z0=Z %[YI!U-'\-'84=0#MBCMBE/WJ.] Q#R1[4O?-(.AH_AHZ
M  X)H[8H]*4_>H$)VQ2'DCVIW>D'0T +WS2#@FC^&E]*.HQ.V*.V*4_>H[T
M(>2#2]\T@Z&C^&CH #J?>CMBE]*/XJ!"=L4'D@TO>D'0T=0%[YI!U/O1_#2^
ME'4!.V*.V*7^*CN:!B'D@T=\T#H:/X:.@ .]';%+Z4?Q4"$["D/7-.'4TG\)
MH#H&>]'3\:3^ 4'^&@!?:D//%+_'2#[QH 8.;E#7T9X"Y\,V_P!*^<U_UP^M
M?1?@ _\ %+V_TH$=31110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>](04O;--!H)XQ1T&._K1WQ29R*3/S4 .]J2C/>D!H =VS1_6FD\8I<Y%/J
MO?%'M3<\YI<]Z0@I>V::#VH)XQ1T&._K1WQ29R*3/S9H =[4GO1GO2 ]J '=
MLT?UII/&*7.1]*?4!>^**;GYLTN>]( H[9I >HH)XQ1T =_6COBDZBDS\U #
MJ0>M&>](#VH =VS132>,4O7\*?4!>^**;GYLTN>](0>]+VS30>U!/&*.@QW2
MCOBDZTF><T .I/>C..:0'M0 [MFCI32>,4N<T^H"]\44W/S9I<XYI  ]:7MF
MF@\8H)XQ1T =TH[XI.M)GYLT .I.V:,XI >,4 .[9H_K32>,4N<T=0%[XHIN
M?FS2YQ0 #UI3TS30>,4$\8HZ ._K1WQ29_2DS\V: '4G;-&<4@/&* ''I132
M>,4N<\T=0%[XHIN?FS2]* #MFE/2F@\8H)[4= '4=\4F<\TF?FS0 ZD[9HZ4
M@/&* ''I132>U+G/-'4!>^**;GYJ7I0 =LTIZ4T'C%!/:CH ZCOBDSGFDS\U
M #J3MFCI2 \8H <>E'M32>U+GO3Z@&.<4?THSSFC^M(0>].44WMBG*>U ,CQ
MB9?K7T-\/S_Q34 ]J^><YF7ZU]#?#\?\4U ?:@1UE%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNBG;>*3&>* &C[PH/WJ>1WH SS0 U>AIO:GXQ2[>* &M]T4@^\*=C/%*1WH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/ HSE@: %[XHZ_A29^8F@'@T +VS1T&?6FY^7%*3P* %[XH[XI,Y8&C/S9H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?9!MZ4!U,=HSQ2^6=W2M7[*">G2E:U'7% =3($9W&CRSM/%:ZVHZXI#:]L4
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MK]Z -GS11YHK&^U^]'VL^M &SYHH\T5C?:Z/M9]: -GS11YHK&^U^]'VOWH
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M"RBLLSG(H\_YNM(.AIF4$TOG#%98G.31YYVFCH!IB49S2M,,5E^>=HH,YR*
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ME"RC%99G.X4HG.XT@-(R@FE\X8K+$QYH\\[:.@&F)1FE:8=*R_//%!G.X<T
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M3?:D!*6Q^-(&YQ36YQ2+US1T >6YQZ4H;C-1GK2C[N* ';^]*6Q47M3FYQ3
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MS9H 8.K4@'R$T\C!^M*!\N* (R/D%*1@BG8[4K#I0 S'[R@=6IX'.:0C!^M
M# /D)H(^45(!\N*3':@!I&"*,?O*>PZ&@#G- #!WI /D)IY&#]:4#Y<4 1D?
M**4C!%.QVI6'0T ,Q\] _BIZCG-(1@_6@!H'R$TA'RBI /EQ28[4 -(P11CY
MZ>P[T*.<T ,'\5 'R$T[&"?>E ^7% $9'RBE(P13L9XI6'0T ,Q\] [T]1SF
MDQ@GWH 8!\F:"/E%2 ?+BDQGCTH :1AA0!\]/8=#0HYS0 P=Z0#Y,T_&#]:4
M#Y<4 1D?**4C#"G8[4K#O0 P#YZ!T:GJ.<TF,'ZT , ^3-!' J3'RXI,9XH
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M* &8^3-*PZ4_'RXI,9/TH ;CY\4 ?,:>PYS0HY)H C'W31CY,T_&.*7'RXH
M8P^[1CY\4[&2/:E8<YH 8!\QH'W33U')-)C'% #<83-(1RM28^7%)C)'M0 W
M'SXHD7I3V'.:60?*IH B*_OD-?0O@#_D7(/I7SZ_%Q&*^@_ /'AV >U '644
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P 4M;Y]*0CK**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D_'$?F:-./]FOG]-.
M/VMOEKZ/\2V_GZ=(N,Y%>61Z"?M#'90!Q$E@68#'2A[ @]*[G^P3YGW*6303
MN^Y0!PGV$^E)]A/I7<_V"?[AH_L _P!PT <.+$^E'V GM7<C03_<I1H)Y^2A
M;C1POV$XZ4?8".<5W/\ 8)Q]RE.@G ^2A <*; ^E L".,5W/]@G/W*7^P3N^
MY1T&<+]@)[4?83CI7=#03S\E)_8)Q]R@1POV @YQ2FP/I7='03@?)1_8)S]R
MGU&<*+ ],4?8">U=U_8)S]R@:"<'Y*.H'"_83CI2"P([5W7]@G'W*4Z"<#Y*
M2 X4V!]*!8'IBNZ_L$Y^Y1_8)S]RCH!PGV D]*7["<=*[H:"<'Y*3^P3C[E#
M$<*+ CM2FP/3%=T=!.!\E']@G/W*?49PHL#TQ2?8"3TKN_[!.?N4#03@_)1U
M X7["<=*3[ 0>E=U_8)Q]RE.@G ^2D@.%-@>F*!8'IBNZ_L$Y^Y1_8)S]RCH
M!PGV D]*7["<=*[H:"<'Y*3^P3C[E# X;[ 1VH-@3QBNZ.@G ^2C^P3G[E/J
M!PHL#TQ2?8"3TKN_[!.?N4#03@_)0MP.%^PG'2C[ 1VKN?[!./N4IT$\?)20
M'"FP/3% L#Z5W7]@G/W*/[!.?N4= .$^P$G.*7["<=*[H:"<'Y*3^P3C[E#
MX;[ 1VH-@3QBNZ.@GCY*/[!.[[E/J!PHL#Z4GV DYQ7=_P!@G/W*!H)P?DH6
MX'"_83CI0+ CM7<_V"<?<I3H)X^2ET X4V!Z8H%@?2NZ_L$[ON4?V"<_<HZ
M<)]@.<XI?L)QTKNAH)P?DI/[!./N4,#AA8$=J#8$\8KNCH)X^2C^P3N^Y3Z@
M<*+ ^E)]@).<5W?]@G/W*!H)Q]RA;@<+]A..E L".U=S_8)Q]RE.@GCY*2V
MX4V!/&*!8'TKNO[!.[[E)_8)R?DHZ <+]@/7%+]A..E=T-!./N4G]@G'W*&!
MPPL".U!L">,5W1T$\?)1_8)W?<I]0.%%@?2D^P'KBNZ_L$Y/R4#03C[E"W X
M;["<=*!8$=J[G^P3C[E*=!/'R4EL!PIL">,4"P/I7=?V"=WW*3^P3D_)1T X
M7[ >N*7["<=*[D:"<?<H_L$X^Y0P.&%@1VH-@3QBNZ.@GCY*/[!.?N4^H'"B
MP/I2?8#UQ7=?V"<GY*4:"=OW*%N!POV$XZ4"P([5W/\ 8)Q]RE.@GCY*70#A
M38$\8H%@?2NZ_L$Y^Y2?V"<GY*.@'"_8#UQ2_83CI7<C03M^Y1_8)Q]RAB.&
M%@1VH-@3QBNZ.@GCY*/[!.[[E/J,X46!]*3[ >N*[K^P3S\E']@G;]RD@.&^
MPG'2@6!':NY_L$X^Y2G03D?)1T X4V!/&*!8'TKNO[!.[[E)_8)Y^2CH!POV
M ]<4OV$XZ5W/]@G;]RC^P3C[E#$<,+ CM0; GC%=T=!.1\E T$[ON4^HSA18
M'TI/L!ZXKNO[!//R4?V"=OW*2 X8V)QTH%@1VKN?[!./N4IT$Y'R4= .%-@3
MVH^P'TKNAH)W?<I/[!//R4= .%^P'.<4IL3CI7=?V"=OW*3^P3C[E# X86!'
M:@V!/:NZ.@G/W*!H)S]RGU X46!]*3[ <YQ7=?V">?DI?[!.W[E" X7["<=*
M!8$=J[G^P3@?)2G03G[E+H!PIL">U'V ^E=T-!.?N4G]@GGY*.@'"_8#G.*D
M.GG;TKMO[!.W[E/.@G:OR4V)G #2S]K0[>]?0G@9/+\.P)Z"O//[!_>J=E>H
M>&H?(TJ-,=*0C:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^Z*/[&7'W16[@48% &%_8R_W11_8R_W16[@48% &%_8R9^Z*/[&7^Z*W<"C
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
